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ABSTRACT
Background: Approximately 9% of patients in hospital have a hospital
acquired infection (HAl). These infections place a burden on the health sector,
patients and carers.
Objectives: To assess the incidence of, and independent risk factors for HAls
occurring in adult surgical patients; to assess the impact of these infections on
the hospital sector; and to show how this information may be used to assess
the potential benefits of prevention.
De8lgn: A prospective survey of the incidence of HAl was conducted.
Resources used by both infected and uninfected patients were recorded and
costed. Generalised linear modelling techniques were used to estimate the
impact of HAlon the observed variation in costs. Logistic regression analysiS
was used to determine independent risk factors for HAL
Setting: A district general hospital in England
SubJects: 2469 adult patients admitted to five surgical specialties between
April 1994 and May 1995.
Results: 7.5% (95% Cl: 6.4, 8.6) acquired one or more HAls that presented
during the in-patient period. The incidence, economic impact and independent
risk factors varied with site of infection. On average HAls increased hospital
costs by a factor of 2.3 (95% Cl: 2.0, 3.0), equivalent to an additional £2,254
(95% Cl: £1,738, £2,770) per case and increased length of stay by a factor of
2.1 (95% Cl: 1.8, 2.5), equivalent to an extra 7.8 days (95% Cl: 5.7, 10.0) per
case. The estimates represent the average gross benefits of prevention. Net
benefits depend on the cost and effectiveness of prevention activities.
Estimates of the gross benefits of a 15% reduction in infection rates and a
framework for assessing the net benefits of prevention are presented.
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Conclusion: The study provides an estimate of HAl by specialty and site for
surgical patients. It calculates the burden on the hospital sector and shows the
benefits that might accrue if HAl rates were reduced.
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CHAPTER 1
INTRODUCTION
1.1 Introduction
Hospital acquired infections (HAl) are infections that are acquired during a
patient's hospital stay. They are not a new problem; however, in recent years
there has perhaps been greater awareness of the scale of the problem and the
health and economic consequences that result from HAl.
In the UK, the issue of HAl has been the subject of a number of research
studies conducted over the past few years, including the research on which this
thesis is based.1-3
In 1992 the Department of Health commissioned the Public Health Laboratory
Service to conduct an audit of infection rates, and infection control polices and
practices in 19 hospitals in England and Wales, the results of which were
published in 1997.1 The audit drew attention to the problem of HAl, and
highlighted considerable variation in infection rates occurring in similar patients
treated in similar settings, and variations in infection control policies and
practices.
At the same time the Department of Health commissioned the Public Health
Laboratory Service and the London School of Hygiene and Tropical Medicine to
conduct a study of the socio-economic burden of HAl. The results of this work
were published in January 2000 and are reported in some detail in Chapter 4 of
this thesis. The research drew attention to the sUbstantial burden these
infections place on scarce health sector resources and on patients and their
carers.2
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This work was used a little later in 1998 by the National Audit Office in their
study of HAl. The study examined a number of issues including the scale of the
problem, the rise of antibiotic resistance, the level of resources allocated to
infection control within NHS Trusts in England, the resources available to
infection control teams, and the potential benefits of investment in infection
control practices. The results were published in February 2000.3 The results
were important in that they again served to highlight the very real problem of
infection in hospitals, and the apparent lack of resources available to infection
control teams to deal with the problem. The report was presented to the
Parliamentary Select Committee of Public Accounts and the subject of a
hearing in March 2000, following which a report was issued." This served to
further raise the profile of the problem of HAl, bringing it to the attention of the
government, policy makers, health care professionals and the general public. In
response the Department of Health has introduced a number of policy initiatives
aimed at strengthening infection prevention and control activities within the
NHS.'
1.2 Thescaleof the problem
Prevalence studies conducted in England and Wales in 19806 and again in
1993/947 found that at anyone time an estimated 9% of hospital in-patients had
an infection that they had acquired after admission. At the same time, it is likely
that many more patients discharged from hospital had an infection related to a
recent hospital admission. More recently the study of the socio-economic
burden of HAl estimated that at least 321,000 patients admitted to NHS
hospitals in England acquired one or more HAls in 1994/5.8 This estimate is
based on the incidence of HAl observed in the study and relates to the number
of infections occurring in adult non-day case patients admitted to the medical
and surgical specialties covered in the study at NHS hospitals in England (an
estimated 70% of adult non-day case admissions), and is further limited to
infections which present during the in-patient period. Thus the actual number of
patients acquiring one or more HAls is likely to be considerably higher.
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1.3 TheImpactof HAlon the Individual
The acquisition of an infection in hospital may have health and financial
consequences for affected patients. The impact on health status and recovery
will vary considerably from one patient to another depending on the type of
infection acquired, the underlying health status of the patient, the effectiveness
of treatment given and how these various factors interact. For example, in
some cases the impact may be limited to minor discomfort, but in other cases
the acquisition of an infection may prolong recovery, cause temporary or
permanent disability and may directly cause or substantially contribute to a
patient's death. An estimated 5000 deaths every year are thought to be directly
caused by an infection acquired in hospital, and HAls are thought to contribute
to a further 15,000 deaths.9
In terms of the economic consequences for the individual, acquiring an infection
in hospital may result in an increase in out of pocket expenditure on health
related items, and a reduction in income due to a delayed return to employment
or in some cases the failure to return to employment. Few studies have
estimated the magnitude of these costs. Some notable exceptions include a
study by Farbry et s/ (1982)10 that indicated surgical wound infections (SWls)
delayed return to work, and the study on which this thesis is based which
assessed the impact HAls had on both patients and their carers. 2
1.4 TheImpacton the healthsector
The acquisition of an infection in hospital may result in the additional use of
hospital and primary health care resources. Additional hospital costs may result
from an increased need for investigations and procedures, increased
dispensary demands, additional nursing and medical care and a prolonged in-
patient stay. Following discharge, patients who have acquired an infection in
hospital may require a greater number of hospital appointments, and/or
appointments with primary health profeSSionals, including general practitioners,
practice nurses and district nurses, than they would have required in the
absence of an infection.
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A number of studies have assessed the economic burden HAls place on the
health sector. These studies vary in scope. The majority concentrate on the
cost to the hospital sector resulting from increased in·patient care, and relatively
few look at costs to the health sector post~ischarge. The types of infections
included vary, some focussing on all types of HAl occurring in selected patient
grouts, while others focus on a specific type of infection. The methods used to
identify, measure and value resources used and attribute them to HAls also
vary, as do the estimates derived. However, despite variations in scope and the
methods employed all point to the substantial burden these infections place on
health sector resources. The socio.economic burden of HAl study estimated
that HAls cost the health sector in England at least £1 billion in 1994/5.2
1.5 Why patientsacquirean infection
Infection occurs as a result of complex interactions between potential
pathogens (bacteria, virus, fungus or protozoan) and the host, in this case the
patient. Within the hospital environment patients are at particular risk of
infections. Patients whose primary illness compromises their immune system,
such as AIDS and various forms of haematological malignancy, are particularly
susceptible, as are the young and the elderly. Treatment regimens, such as
chemotherapy, will also render a patient susceptible to infection and invasive
procedures including operative procedures, and the insertion of intravenous and
intra·arterial catheters, urinary catheters and endo.tracheal tubes offer direct
access for micro.organisms. In addition the patients normal flora is frequently
replaced with hospital flora that is often resistant to antibiotics and so may set
up a potential source of infection.
1.6 Thescopefor prevention
Whilst not all HAls are preventable the evidence indicates that a proportion of
infections can be prevented through improvements in Infection prevention and
control activities. The early results from the National Nosocomial Infection
Surveillance Scheme provided strong evidence that this is the case. Infection
rates occurring in patients who had Specific surgical procedures were found to
38
vary markedly from one hospital to another and the observed variation in rates
continued to be present after adjustment for case mix differences had been
made.5 These results suggest that the variation observed to some extent
reflected differences in clinical practice and serve to highlight the potential for a
reduction in infection rates.
Quantifying the level of infections that can be prevented is difficult: it is difficult
to quantify an event that does not occur. The most frequently quoted estimate,
taken from the results of a comprehensive study conducted in the US (the Study
of the Efficacy of Nosocomial Infection Control - SENIC), suggests that 30% of
HAls could be prevented.11 However, caution should be exercised before
applying this estimate to infections occurring in the UK. The estimate was
derived from a study conducted over 20 years ago in the US. Since that time
there have been many changes in the treatments and care options offered, and
the case mix of patients treated. As such there may be important differences in
the risk profile of patients treated today, compared to that of over 20 years ago.
Nevertheless the results demonstrated that there is scope for a reduction in
rates.
The results of a National Audit Office survey of NHS hospitals in England,
documented in their report 'The Management and Control of Hospital Acquired
Infections in Acute NHS Trusts in England' published in 2000, further highlight
the fact that there is scope for a reduction in infection rates.3 As part of their
survey, infection control teams (ICTs) were asked what proportion of infections
they believed could be prevented. The responses ranged from 5% to 40%.
The responses were subsequently weighted by the number of beds in the
responders' hospitals and a 'bed weighted' average of 15% derived. Whilst this
is somewhat less than the US estimate, it does serve to highlight the belief that
prevention is to some extent possible, whilst the exact proportion that is
preventable remains unknown.
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1.7 Thepotential benefitsof Improvedprevention
Quantifying the benefits of prevention is difficult. Difficulties are associated with
both identifying and valuing infections averted. It is difficult to measure the
benefits of an event that did not take place. However, estimates derived from
the results of the socio-economic study suggest that the benefits of prevention
are likely to be substantial.2 This point was highlighted recently in the NAO
report, which estimated that if a 15% reduction in rates could be achieved this
could lead to the release of health sector resources valued at £150 million per
annum.3 It should be stressed that this estimate reflects the value of resources,
which might be· released for alternative use. It does not represent potential
cash savings. However, given that the NHS is working above capacity in most
sectors HAls have an opportunity cost. The estimates represent the gross
benefits of prevention. Net benefits will depend on the cost of interventions
introduced to achieve such a reduction.
1.8 The rationale for this thesis and the anticipated contribution it
will make
At the time of undertaking this thesis relatively little was known about the cost of
HAls to the health sector in England. It was clear from the results of the 1980
National prevalence study that HAls affected a large number of patients every
year: 9.2% of patients at anyone time were found to be affected in 1980.6
However, data on the magnitude of the economic burden these infections
imposed on the health sector, and indeed on patients and carers were lacking.
Data from a number of international studies, and in particular the results of work
stemming from the SENIC study conducted in the US indicated that HAls were
likely to be plaCing a substantial burden on limited NHS resources and on
patients and carers. Estimates suggested that HAl cost the health sector in the
US at least $4 billion per annum in 1985.12 Whilst studies had been conducted
in the UK,13 14 these were either relatively small, or rather specific in nature
relating to particular patient groups, and were undertaken some years ago. A
more comprehensive estimate of the magnitude of the burden of HAl was
needed. The only national estimates available at the time were an estimate
derived by the Department of Health which, based on a number of broad
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assumptions, estimated that HAls cost the health sector £ 111 million per
annum,15and an estimate derived by Coello et 8/14 which indicated that HAls
occurring in surgical patients cost the health sector in England an estimated
£170 million in 1993.
It was against this background, and in the knowledge that a proportion of HAls
were preventable, that the Department of Health in October 1992 commissioned
a study of the socio-economic burden of HAl. This thesis is based on this
study. The socio-economic burden study aimed to provide a comprehensive
assessment of the costs resulting from HAls occurring in adult, non-day case
patients admitted to specialties that are common to most hospitals. This was to
include costs to the health sector as a result of additional in-patient care, costs
to the health sector arising post-discharge and costs to patients and carers. It
was antiCipated that the results would raise awareness of the magnitude of the
burden of HAls, and the potential gross savings that might result from improved
prevention and control. Through this process it was hoped that a greater
understanding of the economic burden resulting from these infections would be
gained, and that the information generated would assist in policy formation and
inform clinical practice in relation to infection prevention and control. Further
details about this study are presented in Chapter 4.
This thesis is closely linked with the socio-economic burden of HAl study. It
focuses on a sub-section of data relating to adult non-day case surgical
patients. The thesis assesses the incidence and economic impact that HAls
that present during the patient's hospital stay have on the hospital sector as a
result of additional in-patient care. It also explores possible risk factors for
these infections and considers how the information derived may be used to
demonstrate the potential benefits of investment in prevention and inform
prevention strategies.
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Surgical patients were selected as the population of interest as it was felt that it
would be interesting and beneficial to explore in greater detail the incidence and
impact of HAls occurring in this patient group. The underlying study assessed
the incidence and economic burden of HAls occurring in patients admitted to
selected medical and surgical specialties taken together, and also the incidence
and burden of infections occurring in patients admitted to each medical and
surgical specialty. No attempt was made to assess the incidence and economic
burden of HAls occurring in patients admitted to surgical specialties taken
together. A further reason for selecting surgical patients was an interest in
exploring risk factors for infections in this patient group.
As indicated above this thesis focuses on the incidence of HAls presenting
during the in-patient period and the economic impact that HAls had on the
hospital sector as a result of additional in-patient care. The decision to focus on
infections that presented during the in-patient period, and their impact on the
hospital sector was informed by the results and inherent limitations of the earlier
study.
Estimates of the incidence of infections presenting post-discharge, derived in
the earlier study. were based on the responses given to specific questions
within a detailed questionnaire sent to a proportion (approximately one third) of
patients one month post-discharge. The estimates derived indicated that a
proportion of patients experienced symptoms suggestive of a surgical wound,
urinary and/or respiratory tract infection. However, it was not possible to say
whether the symptoms reported represented actual infections. or whether the
infection, if present. was hospital acquired. Furthermore. since only a small
proportion of patients were followed up there was considerable uncertainty
surrounding some of the estimates derived and it was clear that there were
insufficient data available to allow for further analysiS limited to a subset of data
relating to surgical patients from which estimates could be derived with a
degree of certainty.
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Similarly, whilst the underlying study's estimates of the impact HAls had on
hospital costs as a result of additional in-patient care were based on data on the
hospital costs incurred by all study participants, estimates of the costs falling on
the primary health care sector, patients and carers were only derived for a
proportion of patients. The results of the analysis of the impact HAls had on
these other areas of costs clearly showed that HAls imposed a burden on the
primary sector, patients and carers. However, as with the estimates of the
incidence of HAl presenting post-discharge, there was considerable uncertainty
surrounding some of the estimates derived and it was again clear from the
results derived that there were insufficient data available to allow for further
analysis limited to surgical patients from which estimates could be derived with
a degree of certainty.
Similar reasons informed the decision not to examine the impact HAls occurring
in surgical patients had on health status. The underlying study's assessment of
the impact HAls had on health status was based on an analysis of responses
given to the SF-36, included as part of the questionnaire, administered to a
proportion of patients post-discharge. The results of this analysis indicated that
HAls had a negative impact on health status as measured by this instrument.
However, again there was uncertainty surrounding the estimates derived and it
was clear that there were insufficient data available to justify further analysis
limited to a subset of data relating to surgical patients from which robust
estimates could be derived.
The thesis aims to add to the findings of the socio-economic burden study by
providing a more detailed account of the incidence of HAls occurring in this
patient group than presented in the underlying study report and, through the use
of slightly different methodology, explore the economic burden these infections
place on the hospital sector in more detail. It is hoped that this piece of work
will further contribute to our understanding of the economic burden these
infections impose, how costs can be attributed to infection and possible risk
factors for infection. The thesis will subsequently show how information on the
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economic burden imposed by these infections might be used to demonstrate
the benefits of investment in infection prevention and control and how
information on costs and possible risk factors can be combined and used to
inform policy and practice.
1.9 Myrole in the socio-economicburdenstudy
In September 1993 I was appointed project leader for the socia-economic
burden of HAl study. As project leader I was responsible for the day to day
management of the project. developing and implementing the outline protocol.
and writing up and disseminating the results of the study. During the course of
the study my role included a wide range of activities summarised below.
1.9.1 Literaturereview
On appointment I conducted a review of the literature on the epidemiology and
economic burden of HAl. This review was updated at regular intervals
throughout the course of the study.
1.9.2 Establishinglinks with staff at thestudy hospital
At an early stage I established links with staff at the study hospital including the
chief executive, director of clinical practice, director of nursing practice, clinical
directors, business managers. senior nurse managers. nursing staff on each of
the study wards, consultants and their medical teams, laboratory staff. members
of the infection control team and infection control committee. general
practitioners. primary health care managers, district nurse patch managers and
staff from the medical records, medical coding, finance and information
technology departments. This involved writing to selected individuals, setting
up a meeting and subsequently meeting with staff to discuss the aims and
objectives of the study and the methods to be employed. The majority of these
meetings were on a one to one basis. However, when both appropriate and
poSSible, group meetings and seminars were held. This latter approach was
particularly useful when informing ward staff of the project.
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1.9.3 .Further development and Implementation of thestudy protocol
As project leader I was responsible for the further development and
implementation of the study protocol. This included the development of patient
and relative information sheets, consent forms, procedures for recruiting
patients into the study, and appropriate data collection methods. The latter
included the development of data collection sheets and patient questionnaires.
This was done in consultation with members of the steering and adviSOry
groups, other researchers and where appropriate members of the study hospital
staff. Procedures for recruitment and data collection were written up and
circulated to steering group and advisory group members for comment and
subsequent approval, together with patient and relative information sheets and
consent forms and all other data collection forms.
1.9.4 Selection and Implementation of an appropriate data entry
system
It was clear from the outset that the data requirements of this study were
considerable. As project leader I was responsible for investigating the various
data entry systems available and presenting the options to the steering
committee, together with recommendations as to which would be most
appropriate and why. A variety of systems were explored including paper
questionnaires, and subsequent data entry either by project staff or a data entry
company; the use of hand held computers; and the use of scanning software
developed by Formic Ltd. After a thorough investigation of a number of options,
the latter system was selected and purchased. I was subsequently responsible
for setting up the scanning data entry system. This involved creating
questionnaires and data collection surveys with the scanning software, setting
up each individual question within the questionnaire ready for scanning and
subsequently testing the scanning process. Testing involved checking that the
forms were being read correctly and that the process was reliable. This proved
to be a very time consuming process. There were a number of problems with
the early versions of the software that had to be corrected by the software
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manufacturer. This process led to delays in the development of the data
collection forms and used a considerable amount of my time.
1.9.5 Obtaining the approval of the relevant ethical committees prior
to the pilot study
As project leader I was responsible for submitting all relevant documentation to
the ethical committee at the study hospital for their consideration, and
subsequently responding to any queries that they had.
1.9.6 Conducting a pilot study and revising the methods In response
to the findings of the pilot study
As project leader I was responsible for piloting the proposed methods. A small
pilot study was conducted. This identified a number of problems with the draft
data collection sheets and the proposed methods. A report was drafted and
presented to the steering committee together with recommendations for
changes and revisions to the data collection methods and data collection tools.
Changes were agreed and subsequently made to the relevant forms and
procedures. A report summarising the outcome of the pilot study, was
subsequently presented to the Advisory Committee.
1.9.7 Re-submitting the study protocol and data collection forms for
ethical approval prior to the main study
Following the pilot study the protocol and data collection forms had to be re-
submitted to the study hospital ethical review committee for their consideration
prior to the main study. As project leader I was responsible for this process and
for responding to any subsequent queries that they had.
1.9.8 Recruiting and training six research assistants
As project leader I was responsible for the recruitment and training of six
research assistants. Five research assistants were appointed in January 1994
and a further research assistant was appointed in June 1994 when more
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funding became available from the Department of Health. All six research
assistants were qualified nurses.
It was my responsibility to ensure that the research assistants received
adequate training prior to the main data collection period, and further training as
and when required. This was achieved through a training programme
developed and administered prior to the main data collection period, and
additional training given as necessary. A copy of the training programme can
be found in Appendix 1. In addition, a seminar course was developed for the
research assistants (see Appendix 1). Seminars were held on alternate weeks
throughout their period of employment and covered topics such as the
economics of HAl. the epidemiology of HAl. study design, basic statistical
methods and health policy. Lecturers included myself, other members of the
project team and steering committee and external speakers.
1.9.9 Managing the main data collection and entry period
As project leader I was responsible for managing the data collection and data
entry process. A variety of techniques were adopted to assist in this process.
As discussed above protocols setting out the data collection and entry
processes were developed and agreed by the steering committee. The
research assistants received training in all aspects of the study. A document
outlining the standards to be applied during the data collection period was
drafted and approved by the steering committee (see Appendix 2). Each
research assistant received a copy of this document which they were
subsequently asked to read, discuss and sign. At the outset the research
assistants received close supervision. As the project progressed input by
myself was reduced. However, the research assistants were free to contact me
at any time should they have a query, and I ensured that I met with the research
assistants at least once a week at a team meeting.
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1.9.10 Appointing a secretary
At the outset the funding available did not allow for the appointment of
secretarial support to assist me as project leader, and the other members of the
project team. As such, with the exception of some help with a couple of mail
merges, all secretarial and administrative work was undertaken by myself. It
was clear that some support was needed, and a document outlining the need
for additional funds to cover the cost of secretarial support was submitted to the
Department of Health. The Department agreed to make available additional
funding for administrative support and a secretary was appointed in April 1994.
Further support was subsequently employed on an ad hoc basis.
1.9.11 Liaising closely with the research economist and assisting in
the developmentof unit costs for resources used
The project team included a research economist who was primarily responsible
for costing resources used by infected and uninfected patients. As project
leader, I was a member of the interview panel for the appointment of the
research economist. I subsequently worked closely with the economist on all
aspects of his work, and assisted in the development and implementation of
methods used to cost various resources. For example, I worked closely with
the economist to develop unit costs for drugs administered, and procedures
performed and I was solely responsible for developing costs for nursing care
administered to patients based on the amount of care patients received during
the course of their hospital stay.
1.9.12 Liaising closely with theproject statisticians
Whilst data analysis was primarily the responsibility of two statisticians, I worked
closely with both throughout the study. My role involved assisting in the
development of an appropriate strategy for data cleaning, actively engaging in
the data cleaning process, and assisting in the development and
implementation of an appropriate approach to the analysis of data. As the
analysis was undertaken I reviewed and commented on all results, made
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suggestions as to how the analysis could be modified, and contributed to the in-
depth discussion of the results that followed.
1.9.13 Ensuring that the work Is completedwithin an appropriate time
frame
At an early stage it was apparent that, given the scope of the project, it would
not be feasible to complete the study within the two years funding available. As
such I was responsible for drafting a report requesting an extension to the time
frame and additional funding from the Department of Health. The report was
well received and an extended time frame together with additional funding was
successfully obtained from the Department of Health.
1.9.14 Writing the final report and submitting It to the Departmentof
Health
The final report consisted of four documents: parts I and II, separate
appendices, and two stand alone executive summaries that varied in length.2
Part I included background information, details of the methods used, the results
of the study, a discussion of the results, conclusions drawn and
recommendations made. Part II included detailed information about the
methods used to derive unit costs for resources used. As project leader I was
responsible for drafting Part I and the two executive summaries. The research
economist primarily drafted part II and the appendices were the responsibility of
both the research economist and myself. A copy of the executive summary can
be found at the back of this thesis.
Over the course of the project chapters were drafted and circulated to the
project Steering Committee for comment and subsequent approval. Drafts were
also submitted to the Advisory Committee for comment, and later the
Department of Health. A final draft which had been approved by the project
Steering Committee was submitted to the Department of Health in August 1997,
and distributed for internal and external review. A full set of reviewers
comments was received in November 1997. Informal discussion followed and
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a formal response submitted to the Department in February 1998 following
which there was a further period of discussion and debate. Further editing work
and additional analysis was then undertaken. Amendments to the original text,
together with the results of the additional analysis requested were submitted to
the Department of Health in September 1998 and the report was released for
publication in September 1999 and subsequently published in January 2000.
1.9.15 Preparation of the report for publication
The decision was taken that the full report should be published and made
available to a wide audience. As such it was agreed that the input of an editor
and publication team should be sought. I was subsequently responsible for
working with an editor and the Public Health Laboratory production team to
produce an edited version of the report.
1.9.16 Liaising with the Department of Health
Throughout the duration of the study I was responsible for liaising with the
Department of Health and keeping them informed of any new developments
and overall progress. This was done through telephone discussions, letters,
reports and presentations made at the advisory committee meetings held
regularly over the course of the project.
Ualslng with the National Audit Office In relation to their work
on HAl
Whilst the cost study was in progress the National Audit Office embarked on a
study of HAl. As part of their initial work they approached myself, Jenny
Roberts and Nick Graves to discuss the aims and objectives of the cost study.
In several subsequent meetings we discussed the questionnaire they were
planning to use, advised on a number of issues, updated the NAO about the
progress with our study and endeavoured to ensure that any information
relating to the cost study was presented appropriately in the NAO report - 'The
1.9.17
management of HAl in acute NHS Trusts in England.'3
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1.9.18 Disseminationof the findings
The final report was launched on February 17th 2000. I was actively involved in
this process, working closely with the press officers from the three institutions
involved in the research and the Department of Health. I assisted in drafting the
press releases and the organisation of the press briefing. As mentioned above
the report received considerable media attention, including wide coverage in all
the major newspapers. Following the launch I gave a number of interviews for
both national and local television and radio stations. The report was
subsequently sent to all consultant microbiologists, infection control teams and
public health physicians. I was responsible for drafting the covering letter and
overseeing this process.
The main results were also reported in a paper published in the Journal of
Hospital Infection.8 I was responsible for drafting this paper, Circulating it to the
authors for comment and subsequently revising it as necessary and submitting
it to the relevant journals.
During the course of the study and since the report's publication I have made a
number of presentations to conferences and seminars. Appendix 3 provides
details of presentations made over the course of the study.
1.10 My role in this thesis
The preceding section has outlined the key activities undertaken by myself as
project leader for the socio-economic burden of HAl study. All the activities
listed are directly relevant to this thesis. Additional activities undertaken for the
purposes of this thesis include, a more detailed literature review, further
cleaning of the data set, further data analysis and the development of an
economic model to asses the costs and benefits of investment in prevention.
These activities were all undertaken by myself.
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1.11 Aimsandobjectivesof this thesis
1.11.1 Aim
To assess the incidence of, and independent risk factors for HAls occurring in
surgical patients admitted to a district general hospital and the impact these
infections have on the secondary health care sector, and to examine how the
information obtained may be used to assess the potential benefits of investment
in the prevention and control of HAls.
1.11.2 Objectives
The specific objectives were to:
1. Review the literature on the epidemiology of HAl, risk factors for HAl, and
the economic evaluation of HAl.
2. Determine the incidence of HAls occurring in adult, non-day case
patients admitted to selected surgical specialties of a district general
hospital.
3. Explore how the incidence of HAl varies with selected patient
characteristics and identify possible risk factors.
4. Determine the impact HAls occurring in this patient group have on
secondary health care sector resource use and costs.
5. Examine how information on the economic burden of HAls may be used
to assess the potential benefits of investment in the prevention and
control of HAls.
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1.12 Thestructureof thethesis
The thesis begins with a review of the literature. The literature on the
epidemiology of HAl is reviewed in Chapter 2. The chapter covers four broad
areas: the frequency and distribution of HAl; the mortality risk associated with
acquiring an infection in hospital and the number of patients estimated to die
from HAls per year; the aetiology of HAl and specific risk factors for infection,
and the problem of antibiotic resistance.
The literature on the economic evaluation of HAl is reviewed and discussed in
Chapter 3. The chapter includes a discussion of the methodological issues
associated with the economic evaluation of HAl, followed by a review of studies
that have estimated the burden of HAl and those studies that have assessed
the benefits of prevention.
An overview of the study that examined the socio-economic burden of HAlon
which this thesis is based is subsequently presented in Chapter 4, and the
methods which are specifically related to this thesis are presented in Chapter 5.
The results of this work are presented in Chapters 6, 7, 8 and 9. Chapter 6
provides an overview of the sample characteristics. Chapter 7 presents the
results of the analysis that examined the incidence of HAl and specific risk
factors for infection. Chapter 8 presents the results of the economic analysiS
which examined the impact of HAlon hospital costs and Chapter 9 the results
of the analysis that assessed the impact of HAlon length of hospital stay.
How the results of this work might be used to inform clinical practice, is then
explored in Chapter 10. Estimates of the gross benefits of prevention at the
level of the study hospital and at the national level are presented, together with
a framework for assessing the potential net benefits of investment in infection
prevention and control activities. A worked example of a simple model of the
costs and potential benefits of investment in infection prevention and control
activities is presented.
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Finally, the results of this study, methodological considerations and the
implications for infection prevention and control policy and clinical practice are
discussed in Chapter 11 and conclusions drawn.
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CHAPTER2
THE EPIDEMIOLOGY OF HOSPITAL ACQUIRED INFECTION
2.1 Introduction
In this chapter the literature relating to the epidemiology of hospital-acquired
infection (HAl) is reviewed. An overview of the epidemiology of HAl in terms of
its frequency and distribution. the mortality risk associated with acquiring an
infection. and the number of patients estimated to die from these infections
every year is provided. The aetiology of HAl including a discussion of specific
risk factors for HAl and the problem of antibiotic resistance are also examined.
The focus of this chapter will be the problem of HAls occurring in surgical
patients. However. in order to put the problem in context. information relating to
the overall problem of HAl will also be presented where appropriate.
The literature reviewed was identified through a series of consecutive searches.
carried out during the period 1993 - March 2003. using the computerised
bibliographic databases Medline. and PubMed. These two bibliographic
databases were selected as they cover the major journals of relevance to this
thesis. These searches were supplemented by reference follow up, hand
searching of selected journals. and consultation with experts in the field. The
search was limited to papers published in the English language during the
period 1975 - March 2003. and further limited to studies conducted in
developed European countries. the United States of America. Canada and
Australia. This time period was selected. as in the mid 1970s the US study of
the Efficacy of Nosocomial Infection Control (SENIC), was published
representing a time of new understanding and interest in HAls. As such it was
considered appropriate to review literature published from the mid-1970s. The
search strategy involved the use of selected key words (thesaurus terms) and
combining these with a number of "free text" words. The key words used were:
hospital acquired infection; nosocomial infections; healthcare associated
infections; and hospital associated infections. These were combined with the
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following "free text" words: prevalence; incidence; risk factors; risk indices;
antibiotic resistance; antimicrobial resistance; mortality; morbidity and deaths.
The abstract of each paper was subsequently read and a decision made as to
whether the paper was relevant to this review. Those papers that were
concemed with HAls occurring in adult non-day case patients eared for in
specialties common to most hospitals (medicine, surgery, urology, eare of the
elderly, orthopaedics, gynaecology and obstetrics) were considered to be
relevant, as were papers that included both day ease and in-patients and
papers that included both patients admitted to the specialties listed above as
well as those admitted elsewhere. Papers that were limited to day ease
patients, children, or patients admitted to specialties not included in this study,
were excluded from the review.
References cited in papers which had not been identified through the
computerised search were subsequently followed up. Hand searches of the
following journals were also carried out: Journal of Hospital Infection; Infection
Control; American Journal of Infection Control, Epidemiology and Infection
Control; Current Issues in Infection Control; and the British Medical Journal.
Experts in the field including microbiologists and infection control specialists
from the Central Public Health Laboratory Service, at Colindale in North
London, and selected NHS Trusts were also consulted to identify grey literature
such as project reports and policy documents of relevance to this review.
Some papers identified as part of the review of studies that assessed the
economic burden of HAl are also included in this section, since they not only
reported data on the cost of infection but also the incidence of HAls and the
number of deaths occurring in infected patients. The results of the socio-
economic burden of HAl study, on which this thesis is based, are reported
separately in Chapter 4.
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2.2 The frequencyand distribution of HAl
Data on the frequency and distribution of HAl are available from a variety of
sources. A review of the literature indicates that a number of studies have
assessed the frequency of HAl either in terms of its prevalence or incidence
(see sections 2.3 and 2.4). Many hospitals also routinely collect data on the
frequency of selected HAls, and many participate in national surveillance
schemes, the results of which, in some cases, have been published. A recent
National Audit Office survey of infection control indicated that in 1998 "'94% of
infection control teams surveyed carried out some form of surveillance.3
Epidemiological, clinical audit and hospital surveillance studies provide useful
insights into the extent of the problem of HAl in terms of the frequency of the
problem and, in many cases, also provide data on how infection rates vary with
specialty, age and other patient characteristics. However, valid comparisons of
the results of studies conducted in different settings and over time are difficult.
The methods used to determine the incidence or prevalence of HAl employed in
the different studies vary in important respects, which in tum impact on the
results obtained. For example, studies vary in terms of the case definitions and
case ascertainment methods used, the formula used to calculate rates, the
types of infections included and the case mix studied. These differences are
discussed in detail in sections 2.3 and 2.4, in the context of studies that have
assessed the prevalence of HAl (section 2.3) and the incidence of HAl
(section 2.4).
2.3 Prevalenceof HAl
Prevalence figures are a measure of the proportion of individuals in a population
with a specific disease at a single point in time (point prevalence rate) or over a
period of time (period prevalence rate) (figure 2.1). Point prevalence figures are
more common and have generally been used in studies of the prevalence of
HAl. They are usually expressed as a percentage.
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Figure 2.1 Prevalence rate fonnulae
1. Point PR = no. persons with a disease at particular point in time
total population
2. Period PR = total no. persons with disease at some time during the specified period
total population at mid-point of interval
PR = prevalence rate
Multicentre prevalence studies have been conducted in a number of countries.
Table 2.1 provides an overview of prevalence studies that have been conducted
in developed European countries, the US and Australia since 1975. These
studies provide important information on both the overall problem of HAls and
the prevalence of infection among specific patient groups.
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2.3.1 Theoverallprevalenceof HAl
Prevalence studies conducted during the late 1970s estimated the prevalence
of HAls to be between 10-17%. In 1975 the prevalence of HAls occurring in
34,246 patients admitted to five Swedish hospitals was found to be 17%.16 In
1978 10.4% of 1363 patients admitted to 25 Danish hospitals had one or more
HAl and in 1979 12.1% of 1,557 admitted to the same hospitals had one or
more HAls at the time of survey.17
Prevalence surveys conducted between 1980 and the mid 1990s generally
found the prevalence of HAl to be slightly lower at around 9%.6718-21The most
recent study conducted in the UK and Republic of Ireland found 9.0% of
patients surveyed in 1993 had one or more HAls at the time of survey.7 A few
studies conducted during this time period found a lower prevalence. In 1984
Sramova et 8/ (1988)22 found the prevalence of HAls in 12,260 patients
admitted to 23 hospitals in Czechoslovakia in 1984 to be 6.1%, and in 1992 a
study by Sartor et 8/ found that 7.1% of 1389 patients admitted to eight
hospitals in France had one or more HAls, somewhat lower than an earlier
estimate for the same year of 8.6%.20
The results of prevalence studies conducted since 1995 vary, ranging from a
low prevalence of infection rate of just 1.7% observed in a study by Pavia et 8/
(2000)37involving 888 patients admitted to six hospitals in Italy (Cantazano) to
13% observed by Pittet et 8/ (1999) in a Swiss period prevalence study
conducted in 1996.33
Other studies conducted during this time period found the prevalence of
infections to be between 5.9% and 9.3%.213135363839 In 1995 a Greek study
observed a rate of 5.5% increaSing to 5.9% in 1996.31 In 1996 a French
prevalence survey involving 236,334 patients found the prevalence of infection
to be 7.6%: 6.7% of patients studied had one or more infections,35 and a
Spanish survey found the prevalence of infections to be 8.4%: 7.2% of the
51,961 patients studied had one or more HAls.21 In 1997 a Norwegian
prevalence survey found the prevalence of infection to 6.1%.36and in 1999 a
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prevalence study conducted in Greece found the prevalence of HAl to be
9.3%.38
The higher prevalence rate observed in the study by Pittet et al (1999)33can in
part be explained by a number of factors: (I) the study was a period prevalence
study, not a point prevalence study; (2) it was conducted in four teaching
hospitals where you would expect higher rates than in other types of hospitals;
(3) the study was conducted shortly after a national holiday weekend resulting
in a low occupancy rate in the hospitals surveyed and a greater likelihood that
the population studied were a relatively high risk population compared to the
'normal' hospital population.
If the above results are taken at face value they would appear to suggest that
the prevalence of HAl has decreased overtime. However, as indicated in
section 2.2 valid comparisons between studies and overtime are difficult. The
methods employed to detect HAls vary, the case definitions used differ, some
studies have limited the types of infections included and the types of patients
surveyed varies with study. These and other factors will inevitably impact on
the prevalence rates observed and are discussed below.
2.3. 1. 1 Case definitions
The majority of studies have used the Centre for Disease Control (CDC)
definitions of HAl or a modified version. Depending on the timing of the study
either the 1972 CDC23 or the 1988 CDC criteria28 with or without the 1992
modified CDC definition of surgical site infections have been used.29 Some
studies whilst using these definitions have elected to exclude bacteriuria as a
diagnosis for a hospital acquired UTI.21303133 Others have used a variant of the
CDC definitions, adapting them to suit the patient population being studied. For
example, a Norwegian study made some slight modifications to the 1998 CDC
criteria. Details of the changes made were not presented in the paper.36 Other
studies have used the WHO definitions40and a few, such as the UK prevalence
study of 1980 and 1996, have developed their own working definitions of
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infections.6 7 However, the first UK prevalence study definitions were based on
the CDC criteria and the second UK prevalence study definitions were based on
the 1980 working definitions and CDC criteria. The two prevalence studies
conducted in France in May and November 1992 used two different sets of
definitions. The survey conducted in May used the 1988 CDC criteria, and the
survey conducted in November used the definitions of the Conseil Superieur
O'Hygiene Publique de France for the diagnosis of infections of the urinary tract,
chest (pneumonia), surgical wounds and bloodstream infections, which are
similar to the CDC definitions.2O
Whilst the commonly used definitions are very similar they do differ in a number
of important respects that may have an impact on the prevalence rate observed.
For example, the criteria for urinary tract infections may vary with resped to
whether microbiology evidence is required. Consequently, it is possible that in
hospitals where access to microbiology services is limited, or where the culture
is such that few specimens are taken, the infection rate will be underestimated.
Gastmeier et 81 (1998)32 found infections rates were Significantly higher in
hospitals with an on-site laboratory service, than in those who did not have such
facilities. However, it is not clear whether the apparent lower infection rate
observed in hospitals without on-site access to microbiology facilities reflected
an underestimate of the 'true' rate or simply reflected a different case-mix,
which was at relatively low risk of infection, at hospitals where access to on-site
facilities were not deemed necessary.
2.3 1.2 Identification methods
The prevalence studies listed in Table 2.1 also vary in the methods used to
detect HAls. The approach generally adopted involved the following. All
relevant data sources including treatment charts, case notes and microbiology
records were consulted to identify signs and symptoms of infection. If the
evidence obtained met the criteria detailed in the definitions used, an infection
was said to be present. The majority of studies involved hospital personnel in
this process. However, a few utilised external assessors.41 The degree of
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training these staff received varies amongst the studies ranging from just a brief
training session,28 to a relatively substantial training programme.33 41 The
validity of the results obtained depend on the ability of the staff to comply with
the protocol adopted, and assuming compliance, the sensitivity and specificity
of the selected approach. There is some evidence that greater accuracy in
diagnosing HAl is achieved when better qualified staff are involved and when
there is a more substantial training programme.42
Inevitably in some cases there will be a degree of uncertainty as to whether an
HAl is present. To overcome this, some studies instructed the assessor to
indicate the degree of certainty associated with each diagnosis. For example,
in the UK prevalence study, researchers were instructed to classify infections as
'certain', 'probable' or 'possible'. In contrast a German study only recorded
'certain' infections.42 This contributed to the considerably lower overall rate of
3.5% observed in the German prevalence study. When Gastmeier et 81
(1998}42 reworked the UK estimates only including 'certain' infections the
prevalence fell from 9.0% to 4.2%. Whilst this is still higher than the German
estimate, it is a considerably closer estimate. Further analysis indicated that if
the German estimates were limited to infections occurring in hospitals with a
minimum of 600 beds, in line with the types of hospitals included in the UK
study, the estimated prevalence increased from 3.5% to 4.4% in line with the
UK modified estimate (i.e. limited to 'certain' and excluding 'probable' or
'poSSible'infections) of 4.2%.42
2.3.1.3 Sites of infections included
The majority of prevalence studies aimed to include all types of HAls. However,
a few limited the infections included to the commoner infections. For example a
Norwegian prevalence study limited the infections included to the four most
frequent infections: urinary tract, surgical wound, lower respiratory tract and
bloodstream infections.36 Limiting the types of HAls included will inevitably
have an impact on the overall prevalence rate, with the result being an
underestimate of the overall scale of the problem. Studies also vary depending
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upon whether they include all HAls present on the day of survey35 or limit
inclusion to those acquired during the current admission and exclude those
acquired during a previous admission.
2.3. 1.4 Rates reported
As indicated in Table 2.1 some studies present prevalence rates based on the
number of infections per 100 patients discharged,6 161819212230313335-40others
the number of infected patients per 100 patients surveyed7 1719-21242532343538 40
with some presenting both data on the prevalence of HAl (all infections) and the
prevalence of infected patients who may have more than one infection.19213540
38 Studies vary with respect to the criteria used to categorise patients with more
than one infection into a specific infection group based on the type of infections
identified. Whilst Jepsen et al (1980) classified patients according to the
primary infection as identified by the investigator,17other papers did not provide
details about how infections at more than one site were managed.
2.3. 1.5 Case mix included
The risk of acquiring an HAl varies considerably with patient population
depending on both the intrinsic and extrinsic risk profile (see section 2.8). This
risk profile will inevitably vary with case mix surveyed, and this in tum will
impact on the overall rates observed. The prevalence of HAl in patients at high
risk of a HAl is likely to be considerably higher than in low risk patients. This is
clearly illustrated in the sub-group analysis of many of the prevalence studies.
For example, the prevalence of HAl in patients admitted to 157 hospitals in the
UK and the Republic of Ireland ranged from a low of 0% for dental patients, to a
high of 34.2% in patients within the intensive care unit.7 Other multi-centre
studies have also found the prevalence of HAl to vary considerably with
specialty group. Consistently these studies have found the prevalence of HAl to
be highest in intensive care patients1920 223132 343740and in most cases higher
in surgical than medical patients.17 19223132 343740 Furthermore, within selected
specialties the prevalence will vary depending on the risk profile of the patients
studied. For example, the very low prevalence rate observed in the recent
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Italian survey by Pavia et a/ (2000),37 may in part be due to there being a higher
proportion of low risk patients in this study compared to other studies. As the
authors acknowledge, an earlier study had shown that many patients with
complicated conditions migrate to Northern regions or other European countries
for treatment.43 It is likely that the risk of HAl and consequently the infection
rate is higher in these migrating patients.
Prevalence studies vary with respect to the patient groups included. Some
studies, for example have attempted to survey all patients 6 7 16-18 20-22 24, 27 30 31
34-36 40 whereas others limited their survey to patients admitted to selected
specialties.25 42 A number of studies have focussed on the prevalence of HAl
amongst patients treated on intensive care unit44 and a Belgium study was
limited to patients treated in surgical and intensive care units.25 Where all
specialties are included, given that the prevalence of HAl varies considerably
with specialty inevitably the proportion of patients within the various specialties
will impact on the overall rate observed, again making cross survey
comparisons difficult.
Prevalence studies also vary with respect to the types of hospital included.
Some studies include all types of hospitals, whereas others are limited to the
larger hospitals. For example, the first UK prevalence study was limited to
patients treated in hospitals with a minimum of 500 acute beds.6 Limiting the
survey to larger hospitals may result in a higher national prevalence rate than if
all hospitals were included as larger hospitals tend to treat populations at higher
risk. Participating hospitals may be selected on a representative basis or in
other cases hospitals may be asked to volunteer to partiCipate in the study.7
The latter may introduce selection bias. The prevalence rate also appears to
vary with type of hospital, the prevalence being higher in teaching hospitals than
non-teaching hospitals. Jepsen et a/ (1980)17 in a Danish prevalence study
observed a prevalence rate of 13.2% in general surgical patients treated in
post-graduate teaching hospitals compared to an 4.5% in general surgical
patients treated in non-post-graduate teaching hospitals.
The prevalence rate has also been found to vary with care setting (acute, sub-
acute or chronic) in part reflecting the differing risk profiles of the patients within
these different care settings. A period prevalence study by Sax et s/ (2001},45
conducted in a hospital in Geneva in May 1998, found that whilst the overall
period prevalence was 11.3% within acute settings it was 8.4%, sub-acute
11.4% and chronic settings 16.4%. The odds of acquiring an infection were
greater in sub-acute and chronic care settings when compared to acute settings
even after adjustment for case mix factors (odds ratios 2.59 and 2.34
respectively).
2.3.2 Prevalence of specific types of HAl
The prevalence of HAl varies considerably with site of infection. Prevalence
studies have generally found that infections of the urinary tract (UTI) are the
most common, with surgical wound infections (SWls) and lower respiratory tract
infections (LRTls) consistently forming the other most prevalent sltes.? 31 32 17 19
UTls accounted for 23.2% of the infections identified in the UK and Republic of
Ireland Prevalence Survey of 1993/4, SWls 11.7%, and LRTls 22.9%.7 An
exception is a Swiss prevalence study that found SWls to be the most frequent
type of infection (30%) followed by UTls (22%), and LRTls (15%).33 The
authors argue that this in part could reflect the fact that their study excluded
bacteriuria as a criterion for hospital acquired UTI. It should also be noted that
the study was limited to medical, surgical and intensive care patients, which
inevitably is likely to have had an impact on the types and frequency of specific
types of infections observed. The Greek prevalence study also found a differing
pattem.38 The study involving 3,925 patients admitted to 14 hospitals conducted
in1999 found LRTls to be the most frequent type of infection: LRTls accounted
for 30% of infections identified; UTls 22.7%; bloodstream infections (BSls)
15.8% and SWls 14.8%. The authors suggest that this might reflect the high
number of patients in intensive care units on the day of study (6.7%), whilst also
noting that the UK prevalence study conducted in 19907 also identified an
increase in the prevalence of LRTls.
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The need to take into account differences in methodology and the case mix of
the patients studied, may be further illustrated by reference to the two large
multicentre studies conducted in the UK in 19806 and 1993/4.7 The prevalence
of HAl was found to be similar for the two time periods: 9.2% and 9.0%
respectively. It cannot, however, be concluded from these two studies that the
prevalence of HAl has remained stable overtime. The definitions of infection
differed between the two studies, as did the methods used to detect HAl, and
this may have had an impact on the prevalence rates observed. However,
perhaps more importantly despite the two studies involving patients from similar
specialties, important case mix differences were present in the two groups. For
example, whereas in 198037.7% of males and 40.8% of females were 65 years
or over, in 1993 these figures had risen to 48.8% and 50.7% respectively. The
NHS was thus treating a significantly older population than previously had been
the case, and consequently a population at greater risk of acquiring an infection
in hospital. Thus whilst the results may at first appear to suggest that infection
rates have remained stable over time, they may in fact reflect an improvement
in quality of care, given the higher risk population. However, countering this is
the change in discharge patterns that occurred over the intervening years. In
1993/4, patients were being discharged home at an earlier point in their
recovery than was the case in 1980. It might be expected that this would have
resulted in either an absolute reduction in the prevalence of HAl, and/or a
reduction in the prevalence of HAl amongst in-patients and an increase in the
prevalence of HAl in the community.
Given the above it is clear that if valid comparisons are to be made between
prevalence studies, allowances must be made for differences in the intrinsic and
extrinsic risks profile of the populations involved and for differences in the
methods used to assess the prevalence of infection. A paper by Gastmeier et
a/ (1998)42compares the methods used in different prevalence studies, in terms
of the definitions used, how hospitals were selected, training of investigators,
the proportion of infections accompanied by a positive laboratory result and the
availability of data for diagnosing infection (e.g. are laboratory facilities available
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and what is the policy on specimen collection), and the date of study. The
paper concludes that due to the many methodological differences comparisons
of rates between countries should be avoided. However, even in the absence
of such adjustment the results of multi-centre prevalence studies clearly
demonstrate that HAls affect a substantial number of patients.
2.3.3 The prevalence of HAl In patients admitted to surgical
specialties
As indicated above prevalence studies frequently provide information on the
prevalence of HAl in patients admitted to specific specialties. The results of
these studies clearly indicate that the prevalence varies with specialty and with
study. However, for all the reasons indicated above (sections 2.3.1.1 -2.3.1.5)
valid cross study comparisons are difficult. Furthermore, the specialty
groupings adopted vary. Whilst a number of studies provide data on the
prevalence rate amongst surgical patients, in some cases it would appear that
this includes infections occurring in both general surgical patients and patients
admitted to sub-surgical specialties such as gynaecology, urology and
orthopaedics, whereas in other cases the HAl rates presented are limited to
general surgical patients, with rates for the other sub-surgical specialties
presented separately. For example, Emmerson et 81 (1996),7 in a paper that
presented the main results of the UK prevalence study of 1993/4, reported
prevalence rates for nine different surgical specialties, whereas a Greek
prevalence conducted in 199931 and an earlier Spanish survey conducted in
199021 have sub-divided their sample into just two surgical categories: surgical
and obstetric and gynaecology specialties combined. Varying specialty
groupings together with the factors mentioned in sections 2.3.1.1 - 2.3.1.5
accounts at least in part for the wide variation in prevalence rates observed.
For example, the reported prevalence of HAls amongst surgical patients ranges
from a low of just 1.2% observed in a study by Pavia et s/ (2000)37 to the
relatively high level of 13.9% observed in a study by Jepsen et s/ (1980);17 the
reported HAl prevalence rates for obstetric and gynaecology patients range
from no infections observed in a study by Gikas et si (1999)31 to 11.1% in a
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study by Pavia et s/ (2000);37 and the reported prevalence of HAl in urology
patients range from a low of 7% in a study by Scheel et sJ36 to 18.6% observed
amongst patients admitted to Danish teaching hospital in 1979.17
Some papers present data on infections in surgical patients based on the type
of surgery conducted (clean or dirty). For example Sartor et 8/ (1980) provide
rates for clean surgery and other surgery.20 Others have focussed on the
prevalence of SWI according to the type of wound as defined by the wound
classification system: clean, clean/contaminated, contaminated or dirty.19 31
These studies have all found the prevalence to be highest in patients with dirty
wounds. However, there is no overall clear trend for infection rates occurring in
the other wound categories. For example, a Spanish19 prevalence study found
that the prevalence of SWI increased with increasing contamination of the
wound. However, a Greek prevalence study did not observe this trend and
found that prevalence amongst the other groupings differed overtime.31
2.3.4 Frequency of specific types of Infections occurring In patients
admitted to surgical specialties
A number of prevalence studies provide data on the frequency of specific
infections within selected specialties.7 17 2032 The pattern observed varies with
the study. The most recent UK prevalence study indicated that amongst
general surgical patients LRTls were the most frequent type of infection: 2.6%
acquired a LRTI; 2.4% a SWI; 1.9% a UTI and 0.8% a skin infection. Amongst
gynaecology patients a different pattern emerged with UTls being the most
frequent type of infection: 5.1% had a UTI, 2.4% a SWI, 1.0% a LRTI and 0.3%
a skin infection. UTls were also the most frequent type of infection amongst
orthopaedic and trauma patients and urology patients. In orthopaedic and
trauma patients 3.7% had a UTI, 2.8% a SWI, 2.0% a LRTI and 1.4% a skin
infection. In urology and uro-surgical patients 6.1% had a UTI, 1.2% a LRTI,
0.8% a SWI and 0.5% a skin infection.
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2.4 Incidence of HAl
Incidence measures quantify the number of new cases of a disease that
develop in a population of individuals at risk over a specified period of time.
There are two specific types of incidence: cumulative incidence and incidence
density or force of morbidity.
Cumulative incidence is the proportion of people who develop a disease over a
specified period of time (Figure 2.2):
Figure 2.2:Cumulative incidence fonnula
Cl = number of new cases of a disease during a given period of time
total population at risk
Cl = cumulative incidence
Cumulative incidence therefore provides an estimate of the probability, or risk,
that an individual will develop a disease during a specified period of time.
Incidence density, also referred to as the 'incidence rate' or the 'force of
morbidity', measures the number of new cases of a disease during the period of
survey and expresses this figure as a proportion of the time each individual
remained at risk (Figure 2.3).
Figure 2.3: Incidence density fonnula
10 = number of new cases of a disease during a given period of time
total periOd - time at risk
ID = Incidence density
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The incidence density of HAl is therefore a measure of the number of new
cases of HAl occurring during the period of survey, expressed as a proportion of
the time each patient remained in hospital free from infection during the same
time period. That is the number of days from time of admission to either time of
discharge in the absence of a HAl, or where an HAl is present, the day of onset
of the HAl.
The incidence density .can be interpreted as the risk of developing a disease per
unit of time exposed, and as such it is a more precise measure of the impact of
exposure in a population. In addition, determining the incidence density of HAl,
as opposed to cumulative incidence, overcomes some of the confounding
effects of length of stay. Hospital length of stay will vary, both within and
between hospitals, depending on factors relating to case-mix and discharge
policies, and this will inevitably have an impact on the cumulative incidence of
HAl. If the mean length of stay is relatively short, the number of discharged
patients will be relatively high, and as a result the cumulative incidence may
appear low, whereas in situations where the mean length of stay is relatively
long the opposite may occur.46
2. 4.1 Estimates of the Incidence of HAl
Studies of the incidence of HAl have tended to focus on specific infections, or
infections occurring in specific patient groups, rather than consider the
incidence of all types of HAl occurring in a broad case-mix of patients.
However, two studies conducted in England do provide important data on the .
incidence of HAl occurring in a broad case mix of patients.
In 1992, a study involving 3,326 adult patients admitted to the surgical, medical,
gynaecology, and orthopaedic speCialties of a district general hospital in
England found that 7.2% acquired one or more infections that presented during
the in-patient stay.47
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In 1994, an audit of infection control policies and practices in 19 hospitals in
England and Wales included an assessment of the incidence of urinary tract,
respiratory tract and bloodstream infections (the three most common types of
infection), occurring in adult patients, admitted to the medical, surgical,
gynaecology and orthopaedic specialties of the selected hospitals and who had
a minimum stay of 3 days. A total of 81,218 patient episodes involving 72,434
patients were observed, of which 80,752 episodes involving 72,013 patients
could be allocated to specialty groups. Over the study period a total of 2,148
infections were observed, giving a rate of 3.0 per 100 patients and 2.7 per 100
episodes.1
Data from the US provide further insight into the incidence of HAl. In 1975,
Haley et a/,48 as part of a pilot study for the study of the Efficacy of Nosocomial
Infection Control (SENIC), assessed the incidence of HAl occurring in 4,067
patients admitted over an 11 week period to a hospital in Atlanta, USA. Of
these 5.1% of patients acquired one or more HAls that presented during the in-
patient period, and there were 6.0 HAls per 100 admissions. UTls were the
most frequent type of infection accounting for 40% of infections observed,
followed by SWls (33%), and lRTls (16%). Primary bacteraemias accounted
for 2% of infections observed and infections at other sites the remaining 9% of
infections observed.
Similar results were obtained from the SENIC study itself. The SENIC study
investigated the incidence of HAls occurring in patients admitted to 338
hospitals, representing the 6,449 acute care, general medical and surgical
hospitals in the US, over a prolonged period from 1970 - 1975. The HAls
studied were limited to the four most frequent types of infections: urinary tract,
surgical wound, respiratory tract and bloodstream. These four infections were
thought to account for 80% of all HAls.49 A report based on the analysis of a
random sample of 169,526 adult patients admitted to these hospitals over a 12
month period in 1975-1976, supplemented with data on the incidence of
infections at sites other than those studied in the SENIC study taken from data
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from the 75 hospitals participating in the US National Nosocomial Infections
Study, and extrapolated to all adult patients admitted to the 6,449 acute sector
hospitals, estimated that there were 5.7 infections (all sites) per 100 admissions
and that 4.5% of all admissions acquired one or more HAls which presented
during their in-patient admission.49 Based on the results of the SENIC pilot
studies,48and the increasing use of medical technology and no corresponding
evidence of increased safety or infedion control input, the authors concluded
that this estimate was likely to be an underestimate of the incidence of HAI.49
As with prevalence studies, comparisons between the findings of these three
studies should be made with caution. The definitions of infedion and the
methods used to identify infedions, the case-mix of patients studied and the
treatment patterns, including discharge patterns, differed with study.
Meaningful comparisons are dependent on these and other factors being
controlled for.4650
2.4.2 Therelative Incidenceof specific types of Infection
Studies that assessed the incidence of HAl occurring in a broad case mix of
patients also provide important data on the incidence of specific types of
infection. Consistently these studies find urinary trad, surgical wound and
respiratory tract infections to be the most frequent types of infection. The study
by Glenister et 81 (1992) found that UTls were the most frequent type of
infedion, accounting for 27% of all infections observed; SWls accounted for
23%, and pneumonia accounted for 15%.47
Estimates from the US indicate that in 1976/6 urinary tract, surgical wound and
respiratory trad infedions accounted for 42%, 24% and 10% of the total
number of infections estimated to have occurred in patients admitted to the
acute sector hospitals that year. 49
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2.4.3 The incidence of HAls occurring In patients admitted to surgical
specialties
Studies that have assessed the incidence of HAls occurring in patients admitted
to surgical specialties include those that have assessed the incidence of all
types of infection occurring in a broad case mix of patients (including surgical
and medical patients), which have subsequently stratified their results by
specialty; and studies that have assessed the incidence of all types of HAls or
selected types of HAls occurring in selected surgical patient groups.
For example, a study by Glenister et 81(1992) which assessed the incidence of
HAls occurring in medical and surgical adult patients admitted to a district
general hospital (DGH) in England observed an overall incidence rate of 7.2%,
increasing to 9.7% in patients admitted to the surgical specialties (general
surgery, gynaecology and orthopaedics). The incidence amongst general
surgical patients alone was 8.7%, in gynaecology patients 9.3%, and in
orthopaedic patients 13.6%.47
Studies that have limited their focus to the incidence of HAls or selected types
of HAls occurring in surgical patients include those that have assessed the
incidence of infections in patients who have undergone a particular operative
procedure such as a caesarean section,51,52,53-56or hysterectomy.57 Others
have assessed the incidence of a specific type of infection occurring in a
particular patient group. For example, Costantini58 assessed the incidence of
infections occurring in patients cared for on the intensive care unit. Gravel-
Trapper et 8/,(1995)59assessed the incidence of SWls in gynaecology and
obstetrics patients. Leigh et 81(1981)80conducted an eight year study of post-
operative wound infection in two district general hospitals in England between
1971 and 1978. Erbaydar et 81 (1995) 81in a study primarily concerned with
estimating the impact of SWls on length of hospital stay, estimated the
incidence of SWls occurring in general surgical patients who underwent an
operative procedure within a hospital in Turkey.
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The estimates of infections within a selected group of patients vary. For
example, Henderson in a review of studies that assessed the incidence of SWls
occurring in patients who had undergone caesarean sections found the rate to
range from 0-24%.53 Factors previously mentioned relating to the methodology
employed and the case-mix and treatment regimens, may explain much of the
variation observed. More recently, Nice et a/ (1996)55 in an audit of SWls
following emergency and elective caesarean sections in five West Yorkshire
Hospitals in the UK, found that of the 628 women who had a caesarean section,
7.2% acquired a SWI. The SWI rates varied between then hospitals ranging
from 2.5-17.2%. Analysis of surveillance data collected between January 1997
and December 1998 in eight maternity hospitals in France, found the incidence
of all types of infection occurring in patients who had a caesarean section to be
7.4% and just 1.2% for vaginal deliveries.56
2.4.4 The Incidence of specific types of Infection In patients admitted
to surgical specialties
2.4.4.1 The incidence of SWls in patients admitted to surgical specialties
Studies that have assessed the incidence of SWls occurring in surgical patients
have found the incidence to vary. For example, Cruse and Foard (1980)82 in a
ten year prospective study conducted in Canada between 1967 and 1977 and
involving 62,939 wounds observed an incidence rate of 5.7%. In the US the
National Nosocomial Infection Surveillance System (NNIS), between 1986 and
1996, observed a lower rate. Of the 593,344 operations observed 2.6% were
complicated with a SWI63 More recently, Abussaud and Meqdem (1986) in a
study involving 504 surgical patients observed a slightly higher rate: 3.6% of
patients acquired a SWI.64 A similar rate was observed in a randomised
controlled study by Lynch et a/,65 designed to assess the cost-effectiveness of
chlorhexidine body wash as a means of reducing the risk of infection: 3.2% of
3,482 patients had a SWI as defined by purulent discharge from their wound.65
However, when the definition of SWI was relaxed such that patients who did not
have a purulent discharge, but had an ASEPSIS score of more than 10 were
classified as infected, the SWI rate increased to 5.8%.85 A study by Malone et
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a/ (2002) also observed a similar rate: 3.2% of the 5031 non-cardiac surgical
patients included in the study acquired a SWI.66
A slightly lower SWI rate of 2.8% was observed by Culver et 8/87 in a study
conducted in the US. The estimate was derived from data on 84,691 operations
performed at 44 NNIS hospitals in the US between January 1987 and
December 1990. A smaller study conducted by Kirkland et 8/ (1999)68in the US
in 1999 observed a lower rate: 1.2% of 22,742 patients who underwent in-
patient surgery acquired a SWI, and an earlier study by Rubenstein et 8/
(1982)69conducted in Israel in 1979 observed a SWI rate of 1.9% in general
surgical patients and 1.6% in orthopaedic patients.
An earlier study conducted in 1979 and limited to 1,346 patients who had
undergone selected abdominal surgery observed a still lower infection rate of
0.97%70and a five year prospective study conducted by Krukowski et 8/ (1984)
involving 1,504 patients who underwent abdominal surgery at a hospital in the
UK observed a rate of 2.8%, with over 50% of infections identified post-
discharge.71 However, a study by Bremmelgaard et 8/ (1989)12involving 42,228
general surgical and orthopaedic patients found that 6.3% of patients acquired a
SWI. Garibaldi et 8/ (1991) in a study of 1,852 adult surgical patients admitted
to university affiliated US hospitals over a four year period observed a similar
rate: 6.5% of patients studied acquired a SWI.73 A study by Mishriki et 8/
(1990),74 which assessed the incidence of SWls in 702 adult, non-trauma
patients of which 600 were in-patients and 102 day cases, observed a higher
incidence rate of 7.3% and Erbaydar et 8/ (1995)61observed a considerably
higher incidence rate: 15.2% of the 1482 general surgical patients studied
acquired one or more SWls
The variation in the estimates obtained can again in part be attributed to
methodological differences: differing case definitions and detection methods
and varying follow-up times. For example, the relatively high incidence rate
observed by Mishriki et s/ (1990)14can in part be attributed to the definition of
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SWI used which was based on clinical data and the fact that infections
presenting post-discharge were included in the estimate with post-discharge
follow up extending over a period of six weeks: 55% of infections identified
presented after the patient was discharged from hospital. In contrast the
relatively low SWI incidence rate reported by Culver et s/ (1991)67was limited to
the incidence of SWI presenting during the in-patient period and relates to the
incidence of SWI as defined by relatively strict criteria.
The impact of case definitions and case detection methods on the rates
obtained was highlighted in a short report by Reilly et si (2001).75 Over a 28
month period 1,772 patients admitted to a hospital in the UK were followed for a
period of 30 days following clean surgery. The utilisation of a relatively strict
definition for SWI that required the presence of pus from the wound resulted in
a SWI rate of 5%. A wider definition resulted in a SWI rate of 8%. These
estimates relate to SWls presenting within 30 days of clean surgery. If however
the time period of interest was limited to infections presenting during the in-
patient period then the 8% rate fell to an artificially low rate of 1%.
A recent systematic review to assess the evidence of validity and reliability of
the definitions and detection methods used in prospective studies of SWls
published between 1993-1999, highlighted the wide variation found in these
studies with respect to these factors, and how this impacts on the estimates of
infection rates derived and importantly limits valid comparisons being made.76
Forty-one different definitions of SWI were used in the ninety studies included in
the review, of which only five were definitions proposed by multi-disciplinary
groupS.28n-ao
Whilst methodological differences clearly have an impact on the overall rates
observed, case mix differences perhaps playa greater role. Data on the
incidence of SWI and how this varies with wound class clearly demonstrate the
impact that case mix differences have on rates. As might be expected studies
conSistently found the SWI rate to be considerably lower in clean surgery than
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in contaminated surgery. Cruse and Foard's (1980) ten year study of wound
infections clearly showed this. Whilst Cruse and Foord's62study observed an
overall SWI rate of 4.7%, rates varied markedly with wound class. The SWI
rate in clean surgery was just 1.5%, rising to 7.7% in clean-contaminated
surgery, 15.2% in contaminated surgery and 40% in dirty surgery.
More recent studies have continued to observe variation in rates according to
wound class. For example, whilst Abussaud and Meqdem (1986)64in their
study involving 504 surgical patients observed an overall incidence rate of
3.6%, the rate was found to vary from a low of just 1.1% for patients who
underwent clean surgery to 18.5% amongst patients who underwent
contaminated surgery. Similarly Bremmelgaard et s/ (1989)12 in their study
involving 42,228 general surgical and orthopaedic patients found the SWI rate
varied from a relatively low rate of 2.3% in patients who underwent clean
surgery to a high rate of 27.1% in patients who had dirty wounds, with an overall
rate of 6.3%. However, Malone et s/ (2002)66 observed a slightly different
pattem. In their study of 5,031 non-cardiac surgical patients infection rates
were lowest in the dirty wound category: just 1.8% of patients classified as
having undergone 'dirty-infected' surgery acquired a SWI. This compared to
rates of 2.4% in patients who underwent 'clean' surgery, 4.2% in patients who
underwent 'clean-contaminated' surgery and 4.6% in patients who underwent
'contaminated surgery'. The authors attributed this finding to either the
relatively low number (57) of dirty cases studied or differences in wound care
practices.
This variation in SWI rates according to wound class category inevitably has an
impact on the overall SWls rate observed. The overall rate will clearly depend
to some extent on the proportion of patients within each wound class category.
The distribution of other intrinsic and extrinsic risk factors will also have an
impact on the rates observed. These are discussed in section 2.8.
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2.4.4.2 The incidence of UTls in surgical patients
While studies that have assessed the incidence of UTls in patients admitted to
both medical and surgical specialties suggest that between 1 and 3% acquire a
UTI;8182studies limited to surgical patients generally suggest that the incidence
amongst surgical patients is considerably higher.14 Coello et al found that 6.3%
of adult patients admitted to the surgical, urology, gynaecology and orthopaedic
specialties of a DGH in England and who had an operative procedure acquired
a UTI.14 Bueno-Cavanillas et al (1991)83 in a study involving 449 surgical
patients admitted to a hospital in Spain in 1986 observed an incidence of 8.7%.
A study by Melatomaa et al (2000)57which assessed the incidence of HAls
occurring inpatients who had either an abdominal hysterectomy 516 (75%);
vaginal hysterectomy 105 (15%); or laproscopic hystectomy 66 (10%), at a
Finnish University Teaching Hospital during the period October 1993-
September 1994, observed a higher UTI incidence rate of 13.5%. An exception
is a study by Rubenstein et al (1982),69conducted in Israel in 1979: 3.1% of the
967 general surgical patients surveyed and 2.9% of the 968 orthopaedic
patients surveyed acquired a UTI.
2. 4.4.3 The incidence of LRTls in surgical patients
Incidence studies have generally found 0.8 - 0.9% of medical and surgical
patients acquire a respiratory tract infection with the rates varying with type of
patient.84 85 A number of studies have focussed specifically on pneumonias
occurring in ventilated patients (ventilator- associated pneumonias- YAP). The
incidence ofVAPs has been found to vary from 10% to 65%.8&-929394
2.4.4 Evidence of Inter.hospital variation
Evidence from national surveillance schemes indicates that infection rates vary
between hospitals which cannot be explained by case mix differences.95 98 For
example, data from the UK National Nosocomial Infection Surveillance Scheme
indicate that the incidence of surgical site infection varied with both the category
of procedures and hospital. Similarly the incidence of bacteraemia varied by
specialty and within specialty between hospital sites. This inter-hospital
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variation remained after controlling for age structure and other case mix
differences.5 Given that the hospitals involved in this national surveillance
scheme all used the same data collection methods the results suggest that
factors relating to policies and practice may account for the variation observed.
2.4.5 Infectionspresentingpost-discharge
The problem of HAl is not restricted to the hospital stay: a proportion of
infections do not present until after the patient has been discharged from
hospital. Prevalence studies fail to take into account these infections and
incidence studies, until recently, have generally focused on infections
presenting during the in-patient phase. As a result these studies inevitably
underestimate the scale of the problem of HAl.
Studies examining the incidence of SWls presenting post-discharge indicate
that anything from 20-86% of SWls present post-discharge. 5765 717497-105The
variation in the proportion of infections identified post-discharge may be
explained, at least in part, by reference to the different methods used to identify
infections, differences in the case-mix of the population studied and varied
discharge patterns.104106
2.5 National estimates of the number of HAls occurring per annum
National estimates of the number of HAls occurring per annum and/or the
number of patients who acquire one or more HAls have been derived. For
example, in the US Haley et 8/,49 based on data from the SENIC study and the
NNIS survey, estimated that there are at least 2.1 million HAls per annum. The
authors suggest that whilst this figure is substantial it is likely to be an
underestimate of the scale of the problem. They argue that as a result of
advances in medical technology, it is now possible to treat patients who in the
past were untreatable. Many of these patients are at high risk of acquiring an
infection. Whilst medical advances have faCilitated treatment there is no
substantial evidence of improved infection control. As such it is argued that the
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actual figure is likely to be closer to 4 million. Estimates of the number of HAls
occurring in surgical patients alone were not presented
In the UK in 1997 Glynn et S/1 estimated that were at least 100,000 HAls every
year. This estimate was derived from estimates of the incidence of chest,
urinary tract, and bloodstream infections occurring in adult patients admitted for
a minimum of three days to the medical, surgical, orthopaedic and gynaecology
specialties of 19 district general hospitals in England and Wales in 1996.
Extrapolating the results of their study to the national level the researchers
estimated that there were 60,000 HAls of the urinary tract, respiratory tract or
bloodstream per year. When infections occurring in patients admitted to other
specialties are taken into account, together with skin and SWls then this figure
was estimated to increase to 100,000 infections per annum. Estimates of the
number of HAls occurring in surgical patients alone were not presented
2.6 Impactof HAlonmortality
HAls may directly cause death, substantially contribute to the terminal event, or
have little or no role in a patient's death.107 In any individual case it is difficult to
tease out the contribution of the infection to the terminal event. The role that
HAls play in hospital deaths inevitably varies with type of infection, and the
patients underlying disease and health status.
Studies that present information on mortality rates in infected and uninfected
patients show that the mortality rate is significantly higher in infected than
uninfected patients.108-110 89 91 111 112 68 92 113·118 An exception is a study by
Freeman et s/ (1979). Eighty-five infected patients admitted to a US hospital in
1973 were matched with suitable controls. Little overall difference in mortality
rates between infected and uninfected controls was found. However, as
acknowledged by the authors the sample was relatively small and as such
insufficient to pick up a small but statistically significant increased risk if
present.111
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The higher mortality rate generally observed amongst infected patients may
reflect both the increased mortality risk that HAls present, and marked
differences in the distribution of other mortality risk factors in the two groups
(infected and uninfected patients). The case mix of the infected group may,
even in the absence of an infection, render the infected patients at greater risk
of in-patient death than the uninfected patients, with many of the risk factors for
HAl also being risk factors for mortality.118
The results of a prospective study of 4,714 patients admitted to three Spanish
hospitals in 1994/5 provide evidence that many of the risk factors for infection
are simultaneously risk factors for mortality.118The study assessed whether the
SENIC and NNIS indices of intrinsic infection risk were also good predictors of
in-hospital mortality. The results of the crude data analysis indicated that both
indices were related to in-patient mortality. However, the results of the
regression analysis which controlled for the potential confounding effects of
age, sex, American Society of Anaesthesiologists scores (ASA score), cancer,
renal failure, diabetes mellitus and a stay on the intensive care unit, found that
the SENIC index ceased to demonstrate a significant trend with mortality (p =
0.025), while the NNIS index did demonstrates a significant trend (p=<O.001).
The higher mortality rates observed in infected patients may therefore to some
extent reflect the underlying mortality risk. Consequently, deaths occurring in
infected patients may not be directly attributed to the presence of an infection
but attributable to other factors. The task therefore is to assess the specific
contribution of the infection to death. Studies that have attempted to do this
vary in their approach.
83
2.6.1 Methodsused to assess the Impact of HAlon morfality
2.6. 1. 1 Review of case notes
In some studies case notes of deceased patients were reviewed and a
judgement made as to whether the infection was the primary cause of death or
a substantial contributing factor. Gross et al (1980)119present guidelines for
determining whether the presence of an HAl directly caused the patients death
or acted as a contributing factor. However, as Salemi et a/ (1995)115point out
even in the presence of guidelines categorising patient deaths in this way can
be difficult. Salemi et a/ (1995) argue for one category that combines both
deaths directly caused by HAl and those in which the presence of an infection
was a contributing factor, suggesting this would improve the validity of the
mortality data.115
2.6.1.2 Autopsy examination
Other studies rely on the results of autopsy examination for information on the
number of deaths resulting from a HAI.11o For example, Daschner et a/ (1978)
examined autopsy data from 1000 patient autopsies during the years 1975 -
1976. In their study, autopsy findings, complemented by a review of medical
records and the clinical judgement of a pathologist, were used to determine the
presence of an infection and subsequently categorise patients into those whose
HAl directly led to death and those in which the HAl was a contributing factor to
the terminal event. The criterion used for allocating patients into these two
groups was not published. HAl was identified as the direct cause of death in
7.4% and a contributing factor in 6.3% of the 1000 autopsies examined, and
found to be either the direct cause of death or a contributing factor in 800/0of
those autopsied patients who had an infection.
2.6. 1.3 Review of death certificates
An altemative approach adopted by some studies has been to review death
certificates to identify patients for whom HAl has been listed as the cause of
death.115 This approach is thus reliant on the cause of death being accurately
recorded on the death certificate. Failure to report deaths from HAlon the
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death certificate will in some cases result in the death rate being
underestimated. Salemi et al (1995)115in their study of deaths occurring in
patients admitted to a single US hospital who had acquired either a pneumonia,
primary BSI or SWI, found the number of deaths attributable to an infection
increased when the case notes of patients with pneumonia or BSI whose death
certificate did not list infection as a cause of death were examined. Twenty-four
per cent of patients who acquired a pneumonia and 25% of patients who
acquired a BSI died. An examination of death certificates alone indicated that
the infection was either the direct cause or a contributing factor in 15% of
deaths occurring in patients with a pneumonia or BSI. Following an
examination of case notes of those patients for whom the infection was not
listed as the cause of death on the death certificate, the proportion of deaths
attributable to the infection increased to 20% in patients who had a pneumonia
and 19% in patients who had a BSI.115Both of these increases were significant
(p<0.05).
2.6.1.4 Casecontrol approach
Other studies have adopted a case control approach to adjust for severity of
underlying iIIness.108109113,68 91111120121For example, Rose et sI (1977)108
compared mortality rates amongst 40 patients with hospital acquired 8SIs with
that occurring in 40 uninfected matched controls treated at a US hospital
between December 1972 and August 1974. The mortality rate in bacteraemic
patients was 380/0compared to just 10% in controls. During this time period a
further 84 patients had a BSI, however medical notes were not available in 19
cases and suitable control patients could not be found in the remaining cases.
The mortality rate amongst these unmatched bacteraemic patients and 109
additional bacteraemic patients admitted to the study hospital between January
and October 1975 was 34%. The inability of this study to find suitable controls
for all infected patients is a common problem associated with this approach,109
and inevitably may introduce bias into the mortality estimates derived.
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2.6. 1.5 Data stratified by underlying risk
To enable more valid comparisons in death rates both over time, and between
institutions, some studies have assessed the death rate in infected patients and
then stratified the data by underlying risk. For example, a study by Salemi et a/
(1995), based on infection data from a single US hospital for the years 1987-
1992, assessed the number of deaths that were either primarily due to the
presence of an infection or in which the infection played a substantial role and
subsequently stratified the data by underlying risk based on the patients
severity of iIIness.115 The severity of illness classification system used
consisted of five categories ranging from no risk of death expected during the
patients hospital admission to almost certain death expected. For the purpose
of their work the five categories were collapsed into an 'at risk of death during
hospital admission group' and a 'not at risk of death during admission group'.
Of those patients who had acquired a BSI and had been classified as 'not at risk
of death' the infection either directly caused or contributed to death in 5% of
cases, whereas in patients who had acquired a BSI and had been classified as
'at risk of death', the infection either directly caused or contributed to the
patients death in 21% of cases. The association between pneumonia and
death in the 'not at risk of death' and 'at risk of death' groups was 13% and 23%
respectively. The authors concluded that if valid comparisons are to be made
mortality rates should be stratified by risk.
2.6. 1.6 Regression analysis
Regression analysis is another technique that has been used to control for
factors other than the presence of an HAl which might contribute to the patient's
death and delineate the role of the HAI.8991 92 112 118 For example, a study by
Fagan et a/92conducted a stepwise logistic regression analysis which assessed
the independent effects of nosocomial pneumonia on mortality risk in intensive
care patients. The analysis controlled for a range of factors known to be
associated with mortality in intensive care patients. The results indicated that
after controlling for a range of other factors, patients who acquired a pneumonia
were 2.1 (95% Cl: 1.8, 3.6) times more likely to die than uninfected patients.
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2.6.2 Specialty specific mortality rates
Studies that have examined in-patient deaths and more specifically the
contribution of an infection to death have generally found that infections
occurring in surgical patients were more likely to cause or contribute to death
than infections occurring in patients admitted to non-surgical specialties.11o119
For example. Gross et a/ (1980) found that whilst more deaths occurred on the
medical services only 25% were associated with the infection. whereas on the
surgical specialties half of the deaths were associated with infection. A study by
Daschner et a/ (1978) also found that most infections causing or contributing to
death were acquired on surgical specialties.11o
2.6.3 SIte-specific mortality rates
The impact of HAlon mortality risk whilst depending on the patient's underlying
condition and the interplay between the infection and the patient's condition. will
also vary with type of infection. The results of studies which have assessed site
specific death rate have generally found that death rates are higher in patients
with bloodstream and lower respiratory tract infections than in patients with a
UTI.119 For example. unpublished data from the NNIS system in the US which
was presented by Hughes et a/ at the Twenty-second Interscience Conference
on Antimicrobial Agents and Chemotherapy. and reported in an article by
Martone et al. (1998).'22 indicated that whilst overall 0.9% of patients with an
HAl die as a direct result of the infection and in a further 2.7% of cases the HAl
is a substantial contributing factor there was considerable variation in
attributable risk by site. Pneumonia and BSls were found to be greater risk
factors for mortality than infections at other sites: 4.4% of deaths were directly
attributable to bloodstream infections and 8.6% partially attributable; 3.1% were
directly attributable to pneumonia and 10.1% partially attributable. This
contrasts with 0.8% of deaths attributable to 'other sites' and 2.5% partially
attributable to 'other sites'; 0.6% directly attributable to SWls and 1.9% partially
attributable to SWls; and 0.1% directly attributable to UTls and 0.7% partially
attributable to UTls.
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Interestingly whilst the risk of death is generally found to be relatively low in
patients who acquire a UTI, a study by Platt et 8/ (1982) indicated that after
controlling for a number of other factors including severity of illness, age and
duration of catheterisation, the presence of a hospital acquired UTI was
associated with a three-fold increase in risk of mortality.112 While it was
acknowledged that the presence of a significant association between infection
and mortality is not necessarily indicative of a causal relationship, and that the
possibility remains that the UTI was a marker for a factor not included in the
logistic regression analysis, the later was not thought to be the case.
The study by Salemi et 8/ (1995) referred to above, based on infection data
from a single US hospital for the years 1987-1992 assessed the number of
deaths that were either primarily due to the presence of an infection or in which
the infection played a substantial role.115This study found that 19% of patients
who had a BSI and 20% of patients with pneumonia subsequently died as a
result of infection compared to just 1% of patients with a SWI who died from
infection. The authors subsequently compared this to CDC rates of 13%, 13%
and 2.5%. There were no significant differences in the rates observed for both
BSI and SWI but there were for pneumonia.
Delgado-Rodriguez et 8/(1999)118 in their study of 4,714 surgical patients
admitted to three Spanish hospitals in 1994/5 mentioned above found that after
controlling for a range of potential confounders (age, sex, presence or absence
of a cancer, renal failure, or diabetes, stay in the ICU and the NNIS index), the
presence of an organ/space surgical site infection was significantly related to
mortality (Odds ratio 4.9: 95% Cl: 1.5 - 15.6) as were BSls (Odds rati017.3:
95% Cl: 3.5 - 87.0). The acquisition of a single infection at the following sites
was not significantly aSSociated with mortality: superficial incisional wound
infection; deep incision wound infection, respiratory tract infection, urinary tract
infection, infections at sites other than these. In those patients who had more
than one infection the combination of a surgical site and respiratory tract
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infection or a surgical site and bloodstream infection was significantly
associated with mortality, but other combinations were not.
The analysis of data from the French surgical site infection surveillance network
(INCISO) for the years 1997-1999 indicated that the crude mortality rate
amongst patients with a SSI was considerably higher than in uninfected
patients: 5.8% and 1.35 respectively.123 The attributable mortality rate was thus
4.5%. After adjustment for a range of risk factors including sex, age, NNIS risk
index, length of hospital stay prior to surgery, type of surgery (elective or
emergency) and the presence or absence of endoscopic surgery, it was
estimated that 38% of deaths occurring in infected patients were directly
attributable to the infection. Subjective surgeon assessment estimated that
25% were directly attributable to the infection, a rate that was also reported by
the US NNIS system.124
A case control study by Kirkland et s/ (1999)68 examined surgical site infections
and mortality. Over a four-year period (1991-1995) 272 patients who underwent
surgical procedures at a hospital in the US acquired a surgical site infection. Of
these 255 (94%) were successfully matched with uninfected controls. Mortality
rates were found to be twice as high in infected than uninfected patients: 7.8%
of infected patients died compared to just 3.5% of uninfected patients.
A study by Leu et a/ (1989) which focused on hospital acquired pneumonia in
115,921 patients admitted to a US hospital over a five year period from January
1st 1979 to December 31st 1983, observed a mortality rate of 30% amongst the
890 patients who acquired a pneumonia (initial episodes only). The attributable
mortality, derived from a case-control analysis of a sub-sample of 74 patients,
was estimated to be 33%.91
A case control study by Rose et aJ108 focussed purely on 8SIs occurring in
patients admitted to a US hospital over a two year period from December 1972
to August 1974. Over this period 124 patients had a 8SI. Medical records were
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available for review in 105 cases. Adequate control patients were identified for
just 40 of these cases. The crude mortality rate in patients with a BSI was 38%
compared to 10% in uninfected controls. The authors acknowledged that the
failure to find suitable matches for all cases may have introduced bias into the
results. As such cases for which no controls could be found were also reviewed
together with an additional 125 BSls occurring in 113 patients admitted between
January 1975 and October 1975. The medical records were available for 109 of
these additional cases. The mortality rate amongst the 65 unmatched cases
and the 109 additional cases was 34%. A study by Sprengler et a/ (1978)109
observed a similar mortality rate: 30% of patients with bacteraemia died
compared to 40/0 of uninfected matched controls giving an estimated attributable
mortality rate of 26%. Estimates of the risk ratiO for death indicated that
infected patients were 14 times more likely to die than uninfected patients.
A case control study of hospital acquired BSls occurring in 4,002 critically ill
patients treated on the surgical intensive care unit indicated a lower risk ratio.
The study observed a crude mortality rate of 50% in infected patients compared
to just 15% in matched uninfected patients.113 The estimated attributable
mortality rate was therefore 35% (95% Cl: 25%, 45%), a higher rate than that
observed in the study by Sprengler et al. However, the risk ratio for death was
lower: 3.31 (95% Cl: 1.78,6.15).113
Other studies which have specifically examined the relationship between
bacteraemias and mortality indicate that BSls resulting from hospital acquired
UTls have a case fatality rate of between 13 and 30%.125-127However, the
majority of deaths occurred in patients with severe underlying disease.125
2.6.4 Specialtyand site-specific mortality estimates
Some studies have focussed on infections occurring in selected patient groups
and/or specific infections occurring in selected patient groups. For example, a
number of studies have assessed the impact of pneumonia on mortality in
patients treated on intensive care units. A study by Fagon et a/ (1996) involving
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1,978 patients admitted to an ICU, observed a death rate in patients who
acquired a pneumonia of 52.4% compared to 22.4% in patients who had not
acquired a pneumonia. Multiple stepwise logistic regression analysis was
subsequently conducted to assess the independent effect of hospital acquired
pneumonia on mortality risk in patients admitted to the ICU.92 The results of
their multivariate analysis that controlled for a range of factors known to be
strongly associated with death in ITU patients indicated that pneumonia was an
independent risk factor for mortality in these patients (odds ratio: 2.1 (95% Cl:
1.6, 2.8). 8SIs were also associated with an increase risk of death (OR: 2.5;
95% Cl 1.8, 3.6). The acquisition of a UTI was significantly associated with
mortality in the univariate analysis but as in other studies was not significantly
associated with mortality in the multivariate analysis.89
In contrast to this, a study by Craven et s/ (1988) found that whilst pneumonia
was associated with death, it was not among the seven variables remaining
after multivariate analysis, thus highlighting some doubt about the direct effect
of pneumonia on death.89 The rigorous approach to the diagnosis of
pneumonia may in part explain the different findings. Fagon et s/ (1996)92
adopted strict criteria for the diagnosis of pneumonia. The diagnosis was
dependent on microbiological evidence of infection. All patients who developed
a new and persistent infiltrate and had purulent tracheal secretions underwent
immediate fiberoptic bronchoscopy at which time specimens were taken using a
protected specimen brush and bronchalveolar lavage. Diagnosis was then
confirmed from the results of the diagnostic tests. This strict approach
distinguishes their study from earlier studies which included clinically diagnosed
pneumonia and thus probably includes patients with lung processes that mimic
pneumonia. The authors offer this distinction as a possible explanation for the
differences observed between their results and that of earlier studies that failed
to identify pneumonia as a risk factor.8789 128 However, it is of course possible
that the very process of conducting a fiberoptic bronchoscopy may have
increased the patient's mortality risk.
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2.6.5 Number of deaths associated with HAls per annum
Estimates of the number of deaths occurring annually within a given country are
also presented in the literature. For example, in the US, Haley combined data
from the SENIC study49 with data from a concurrent assessment of mortality
performed in the NNIS system129 to derive estimates of the number of deaths
either directly or partially attributable to infection. The results indicated that in
1982, an estimated 19,027 deaths were attributable to HAl and a further 58,092
deaths partially attributable to HAl.122 If these estimates are accepted, then in
1982 deaths from HAl alone were the 11th leading cause of death in the US,
and deaths that were partly or solely attributable to HAl, were the 4th leading
cause of death.11
Equivalent data are not available for the UK. However, assuming a similar
mortality rate, it has been estimated that 5,000 in-patient deaths per year might
be primarily attributable to HAl and a further 15,000 in-patient deaths might be
partially attributable to an infection acquired in hospital. 9 These estimates are
inevitably crude; however, they represent the best estimates available to date.
2.7 Aetiology of HAl
This section provides an overview of the aetiology of HAl drawing on a range of
literature in recognised texts on issues relating to hospital infections and where
appropriate relevant papers.130-132
HAls occur when micro-organisms invade a patient and cause disease. The
micro-organisms may be from an endogenous source that is from a site within
the patient, or from an exogenous source e.g. from another patient or from the
environment. If the causative micro-organisms are normally present in the
patient (a commensal) an infection may develop as a result of a change in the
relationship between the micro-organisms and the patient. If the micro-
organisms are transported from an external source to the patient, an infection
may develop if the balance between the agent and the patient's defences
favours the rnicro-organisms. The interaction between micro-organisms, the
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route of transmission and patient is called the chain of infection. The
environment had a significant impact on all elements in this chain.
2.7.1 M/cro-organ/smIPathogen
A micro-organism that leads to a disease state in an individual is called a
pathogen. It can be a bacterium, a protozoan, a virus or a fungus, although the
vast majority of HAls are caused by bacteria.61920 77 The ability of the organism
to cause disease, its pathogenicity, varies considerably amongst the diverse
members of the microbial world. For example, Staphylococcus aUf9US (S.
auf9Us) is a major pathogen responsible for between 10 and 20% of HAls,6 1920
77 and has relatively high pathogenicity compared to Staphylococcus
epidermidis (S.epidermidis), a member of the same bacterial genus
(Micrococcaceae). S. epidermidis is a normal skin commensal and rarely
associated with significant infection in a non-susceptible host. The relatively
high pathogenicity of S. aUf9UScan be attributed to the presence of specifiC
virulence factors that enhance its potential ability to cause disease.
Virulence refers to the degree of pathogenicity of an organism and may be
described by reference to epidemiological factors including morbidity, mortality
and communicability, or by clinical factors characterising the severity of the
infection observed. Organisms such as S. aUf9US,Stf9ptococcus pneumoniae
and Mycobacterium tuberculosis can be regarded as principal pathogens,
regularly causing disease in immunocompetent individuals. However, when
considering the aetiological agents involved in HAl, a considerable number of
non-principal organisms are implicated. Pseudomonas aeruginoSB,
Enterococcus faecalis and indeed S. epidermidis are major causes of HAl and
yet rarely cause disease in people with intact host defences. Such organisms
can be regarded as opportunists. This opportunism is a dired result of
hospitalised individuals being more likely to lack an intact innate or acquired
immune system, and therefore make up a more susceptible population.
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2.7.2 Route of transmission
Micro-organisms can be transmitted to patients by a variety of routes including
direct contact (e.g. hands of staff), indirect contact (e.g. via a piece of
equipment), by the airborne route in droplet nuclei, by ingestion (e.g.
contaminated hospital food) or by inoculation (e.g. via blood transfusion).
2.7.3 Patient
Individuals are protected from microbial invasion by non-specific and specific
defence systems. The non-specific defence system includes the skin, mucous
membranes, certain bodily secretions and the inflammatory response. The
intact skin provides a tough outer layer which few microbes can penetrate. Anti-
bacterial substances, present in the sweat and the secretions of the sebaceous
glands, add further protection, and microbes normally found on the skin (e.g. S.
epidermidis) protect against invasion by pathogens through competition for
nutrients. The mucus membranes of the respiratory tract produce mucus that
traps particles that enter the airway. The cilia then move the mucus upwards to
the oropharynx where it is swallowed or expectorated. Lysozyme, present in
tears and saliva, is capable of breaking down (lysing) bacterial cell walls
especially those of Gram positive bacteria. Finally, the inflammatory response,
classically characterised by redness, heat, swelling and pain at the site of
invasion represents the initiation of the specific defence system. This system
comprises the humoral and cellular arms of the immune system. Both may be
acquired naturally through infection or artificially through vaccination.
Within the hospital environment individuals are exposed to greater microbial risk
than in the community. On admission to hospital the normal skin flora are often
replaced by strains of hospital bacteria that are more resistant to antibiotics and
can cause serious infection if they enter the body. Northey et s/ (1974) in a
study of intensive care patients found that within two weeks of admission nearly
every patient was colonised with infective bacteria and this often involved
resistant organisms.133
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Medical and surgical therapies often require therapeutic interventions that
breach the natural defence mechanisms providing a route of entry for invading
micro-organisms. For example, surgical procedures and intravenous therapy
result in a break in the integrity of the skin, and urethral catheterisation provides
a direct route of entry for micro-organisms to enter the urinary tract: micro-
organisms may enter during the process of catheterisation, or they may travel
retrogressively through, or along, a urinary catheter. Similarly the insertion and
presence of an endotracheal tube provides a direct route of access for micro
organisms, bypassing the protective action of the mucous membranes and cilia
of the lungs, which may also be inhibited by drugs administered.
Whilst the presence of a route of entry increases the risk of infection, it does not
necessarily follow that an infection will result. The development of an infection
is dependent on the pathogenicity of the invading agent, and the susceptibility
of the host, in this case the patient. The very young are particularly susceptible
since their immune system is in an immature state. The elderly are similarly at
greater risk since their immune system is less efficient. Patients with illnesses
that affect the immune system, such as AIDS, leukaemia and other
haematological malignancies are particularly vulnerable to infection. These
patients who are generally immuno-suppressed and as such susceptible to
infection, are made more vulnerable by the toxic effects of the drug therapy they
receive. See section 2.8 for a more detailed discussion of risk factors for
infection.
2.7.4 Environment
Environmental factors such as temperature, air movement and the presence of
chemicals, gases and toxins may have an effect on any of the factors involved
in the development of infection. Particular environmental factors may limit,
inhibit or prevent the development of an infection. For example, environmental
factors such as temperature and humidity may promote or inhibit the growth of
micro-organisms in their reservoir. Movement and velocity of the air may affect
transmission of micro-organisms from source to susceptible host.
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2.8 Risk factors for HAl
As indicated above infections occur as a result of complex interactions between
specific factors relating to the patient's condition, the treatment administered
and the environment (see section 2.7). The risk of acquiring an infection in
hospital therefore varies considerably from one patient to another. Studies that
have assessed risk factors for HAl have identified a number of factors that are
significantly associated with the presence of HAl. However, these factors are
not necessarily causative factors - they may simply be closely related to the
actual risk factor and, as such, act as a marker for the risk factor. Furthermore,
some risk factors may occur simultaneously with other factors, exerting an
additive or even synergistic effect: that is they are interrelated. Thus when
examining risk factors for infection the problem is not only to find factors that are
significantly associated with HAl, but also to identify which factors are
independently associated with the presence of an infection.
The technique adopted to do this has generally been multiple logistic regression
analysis. Those factors identified in the univariate analysis as being
significantly associated with the presence of an infection are entered into a
logistic regression analysis in an attempt to identify independently significant
factors. However, the possibility still arises that the factors identified are
markers for other factors. Thus the validity of the results obtained are to some
extent dependent on the completeness of the original variables introduced -
how comprehensive the list of variables included was.
Risk factors for infection can be classified into two broad groups: intrinsic risk
factors and extrinsic factors. Intrinsic risk factors are specific factors relating to
the patient's condition that place them at risk of acquiring an infection, they
reflect the patient's susceptibility to infection. Patients with conditions that affect
the immune system, such as leukaemia and HIV, are inevitably at greater risk of
acquiring an infection than patients without these conditions. Other intrinsic risk
factors include old age, diabetes, and obesity. Extrinsic risk factors relate to
factors external to the patient and include factors that increase the risk of micro-
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organisms entering the patient. For example, medical interventions that breach
the intad protedive skin barrier and urethral catheteristaion which provides a
dired port of access for invading micro-organisms.107
There are many examples in the literature of studies that have examined risk
fadors for HAls at any site or specific sites.6213.4135 13611933576671-7483 137-142
The following sadions examine this literature in more detail, focusing on studies
that have assessed risk fadors for HAls at all sites and then studies that have
focussed on risk fadors for surgical wound, urinary trad, respiratory tract and
bloodstream infections.
/
/ 2.8.1 Risk factors for HAl. at any site
Studies that have examined risk fadors for HAls have identified a range of
fadors induding age;83 length of pre-operative stay;1983severity of underlying
illness as defined by fadors such as diagnostic group, number of co-
morbidities, the American Society of Anaesthesiologists score (ASA score),
specific co-morbidities, and blood loss during surgery; type of admission,375783
pradising surgeon,33 74 mainutrition,14Opresence of devices such as central
venous or urinary catheters,33, and wound dass (dean, dean contaminated,
contaminated or dirty).
Some of the risk fadors identified in these studies appear to be universally
applicable to most patient populations, whereas others appear to be unique to
the sample studied. Whilst in some cases this may refled a genuine difference
in the risk profile of the patients studied, in others it may simply refled
differences in the approach taken to assess risk fadors for HAl, and, in
particular, the range of explanatory variables induded in the analysis.
As indicated above, studies have generally identified more than one risk factor
for infection within a patient population. For example, a logistic multiple
regression analysis of data coIleded for a Spanish prevalence study identified
the following risk fadors: the number of intrinisc risk factors (coma, renal failure
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diabetes, hypoalbuminaemia, pressure sores, alcoholism, smoking and drug
addiction); number of extrinsic factors (urinary catheterisation, peripheral
vascular catheterization, central catheterisation with peripheral insertion,
parenteral nutrition, tracheostomy and mechanical ventilation); baseline risk
(three categories of clinical prognosis: severe, moderate and mild); length of
stay prior to infection; and number of diagnoses. These factors were all found
to be significantly associated with infection (p<0.001 ).19 Interestingly whilst
infections rates were found to increase with age, the results of the logistiC
regression indicated that age was not Significantly associated with infection
when other factors were taken in to account. In contrast an Italian prevalence
study found that after controlling for a range of factors in a multiple logistic
regreSSion analysis, age was significantly associated with HAl, together with
ward of stay, urinary catheterisation and receiving antibiotics.37
Another example is a study by Meltomaa et s/ (2000)57 that assessed the risk
factors for HAls occurring in 687 women who underwent a hysterectomy at a
University Teaching Hospital in Finland between October 1993-September
1994. The results of the multivariate analysis indicated five significant risk
factors for an infection at any site: lack of antibiotic prophylaxis, blood loss
during surgery of over 100mls (blood loss greater than 100 mls and less than
300 mls was associated with greater risk than blood loss in excess of 300mls, a
situation which may have been due to patients with over 300mls of blood loss in
some cases receiving a blood transfuSion); intermittent catheterisation;
anaemia; and post-operative administration of laxatives and cholinergic agents
for urinary or bowel problems. However, when UTls were excluded from the
analysis, intermittent catheterisation ceased to be a risk factor.
2.8.2 Risk factors for surgical wound Infections
Studies have identified a number of intrinsic and extrinsic risk factors for SWls.
Intrinsic risk factors include age, severity of iIIness,66 73 diabetes66 wound
class, n 73 infections at other sites prior to surgery,139 malnutrition,140 obesity141
and weight loss of greater than 10% during the six months prior to surgery.66
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Extrinsic risk factors include length of pre-operative staY,62 74 83 the
administration of a pre-operative shave,6274 length of surgery;6266 73 97 and the
presence of prophylactic abdominal drains, which have been shown in both
clinical and experimental studies to be associated with higher infection rates.
Mishriki et 8/ (1990)14in a study of 702 adult, non- trauma patients assessed
how the incidence of SWI rate varied with 23 potential risk factors: age, sex,
pre-operative stay (days), current antibiotic treatment, co-existing diabetes,
current immunosuppression, nutritional state. coexisting metabolic disease, pre-
existing malignancy, preoperative shaving, prophylactic antibiotic treatment,
type of skin preparation, duration of operation, operating surgeon, operating
theatre, operation site, size of wound, type of wound closure, suture technique,
use of deep tension sutures, type of wound dressing, use of surgical drains and
main ward of stay (a modified data set was used for day cases). The authors
selected these 23 factors as they had been shown in earlier studies to be
related to SWls. Of these 23 potential risk factors, only four were found to be
significantly associated with SWls: age> 55 in clean, clean-contaminated and
dirty categories (p= <0.05); pre-operative stay> 3 days in clean-contaminated
category (p = <0.05); pre-operative shaving in' the contaminated group
(p=<0.005); and individual surgeon in the clean category (p=<0.001). A forward
stepwise regression analysis of ten independent variables was undertaken
(age, preoperative stay, shaving, prophylactic antibiotics, skin preparation,
surgeons, operating time, suture type, deep tension sutures, drains). It is not
clear from the paper why these 10were selected from the 23 possible variables.
However, the results confirmed the univariate analysis although the overall
contribution of these variables in the clean and clean-eontaminated category
was found to account for a small proportion of the overall variation. The
association between surgeon and SWI had greatest significance. The
elimination of a single surgeon's case load from the sample would have
reduced the SWI rate by over 40%.
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Garbaldi et 8/ (1991)73 assessed the risk factors for SWI in a study of 1852 adult
surgical patients admitted to a university affiliated US hospital over a four year
period from January 1982 to January 1986. Four independent variables which .
were highly predictive of SWI were identified from a stepwise logistic regression
analysis of potential risk factors. These were wound class; ASA score; duration
of procedure; and the results of an intra-operative culture However, the
presence of intra-operative positive cultures had little explanatory power. The
predictive power of a positive culture was low (32%) and the false positive rate
was high (820/0)and concordance with isolates from infected wounds low (41%).
A study by Kampf et 8/142 utilised data collected as part of the first national
prevalence survey conducted in Germany in 1944. The results of the multiple
logistic regression analysis which included a number of variables found that the
department (surgery or intensive care), age (>45 years), diabetes mellitus, male
sex and size of hospital (> 600 beds) were Significantly associated with SSls.
2.8.3 Risk factorsfor urinary tract infections
The presence of a urinary catheter and the duration of catheterisation are key
risk factors for this type of infection.1 134137138143144 While 1% of non-
catheterised patients will develop bacteriuria, between 10 and 30% of
catheterised patients will develop bacteriuria and between 10 and 30% of these
patients will develop symptoms of a UTI.81 During the process of
catheterisation bacteria may be introduced into the bladder, and following
insertion, the bacteria may migrate from the peri-urethral area into the bladder,
either through the catheter lumen or along the catheter - mucosal surface.
Studies have indicated that the process of catheterisation is associated with a
1% risk of bacteriuria, and each subsequent day that the catheter is in situ there
is a 3-10% risk of developing bacteriuria.143145 Following removal of the
catheter, patients continue to remain at risk of acquiring an infection. For
example, Harstein et s/ found that 11% of catheterised patients developed
bacteriuria within 24 hours of the catheter being removed.143
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Urinary catheters are frequently used in the care and treatment of patients in
both the acute and long term care setting. A study of indwelling catheterisation
and related nursing practice in adult patients admitted to specialties other than
mental handicap, psychiatry or obstetrics at five district general hospitals in
England found the prevalence of catheterisation was 12.6%.148Data from the
US suggests that between 15 and 25% of patients in the acute care setting
were catheterised. 81
Catheterisation rates vary with specialty and from one care setting to another.
The results of a recent audit of infection control policies and practices in 19
district general hospitals in England and Wales clearly demonstrates this.1 The
median catheterisation rate observed in adult patients admitted to selected
specialties at 19 different hospitals, and who had a minimum in-patient stay of
three days was considerably higher in patients admitted to the gynaecology
specialty (40.4%: range 20.9% - 72.0%), when compared to the medical (11.6:
range 5 -17%); surgical (34.4%: range 16.2-50.0%); and orthopaediC (17.3%:
range 10.1 - 26.0%) Specialties.
In addition to duration of catheterisation a number of other independent risk
factors for UTls in catheterised patients have been identified. A study of 1474
catheterised patients identified eight additional independent risk factors:
absence of use of a urinemeter, microbial colonisation of the drainage bag,
diabetes mellitus, absence of antibiotic use, female patient, indications for
catheterisation other than drainage during surgery or output measurement,
abnormal serum creatinine and catheter care violations.138 More recently,
Glynn et sI (1997)1 identified seven risk factors in addition to catheterisation: the
risk was found to increase with increasing number of cathetensations, an ICD9
diagnosis other than endocrine diseases; female sex; transfer or emergency
admission as opposed to elective admission, increasing age; and length of
hospital stay. However, as pointed out by Glynn et sI (1997) it was not clear
whether longer length of stay was a risk factor for this type of infection or a
result of the infection itself.
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A study by Kampf et 8/142 utilised data collected as part of the first national
prevalence survey conducted in Germany in 1944. The results of the multiple
logistic regression analysis which included a number of variables found that
unconsciousness, old age (>75 years) prior operation, female sex and the size
of the hospital (>200 bed) were all significant risk factors for UTls. The authors
argued that the first four risk factors were likely to reflect need for urethral
catheterisation, which as indicated above, and acknowledged by the authors
has been shown to be a key risk factor for this type of infection. With regard to
hospital size they suggest that this may reflect the lower use of urine cultures in
smaller hOSpitals, which can be critical to a diagnosis of UTI when using the
CDC definitions.
2.8.4 Risk factors for lower respiratory tract Infections
Specific risk factors for lower respiratory tract infections (LRTls) include the
presence of a nasogastric tube, mechanical ventilation, aspiration, specific lung
disorders such as chronic airway disease and depressed consciousness.1 147
However. as with infections at other sites the severity of the patient's condition
will also have an impact on the risk of infection. The precise range of factors
identified in these studies again varies from one study to another, which, as
discussed above, may reflect both genuine differences in the risk profile of the
population studied and/or the comprehensiveness of the methods employed to
assess risk. For example, a recent audit of infection control in 19 hospitals in
England and Wales identified the following risk factors for LRTls occurring in
adult patients admitted to medical and surgical specialties: the presence of a
naso-gastric tube with the risk increasing with the number of days the tube was
in place (1 day; 2 or more days); the presence of other devices with the risk
again increasing with the number of days these were in situ (1 device,
2+devices): an ICD9 grouping other than endocrine diseases; four or more
discharge diagnoses; sex with males at greater risk than females; age over 50;
and length of stay with the risk of infection increasing with increasing length of
stay (6-10 days. 11-15 days. 16+ days). In contrast Kampf et 8/ (1998)147 in
their analysis of data from a prevalence study conducted in Germany identified
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the following factors as being significantly related to the presence of a LRTI:
polytrauma, impaired consciousness, chronic airway diseases, prior surgery
and cardiovascular diseases. The differing results may simply reflect the fact
that different explanatory variables were included in the analysis. For example,
the study by Kampf et 8/1.7failed to include data on the presence of a naso-
gastric tube, but included far more detailed information on diagnosis than the
study by Glynn et 8/ (1997),1
2.8.5 Risk factors for bloodstreamInfections
In addition to factors relating to the patient's underlying susceptibility to
infection, a number of specific risk factors for BSls have been identified in the
literature including the presence of intravenous and central venous Jines,
invasive procedures, and the presence of infections at other sites - in particular
the presence of a UTI.1148Glynn et 8/19971 in a multivariate analysis of data_- ---~-
on adult patients admitted to 19 hospitals in England and Wales identified the
following risk factors: the number of central venous catheters; the presence 0'1\
other infections, an IC09 diagnosis other than endocrine diseases (the )
reference category); three or more discharge diagnoses, and length of hospital
stay, the risk increasing with increasing length of stay. However, as indicated
above it was not clear from the results of their analYSis whether the longer
length of stay in infected patients acted as a risk factor for the infection or was a
consequence of an infection acquired in hospital.
2.9 Riskindices
Based on the information derived from studies of risk factors for infection,
composite measures of risk, based on a combination of risk factors, have been
developed. These measures, described as risk indices, aim to control for the
underlying infection risk of a patient population and thus facilitate the valid
comparison of rates of HAl from one population to another. Risk indices have
primarily been developed to assess the risk of acquiring a surgical wound
infection, although some have also proved to be good predictors of infections at
other sites.
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For example, based on data from the US Study of the Efficacy of Nosocomial
Infection (SENIC) Haley et s/ (1985)149 developed a risk index for SWI. Of the
ten potential risk factors for SWI included in the logistic regression analysis, four
were found to be significantly associated with SWI: an operation involving the
abdomen; an operation lasting over two hours; an operation classified as
contaminated or dirty-infected based on the traditional wound classification
system and three or more diagnoses on discharge (a proxy for intrinsic patient
risk). In the final model all four risk factors had nearly equal coefficients. As
such the risk index developed weighted all four risk factors equally, and patients
were allocated to one of five groups based on the number of risk factors
present: no risk factors, one, two, three and four risk factors.
The US NNIS surgical wound infection risk index, is an adaptation of the SENIC
index.87 Each surgical patient undergoing an operative procedure is allocated
to a risk group based on how many of the following risk factors the patient had.
1. American Society of Anaesthesiologists (ASA) pre-operative score of 3, 4 or
5.
2. An operation classified as either contaminated or dirty-infected according to
the traditional wound classification system.
3. An operation with duration of surgery more than T hours, where T depends
on operative procedure performed.
The ASA score is an index designed to assess the pre-operative health status
of patients. It ranges from 1 for an otherwise healthy patient to 5 for a patient
not expected to survive the next two hours. Thus it is a slightly more detailed
approach to assessing intrinsic risk than that used in the SENIC index of three
or more discharge diagnoses. Furthermore it is assessing health status prior to
surgery, whereas in the SENIC index assessment of health status is based on
number of diagnoses at time of discharge from hospital, which in infected
patients could be affected by the presence of an infection.
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The NNIS index also differs from the SENIC index with respect to the
information included regarding length of surgery. In the SENIC index there is
simply a two hour cut off point: patients with surgery lasting more than two
hours are considered to be at greater risk than patients whose surgery took less
than two hours. In the NNIS index, only those patients whose surgery took
longer than might be expected (T) are included. The 'T' value, as it is known,
was determined from information on the distribution of duration of surgery for
different operative procedures. The 75th percentile of each distribution was
identified and rounded to the nearest whole hour and used as the cut off point
for distinguishing between short and long duration. The T value identified in this
way is thus a means of identifying surgery that is taking longer than usually
expected. A study by Culver et 8/ (1991) involving data on 84,691 operations
performed on patients admitted to 44 NNIS hospitals during the period January
1987 through to December 1990, found the NNIS indices to be a better
predictor of SWI risk than the traditional wound classification system.67 It was
also found to be a reasonable predictor of postoperative infections at other
sites.67 The application of this index elsewhere is widespread. However there
are a number of important considerations. The T value was calculated from the
distributions of duration of surgery in patients undergoing operative procedures
within the NNIS scheme. It is questionable how accurately these reflect the
distribution of duration of surgery conducted elsewhere and at different points in
time. It is feasible that with the advancement of technology some procedures
conducted today are carried out in less time. There is thus a need to question
the validity of the T values prior to incorporating them in the index and if
possible develop Specific T values for the health care setting of interest.
The other issue to consider is that two of the risk factors, wound class and
duration of surgery, are potentially also markers of quality of care.
Consequently, adjustment for them in a comparative analysis of rates may
mask rather than highlight a potential problem area.
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2.10 The problem of microbial resistance to antibiotics and other
antimicrobials
Microbial resistance to antibiotics is a problem which, at the time of their
discovery in the late 1930s, was unimaginable. Antibiotics were viewed as the
magic bullet designed to treat all infections, and they undoubtedly led to safer
medical and surgical practice and increased life expectancy.150 However, soon
after their discovery problems relating to resistance developed as micro-
organisms developed mechanisms to circumvent these drugs. and there is now
the very real prospect of a post-antibiotic era.151 Bacterial evolutionary
responses to the selective pressure of antibiotics have resulted in micro-
organisms resistant to virtually every known antibiotic. In 1941 virtually all
strains of S. aureus were sensitive to penicillin. Within three years of its
introduction several strains of S. aureus became capable of f3 lactamase
production, enabling hydrolysis of the f3 lactam structure present in penicillin,
thereby removing the drugs clinical efficacy.150 In an endeavour to overcome
this specific resistance problem, semi-synthetic penicillins were produced.
Methicillin was the first such synthetic peniCillin, but was superseded by a less
toxic derivative, tlucloxacillin, although methicillin is still used for in-vitro
sensitivity testing as it has identical resistant patterns to those of f1ucloxacillin.152
Soon after the drugs introduction methicillin resistant S. aureus (MRSA)
developed,153and the frequency of isolation of this organism has increased
steadily. MRSA strains are resistant to all penicillin derivatives and are in many
cases resistant to other antibiotics. Vancomycin and teicoplanin are the only
two conSistently effective agents of use clinically.150 Many other examples of
antibiotic resistant micro-organisms can be cited. For example the global rise of
vancomycin resistant enterococci (VRE), and multi-drug resistant
Mycobacterium tuberculosis (MORTB). A number of reports have documented
the scale of the problem and situation.154-160
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2.10.1 The development of antibiotic resistance
Antimicrobial resistance may be innate or acquired. Innate resistance refers to
bacteria inherently resistant to one or more antibiotics. Many of these bacteria
do not represent a threat to healthy humans. but may give rise to infection in
hospitalised patients. Examples include the Pseudomonas species and some
Enterococci.
Acquired resistance may develop as a result of mutations in a small proportion
of a bacterial population. In the presence of the antibiotic to which it is resistant,
the proportion of these altered bacteria multiply and become more dominant.
For example, some mycobacterium tuberculosis are naturally resistant to the
antibiotic streptomycin. In the presence of this antibiotic these bacteria soon
become dominant in a population.
Acquired resistance may also develop through the transfer of genetiC material
encoding resistance from one bacterium to another. This can occur through the
direct transfer of genetic material on plasmids, on a bacterial virus or a
bacteriophage, or via the direct transfer of DNA. As before in the presence of
antibiotics. the susceptible bacteria are killed. thereby selecting out resistant
strains that subsequently become more dominant in the population.
More specifically antibiotic resistance develops through a variety of molecular
mechanisms that pathogens have developed to circumvent antimicrobials. The
House of Lords report on antibiotic resistance describes five broad mechanisms
that give rise to antibiotic resistance: inactivation. where the bacteria can
inactivate the drug before it reaches its target within the bacterial cell;
impermeability, where the outer layers of the cell is impermeable preventing the
drug from entering the cell; alteration of target site, where the target is altered
so that it is no longer recognised by the antibiotic; efflux, where the drug enters
the bacteria but is then pumped out; and by-pass where the bacteria acquire an
alternative metabolic pathway resulting in the antibiotic's target being made
redundant.154
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Inappropriate prescribing is a key factor in the development of resistance. This
includes the inappropriate use of antibiotics for self-limiting or viral infections
such as colds, and some sore throats, and where antibiotics are justified, an
inappropriate drug and/or treatment regime selected. The House of Lords
Report on antibiotic resistance comments that in the UK. whilst the present use
of antibiotics is conservative compared to that in other countries, between 5-
50% of antibiotic preSCriptions are inappropriate, the proportion varying with
geographical location.154In the US it has been estimated that over half of the
antibiotics prescribed are prescribed inappropriately; that is antibiotics are not
indicated or they are incorrectly prescribed.161The availability of antibiotics over
the counter in some countries also contributes to the situation, as does the
failure of patients to complete a full course of antibiotics.
There is some evidence to suggest that the inappropriate use of antibiotics in
animal husbandry is another contributing factor. Of particular concern is the
use of antibiotics in low quantities as growth promoters. Antibiotic resistance
may be transferred directly from animals to humans via the food chain. or
resistance may be transferred from the communal bacterial populations of
animals to the commensal bacterial populations of humans and this transferred
resistance eventually evolving into human pathogeniCforms.154
2.11 Conclusion
This chapter has examined the extent of the problem of HAl in terms of its
frequency and distribution as measured by prevalence and incidence studies,
the mortality risk associated with acquiring an infection in hospital. the aetiology
of and risk factors for HAls. and the problem of antibiotic resistance. It is clear
from the literature that HAls affect a substantial number of patients every year.
and that acquiring an infection in hospital increases an individual's mortality risk
and in some eases ean directly cause death or substantially contribute to death.
It is also clear that the risk of acquiring an infection varies considerably from
one patient to another. and a number of risk factors for these infections have
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been identified. Some are directly related to the patient's condition (intrinsic risk
factors), whilst others relate to the process of treatment and care (extrinsic risk
factors). The recognition of these factors provides valuable information that can
then be used to plan care and treatment which aims to reduce the impact of
these risk factors. It is also clear from the literature that microbial resistance to
antibiotics is a growing problem and one that needs to be tackled now.
This thesis aims to provide more timely data on the incidence of HAl occurring
in adult patients admitted to five surgical specialties common to most general
hospitals. It also aims to identify independent risk factors for these infections,
and provide some data on the impact HAl has on mortality risk in this patient
group. The thesis will not examine the important area of antibiotic resistance.
This was considered beyond the scope of both the underlying study and this
thesis. The following chapter will consider the economic burden of HAl and the
potential economic benefits of prevention.
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CHAPTER3
THE ECONOMIC EVALUATION OF HAl
3.1 Introduction
Economic evaluation is concerned with the assessment of the costs and
consequences of alternative practices,162 thus enabling the comparison of
alternative interventions in order to obtain the maximum health gain for a given
expenditure, or the lowest expenditure for a given health gain.
In the context of hospital acquired infection (HAl), it is clear from the preceding
chapter that HAls affect a substantial number of patients every year. Whilst it is
unlikely that all infections can be prevented,163the evidence suggests that a
proportion of these infections could be prevented through improvements in
infection control practice.164 Evidence from the study of the efficacy of
nosocomial infection control (SENIC) conducted in the US indicated that
hospitals with an organised hospital wide infection control programme which
included intensive surveillance, the feedback of results to those who need to
know, one infection control nurse per 250 beds and the involvement of an
infection control physician or microbiologist, on average achieved a 32%
reduction in infection rates over time.11 This evidence informed guidance
issued by the Department of Health in 1995,9 which stated that about 30% of
HAls could be prevented through improvements in infection control.
More recently, the National Audit Office (NAO) in England conducted a survey
of NHS hospitals in which they asked infection control teams (ICTs) whether
they believed a 30% reduction in rates could be achieved in their NHS Trust:
39% thought this could be achieved, 49% thought the estimate was too high,
and the remaining 12% either did not know or did not answer the question. The
NAO survey also asked ICTs to estimate what proportion of infections they
considered to be preventable in their Trust. The responses varied from less
than 5% to over 35%. The average percentage reduction across all NHS
Trusts, adjusted for the number of beds in the individual hospitals that
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responded, was 15%.3 Whilst this is a subjective assessment of the proportion
of HAls that are preventable, it does demonstrate that there is a strong belief
that a proportion of infections can be prevented. Evidence from studies which
have assessed the incidence of HAl overtime in response to various
interventions provides harder evidence that a proportion can be prevented (see
section 3.6.2).
Whilst it is clear that a proportion of HAls can be prevented, the prevention of
HAls is not cost free. Economic evaluation is thus concerned with estimating
the costs associated with these infections, and the cost of activities that aim to
prevent infection and their economic consequences, thus providing valuable
data which can contribute to decision making regarding the allocation of
resources to infection control and their use.
This chapter considers the literature relating to the economic evaluation of HAl.
It begins with an overview of the processes and techniques of economic
evaluation and discusses these in the context of HAl. Studies that have
assessed the economic burden of HAl and the benefits of investment in
prevention activities will then be revieWed.
The literature reviewed was identified through a series of consecutive searches,
carried out during the period 1993 - March 2003, using the computerised
bibliographic databases Medline and PubMed, supplemented by reference
follow up, hand searching of selected journals, and consultation with experts in
the field. The search was limited to papers published in the English language
during the period 1975 - March 2003, and further limited to studies conducted
in the developed countries of Europe, Canada, Australia and the USA. As with
the literature review reported in Chapter 2, the decision to limit the review to
literature published from the mid 1970s onwards, was based on the fact the
Study of the Efficacy of Nosocomial Infection was published at this time,
representing the beginning of a period of renewed interest in HAl.
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The search strategy involved the use of selected key words (thesaurus terms)
and combining these with a number of "free text" words. The key words used
were: hospital acquired infection; nosocomial infections; health care associated
infections; hospital-associated infections. These were combined with the
following "free text" words: economic; burden; costs; resources; cost of illness;
evaluation; length of stay. The abstract of each paper was subsequently read
and a decision made as to whether the paper was relevant to this review.
Those papers that were concerned with methodological approaches to
assessing the economic burden of HAls and studies that specifically assessed
the economic burden resulting from HAls occurring in adult non-day case
patients cared for in specialties common to most hospitals (medicine, general
surgery, urology, care of the elderly, orthopaediCS, gynaecologyand obstetriCS)
were considered to be relevant. Papers that were limited to day case patients,
children, or patients admitted to speCialities not included in this study were
excluded from the review.
References cited in papers that had not been identified through the
computerised search were subsequently followed up and hand searches of the
following journals were carried out: Journal of Hospital Infection; Infection
Control; Epidemiology and Infection Control; American Journal of Infection
Control, Infection Control and Hospital Epidemiology, Current Issues in Infection
Control; British Medical Journal. Experts in the field were also consulted to
identify grey literature such as project reports and policy documents of
relevance to this review. Experts included microbiologists, infection control
doctors, infection control nurses and health economists from the Central Public
Health Laboratory Service, the London School of Hygiene and Tropical
Medicine, the National Audit Office, and NHS Trusts in England. The published
results of the study of the socio-economic burden of HAl, the study on which
thesis is based, are not presented in this chapter, but presented in Chapter 4.
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3.2 Economicevaluation
Economic evaluations take a number of different forms including the following
approaches: cost of illness, cost-effectiveness, cost utility, and cost-benefit
analysis. Drummond (1987), when describing the various techniques available,
classifies them into two distinct groups based on whether they enable a partial
or full economic evaluation.162
3.2.1 Partialeconomicevaluations
Economic evaluations which do not include a comparator and fail to include
both costs and consequences may be considered partial evaluations. They
may be limited to a description of the outcome, or the costs, or include both
costs and outcomes but no comparator. Alternatively they may include a
comparison of two or more alternatives but be limited to the analysis of the
efficacy or effectiveness or alternatively the costs involved.
Cost of illness (burden of illness) studies are examples of partial economic
evaluations. These studies are limited to an assessment of the costs
associated with a particular illness. They aim to identify, measure and value the
direct, indirect and intangible costs of a particular illness. The approach
represents one of earliest forms of economic evaluation.165 For example, Petty
in the 17th century employed a human capital approach to assess policies such
as moving people from inner London to Hampstead Heath to prevent them
catching the Plague, and later in the mid-nineteenth century cost of illness
studies were used to justify public health activities.165
Cost of illness (COl) studies became increasingly popular in the 1950s and
1960s,166following which their popularity declined with many questioning their
value. In the past COl studies have been conducted to demonstrate the
economic burden of a disease and thus facilitate comparison of the burden of
different diseases and assist in decision-making regarding prioritising health
care and the subsequent allocation of resource. However, it has been argued
that data limited to the burden of disease has little value and may be
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misleading. By definition these studies are limited to the cost of the disease
and do not attempt to look at the potential effectiveness or cost of interventions
to prevent or treat the illness, and the benefits that might result. As such COl
studies do not provide direct guidance on the allocation of resources.167
Byford et s/ (2000) argue that without data on the costs and effectiveness of
prevention activities informed decisions about the allocation of resources cannot
be taken. The situation might arise when a decision is taken to allocate more
resources to the treatment or prevention of a particular disease simply because
it is more expensive than the others that are being considered. However,
without knowledge of the cost of the activities being considered and their
effectiveness the decision might result in additional resources being used for
little health gain.168
Similarly illnesses which impose a relatively small burden, but are easily
preventable may be overlooked. Byford et s/ (2000)168cite the example of
phenylketonuria, a disease which has a relatively low incidence and imposes a
relatively small burden on society, but which is easily preventable at low cost,
resulting in substantial health gains to the individuals concerned. Byford et s/
(2000)168thus argue that the results of some COl studies may divert the
attention of policy decisions makers away from areas where improvements and
health gains can be made at low cost
However, despite these limitations, COl studies do provide valuable data.
Whilst the results do not represent the net benefits of investment in a particular
activity, they do represent the resources that might become available if the
disease did not exist. As such the results represent the potential benefits that
might arise in terms of costs avoided, if the disease could be eliminated. These
data can subsequently be used in conjunction with data on cost and
effectiveness of activities which aim to prevent the illness and the results used
to inform policy. The results of COl stUdies can also serve to highlight the
magnitude of a problem and the items that are most costly, so facilitating
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managers' attempts to improve the efficiency of provision. They may also be
influential in setting the agenda for policy initiatives and for initiating further
evaluative studies.169 In the context of HAl a review of the literature indicates
that a number of COl studies have been conducted; these are reviewed in
section 3.4.
3.2.2 Full economicevaluations
Economic evaluations that assess both the costs and consequences of two or
more alternatives may be classified as full economic evaluations.162 Cost-
effectiveness analysis, cost utility analysis and cost-benefit analysis are all
techniques that might be used in a full economic evaluation.
3.2.2.1 Cost-effectivenessanalysis
This type of analysis involves the comparison of alternative activities, which
produce health outcomes that can be measured in the same units. For
example, it might involve the comparison of interventions whose outcome can
be measured in terms of the cost per life year gained or in the context of HAl
the cost per infection averted. Alternatively the results can be presented as life
years gained (or the number of infections averted) per pound spent. This type
of analYSis therefore allows the comparison of interventions with differing costs
and levels of effectiveness. Furthermore, providing the interventions
considered have a common effect, this approach can be used to compare the
costs and consequences of a range of different interventions
3.2.2.2 Cost-utility analYSis
In this type of analysis the outcome is expressed in terms' of utility thus
reflecting the preferences individuals or society have for a particular set of
health outcomes. It thus assesses outcomes in terms of quality of life with the
frequently used measure being quality adjusted life years (QALY). Other
alternatives include healthy years equivalent (HYE) and disability adjusted life
years (OALY). The results of this type of analysis are expressed in terms of the
cost per quality adjusted life year gained, cost per healthy year gained, or cost
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per disability adjusted life year gained by undertaking one intervention instead
of another. Providing utility measures can be developed this approach allows
the comparison of a range of interventions, and their multiple effects. However,
the approach is frequently hampered by difficulties in obtaining appropriate
utility data.
3.2.2.3 Cost-benefit analysis
Cost-benefit analysis involves a monetary value of both the costs and the
benefits of the interventions being considered. Thus this type of analysis can
be used when outcomes can be measured in financial terms, and enables the
comparison of alternatives whose outcome cannot be reduced to a single
common unit of effect and interventions that produce multiple outcomes. In the
context of HAl, the costs of a range of activities aimed at reducing the risk of
infections could be examined and a monetary value applied to the outcome
measure of the number of cases of HAl averted.
3.3 Theeconomicevaluationof HAl
In 1992 Haley commented that the number of studies estimating the economic
burden of HAl has increased sharply since the mid 1970s.170 Since that time
many more studies have been published. Many of these are partial evaluations
adopting a cost of illness approach, whereas others have attempted a full
economic evaluation adopting techniques such as cost effectiveness and cost
benefit analysis. Economic modelling, utilising data from a variety of data
sources, has also been conducted. Studies which have included an
assessment of the economic burden of HAl are discussed in section 3.4 and
those that have assessed the cost and benefits of investment in infection control
are considered in section 3.5.
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3.4 Estimates of the economic burden of HAl
As indicated above, a number of studies have assessed the economic burden
of HAl. Tables 3.1 - 3.6 provide an overview of studies conducted since 1975
that have assessed the burden of HAl to the hospital sector and the estimates
derived. Table 3.1 presents estimates of the economic impact of all types of
HAl and Tables 3.2 - 3.6 present estimates of the economic impact of specific
types of infection.
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The estimates presented in Tables 3.2-3.6 demonstrate that the estimated
impact of HAl not only varies considerably with site of infection, but also with
study. The observed variations can in part be attributed to methodological and
case-mix differences. Methodological differences include variation in the range
of costs included, the methods used to attribute resources to HAl, and the
methods used to value resources. Other methodological differences relate to
the definitions of HAl used, and the methods used to identify HAls.
Variations in the case-mix studied include important differences in the types of
patients studied and the treatment regimes received. For example, some
studies include a broad case mix of patients whereas others focus on a
particular patient group defined by operative procedure or specialty. Treatment
pattems also vary with hospital and over time. For example, patients are
discharged home at an earlier point in their recovery today than a few years
ago. This changing treatment pattem will inevitably impact on the cost
estimates derived and will prohibit valid direct comparisons between the results
of studies conducted at different times.
Despite these important differences, some common themes emerge from the
literature. Before considering these, some of the key methodological
differences and issues that emerge from the literature will be discussed.
3.4.1 Therange of costs resulting from HAl
The acquisition of an infection in hospital may have an impact on the costs
incurred by the health care sector, community care services, affected patients,
those who care for them, the economy and the environment. For example,
HAls may result in additional costs to the hospital sector, general practitioners,
district nursing services, community midwifery services and a range of other
health and community care services. Patients may experience an increase in
personal expenditure on items such as drugs and dressings and incur financial
losses due to a reduction in eaming capacity as a result of delayed, or in some
case a failure to return to work. Patients may also incur non-financial costs in
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the form of a temporary or long term reduction in health status. Informal carers
may also lose work or leisure time. Society may be affected also. Production
losses may result from a delayed or non-return to work. Environmental costs
may ensue as a direct consequence of efforts to treat HAls, e.g. the treatment
of HAls may result in an increase in the use of dressings, which subsequently
have to be destroyed, at a cost to the environment.'84
The range of costs to be included in an evaluation of the burden of HAl will
depend on the viewpoint to be taken. If a societal viewpoint is adopted than all
costs should be included, whereas if the viewpoint of the health service is
adopted then the range of costs may be limited to those that impact on the
health service. Studies that have estimated the economic burden of HAl tend to
limit the range of costs included to those that fall on the hospital sector as a
result of additional in-patient care. Haley (1992)170 suggests that this deficiency
is perpetuated by the use of economic studies to persuade hospital managers
of the financial importance of infection. There are however a few exceptions.
Davies and Cottingham (1979)13 in their study of HAls occurring in orthopaedic
patients, included the impact of infection on primary health care services, and
Elliston et 8/185 in a small study involving 71 patients who had a surgical wound,
examined the incidence of SWls presenting after discharge and their impact on
community health care services Kirkland et s/ (1999)88 in their study of SWls
occurring in surgical patients admitted to a hospital in the US extended their
cost analysis to include the costs associated with re-admission to hospital within
30 days of discharge. Hyryla et 8/ (1994)177 considered the implications of HAl
for the Finnish social security system; Poulsen et 8/ (1994)176 examined the
impact of HAlon the Danish social security system; Persson et s/ (1988)188
included a value for the loss of health suffered by patients as a result of an HAl;
Fabry et 8/ (1982)10 examined whether SWls delayed the time of retum to work;
and Dashner (1989)184 has examined the environmental consequence of
selected treatment interventions.
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3.4.2 Attributing resourcesto HAl
McGowan (1982) notes that attributing resources and their associated costs to
HAl is difficult.187 Studies have generally used one of three key methods to
attribute costs to the presence of infection: the concurrent method, comparative
method and comparative method with matching (see Haley et al., 1980;
McGowan, 1981; McGowan, 1982; and Haley, 1992 for a detailed discussion of
these methods).48170187188
With the concurrent method a suitably qualified individual reviews patient
records and identifies which resources were used as a result of an infection.
Given the subjective nature of assessment of resources attributed to infection
the validity and reliability of the approach has been questioned.187 It has also
been suggested that physiCian reviewers may be reticent about attributing the
use of resources to HAl, and as such costs are likely to be underestimated.48
To a degree some of these criticisms were overcome in a study by Wakefield et
sI (1987).189 Trained personnel reviewed medical records, using a carefully
prepared protocol -'the appropriateness evaluation protocol' - to assess
whether each in-patient day was (a) attributable to the reason for admission, (b)
jointly attributable to the reason for admission and the HAl, or (c) attributable to
the HAl alone. This approach has been found to be both repeatable and
valid.190-192However, the approach is dependant on detailed and accurate
hospital records being available.
The comparative method involves assessing the cost of resources used by
infected and uninfected patients, and then attributing the differences between
the costs observed to the presence of an infection. This method therefore
assumes that the two groups (infected and uninfected patients) are the same in
all respects except for the presence or absence of an HAl. This is clearly not
the case. There may be many factors, other than HAl, which differ between
these two groups and which also have an impact on resources used.
128
The comparative method with matching attempts to control for factors other
than HAl that might differ between the two patient groups. Infected patients are
matched with one or more uninfected patients on the basis of factors thought to
have an impact on resource use. Studies have generally matched patients
using a combination of the following factors: age, sex, diagnosis, number of co-
morbidities and type of operation (Tables 3.1 - 3.6). The resources used by
patients and controls are then compared, and the differences in costs attributed
to the HAl. Haley (1991) notes that it is important that the differences between
the cost incurred by infected and uninfected patients are first determined for
individual patients, and then either summed (or averaged) to determine the total
(or average) costs attributable to infection. Haley (1991)193notes that a
common mistake in studies of this type is to break the matching, and simply
compare the total costs incurred by infected patients, to cost incurred by
uninfected patients. This approach is invalid and may lead to biased estimates
of the costs attributable to HAl.
This comparative method with matching approach is hampered by practical
difficulties associated with finding suitable control patients. Many studies have
been unable to match all infected patients with uninfected controls. Haley et s/
(1980)48 in a review of matched studies conducted between 1953 and 1975,
found considerable variation in the percentage of infected patients successfully
matched with uninfected patients. Successful matching of infected patients with
uninfected patients ranged from a low of 32 per cent to 100 per cent. Scheckler
et 8/ (1978)171in a study to assess the economic burden of HAls occurring in
104 patients admitted to a community hospital in the US between January and
March 1978, was unable to find a sufficient number of suitable controls and as
such had to abandon this approach to attribution of costs. Rubenstein et s/
(1982}69 in a study involving 152 infected general surgical and orthopaedic
patients was only able to find suitable controls for 59% of patients. A similar
proportion of infected patients were successfully matched in a study by
Kappstein et s/ (1992)182which assessed the excess costs and LOS resulting
from ventilator associated pneumonia occurring in patients admitted to the
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intensive eare unit of a University Teaching Hospital in Germany. Kappstein et
a/ found that after excluding eases that died during their admission, suitable .
controls could only be found for 34 of the 57 eases (60%). A more recent study,
conducted in the UK, successfully matched 67 (85%) of the 79 infected surgical
patients for whom medical records were available for review,14whereas a study
conducted in Turkey in 1994 involving general surgical patients successfully
matched only 67% of their 225 infected patients.61
Freeman (1979)111notes that the ability to find matched uninfected patient
depends on the size of the pool of uninfected patients and the number of
matching characteristics. The absence of a suitable pool of uninfected patients
may necessitate a reduction in the number of matching parameters, thus
reducing the comparability of the infected and uninfected groups, and/or the
exclusion of unmatched infected patients from the analysis, which in some
cases, may limit the analysis to an un-representative subset of infected patients.
Both responses may have an impact on the accuracy of the estimates of the
costs attributable to HAI.193
In 1980 Haley et a/ (1980) compared the concurrent and comparative method
by using both to study the same population.48 Haley found that the closer the
matching the lower the estimate of the number of additional days attributable to
infection. However, regardless of the level of matching the comparative method
appeared to overestimate the number of days attributable to HAl compared to
the results derived using the concurrent method. At the same time it was
acknowledged that the concurrent method may underestimate the cost of HAl.
The physician-epidemiologist tended to attribute extra days to HAl only if they
were clearly the consequences of a HAl.
Haley (1991) suggests that one of the problems with studies utilising the
comparative approach is that matching parameters such as age, sex, service,
first diagnosis and first operation do not adequately control for differences
between infected and uninfected patients which may have an impact on
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resource use.193 Matching should ensure that prior to the acquisition of an
infection, infected and uninfected patients have the same predicted length of
stay and level of resource use. Haley argues that diagnostic related groups are
the best predictor of length of stay, and that this should be included in such
studies, together with the number of discharge diagnoses. This latter measure
increased the predictive power of the diagnostic group on length of stay and
level of resources used. Together these factors have been found to explain
34% of the variance in length of stay.193
3.4.3 Estimating the cost of resources attributable to HAl
Economists measure costs as the benefit forgone by using resources in one
way rather than in another, more precisely the next best alternative use. In the
context of HAl, it is probable that resources used to care for patients with an
HAl would, in the absence of the infection, have had alternative uses. The
benefits forgone represent the opportunity costs of HAl.
Deriving estimates of the opportunity costs of HAl presents a number of
difficulties. The most common method to estimate the value of resources used
in one way, as opposed to another, is by applying monetary prices. However,
prices will only approximate the opportunity costs if markets are 'perfect'. For a
number of reasons markets are not 'perfect.' For example there are problems
associated with uncertainty, imperfect information, externalities and the number
of firms given size of the market.1M Furthermore, few health care systems
generate prices and when they do, for example charges in the US health
system, they may not reflect the cost of resources. For example, cost shifting
may be present as a result of hospitals shifting their· charges for under-
reimbursed costs to those payers with which they can recover more than their
costS.170195 To overcome these diffICulties some studies, particularly those
conducted in the US, have applied a cost-to-charge ratio in an endeavour to
convert charges to costs. This measure is generally the ratio of the sum of the
total hospital expenditure per annum to the sum of patient charges per annum.
The cost-to-charge ratio typically lies between 0.6 and 0.8.193 This approach
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overcomes some of the bias associated with applying charges, however the
estimate derived is a somewhat crude estimate of total costs attributable to HAl,
and as a result of cost shifting, may not be accurate for individual patients and
departments.193 This latter criticism can be overcome to a degree by stratifying
the resources and associated charges attributable to HAl by individual
departments, and applying a department based cost-to-charge ratio to these
charges.
Dawson (1994) argues that the costs derived from the UK health sector are
usually the result of mechanistic accounting conventions designed to recover
expenditure rather than reflect resource use.196 For example, the allocation of
overheads and capital charges are made by convention. These costs are a
significant proportion of total costS.197
In many studies average unit costs are applied. For example, the number of
additional days a patient with an HAl remains in hospital is determined and an
average cost per bed day applied. This approach may also introduce bias into
the estimates derived. Average costs are a function of the total quantity
produced. Thus if the cost per day in hospital is considered, the average cost
per bed day is a function of the total number of bed days produced. Average
cost estimates derived from hospitals operating at different levels of capacity
will therefore differ. Furthermore daily costs will differ over the period of
hospitalisation. For example, HOllingsworth et 8/ (1993) found that patients
admitted to hospital with a fractured neck of femur incurred relatively high daily
costs during the first few days in hospital, after which they decreased.198 This
pattern of daily costs is likely to vary with type of patient and in patients who
acquire an infection in hospital.
An alternative approach to those identified above is the cost accounting
approach, or what Haley (1991) has described as 'micro costing.'193 This
involves determining the actual cost of delivering the identified services. This
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approach provides more accurate and valid estimates of the costs attributable
to HAl but is time consuming, costly and difficult to conduct.
3.4.4 Alternative measures of the /mpaet of HAl
An altemative measure of the impact of HAlon resource use is the number of
additional days patients remain in hospital as a result of HAl. Haley argues that
this is a harder measure of the cost of HAl as it is subject to less variation from
year to year than charges which are subject to inflationary pressures.170 193
Studies generally provide estimates of both the number of additional days in
hospital and the costs incurred. A few studies have also presented data on the
number of antibiotic days and the number of investigations.1•
3.5 Estimatesof the economicburdenof HAlto the hospital sector
As indicated above the estimates of the economic burden of HAl presented in
Tables 3.1 - 3.6 vary considerably with the site of infection and also within any
site specific category. Whilst in part this can be attributed to methodological
and case mix differences some common themes emerge from the literature and
are discussed below.
3.5.1 Estimates of the cost of spec/fie types of HAl
Infections of the urinary tract are generally the least expensive, whereas the
more costly infections tend to be infections of the bloodstream, chest and
infections at more than one site. This is clearly demonstrated in the few studies
that have assessed the cost of different types of infection occurring in the same
patient population. A US study which estimated the impact of HAls at differing
sites occurring in patients admitted to three hospitals in the US in 1975/6 found
that on average UTls increased the patients LOS by one day (additional cost
$594); pneumonia increased the patients LOS by six days (additional cost
$4,947); BSls - seven days (additional cost $3,061) and SWls seven days
(additional cost $2,734).1'.
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Data from a UK study of 67 surgical patients with an HAl estimated the cost per
UTI to be £467, SWI £1,454 and multiple infections £3,362. On average UTls
extended the hospital stay by 4 days, SWls 10 days and multiple infections 26
days.14
Overall the results presented in Tables 3.2-3.6 indicate that there are marked
variations in the estimates of the impact of different types of infections on the
hospital sector. Estimates of the number of days that may be attributable to a
UTI vary from 1 to 13 days. In contrast estimates of the impact of SWls on
hospital LOS range from a low estimate of 1.3 additional days in a study limited
to women who had a caesarean section175to 33.2 additional days in a study
which involved patients whose infection warranted compensation from the
Finnish Social Security system.177 Estimates of the impact of 8SIs on hospital
LOS range from 7 to 14 extra days, and estimates of the impact of chest
infections vary from 2.5 to 10.3 additional days. Finally estimates of the impact
of HAls at more than one site vary from 18 to 26 additional days.
3.5.2 Est/mates of the cost of HAls occurring /n selected patient
groups
Costs have also been found to vary considerably with patient group. This may
reflect differences in the type of infection occurring in the selected patient group,
which in turn have different resource implications, and/or the implications of the
infection for resource use in the selected patient group. Infections occurring in
intensive care patients have been found to be particularly resource intensive.
For example, Pittet et 8/ (1994) estimated that 8SIs occurring in ITU patients
cost $40,000 per survivor.113 Amongst the surgical specialties, infections
occurring in orthopaedic patients also appear to be particularly costly. Coello et
s/ (1993) estimated the average cost per HAl occurring in orthopaedic patients
to be £2,646. This compared to £1,365 per HAl occurring in general surgical
and urology patients, and £404 per HAl occurring in gynaecology patients.14
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3.5.3 The distribution of the additional hospital costs resulting from
treatingHAls
Some studies have attempted to disaggregate the cost estimates derived and
have examined the distribution of the in-patient costs. For example, Coello et a/
(1993) estimated the costs associated with an extended length of hospital stay,
antibiotics, microbiology tests and radiological investigations: 93% of the total
additional cost incurred by surgical patients with an HAl could be attributed to
an extended length of stay.14 A number of other studies have also looked at the
distribution of costs, but as with the 'study by Coello, they have generally limited
the distribution of costs to those linked to time in hospital, antibiotics,
microbiology tests and x-rays (e.g. Davies and Cottingham, 1979; 13Wakefield
et a/., 1987)189
3.5.4 Thenational burdenof HAls
National estimates of the burden of HAl are also presented in the literature. In
the US HAls have been estimated to cost the hospital sector $4 billion,12 and in
a paper by Losos et a/ (1984)199 the direct and indirect costs of HAls affecting
patients in Canadian acute care hospitals were estimated to be between $300
and $1billion depending on the estimates of incidence and excess length of stay
used.
In the UK, in 1981 a crude estimate of the additional costs of HAl was
presented in an editorial in the Journal of Hospital Infection.2oo Based on the
assumption that HAls extend LOS by at least three days; the average cost per
day in hospital is £50; and 5% of patients acquire an infection in hospital, it was
estimated that HAls were costing the hospital sector in England alone at least
£30 million per annum.
In 1988, a Joint DHSS/PHLS working group derived an estimate that was
considerably higher. It was estimated that in England 950,000 bed days were
lost per annum, at a cost to the NHS of £111 million.(DHSS/PHLS, 1988) This
figure was derived using what Haley has termed the .back of the envelope
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approach' or crude weighting.170 It was assumed that 5% of patients acquire an
infection in hospital and this, on average, extends the hospital stay by four days.
These assumptions were then applied to the total number of admissions to NHS
provider units in England and an estimate of the number of bed days lost, and
costs incurred, based on an average cost per day, derived.
In 1993 Coello et af14 based on the results of a study examining the burden of
HAl occurring in surgical patients admitted to one district general hospital
estimated that HAls occurring in surgical patients alone cost NHS hospitals in
England. £170 million per annum.
As indicated above the overall cost to the hospital sector is a function of both
the cost per case and the incidence of HAl. Data from the US indicates that
although UTls account for 45% of HAls. they only account for 13% of the
additional costs incurred. whereas pneumonia accounts for 19% of HAls. but
accounts for 39% of the additional costs and SWls account for 29% of HAls, but
account for 42% of the additional costs. BSls account for 2% of HAls, but 4% of
additional ccsts.n
3.6 Assessmentof the benefitsof prevention
Studies that have assessed the benefits of prevention vary considerably in
scope and study design. They can be broadly categorised into those that have
assessed the gross benefits of prevention. that is they have not taken into
account the costs of achieving a reduction in rates; those that have taken into
account the costs of prevention and assessed the net benefits of prevention;
and those that have looked at the cost of carrying out selected ineffective
'prevention' activities.
When evaluating an economic study Drummond (1987)162 suggests that the
evaluator should consider ten key questions which aim to identify the presence
or absence of ten methodological features of a well conducted economic study.
However. in the context of studies that have assessed the costs and benefits of
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infection control practices, Drummond201 suggests that the following six areas
are of particular relevance and should be considered in any assessment: the
viewpoint selected; the alternatives selected for comparison; the range of costs
and benefits considered; how costs and benefits were assessed; whether
incremental analysis was conducted; and whether the evaluation included
sensitivity analysis.
As in any economic evaluation a choice of viewpoints can be selected, ranging
from a very broad viewpoint such as that of society, to a narrower viewpoint
such as the health sector, the hospital sector or the infection control team itself.
The majority of studies reported in the literature take the viewpoint of the
hospital sector and neglect costs and benefits falling elsewhere.
The alternatives selected will clearly depend on the focus of the study.
However, as pointed out by Drummond201 it should be noted that one of the
problems facing such economic evaluations is that infection control practices
tend to be complementary - they do not work in isolation. As such it is difficult
to tease out the costs and benefits of a particular infection control practice. An
exception is those studies that have assessed the costs and benefits of
selected prophylactic antibiotic regimes. These studies tend to be part of a
randomised controlled study, designed to control for factors other than the
presence or absence of the drug that might impact on infection rates.
The range of costs and benefits included to a greater extent will depend on the
viewpoint adopted in any given study. As indicated above this tends to be the
hospital sector and as such the range of costs and benefits tends to be limited
to those experienced by the hospital sector
The methods by which costs and benefits are assessed are clearly of great
importance. This includes how the costs associated with the intervention are
identified and valued and how avoided costs, that is the costs of infections
averted are identified and valued. The methods by which the costs are
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identified, attributed to HAl and valued will have implications for the reliability
and validity of the results obtained.
Incremental analysis is also important. Incremental analysis provides important
data on how much should be invested in infection control practice. It allows for
the determination of the most economically optimal level of control, such that
any additional investment in infection control will result in costs greater than the
benefits that are likely to result, and any less investment will result in benefits
greater than the costs of achieving a lower infection rate. Drummond201 makes
reference to a study by Persson et 81 (1988),186 which assessed the costs and
benefits of antibiotic prophylaxis in patients undergoing total hip replacements,
and adopted this approach to the analysis of data.
Testing the sensitivity of study results to underlying assumptions is also
important. Economic evaluations frequently include a number of assumptions,
and the robustness of the results to changes in the parameters used in the
study should be assessed. Drummond201 makes reference to a study by
Weinstein et 81 (1986)202 in which assumptions about the range of clinical
practices and costs were subjected to sensitivity analysis.
3.6.1 Estimates of the gross benefits of prevention
The results of the recent NAO survey of ICTs at acute NHS Trusts in England
indicated that ICTs believed that a proportion of infections could be prevented.
Estimates of the proportion of infections that could be prevented through
improvements in infection control varied with NHS Trusts. After adjustment for
the number of beds at each hospital, the results of the survey indicated that on
average ICTs believed that a 15% reduction in infection rates could be achieved
(bed weighted average). Applying this figure to the most recent estimate of the
national burden these infections place on the health sector in England, the NAO
estimated that a 15% reduction in infection rates would result in the release of
resources valued at £150 million.3 This estimate represents the gross benefits
of prevention. The net benefits of prevention would be dependent on the costs
of achieving a reduction in rates.
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3.6.2 Estimatesof the net benefits of prevention
Studies that have estimated the net benefits of prevention can be broadly
categorised into those that have assessed the benefits of an effective infection
control programme, those that have focussed on the costs and benefits of
prophylactic antibiotics; and those that have assessed the costs and benefits of
selected infection control practices. The approach adopted in these studies
varies, with some utilising economic modelling techniques and others,
particularly those concerned with assessing the costs and benefits of alternative
prophylactic antibiotic regimes, utilising a randomised controlled trial study
design.
3.6.2. 1 Studies that have assessed the benefits of an effective infection
control programme
A number of US estimates of the potential benefits of investing in an infection
control team and programme are presented in the literature. In 1975, the US
Centre for Disease Control estimated the cost and benefits of an infection
control programme implemented in a 250 bed hospital. These estimates were
subsequently revised in 1979, and further adjusted to 1985 prices in 1986.11
The cost of establishing and maintaining an infection control programme in
1985 prices was estimated to be $60,000. This estimate includes the cost of
employing an infection control nurse, a part time physician consultant, half-time
clerical support, consumables and the cost of overheads. Earlier work indicated
that HAls cost the average 250 bed hospital $1 million per year. Consequently
a 6% reduction in the costs associated with infection would pay for the cost of
the infection control programme and any further reductions would result in
greater returns for the investment.
Dixon (1987)203presents a similar hypothetical model of the costs and benefits
of infection control in the US. The model relates to a hypothetical 250 bed
hospital, with 12,000 adult and paediatric admissions per year. Based on the
findings of the SENIC study Dixon estimated that in the absence of an effective
infection control programme this hypothetical hospital would have an estimated
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713 HAls per year; whereas in the presence of an effective programme there
would be an estimated 487 HAls per year. Estimates of the costs of these
infections were subsequently made, utilising data from an earlier study by Dixon
in 1978.181 The results indicated that HAls occurring in a hospital without an
effective infection control programme would cost the hospital sector in terms of
excess charges an estimated $800,000 per year, whereas the cost in hospitals
with an effective programme would be $550,000: a cost saving of $250,000 per
year. Dixon subsequently estimated the cost of an effective infection control
programme, to be $80,000. When these costs are taken into account, the net
savings to the hospital per year were estimated to be $190,000. Dixon
acknowledges that these estimates are crude. In reality the level of savings
may vary considerably. However, he points out that the costs used in his model
were conservative estimates of the economic burden of HAl and as such the
actual savings could be more substantial. He also notes that the estimates
used were average costs estimates. As such in a hospital that treats a greater
proportion of high risk patients or provides high tech care, the costs savings
may again be greater than estimated in his model. Finally he notes that the
estimates of incidence and the level of HAls that can be prevented were taken
from the SENIC data derived in 1978. The SENIC study found that incidence
rates were increasing in hospitals without effective programmes and falling in
hospital with such programmes. As such again the benefits might be greater in
some hospitals. However, in other cases the estimates may be over estimates.
For example, the potential for reducing HAls rate may be lower in some
hospitals as a result of a low risk case mix.
In 1994, Wenzel presented a similar model of the costs and benefits of
investment in infection control programmes as part of a lecture at the 3rd
International Conference of the Hospital Infection society.204 Based on a
number of assumptions, about the cost of an effective infection control
programme, the number of admissions per annum to a 250 bed hospital, the
incidence of HAl and the impact these infections have on length of hospital stay
and costs, Wenzel demonstrated that depending on whether the incidence of
140
HAl was 10% or 5%, the costs of the programme would be re-cooped if 12.5 to
25% or infections were prevented. It should be noted that the costs of infection
included in this model were limited to the marginal costs estimated to amount to
$84,000. If the full costs of hospitalisation had been included in the cost
estimates, estimated at $2.52 million, the proportion of infections that would
need to be prevented to cover the cost of the infection control programme would
be substantially reduced. If a wider cost perspective was taken, such that costs
incurred by the health service post-discharge and the cost to the patients and
carers were included the proportion of infections that would need to be
prevented to cover costs would be lower still.
Wenzel (1995)204 also presented estimates of the cost per life year gained as a
result of effective prevention activities. These estimates were derived from a
hypothetical model incorporating data on the cost of an infection control
programme in 250-bed hospital, and incidence, mortality and attributable
mortality rates. The results indicated that if it could be assumed that the quality
of life of those patients who would have died from an infection if it had not been
prevented was excellent, the cost per year of life saved compared favourably
with the cost per life year saved as result of other preventative programmes,
and the cost per quality adjusted life year of other programmes. Furthermore.
Wenzel argued, that even if the quality of life year was only a small proportion of
100% or if the programme costs were considerably higher that those estimated
in the model, infection control would continue to compare favourably to other
programmes and as such was one of the most cost effective prevention
activities. However, it should be noted that this model assumes that infections
that directly cause mortality are preventable. It is not clear how preventable
such infections are or how costly prevention of such infections would be.
Further work is perhaps required to refine such a model and apply it to a
specific situation such as a particular type of infection occurring in a defined
patient group. However, despite this limitation, the models presented in the
paper by Wenzel (1995) provide valuable insight into how cost and mortality
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data can be used in conjunction with other data variables to demonstrate the
potential benefits of investment in infection control.·
An economic model developed by Miller et al (1989)205 also demonstrates the
benefits of investing in an effective infection control programme. The model
incorporated data on admission and infection rates at the University of Virginia
Medical Centre in the US in 1985, hospital charges associated with infections
and the likely level of effectiveness of an infection control programme as
defined by the SENIC study. Based on this data, Miller et al (1989) estimated
that in 1985, the infection control programme which, with the exception of
reporting back surgeon specific rates, met the criteria for a very effective
programme as defined by SENIC, generated income amounting to $2,401,709.
In the UK Currie et al (1989),206assuming the national burden of HAl amounted
to £111 million (based on an earlier Department of Health estimate) estimated
that a reduction in the incidence of HAl by 20%, 32% and 50%, after offsetting
the costs of the infection control teams and their programmes, would produce
annual savings of £15.6 million, £29.3 million and £50 million respectively to the
NHS.
3.6.2.2 Studies that have assessed the costs and benefits of antimicrobial
prophylaxis
A number of studies have assessed the costs and benefits of antimicrobial
prophylaxis,175186207-212and a review article by McGowan (1991) 213 discusses
issues relating to the assessment of the costs and benefits of this form of
prevention. Many of these studies have found that the benefits, measured in
terms of a reduction in the incidence of HAl and the associated costs, outweigh
the costs of the intervention, although the level of benefits differs with
altemative regimens.186211213 For example, Shapiro et al (1983)207examined
the costs and benefits of antimicrobial prophylaxis in abdominal and vaginal
hysterectomy. The use of the prophylactic antibiotics was found to reduce costs
by $102 and $492 per patient respectively. However, the authors note that
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these savings would be lost if more expensive antibiotics had been used
(unless they were more effective), and if the duration of administration was
extended. Mugford et al (1989)175 examined the costs and benefits of
prophylactic antibiotics administered to patients undergoing caesarean section.
Data on the effectiveness of prophylactic antibiotics were obtained from 58
controlled trials, and estimates of the costs associated with the alternative
antibiotic regimens, and the costs of treating infections if they occurred were
derived locally. The administration of prophylactic antibiotics was associated
with a significant reduction in the incidence of SWI and a reduction in health
care costs. Expenditure on prophylactic antibiotics was more than
compensated for by the savings that resulted from a reduction in the incidence
of HAls and the associated treatment costs.
Persson et a/(188)188 examined the use of prophylaxis in total joint replacement
surgery. Four approaches were considered, both in isolation and combination:
systematic antibiotics, polymethylmethacrylate cement impregnated with
gentamicin; surgical enclosure, exhaust ventilated suits. This study is
interesting in that it did not simply look at the costs to the hospital sector, but
also assigned a value to the effects of loss of health. The authors argue that
the selection of an appropriate prophylactic regime should not be solely based
on reducing costs to the hospital sedor. The inclusion of a variable
representing the value of loss of health, produced an economic optimum that
allowed selection of a more costly regime and subsequently further reductions
in infection rates and the need for re-operation.
3.8.2.3 Studies that assessed the costs and benefits of specific prevention
activities
In addition to the above some studies have assessed the costs and benefits of
specific infection control practices. For example, O'Oonoghue et a/ (1992)178
assessed the costs and benefits of procedures introduced to curtail an outbreak
of ten serious surgical wound infections occurring in orthopaedic patients that
occurred within 1-2 weeks of surgery. The cause of these infections was
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thought to be five damaged mattresses, found to be colonised with S.SUf8US,
E.fsecslis, coliforms and Pseudomonss species, which were subsequently
replaced. The costs of this intervention was assessed and compared to the
cost of the infections, through a retrospective case control study. The ten SWls
were estimated to cost the hospital sector £22,199. The cost of replacing the
mattresses was just £182.
A study by Lynch et sI (1992) 65 assessed the cost and effectiveness of using
chlorhexidine detergent in pre-operative whole-body disinfection as a means of
preventing SWls. The results of their randomised controlled trial, conducted
between April 1987 and December 1999, indicated that whilst the SWI infection
rate was lower in patients who used the chlorhexidine body wash than that
observed in patients who received the placebo, the difference was not
significant at the 0.05 level of significance, and there was no significant
difference in the costs of treating infected patients in the placebo or treatment
group.
Slater et sI (2001)214estimated the potential savings of employing a vascular
catheter-care specialist nurse for the surgical leu within a US hospital, as a
means of tackling the problem of catheter associated BSls. The costs of
employing the nurse were compared to the potential savings that might accrue if
one infection per month was prevented. The potential benefits in terms of the
estimated value of resources released if one infection per month was prevented
were found to be greater than the costs of employing the nurse. A specialist
nurse was subsequently employed. Within nine months of employment 18
fewer BSls than the previous year had been identified. Assuming that on
average each bloodstream infections utilises hospital resources valued at
$6,000 per infection, this represented gross savings estimated at $108,000 and
estimated net savings of at least £58,000.
Plowman et s/ (2001)215developed a model for estimating the costs and
benefits associated with the routine use of silver alloy coated urinary catheters
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as a means of preventing a hospital acquired catheter related UTI. The results
of their model indicated that in England a 14.6% reduction in UTls in
catheterised medical patients and a 11.4% reduction in surgical patients would
cover the cost of this intervention and any further reductions would result in net
benefits.
3.B.3 Estimates of cost savings resulting from not carrying out
'prevention' activities which have little or no positive effect
A number of studies have looked at the. appropriateness of allocation of
resources to infection control practices considered to have little or no positive
preventative effect. For example, lawrence et al.216 assessed the costs of
routine pre-operative urine testing and subsequent treatment of asymptomatic
bacteriuria in patients admitted for elective non-prosthetic knee surgery. The
results indicated that routine screening and treatment cost $1.5 million per SWI
prevented.
Daschner (1984) provides a summary account of a number of changes that
were made to infection control policy and practice in a hospital in Germany and
the estimated cost savings.217 The aim was to move to more cost effective
practise and away from infection control lrituals' with little or no proven efficacy.
For example, in the absence of an epidemic, routine environmental culturing
and screening of staff for staphylococci was discontinued as was twice daily
meatal care with PVP-iodine, changing of intravenous infusion sets every 24
hours and the use of in-line filters as a means of reducing urinary tract and
bloodstream infections. These other changes were made in response to
research findings. The estimated cost savings to the hospital sector as a result
of these and other changes in practice over a six year period between 1977 and
1982 was 5,522.471 OM.
3.7 Conclusion
The economic evaluation of HAl presents a number of methodological
difficulties. To date studies have tended to focus on the assessment of the
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burden of HAl and relatively few have assessed the costs and benefits of
investment in infection control activities. Studies that have assessed the
economic burden of HAls vary in scope and in terms of the methods used.
However, despite these differences it is evident that the burden imposed is
substantial. It is also evident that the economic burden varies with type of
infection and admission specialty.
Evidence from a variety of sources indicates that whilst not all infections can be
prevented some can, and studies that have directly assessed the costs and
benefits of infection control activities, and the results of economic modelling
exercises indicate that the benefits of investment in some cases may be
considerable.
Many of the studies that have assessed the burden of HAl and the benefits of
prevention have been conducted in countries other than England. Whilst the
overall message that HAls utilise considerable levels of health sector resource
and impose a burden on the primary health sector, patients and carers is likely
to be transferable to HAls occurring in patients admitted to hospitals in England,
the magnitude of resource use may vary. Similarly, whilst the overall message
that investment in infection control activities may result in positive benefits, both
in terms of health gains and the release of resources for altemative use is likely
to be applicable to the situation in England, the magnitude of these benefits
may also vary.
This thesis aims to provide more timely and relevant data on the costs
associated with HAls occurring in adult patients admitted to five surgical
specialties common to most hospitals in England. These data may
subsequently be used to demonstrate the burden these infections impose and,
in conjunction with information on the cost and effectiveness of prevention
activities, may be used to assist in demonstrating the benefits of prevention,
and the results subsequently used to inform policy and practice.
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CHAPTER4
THE STUDY OF THE SOCIO·ECONOMIC BURDEN OF HAl
4.1 Introduction
As indicated in chapter one of this thesis, this work has developed from a study
that assessed the socio-economic burden of hospital-acquired infections (HAl)
occurring in adult, non-day case patients admitted to selected medical and
surgical specialties of a district general hospital (DGH) in England.2 This thesis
is concerned with the incidence of HAl occurring in a sub-set of patients
admitted to the surgical specialties, and the costs incurred by the hospital sector
during the hospitalised phase. The methods employed in the socio-economic
burden of HAl study have been reported in detail elsewhere.2 However, since
the methods employed form part of this thesis an overview of the study is
provided in this chapter. The aims and objectives of the study are presented,
followed by an overview of the research methods employed. Special attention is
given to methods of relevance to this thesis.
The chapter limits itself to work undertaken as part of the socio-economic
burden of HAl study. Details of how a subset of data relevant to this thesis was
selected, the statistical analysis undertaken for the purpose of the thesis and
management issues relevant to the thesis alone are presented in the following
chapter (Chapter 5). A summary of the main results of the Socio-economic
Burden of HAl study can be found in the study's Executive Summary, at the
back of this thesis. A copy of a peer-reviewed paper, which presents the main
results of the in-patient analysis, can also be found at the back of this thesis.'
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4.2 Aimsandobjectivesof the socio-economicburdenof HAlstudy
4.2.1 Aim
The socio-economic burden of HAl study aimed to assess the burden of HAl in
terms of the costs to the public sector, patients, their families and society as a
whole.
4.2.2 Objectives
The specific objectives were:
I) To determine the overall burden of HAl in terms of:
a) the cost to the secondary and primary health care sectors and
community care services;
b) the impad on the health status of patients;
c) the costs to patients and their families, and to the economy.
II To establish the relative costs of different types of HAl.
III To determine the type of patients that incur the highest costs for specifiC
infections.
IV To use the data obtained to construct models to predict the effects of HAl
on the cost categories described above.
4.3 Overviewof study design
The socio-economic burden of HAl study was designed to assess the impad of
HAlon the secondary and primary health eare sectors, community eare
services, informal carers and patients themselves. Adult, non-day case patients
were recruited from selected wards of a DGH and daily profiles of the resources
used by patients with and without 8 HAl were obtained. Those patients who
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presented with a HAl during their in-patient stay and a sample of patients who
did not, were followed up after discharge from hospital, using a structured
questionnaire. This questionnaire aimed to alert the project team to possible
infections experienced after discharge from hospital and provided information
on care received from health and community care services, family and friends.
It also provided information on costs incurred by patients and health status post-
discharge. More detailed information about care received from health care
services post-discharge was subsequently obtained from the patients' health
care records. Estimates of the cost of the resources used were made.
Statistical data analysis was subsequently conducted to determine the extent to
which observed variations in the level of resources used, and the costs
incurred, could be explained by the presence of a HAl. Ethical committee
approval was obtained from the study hospital's Ethical Review Committee prior
to both the pilot study and main study in September 1993 and March 1994
respectively.
4.4 Studysite
Resources were available to explore the impact of HAls occurring in patients
admitted to selected specialties at one site. To enhance the applicability of the
results to other health care settings in the UK, tertiary referral centres were
excluded in favour of a DGH. Other selection criteria included similar service
provision to other DGHs and easy access to the two institutions involved in the
research: the Public Health Laboratory Service and the London School of
Hygiene and Tropical Medicine.
The study hospital selected was part of an NHS Trust providing general acute,
selected regional tertiary specialist and primary care services. It was the Trust's
largest single provider of acute health care. At the time recruitment and data
collection for the main study commenced (April 1994), the study hospital, which
served a population of 260,000, had 579 beds, and an out-patient and an
accident and emergency department. The in-patient caseload for 1994/95 was
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39,898, of which 9,298 were elective cases, 20,358 emergency cases and
10242 day cases.
The budget for 1994/95 was £67 million. The aggregate resources employed
by the Trust were organised into 32 directorates: 15 clinical directorates; 7
support directorates and 10 overhead directorates. Each directorate was
responsible for its own budgets and was managed as quasi-independent firm
producing a pre-defined range of intermediate goods and services. Of the total
resources employed by the Trust, 48% were managed by the clinical
directorates, 18% by the support directorates and 34% by the overhead
directorates.
A retrospective assessment of how representative the study hospital was of
others in England was undertaken in terms of the number of bed days
produced, number of staff employed, the average cost per bed day, the average
length of stay and the expected length of stay given the case mix of patients.
Data on the number of bed days produced, number of staff employed and
average cost per bed day at the study hospital and for hospitals throughout
England were retrieved from the Chartered Institute of Public Finance
AccountantslHealthcare Financial Managers database.218 The study hospital
values for these three variables were found to lie within the interquartile range
of the distributions. The Health Services Indicators database219 provided
information on the average length of stay, and expected length of stay given the
case mix of patients for some of the specialties involved in this study, at both
the study site and at other hospitals throughout England. The study hospital
values for these variables fell within the interquartile range of the distributions.
These findings suggest that for the variables considered, the study hospital was
not atypical of other hospitals throughout England.
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4.4.1 Infection control arrangements at the study hosp/tBl
Infection control prevention and control policies and procedures operate at
many different levels within any health care setting. This section describes the
'formal' infection control arrangements present at the study site.
The Infection Control Team (ICT) consisted of two Infection Control Nurses
(ICNs) and a microbiologist who designated approximately three hours to
infection control matters per week. The infection control team covered 579
acute sector beds and a further 60 non acute beds at two other hospitals. This
is equivalent to one ICN per 289 acute beds and 30 non acute beds. This ratio
of ICNs to number of beds compared favourably with the national average at
the time of one ICN per 477 acute and 376 non acute beds in 1995.220
The responsibilities of the ICT were similar to those set out in the document
entitled •Hospital Infection Control: Guidance on the control of infection in
hospitals' issued by the Department of Health in 1995.8 The ICT routinely
carried out 'alert' organism and condition surveillance, and when time allowed,
targeted surveillance. The ICT reported to the Chief Executive and to the
Hospital Infection Control Committee(HICC).
The HICC consisted of the ICT, a Consultant in Communicable Disease
Control, the Director of Nursing Practice (representing the Chief Executive), a
surgeon, another consultant and an occupational health physician. The HICC
responsibilities were similar to those set out in the above mentioned document.
Link nurses were not present in the hospital at the time the data were collected
but have since been established.
4.5 SampleSize
The primary aim of the Socio-economic Burden of HAl study design was to
compare the level of resources used by infected patients (and the associated
costs) with those used by uninfected, but otherwise similar patients. A large
component of resource use depends on length of stay (LOS). Since relevant
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data on resource use were not readily available, the sample size calculations
were based on a planned analysis of LOS comparing the mean values in
patients with and without an HAl and using the difference betwf!)enthe means
as an estimate of the true effect of HAl. The aim was not to test if there was a
difference, but to derive adequate estimates of the magnitude of the effect. In
order to do this there needed to be enough individuals in both the infected and
uninfected groups so that, despite the large variation in individual LOS values,
the confidence interval on the difference between the means would be
acceptably narrow. The size of the smaller group primarily determines the
precision of an estimate obtained as the difference between two group means.
Since it was known that those infected would be only a small proportion of those
in the cohort of admissions recruited into the study, it was clear that they would
be the smaller group. The number recruited therefore had to be of sufficient
size to ensure a large enough group of infected patients.
In order to derive sample size estimates information on the variability of LOS in
both uninfected and infected patients was required. This information was
obtained from a study by Coello et s/ (1993)14 where LOS differences had been
combined to calculate the standard error of the difference between mean LOS
in infected and uninfected patients from three separate specialties
(gynaecology, orthopaediCSand general surgery and urology combined). It was
assumed that the estimate required was the difference between the mean stay
given a HAl and the mean stay for similar patients without a HAl. The precision
of such an estimate is measured by its standard error, usually as a percentage
of the value of the estimate. As indicated above a small case control study1.
provided data on the LOS differences between those with and without a HAl in
three different specialties The standard errors of the LOS differences can be
expressed in terms of the number of cases required, assuming at least an equal
number in the non-HAl group.
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It was assumed that a 10% precision would be adequate (i.e. that the standard
error should be less than or equal to 10% of the estimate) and that stratified
analysis would increase precision to some extent. On this basis it appeared
that about 400 cases would be sufficient. Consequently if around 6% of
admissions acquire one or more HAls, 6800 admissions would be required to
produce sufficient cases.
At an early stage in the socio-economic burden of HAl study it became apparent
that given the resources available for data collection, it would not be feasible to
recruit a sample of more than about 4700 patients. Assuming a HAl incidence
rate of 6%, this sample size would yield about 282 cases of HAl. It was
calculated that this reduction in the size of the smaller comparison group would
reduce the precision of the analysis, defined as above, by approximately 4% so
the standard error of the difference in the mean LOSs increased to 14% of the
observed difference. It was concluded that this would still be sufficient to
provide adequately precise results. In the event a smaller sample was recruited
but a higher incidence rate was observed: 3980 patients were recruited, of
which 7.8% (309 patients) acquired and presented with an HAl in hospital. At
the end of the study the observed difference in mean LOS was actually found to
be 13.8 days with a standard error of 1.3 or 9.4% of the difference and as such
the attained precision with the reduced sample size was better than originally
planned.
4.6 Subjects
The focus of the study was the socio-economic burden of HAls occurring in
adult in-patients admitted to specialties common to most hospitals. Adult
patients (over 18 years of age) who had an in-patient stay of 30 hours or more,
and who were admitted to the following specialties were therefore eligible for
recruitment into the study: general surgery, general medicine, urology,
gynaecology, orthopaedics, ear, nose and throat, elderly care and, if they had
undergone a caesarean section, obstetrics. Nationally, adult, non-day case
patients admitted to these speCialties at other NHS hospitals in England
153
accounted for 70% of all adult non-day case admissions in 1994/5.221
Resource constraints prohibited the recruitment of all patients admitted to these
specialties. The study was therefore limited to patients admitted to the selected
specialties on deSignated wards. Details of the number of wards involved in the
study can be found in Appendix 4
4.7 Recruitment
Recruitment commenced in April 1994 and continued until May 1995. The
informed written consent of eligible patients was obtained by one of six research
assistants, all of whom were experienced Registered Nurses. The research
assistants were responsible for recruitment and data collection on specific study
wards. Details of the wards each research assistant was responsible for can be
found in Appendix 4.
The recruitment process involved the following. The aims and objectives of the
study, together with details of the information required, the data sources to be
accessed and the extent of the patient's active involvement in the study were
explained. It was stressed that any information obtained would be kept strictly
confidential. Patients were then given an opportunity to ask questions and an
information sheet about the study was given to the patient to read in their own
time. After a suitable period of time the research assistant returned and
answered any further questions the patient might have. If the patient agreed to
partiCipate their written consent was obtained. Finally, the research assistants
informed participating patients that if they had any further questions they could
either ask them when they visited the ward each day, or contact them or the
project co-ordinator by phone. The information sheet included the name and
telephone number of the research assistant who recruited them into the study
and the project co-ordinators contact details. These numbers were also
included on posters displayed on the ward which outlined the aims and
objectives of the study, the project information book kept at the nurses station
on each ward, and in the letter sent to patients followed up post-discharge.
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As far as possible patients were recruited into the study on the day of admission
to hospital. If on admission to hospital a patient was too ill to give consent,
demographic and clinical data were collected, but not included in the study until
the patient was able to give consent. Any data collected on patients who
subsequently did notwish to participate in the study were destroyed.
Where a patient's condition precluded the research assistant obtaining their
consent at any time during the hospital stay, the consent of a close relative was
sought.
Every effort was made to ensure that patients who declined participation in the
study felt comfortable with their decision. It was emphasised that their non-
participation would not affect their treatment in any way. The sex, age group
and admission specialty of patients who declined participation were recorded,
enabling the representativenessof the sample to be checked.
Time constraints prohibited the recruitment of all eligible patients. Although
recruitment itself did not take up a lot of time. the collection of detailed data on
resource use throughout the study-participants' stay did. The research
assistants were instructed to give priority to the collection of full data sets on all
study participants rather than recruiting all eligible patients.
Selection bias was avoided through guidelines, training, supervision and on
going monitoring of the recruitment process. Information on the reason for non-
recruitment was recorded together with the sex, age group and admission
specialty of eligible patients enabling the representativeness of the sample to be
checked.
Examples of the data collection form used to record these data, the patient
information sheet and patient and relative consent forms are given in Appendix
5. No attempt was made to recruit patients during periods of annual leave and
baseline data were not recorded on these patients.
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4.8 Datacollected
The following data were collected: baseline data relating to the patient
population, data on the presence or absence of HAls presenting during the in-
patient and post-discharge phase; information on health sector and community
service resource use; the cost of resources used; costs incurred by the patient
themselves and their family and friends and information on the impact of HAlon
the health status of patients (Table 4.1).
This thesis explores the economic impact that HAls occurring in surgical
patients have on the secondary health care sector as a result of additional in-
patient care. As such the following categories of data are relevant to this work:
baseline data relating to the patient population, data on the presence or
absence of HAls presenting during the in-patient phase; information on health
sector resources use (secondary sector only) and the cost of resources used
The following sections provide details of the data variables of relevance to this
thesis, the data sources used, and an overview of the methods developed to
derive appropriate cost estimates of the resources used. Further details of the
methods used to derived cost estimates for resources used can be found in the
detailed account provided in Part II of the report of this study.2
156
Categories of information
An overview of the data collectedTable 4.1:
Patient characteristics: Age, &eX, reason for admlasion, diagnosis, co-
molbklitiea, household lize, social clasa and aoclo-
economic group
Care received from formal and Informal caret'8 prior to
admlasion.
Hospital acquintd Infection data:
SIte, date of onaat and, if known, pathogen.
HAle presenting during the hospital stay
Infectiona presenting poat-dlscharge
SIte and, If data are available, date of onset and
pathogen.
Health- sector resource use and costs:
Secondary sector
Primary sector
Community care services
Investlgatlona, care and treatment received
Investlgatlona, care and treatment received
Care received
Coats to the patient and their family and friends:
Patient
Family and friends
Expenses Incurred by pa1lants.
Time of reaumlng norm.' daRy .ctIvitlea
TIme of return to paid employment
Care received from family and friends.
Effect of HAl on general health status.Impact of HAle on health status:
4.8.1 Data on patient characteristics
Data on patient characteristics included age, sex, reason for admission, primary
diagnosis and co-morbidities both on admission to hospital and discharge from
hospital, route of admission (e.g. elective via pre-admission clinic, elective direct
to the ward or emergency via the accident and emergency department), the
specialty of the admitting consultant. dates of admission and discharge, and
discharge destination. This information was obtained from the medical and
nursing notes.
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Information on the patient's current or most recent occupation, employment status
prior to admission to hospital (e.g. unemployed, self employed, employed), and
household size and composition was obtained from either the patient, a relative or
the medical/nursing records. If obtained from the medical or nursing notes, as far
as possible it was verified with the patient and/or relative or friend. Based on the
information provided (current or most recent occupation and employment status
prior to admission to hospital) patients were categorised into social class and
socio-economic groups according to the OPCS classification system.222
Information on the care received prior to admission from the formal sector and
family and friends was also obtained. Formal sector care included distrid nursing
services, meals on wheels and home help services. Care from family and friends
included assistance with daily activities of living such as washing, dressing and
cooking and regular visits made by family and friends to check that the patient was
managing. This information was obtained from the patients, their relatives or
friends, or the medical or nursing notes. If obtained from the medical or nursing
notes, as far as possible it was verified with the patient and/or retative or friend.
4.8.2 Data on HAis presenting during the hospital phase
HAls presenting during the in-patient phase were identified using the reference
method of surveillance described in the Public Health Laboratory Service (PHLS)
report 'A Study of Surveillance Methods for Deteding Hospital Infections.'77 This
method aims to identify all patients with a HAl. It involves liaison with ward
personnel and consulting all relevant data sources, such as laboratory reports and
nursing and medical records, to identify Signs and symptoms associated with
HAls. If these met the definitions of infections used in this study a HAl was
recorded, together with the site of infection, date of onset and, if known, the
pathogen(s) involved. The definitions used in this study were those developed as
part of the aforementioned PHLS report.77 Minor changes were made to the text
to aid interpretation and use (Appendix 6).
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4.8.3 Data on health sector resource use during the hospItal phase
Data on the resources used during each patient's stay in hospital were
collected. This included all investigations carried out (for example X-rays,
laboratory tests, endoscopies and cardiac tests); procedures performed (for
example· operations, insertion of intra-vascular catheters, insertion of urinary
catheters); care administered (for example care administered by nurses,
physiotherapists, occupational therapists) and drugs and intravenous infusions
administered. This information was obtained from a variety of data sources
including medical and nursing notes, the notes of other relevant health care
professionals, laboratory print outs and drug prescription charts. Informationwas
also obtained about care organised for dependants whilst the patient was in
hospital, for example respite care. This information was obtained from the patient
or a relative or friend.
4.9 Methods used to derive cost estimates of the resources used
A detailed approach was taken to the estimation of the cost of resources used.
This section provides an overview of the methods used to derive estimates of
the cost of hospital resources used during the patient's in-patient stay. A
detailed account is reported elsewhere, together with an account of the
methods used to derive estimates of the costs of other resources used.2
4.9.1 Methods used to derive cost estimates of hosp/tal resources
used during the In-patient phase
As indicated in section 4.3 information on the resources used by patients during
their admission was collected for each patient regardless of whether they had
an infection. These resources may be broadly classified into two groups those
associated with occupying a hospital bed (i.e. the cost of maintaining a hospital
bed) and those relating to specific care and treatment administered to individual
patients.
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Estimates of the costs of occupying a hospital bed were derived as follows.
Data on the costs of the overhead directorates were obtained from the Trust.
Overhead diredorates included the following: finance, estates, hotel services,
personnel, planning, Trust management, technical services, education and
training and the reserves diredorate.
An allocation model was subsequently developed whereby specialty specific
estimates of the average daily cost of occupying a bed were derived. The
model took into account the proportion of individual overhead diredorate costs
used by each specialty and the proportion of individual overhead diredorates
costs used by the other overhead diredorates. A detailed account of the
allocation model and the assumptions that informed it can be found elsewhere.2
The resulting specialty specific estimate of the cost per bed day was
subsequently multiplied by the patient's length of hospital stay to derive
individual patient estimates of the cost of occupying a bed.
Costs associated with care and treatment administered included the cost of
medical time, nursing time, the time of other health care professionals such as
physiotherapists, and the cost of diagnostic investigations, procedures carried
out and consumables used.
Cost of medical care: The amount of medical care patients receive varies with
the patient. In order to gain an accurate assessment of the cost of medical care
received, it would be necessary to record and cost all contads that patients had
with members of the medical profession over the course of their hospital
admission, and determine the time medical staff spent planning and organising
care for individual patients. Unfortunately, resource constraints prohibited such
an approach. The average daily cost of medical care was derived for each
specialty and allocated to patients in the study in accordance with the length of
hospital stay.
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Cost of nursing care: Nursing costs were allocated to patients based on the
amount of nursing care patients received each day. The method used to
allocate nursing care costs was based on a system developed and extensively
validated in Australia. It was subsequently introduced to the Hammersmith
Hospital, London in 1988 and internally validated. The system involves
allocating patients to one of seven care groups determined by the amount of
care received within a nursing shift. The seven care groups represent a
spectrum of care extending from patients that require minimal care (care group
one) to those who require extensive nursing care (care group seven). An
appropriate cost is then calculated for each care group based on the amount of
available nursing time patients falling into each care group are thought to
consume. The cost of nursing care for each patient can then be calculated by
summing the nursing care costs for each nursing shift over the whole hospital
stay.
Cost of contacts with professionals allied to medicine: Average costs of
consultations with chiropodists, speech therapists, dieticians, occupational
therapists and physiotherapists were derived from cost and activity data
supplied by the study hospital and allocated in accordance with the number of
contacts supplied to individual patients
Costs of investigations: The cost of radiological investigations were derived by
applying Komer weights to cost and activity data supplied by the study hospital.
The average unit costs of microbiology, chemistry, haematology and
histopathology tests were derived from cost and activity data supplied by the
trust.
Cost of surgery: The costs associated with surgery were derived by first
calculating a cost per session for each specialty from which a cost per minute of
theatre time for each specialty could be derived. The derived costs included the
cost of running the theatre. This included the cost of nursing staff, technicians,
management and administrative staff; the cost of consumables associated with
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the prevision of surgical interventions, including pharmacy inputs, medical
gases, drapes, surgical equipment and dressings; and finally indirect and capital
inputs. The cost per session did not include the cost of a surgeon's time which
was included in the costs of medical time allocated separately to each patient
on a daily basis
The second stage involved calculating the cost per procedure. This was
achieved by applying the specialty specifiC cost estimates derived above (cost
per minute of theatre time for each specialty) to data on the average time
associated with procedures classified according to level of complexity (i.e.
minor; intermediate and major and a number of intermediate levels). This
information was supplied by the study hospital.
The third and final stage involved classifying the operative procedures
undergone by individual patients by level of complexity using the classification
system described above which is used by BUPA (1993),223 and subsequently
applying the appropriate cost estimate derived as described above. Further
details about the methods used, including how sub-procedures were costed, are
reported elsewhere.2
Cost of pharmaceuticals: Estimates of the cost of pharmaceuticals supplied
were derived by combining the price of the drugs (determined as a result of
negotiation between the pharmacy at the study hospital and the pharmaceutical
industry), with the costs of any consumables associated with the delivery of the
drug. For example, the cost of an intra-muscular antibiotic would include the
cost of the drug, a syringe, the fluid with which the drug is mixed, and two
needles (one used to mix the drug and one to administer the drug).
The costs of consumables supplied to patients: The cost of consumables such
as intravenous catheters, wound drains, and urinary catheters were derived
from the NHS supplies catalogue (1994).224 The combination of resources used
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to supply a product was based on information provided by an F-grade nurses
familiar with clinical practice at the study hospital.
Once these unit costs were available they were multiplied by the data collected
on resources used by the patients. This allowed the development of cost
profiles for all study participants. These profiles provided information on the
total cost of resources and the contribution of specific components of cost to the
total costs incurred.
4.10 DataManagement
Data were recorded on data collection forms designed using optical scanning
software designed by Formic Ltd (see Appendix 7 for examples). The data
were then scanned onto the scanning software database and exported in either
Dbase or SPSS format for analysis at the Central Public Health Laboratory and
London School of Hygiene and Tropical Medicine. This method of data entry
has been shown to be 99.9% accurate in test-re-test studies.225 Prior to
analysing the data a number of data checks were made to eliminate any
substantial recording errors. The data cleaning process included checking that
all surveys had been scanned completely and a number of range, categorical
and logical checks. For example, checks were made that the date of discharge
was after the admission date; that only females were recorded as having been
admitted to the gynaecology and obstetric wards and specialties, that the ages
recorded fell within an acceptable range (18-100), and the ICD9 diagnosis
codes were valid and appropriate given the patient's sex and admission
specialty.
At all times patient information was handled in ways that maintained patient
confidentiality. Patients participating in the study were identified by a unique
study number. This number was the only form of patient identification stored on
the database. Personal details, such as the patient's name, address and
hospital number, were stored on a separate computer whose use was restricted
to named individuals. Those responsible for collecting and handling data
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received appropriate training and were asked to sign a document outlining the
standards for data handing, and record keeping. A copy of this document is at
Appendix2
4.11 Dataanalysis
4.11.1 Checking for recruitment/select/on biBS
The age, sex, admission type and admission specialty distributions of patients
recruited into the study were compared to the distributions that would have
been present if all eligible patients were recruited.
4.11.2 Incidence of HAls presenting during the In-pat/ent period
The number of patients with one or more hospital-acquired infections presenting
during the in-patient period was expressed as a percentage of the number of
patients discharged and 95% confidence intervals derived. Site and specialty
specific estimates were also derived.
4.11.3 Incidence of HAls present/ng post-dlscharge
Estimates of the proportion of patients reporting symptoms and treatment which
met the study criteria for infections presenting post-discharge were derived for
four groups of patients: patients who did not have an HAl identified either during
the in-patient or post-discharge phase; patients who had no in-patient HAl, but
had evidence of a possible infection post-discharge; patients who had an HAl
identified during the in-patient phase but no evidence of an infection post-
discharge and finally patients who had an HAl identified during the in-patient
phase and had evidence of a possible infection post-discharge.
4.11.4 Attrlbut/on of costs to HAls
4. 11.4. 1 In-patient analysis
Attributing resource use and costs to the presence of an infection presents a
number of difficulties. Factors other than infection may have an impact on
resource use. In this study linear regression modelling techniques were used to
control for a range of factors that could potentially influence the level of
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resource use: age. sex. diagnosis. number of co-morbidities. admission
specialty, and admission type. Since the cost and length of hospital stay
distributions included a few very high values they were skewed to the right. For
this reason the analYSis was performed assuming that the underlying
distribution was Gamma in form (this distribution. very similar to the log-Normal,
is appropriate for skewed data).226 Estimates of the impact of one or more
hospital-acquired infections. and of specific types of infection, adjusted for the
effects of confounding variables were derived from this modelling process.
During the analysis the effects of social class. nursing dependency (defined as
the average level of nursing care required from admission to the time the HAl
was identified) and disease stage were also investigated. This last variable is a
measure of severity of illness, derived from information on the patients' age,
sex. diagnosis. co-morbidities, operation codes. admission type. length of in-
patient stay and discharge destination. Previously validated algorithms227 were
used to allocate patients to one of three disease stage groups (lOW,medium
and high) depending on the severity of their illness using software developed by
CHKS Ltd. The inclusion of these additional variables was found to have very
little effect on the estimated impact of HAlon hospital sector costs once the
other explanatory variables had been taken into account.
4.11.4.2 Post-discharge analysis
The primary outcome measures for the post-discharge analysis included the
number and cost of general practitioner. district nurse. hospital doctor. health
visitor and community midwife visits. and the costs to patients and their informal
carers. As with the in-patient analysis. the variables had skewed distributions.
Ideally the distribution used in the in-patient analysis (Gamma distribution)
would have been used in the post-discharge analysis. However. the data had
many zeros for these outcomes. Consequently the Gamma distribution was
considered inappropriate and a log normal distribution was used for the
regression modelling.
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4.11.5 Impact of HAl on health status
This aspect of the analysis was limited to the impact of HAlon health status as
measured by the responses given to the general health status questionnaire,
the Short-form 36 (SF-36), administered within the post-discharge
questionnaire. Mean scores for the eight dimensions of health covered by the
SF-36t were derived using the standard SF-36 scoring algorithms228 and mental
and physical summary scores subsequently derived, again using the standard
scoring systems.229 These were compared to the norms derived in the Oxford
Healthy Lifestyle Study230using the two sample unpaired t-test, Mean scores for
each dimension of health and for the two summary measures were then
determined for patients within each of the four HAl groups and the impact of
HAlon these measures determined. Regression analysis as described above
was used to control for factors other than the presence of an infection that might
influence the scores obtained.
4.11.6 Deriving national estimates of the number of patients who
acquired one or moreHAls
National estimates of the number of adult patients who acquired one or more
infections in hospital, which presented during the in-patient stay were derived by
applying the observed in-patient incidence rate and 95% confidence interval to
data on the number of adult patients (~18),excluding day cases. admitted to
similar specialties, in NHS provider units throughout England in 1994/5. The
same approach was used to derive specialty specific estimates of the number of
patients acquiring one or more infections and estimates of the number of
patients acquiring specifiC types of infection.
4.11.7 Deriving national estimates of the cost of HAis to the hospital
sector
Estimates of the burden these infections imposed on the hospital sector were
derived from data on the observed incidence of hospital-acquired infections
presenting during the in-patient period; the estimated ratio of the hospital costs
incurred by infected compared to uninfected patients obtained from the linear
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modelling analysis; the mean hospital costs incurred by uninfected patients; and
data on the number of adult admissions. If N is the number of patients admitted
nationally, C the baseline cost of treating uninfected patients, i the estimated
incidence and , the estimated ratio of costs incurred by infected compared to
uninfected patients, then Ni C(,-1) provides an estimate of the national burden.
The variance of this estimate was derived from the standard deviations of the
estimates of the incidence and ratio of costs, sdi and sd, respectively, as follow:
N2C2 [fsdr2 + (,_1)2 sdf]
This estimated variance was subsequently used to obtain 95% confidence
intervals for the estimates of the national burden of infection, it being assumed
that the sampling error in such an estimate would be approximately normal.
Estimates of the number of additional days patients remained in hospital and
site and specialty speCific estimates of the burden imposed were made using
the same approach.
4.12 Project Management
The socio-economic burden of HAl study was a joint venture by the Central
Public Health Laboratory and the London School of Hygiene and Tropical
Medicine. The project team were responsible for the organisation and conduct
of the study. Over the course of the study it comprised of the following
members: a project co-ordinator, research economist, six research assistants, a
statistician, a project secretary and a part-time administrative assistant.
The project team was advised by a multidisciplinary steering group consisting of
experts in infection control, microbiology, epidemiology and economics. The
project steering group met as and when was required. The project steering
group and team were advised by a multi-disciplinary Advisory Committee
comprising OH representatives, and experts in infection control, microbiology,
economics and community nursing. Appendix 8 provides details of the
members of the project team, steering group and adviSOrycommittee.
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4.13 ProjectTimetable
The socio-economic burden of HAl study was commissioned by the OH to the
Central Public Health Laboratory and London School of Hygiene and Tropical
Medicine in October 1992 and a project co-ordinator (Rosalind Plowman)
appointed in July 1993. The study comprised of four key phases listed below.
Phase 1: This was conducted over a period of nine months from July 1993 to
March 1994 and involved a literature review. the development and piloting of
the study tools and research methods, and their subsequent modification in the
light of the findings of the pilot study.
Phase 2: This was conducted over a period of 16 months from April 1994 to
July 1995 and constituted the main data collection period.
Phase 3: This was conducted over a period of 13 months from August 1995 to
September 1996 and involved the validation, analysis and interpretation of the
data set for the purposes of the costs study and final Department of Health
Report.
Phase 4: This involved the preparation of the final cost study report and its
submission to the Department of Health for internal and external review and
subsequent modification. This was conducted over prolonged period of time.
The report was submitted to the Department of Health in August 1997 and
distributed for internal and external review. A full set of reviewer's comments
was received in November 1997. A formal response was submitted to the
Department of Health in February 1998 following which there was a period of
discussion and debate. Further editing work and additional analysis was
undertaken. Amendments to the original text together with the results the
additional analysis requested were submitted to the Department of Health in
September 1998 and the report accepted for publication in September 1999,
and finally released in January 2000
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4.14 Conclusion
This chapter has provided an account of the methods used in the socio-
economic burden of HAl study. The methods used in the socio-economic
burden of HAl study, in particular those that relate to the impact of HAlon
hospital resource use and costs, are common to this thesis. The following
chapter builds on the information presented in this chapter. Details about how
data on patients of interest to this thesis were selected from the socio-economic
burden of HAl data set are presented, together with an account of the analysis
undertaken.
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CHAPTER5
METHODS
5.1 Introduction
The preceding chapter has described in some detail the study to which this
thesis is linked. As stated in the preceding chapter the methods employed in
the socio-economic burden of HAl study are common to this thesis. In this
chapter the aims and objectives of this thesis will be presented and discussed,
followed by a detailed account of the methods which are particular to this work.
The chapter describes how a subset of data was selected from the data set
collected as part of the socio-economic burden of HAl study, and the statistical
analysis undertaken. Details regarding data and project management are also
presented.
5.2 The alms and objectives of this thesis
5.2.1 Aim
To assess the incidence of, and independent risk factors for HAls occurring in
surgical patients admitted to a district general hospital and the impact these
infections have on the secondary health care sector, and to examine how the
information obtained may be used to assess the potential benefits of investment
in the prevention and control of HAls.
5.2.2 Objectives
The Specific objectives were to:
1. Review the literature on the epidemiology of HAl, risk factors for HAl, and
the economic evaluation of HAl.
2. Determine the incidence of HAls occurring in adult, non-day case
patients admitted to selected surgical specialties of a district general
hospital.
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3. Explore how the incidence of HAl varies with various patient
characteristics and identify possible risk factors.
4. Determine the impact HAls occurring in this patient group had on
secondary health care sector resource use and costs.
5. Examine how information on the economic burden of HAls may be used
to assess the potential benefits of investment in the prevention and
control of HAls.
5.3 Overview of study design
As detailed in the preceding chapter, the study to which this thesis is linked was
designed to assess the impact that HAls occurring in medical and surgical adult
patients had on the secondary and primary health care sector, community care
services, informal carers and patients themselves. This thesis is concerned
with the incidence of HAls occurring in patients admitted to the surgical
specialties and presenting during the in-patient period, risk factors for these
infections and the impact these infections had on secondary health care sector
resource use and costs as a result of additional in-patient care. Thus data
relating to the incidence of HAl occurring in surgical patients, risk factors for
these infections and the resources used during the in-patient period, collected
as part of the socio-economic burden of HAl study, are of relevance to this
thesis. An overview of how these data were collected, and the analySiS
undertaken for the purposes of this work follows.
Adult, non- day-case patients were recruited from selected wards of a district
general hospital. Background demographic data were collected on aU patients
together with information on selected risk factors. Information on infections
presenting during the hospitalised phase was obtained through surveillance
using validated surveillance methods and case definitions. Data on resources
used by all patients were collected resulting in daily profiles of the resources
used by patients with and without a HAl. Estimates of the cost of the resources
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used were made. A sub-set of data relating to patients admitted to the surgical
specialties was subsequently identified and statistical data analysis conducted
to determine the incidence of HAl, independent risk factors for infection, and the
extent to which observed variations in the level of resources used, and the costs
incurred, could be explained by the presence of a HAl. How information on the
economic burden of HAls may be used to assess the potential benefits of
investment in the prevention and control of HAls was subsequently explored.
Details regarding the study setting, how patients were selected and recruited
into the study, the data variables of interest and data collection methods
employed can be found in section 4.4-4.8 of Chapter 4. The following section
describes how the subset of data of relevance to this thesis was selected.
5.4 Selection of surgical patients and relevantdata for the purposes
of the PhDthesis
This thesis is concemed with the incidence of HAls occurring in adult patients
admitted to selected surgical specialties, risk factors for these infections, and
the impact these infections have on hospital resource use and costs as a result
of additional in-patient care. The wider socio economic burden of HAl study
included data on patients admitted to five surgical specialties: general surgery,
orthopaedics, urology, gynaecology, and if they had undergone a caesarean
section the obstetric specialty. This section provides details of how patients
admitted to these Specialties were identified and how the subset of data
relevant to this work was compiled.
Patients admitted to the five specialties of interest could be identified from the
underlying data set on the basis of admitting ward, specialty or consultant. It
was decided to select patients on the basis that their admitting consultant was
not an ENT surgeon, physician or geriatrician, but a general surgeon,
gynaecologist, urologist, obstetrician or orthopaedic consultant.
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Prior to selecting patients on the basis of their consultant code the validity of
this approach was checked. The final data set was renamed and the admission
consultant, ward, specialty and diagnosis cross-checked to assess the face
validity of this information: i.e. given the consultant's speciality would you expect
the documented ward and admission specialty. Unusual records were
highlighted and looked at in more detail. That is reports including primary
diagnosis, co-morbidities, ward transfer and consultant transfers were
generated and examined. Judgements were subsequently made about the data
and the data file modified as necessary. For example, if the patient's consultant
was recorded as being a gynaecologist, but the ward, specialty and diagnosis
indicated the patient was a urology patient, the assumption was made that this
was a urology patient and the consultant code changed to indicate that this
assumption had been made. Or if the consultant, specialty and diagnosis
indicated that the patient was a gynaecology patient but the ward was surgical,
it was assumed that there were no beds available on the gynaecology wards
and no changes were made. Once this process was complete patients were
selected on the basis of admitting consultant code and reports generated and
checked again. Having completed this second check the data set for this work
was selected, and saved as a separate data file.
Within this limited data set there were eight patients who were transfers from
another ward or hospital. These patients by definition will have incomplete in-
patient data sets: their data sets will relate to varying proportions of their
hospital stay. Consequently these eight patients were excluded from the final
data set used.
Having identified the patients, data relating to their hospital stay were obtained
from the relevant survey databases, and datasets specific to the needs of this
thesis were created. For example, datasets limited to surgical patients were
created for information on operations undertaken, procedures performed,
investigations carried out and nursing care administered. Further data checking
was also carried out, including range, categorical and logical checks.
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Whilst carrying out this procedure it was noted that the number of surgical
patients for whom there were data on operative procedures appeared rather
low. The data relating to the first operation indicated that only 1936/2469
(78.4%) patients included in the surgical data set, had evidence of a first
operation having been performed. In 533 cases (21.6%) there was no evidence
of a first operation having been performed. This rather surprising observation
was felt to warrant further investigation. Did the data accurately reflect the
procedures performed? If the data set was a valid account of procedures
performed, did the level of surgery performed in the recruited sample reflect the
level performed in the wider population sample? Had important information not
been entered and as such was the data set incomplete?
In order to investigate these important questions the hospitals Patients
Administration System (PAS) data set for the year 1994/5 was analysed to
determine what proportion of the wider hospital population, admitted to the
specialties included in this study, had an operative procedure. The analysis
revealed that during the year 1994/5 67% of the patients admitted to the
surgical, gynaecology, orthopaedic and urology specialities had an operative
procedure. This was in fad lower than the percentage of patients in the study
sample who had undergone an operative procedure. At face value this was an
encouraging finding. Furthermore, it was noted that not aUthe operation codes
included in the PAS data related to actual operations. Some referred to
procedures such as blood transfusions and endoscopies. Despite this it was
considered necessary to explore the situation further.
As far as possible the PAS records of study patients who did not have any
evidence within the study database of a surgical operation having taken place
were checked. Of the 533 patient records checked, data were available for 524
patients. In 148 (28.2%) cases there was evidence that an operative procedure
had taken place (i.e. an opes code included in the PAS database). However,
in 43 cases the operation codes were for procedures, which in this study were
not classified as an operation - e.g. blood transfusion, removal of catheter and
174
endoscopy. As such according to the PAS database it would appear that 105
(20%) of the 524 patients for whom no operation data were available in the
study database and data was available in the PAS database, in fact had one or
more operations. As such, the operation codes for these 105 patients were
entered into a newly created data variable within the reduced operations
dataset. The project economist subsequently derived cost estimates for all 105
cases and the information was entered onto the database within a newly
created variable denoting revised operation costs, and it was accepted that the
remaining 419 patients did not have an operation. It was also accepted that the
15 patients for whom there was no evidence of surgery having taken place in
the study database and no evidence of admission in the PAS database, did not
have surgery. As such an estimated 2041 (82.7%) of the 2469 patients
included in this study had one or more operative procedures.
This process of checking the validity of the operation data revealed a second
related problem. It was noted that of the 1936 patients for whom there were
data within the study database on the surgical procedure performed, cost
estimates were only available for 1830 patients: 106 of the 1936 patients for
whom operation data were available did not have a cost derived for the
operation performed. This situation was addressed as follows. In 57 of the 106
cases for whom there was evidence within the study database of an operation
having been performed but no cost estimates, costs were derived and entered
onto the database. Estimates were derived using the methods developed for
the underlying study, reported in detail elsewhere2 and briefly summarised in
section 4.9.1. In the remaining 49 cases there was evidence of surgery having
taken place, but procedure codes had not been entered onto the database. As
far as possible these codes were obtained from the PAS database and cost
estimates derived. In 37 cases procedure codes were obtained from PAS and
subsequently used to derive cost estimates. However, in two cases there was
no evidence of an operation in the PAS database and in the remaining ten
cases there was no evidence of admission to hospital in the PAS database.
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Once new operation costs had been derived and entered the final stage was to
compute a new total cost estimate substituting the newly derived operation cost
data for that originally used.
Having created a number of datasets limited to surgical patients, a number of
new variables summarising specific aspects of resource use were subsequently
computed from the raw data. For example, a variable was created to denote
whether patients had received antibiotics prior to the onset of infection. In order
to create this variable, it was first necessary to create an antibiotic data set from
the many data collection forms that included antibiotic drugs. Antibiotic drug
use had been recorded on six different types of data collection forms. These
forms had been designed to collect data on oral drugs, intravenous and intra-
muscular drugs, intravenous infusions, operations performed, and drugs that
had not been listed elsewhere. The latter included two different data collection
forms one with space for recording data on up to six drugs not listed elsewhere
and the other space for recording up to 12 drugs that had not been specifically
listed elsewhere.
With the exception of the last three forms, the data collection forms related to
two-week periods. That is for each type of data collection form there was a
form relating to weeks 1-2, another for weeks 3-4 and so on. In order to create
one antibiotic database, data collection forms relating to the different two-week
periods were merged. These merged datasets, relating to different types of
data collection forms, were then brought together into one antibiotic dataset.
Once an antibiotic database had been created it was then possible to create a
new variable denoting whether the patient had received antibiotics prior to the
onset of an infection, and whether the antibiotics received were administered
via the oral, intravenous or intramuscular route, or by all three modes of
administration.
176
Using a similar approach three new variables were created to denote whether
patients had a urinary catheter, one or more wound drains or a naso-gastric or
endotracheal tube in situ prior to the onset of infection.
5.5 Dataanalysisundertakenfor PhDthesis
The data were analysed using SPSS 10 and STATA version 7. The data
analysis included a descriptive analysis of the data set, a more detailed
exploration of the incidence of HAl and possible risk factors for these infections,
and estimation of the costs attributable to HAl.
5.5.1 Descriptiveanalysis
A descriptive analysis was undertaken. This included an exploration of the age,
sex, specialty, admission type, primary diagnosis, and number of co morbidities.
Where appropriate cross tabulations were developed, and tests for significance
were conducted using the Chi-Square test. In order to check the
representativeness of the recuited sample the age, sex, admission type and
admission specialty distributions of study participants and eligible patients who
either declined or were not recruited due to practical reasons, such as
insufficient time, were analysed and compared. Appendix 9 provides details of
how the variables listed were categorised for the purpose of the analysis.
5.5.2 IncidenceofHAland Identification of risk factors
The incidence of HAl was assessed in terms of the following two definitions:
i) the number of patients with one or more HAls expressed as percentage of
the number of patients discharged
ii) the number of primary HAIsl1000 patient days at risk
For each definition a single variable analysis was conducted to assess how the
incidence varied with selected patient characteristics (age, sex, admission
specialty, admission type, diagnosis group, number of co-morbidities, presence
of absence of diabetes mellitus, and whether the patient had an operation).
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Based on definition (i) above, a multivariable logistic regression analysis was
conducted to assess which factors were independently associated with risk of
acquiring an infection. The significance of the effects of each variable in the
analysis was assessed using likelihood ratio X2 tests.
The above analysis was repeated for each type of infection: urinary tract,
surgical wound, chest, bloodstream, skin and infections at sites not classified
elsewhere. The variables included in the risk factor analysis varied slightly with
site of infection. For example, the analysis examining the incidence of UTls
included a variable denoting presence or absence of a catheter prior to the
onset of infection. Further details of the variables included are presented in the
relevant result sections in Chapter 7.
5.5.3 EconomicImpact
The analysis considered the impact of HAlon two measures of resource use:
hospital costs and length of hospital stay.
5.5.3. 1 Single variable analysis
Single variable analysis was conducted to assess how hospital costs and length
of hospital stay (LOS) varied with infected and uninfected patients and other
patient characteristics including age, sex, admission specialty, admission type,
primary discharge diagnosis group, and number of co-morbidities. The mean
and median hospital costs incurred and length of hospital stay were calculated
together with the 25th and 75th percentiles, minimum and maximum values and
the standard deviation. As the data were skewed the significance of the
observed differences was assessed using the non-parametric Mann-Whitney
and Kruskal-Wallis tests.
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5.5.3.2 Multivariable analysis - overview
The single variable analysis indicated that both LOS and hospital costs not only
varied with HAl status but also with a number of factors including age, sex,
admission type, and number of co-morbidities (see Chapters 8 and 9). In order
to assess the independent effect of HAlon hospitals costs and LOS
multivariable regression analysis was undertaken. The aim was to assess the
impact of HAlon hospital costs and LOS after controlling for other factors that
might influence the magnitude of the costs incurred and a patient's LOS. With
the exception of primary discharge diagnosis group the regression analysis to
assess the impact of HAlon LOS and costs included all the factors included in
the single variable analysis (equations 1 and 2). Primary discharge diagnosis
group was excluded as the number of patients in many of the subgroups was
very small.
Equation 1:
Hospital costs regressed on sex, age, admission specialty, admission type,
number of co-morbidities, HAl status.
Equation 2:
Length of stay regressed on sex, age, admission specialty, admission type,
number of co-morbidities, HAl status.
Further details of the explanatory variables included in this analysis can be
found in Appendix 9.
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5.5.3.3 Normal linear regression - no transformation of dependent variable
Multiple regression analysis is based on a number of assumptions:
independence, linearity, normality, and constant variance:
1. The observations should be independent.
2. The relationship between the dependent and independent variables should
be linear.
3. For each combination of values of the independent variables, the distribution
of the dependent should be normal.
4. For each combination of values of the independent variables the distribution
of the dependants should have a constant variance.
These conditions were not met in this data set. Both dependent variables (LOS
and hospital costs) had a skewed distribution and the variance was not
constant. Figure 5.1 plots the quantiles of LOS against the quantiles of the
normal distribution and Figure 5.2. the quantiles of hospital costs against the
quantiles of the normal distribution. If the data were normally distributed the
plotted points would lie approximately on a straight line. It ean be seen from
figures 5.1 and 5.2 that this is not the case with respect to the LOS and cost
data, indicating that both the LOS and cost data are not normally distributed.
Figure 5.1: A plot of the quantlles of LOS against the quantiles
of the normal distribution
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Figure 5.2: A plot of the quantiles of hospital costs against the
quantiles of the nonnal distribution
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A quantitative assessment of the deviation from Normality was made using the
Shapiro Francia W' test. The results presented in Table 5.1 indicate that both
the LOS and cost data were not compatible with a Normal distribution (p=
0.00001).
Table 5.1 : Shapiro- Francia W' test for nonnal data
Shapiro- Francia W' test for normal data
Variable Obs W' V z Prob>z
Length of stay 2469 0.56361 499.748 7.979 0.00001
Hospital costs 2469 0.50115 571.277 8.047 0.00001
5.5.3.4 Linear regression - log transformation of dependent variable
A frequently used method to deal with skewed data is to transform the data onto
a log scale. Transforming the LOS and hospital costs data on to the log scale
(log LOS base 10 and log Cost base 10) produced a distribution that is closer to
the normal distribution (figure 5.3 and 5.4).
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Figure 5.3: A plot of the quantiles of LOS transfonned onto the log scale
(base10) against the quantiles of the nonnal distribution
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Figure 5.4: A plot of the quantiles of hospital costs transformed onto the log
scale (base10) against the quantlles of the normal distribution
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However, it is clear from Figures 5.3 and 5.4 that even after transformation onto
the Log (base 10) scale there remains positive skewness, with this being more
marked in the case of hospital costs than hospital length of stay.
Transformation onto the Log 10 scale does not pull the tail of the distribution in
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quite enough. The higher observed values are still higher than expected given
the mean and standard deviation. A shifted transformation may have produced
a distribution closer to the normal distribution, but its use would make
interpretation more difficult. Furthermore, even in the absence of a shifted
transformation, interpretation problems arise. The estimates and confidence
intervals derived from regression models in which the dependent variable is
transformed onto the log scale are measured on the log scale. To obtain a clear
interpretation the estimates would need to be transformed by exponentiation
(anti.. logarithms) back to the original scale. This would produce estimates of
the ratio of hospital costs and LOS for each level of a variable category group
compared to the categories base line. Thus for the HAl variable it would
produce a ratio of hospital costs incurred by infected patients compared to
uninfected patients, and a ratio of hospital LOS in infected compared to
uninfected patients. Difficulties arise when estimating the magnitude of these
increases in terms of additional costs incurred and the number of extra days
patients remain in hospital. Whilst the ratio of costs or LOS could be applied to
the arithmetic mean costs or LOS of uninfected patients, it is questionable
whether this is appropriate given that the ratios were derived on the log scale.
5.5.3.5 Generalised linear modelling assuming a gamma distribution
An alternative approach to dealing with the problem of LOS and hospital costs
having a skewed distribution is to assume that the skewed outcome variables
have a Gamma distribution, which is very similar in form to the Log/Normal
distribution, and construct generalised linear models which allow estimation of
the effect of HAlon LOS and costs, allowing for the effects of the other factors
included in the model, utilising a maximum likelihood approach. This approach
was used in this analysis.
The Gamma distribution has a decreasing coefficient of variation (standard
deviation/mean) as the mean increases. To assess whether it was appropriate
to assume an underlying Gamma distribution the mean LOS and mean total
costs were plotted against the standard deviation for LOS and total costs
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(Figures 5.5 and 5.6) and the coefficients of variation (sd/mean) plotted against
the categories involved for both LOS and costs (Figures 5.8 and 5.9). Figures
5.5 and 5.6 show that the standard deviation for LOS and total costs increases
with increasing mean LOS and total costs and Figures 5.7 and 5.8 show that
the coefficients of variation for both LOS and total costs decrease Slightly with
increasing mean. As such, for the purposes of the analysis it was considered
appropriate to assume an underlying Gamma distribution.
Figure 5.5: A plot of the mean length of stay against the
standard deviation for length of stay
80
o
80
40
20 40
(mean) 101
80
Figure 5.6 A plot of the mean hospital costs against the
standard deviation for hospital costs
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Figure 5.7: A plot of the coefficient of variation of lOS
against the categories Involved
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Figure 5.8: A plot of the coefficient of variation of hospital costs against the
categories involved
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The models developed used a) an identity link and b) a log link. Models
incorporating an identity link assume additive effects and consequently enable
estimates of the mean additional costs and lOS incurred by infected patients to
be taken directly from the model. That is the fitted coefficients associated with
HAl directly estimate the additional costs incurred by infected compared to
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uninfeded patients, or the number of extra days infected patients remain in
hospital compared to uninfected patients, after controlling for the effeds of all
the other factors included in the model. In contrast models incorporating a log
link assume multiplicative or proportional effects and as such provide estimates
of the ratio of costs and LOS incurred by infeded and uninfeded patients.
Both simple models which assessed the main effects of the independent
variables identified in equation one and two on costs and LOS and more
detailed models which assessed two way interactions between HAl and the
independent variables were fitted and compared. The statistical Significance of
each variable in the generalised linear model was determined using the
likelihood ratio X2 test.
Models were also developed to assess the impact of specific types of infedion
on costs and LOS. The above approach was repeated substituting the HAl
explanatory variable for a variable denoting infections at the following sites:
urinary tract, surgical wound, lower respiratory tract, skin, blood, other single
site infections not classified elsewhere and multiple sites. The analysis
assessed how hospital costs and length of hospital stay varied in patients with
these different types of infection compared to uninfected patients. having
controlled for fadors that may have had impad on length of hospital stay and
costs.
5.5.4 Distribution of costs Incurred
The distribution of the costs associated with infected and uninfected patients
was assessed. Costs were classified into one of 16 categories: hospital
overheads; diredorate management; capital charges; medical time; nursing
care; paramedics and specialist nurses; physiotherapy; surgical interventions;
consumables used for specific procedures; antimicrobials; non-antimicrobial
drugs; microbiology tests; other pathology tests; endoscopies; radiology; and
other tests.
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The mean costs incurred by infected and uninfected patients were determined
for each category, and the additional costs incurred by infected patients
calculated, together with the percentage contribution of each category to the
overall additional costs incurred. Generalised linear modelling techniques using
the maximum Ukelihood approach described above were subsequently
conducted to assess the impact of HAlon the different cost categories after
controlling for the effects of sex, age, specialty, admission type, number of co-
morbidities and HAl status.
5.6 Datamanagement
Issues relating to data management have been discussed in the preceding
chapter (see section 4.11). The data handling standards applied in the socio-
economic burden of HAl study were maintained throughout this work.
5.7 Study timetable
As outlined in the preceding chapter the socio-economic burden of HAl study
comprised four phases, all of relevance to this thesis.
Phase 1: This involved a literature review, the development and piloting of the
study tools and research methods, and their subsequent modification in the light
of the findings of the pilot study. This was conducted over a period of nine
months from July 1993 to March 1994.
Phase 2: The main data collection period. This was conducted over a period of
16 months from April 1994 to July 1995.
Phase 3: The validation, analysis and interpretation of the data set for the
purposes of the socio-economic burden of HAl study and final Department of
Health Report. This was conducted over a period of 13 months from August
1995 to September 1996.
187
Phase 4: The preparation of the final socio-economic burden of HAl study report
and its submission to the Department of Health for internal and external review
and subsequent modification. This was conducted over prolonged period of
time, culminating with the publication and subsequent release of the final report
in January 2000.
These four phases of the project were followed by four further phases which
were exclusively concerned with the surgical subset.
Phase 5: Surgical patients were identified and a separate PhD data set which
included data variables of relevance to the planned analysiS was created.
Further data checks were made and the data cleaned as necessary. New data
variables relating to the presence or absence of selected risk factors prior to the
onset of infection were computed.
Phase 6: The subset of data was analysed. This included a descriptive analysis
of the data set, and exploration of the incidence of and key risk factors for
infection; and an assessment of the impact of HAlon hospital resources use
during the in-patient hospital stay and associated costs.
Phase 7: This involved an exploration of how the costs estimates derived may
be incorporated into models to assess the potential benefits of investment in the
prevention and control of HAls.
Phase 8. In parallel with the work described in phases 5-7, a more detailed and
in depth review of the literature was conducted, and the thesis drafted.
5.8 Conclusion
This chapter has provided an account of the methods used in this study. The
following four chapters present the results of this work. Issues relating to the
validity and limitations of the approaches used are discussed in Chapter 11.
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CHAPTERS
SAMPLE CHARACTERISTICS
S.1 Introduction
This chapter presents the results of the descriptive analysis which assessed the
key characteristics of the sample recruited and how representative they were of
all eligible patients. Data relating to the sample size, and time of recruitment
are presented first. This is followed by the results of the analysis that explored
how a range of patient characteristics were distributed including: age, sex,
specialty, admission type, discharge diagnostic group, number of co-
morbidities, operations performed, discharge destination and care planned on
discharge from hospital.
S.2 Sample size
Between April 1994 and May 1995 3534 adult, non-day case patients admitted
to the surgical specialties covered in this study were eligible for recruitment. Of
these 2477 (70.1%) patients agreed to partiCipate in this study, 197 (5.6%)
declined partiCipation, 851 (24.1%) were eligible for recruitment but were not
invited to participate in this study due to time and resource constraints, and in a
further nine (0.3%) cases the reason for non-recruitment was not recorded. Of
the 2477 surgical patients recruited into the study eight were excluded from the
analysiS as they were transfers from another ward or hospital and as such
differed from the rest of the sample in important respects: 2469 patients were
therefore included in the analYSis(Figure 6.1).
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The results of the analysis which compared the age, sex, admission type and
admission specialty distributions of patients recruited into the study with eligible
patients who were not recruited are reported in Appendix 10. The results
indicated that the proportion of patients who were aged 60 years and over was
similar for patients in the two cohorts. However there were statistically
significant differences with resped to the sex, admission type and admission
specialty distributions in the two cohorts of patients. There were fewer male
patients, emergency admissions, and general surgical and urology patients in
the recruited cohort, and more female patients, elective admissions, and
orthopaedic, elderly care, ear nose and throat, obstetric and gynaecology
patients. However, the results of the analysis which compared the age, sex,
admission type and admission specialty distribution of patients recruited into the
study, with that which would have been present if all eligible patients had been
recruited, found that the differences between the cohort of recruited patients
and the intended cohort of all eligible patients was small. Consequently, since
the HAl and non-HAl comparisons controlled for these factors, it is reasonable
to assume that the results obtained are generalisable to all eligible patients,
despite the significant differences between those recruited and those not
recruited.
6.3 Dayrecruited
Information on the day recruited was available for 2462 (99.7%) patients. The
majority of patients were recruited during the early part of their admission: 94%
were recruited within the first six days of admission with 31.2% recruited on day
one; 13.7% on day two and 27.5% on day three. Figure 6.2 provides further
details of when patients were recruited into the study. In those cases where
patients were recruited quite late, this was either due to the patients condition
precluding them being invited to partiCipate until this time, or due to the
research assistant being unable to find a suitable time to recruit the patient until
quite late into their admission.
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Figure 6.2: The cumulative percentage of patients recruited by day of
admission (n= 2462)*
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6,4 Ageandsexdistribution
Of the 2469 patients recruited into the study 1466 (59.4%) were female and
1003 (40.6%) were male. The minimum age was 18 years and the maximum
94 years, with a mean age of 54.5 years (SO ± 18.4). Table 6.1 provides further
details of the age and sex distribution.
T bl 61 A d d' biba e . ~gean sex IS utlon, ,
Male Female All patients
~egroup n % n % n %
18-3-4 126 24.51 388 75.49 514 20.82
35 - 5-4 217 32.24 456 67.76 673 27.26
155-74 514 5-4.05 437 45.95 951 38.52
175+ 146 44.11 185 55.89 331 13.41
~lp8t1ents 1003 40.62 1466 59.38 2469 100.00
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6.5 Specialty distribution
Figure 6.3 shows the distribution of patients by admission specialty. Overall a
greater proportion of patients (36%) were recruited from the general surgical
specialty than from the other specialties covered.
Figure 6.3: Distribution of patients by admission specialty
Urology
19%
General surgery
36%
Obstetrics
9%
Gynaecology
16%
Orthopaedics
20%
Table 6.2 shows the specialty and sex distribution. It can be seen that the
sample included a greater number of female than male patients. This is in part
due to the inclusion of two exclusively female specialties (obstetrics and
gynaecology). Within the surgical and orthopaedic specialties also more female
than male patients were recruited. The only specialty with more male than
female patients was urology.
Table 6.2: Sex and specialty distribution
Specialty
Male patients Female patients
n
n % n %
General surgery 884 388 43.9 496 56.1
Orthopaedics 501 219 43.7 282 56.3
Urology 472 396 83.9 76 16.1
Gynaecology 386 0 0.0 386 100.0
IObstetrics 226 0 0.0 226 100.0
~I patients 469 1003 40.6 1466 59.4
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Table 6.3 shows the age and specialty distribution. Approximately half of the
sample (48.1%) were aged 18-54 and the remainder (51.9%) aged over 55
years. As to be expected the gynaecology and obstetric specialties had a
younger age profile than the other specialties.
Table 6.3: Age and specialty distribution
18-34 35-14 55-74 75+
!Specialty n n % n % n % n %
!General surgery 884 141 16.0 280 31.7 359 40.6 104 11.8
I""........... edics 501 62 12.4 100 20.0 225 «.9 114 22.8
~rology 472 33 7.0 74 15.7 274 58.1 91 19.3
~ynaecology 386 88 22.8 184 47.7 92 23.8 22 5.7
Pbstetrica 226 190 84.1 35 15.5 1 0.4 0 0.0
All patlen1a 2469 514 20.8 673 27.3 951 38.5 331 13.4
6.6 Type of admissions
Table 6.4 shows the number and percentage of patients by admission type.
These seven routes of admission were re-classified into two groups, elective
and emergency admissions, as indicated in Table 6.4. Of the 2469 patients
recruited into the study, 1629 (66%) were elective admissions and 840 (34%)
were either urgent or emergency admissions. Table 6.5 shows how the number
and percentage of patients admitted via these two different routes varied with
specialty. It can be seen that, with the exception of the obstetric specialty, all
admission specialties had more elective than emergency admissions.
Tabl. 6.4: Admission type distribution
jAdmlsslon route Number of % !Grouped admission category
patients
jElective via pre-admiaalon clinic 365 14.8 Elective
jEleCtive - direct to the ward 1264 51.2 Elective
~nt -direct to the ward 100 3.9 Emergency
jEmergency via A+E 868 27.1 Emergency
jEmergency via the OPD 55 2.2 Emergency
~mergency via GP 7 0.3 Emergency
IEmergency via community midwife 10 0.4 Emergency
~ patlen1a 2469 100
A+E • Accident and emergency department
OP~ • Out-patlen1a Department
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Table 6.S: Admission type distribution by admission specialty
~pecialty n Admission type
Elective Emergency
n % n %
peneralsurgery 8M 588 66.5 296 33.5
Orthopaedcs 501 281 56.1 220 43.9
Urology 472 347 73.5 125 26.5
Gynaecology 386 309 80.1 rt 19.9
jObstetrics 226 104 46.0 122 54.0
lAD patients 2469 1629 66.0 840 34.0
6.7 Re-admissionsto hospital
e.7.1 Number of patients classified as 're-admissions'
Patients were classified as a 're-admission' if they had a hospital admission
within the last month. Of the 2469 patients recruited into the study 263 patients
(10.7%) were classified as re-admissions. Of the remaining 2206 patients, in 10
cases information on re-admission status was not recorded. These patients
were assumed not to be re-admissions, the assumption being that if they were,
this information would have been recorded. Of the 263 patients classified as re-
admissions, in 228 cases (86.7%) the admission was linked to the earlier
admission, in 17 cases (6.50/0) the admissions were not linked and in 18 cases
(6.8%) information on whether this was a linked admission was not recorded.
e.7.2 Characteristics of patients classified as 're-admissions'
Table 6.6 provides an overview of the patient characteristics of patients
classified as re-admissions (i.e they were in-patients less than a month prior to
the admission in which they were recruited). Of the 263 re-admissions 45
(17.1%) had a HAl, with eight presenting with a HAlon the day of admission, 31
presenting with an HAl at some point during their admission and in the
remaining six cases the date of onset of infection was not recorded. Table 6.7
shows the number and percentage of re-admissions presenting with an HAl by
admission specialty. Of the 263 patients re-admitted to hospital within a month
of discharge three patients died in hospital. All three patients were male
surgical patients, two aged 73 years and one 54 years. One patient had a HAl
- a BSI acquired during their previous admission.
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Table 8.6: Characteristics of patients admitted within month of a previous
admission
n %
Patiefltcha~stic
Sex
Male 91 34.6
Female in 65.4
Age group
18-34 96 36.5
35-54 62 23.6
55-74 83 31.6
75+ 22 8.4
~pecialty
General surgery 82 31.2
Orthopaedics 28 10.6
Urology 49 18.6
Gynaecotogy 34 12.9
Obstetrics 70 26.6
~Ischarge diagnosis group
Infectious & parasitic diseases 1 0.4
Neoplasms 41 15.6
Endocrine, nutritional & metabolic diseases & Immunity disorders - -
Diseases of blood & blood forming organs - -
DIseases of the nervous system & sense organs - -
Diseases of the circulatory system 18 6.8
DIseases of the respiratory system - -
DIseases of the digestive system 35 13.3
DIseases of the genitourinary system 42 16
Complications of pregnancy, childbirth & puerperium & certain
77 29.3
conditions originating In the perinatal period
DIseases of the lido & subcutaneous tissue 3 1.1
DIseases of the musculoskletal system & connective tissue 14 5.3
Injury & Poisoning 17 6.5
Symptoms, algns & ill-defined conditions; mental disorders &
15 5.7
congenital abnormalitlea
~ ....._ttIes
None 147 55.9
One 82 31.2
Two 23 8.7
Three or more 11 4.2
HAl
No 218 82.9
Ves 45 17.1
r death
No 256 97.3
Ves 7 2.7
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Table 8.7: The distribution of patients admitted within a month of a previous
admission to hospital by presence or absence of a HAl and admission
specialty
HAl
Specialty No v..
n n % n %
General surgery 82 72 27.4 10 3.8
_.v",_vdica 28 21 8.0 7 2.7
Urology 49 45 17.1 4 1.5
[Gynaecology 34 23 8.7 11 4.2
pbatetric8 70 57 21.7 13 4.9
[fotal 263 218 82.9 45 17.1
Of the 263 patients who were classified as re-admissions, 70 (26.6%) had
already participated in this study. Of these 70 patients seven (2.7%) had a HAl
during their previous admission. Three had a SWI, two had UTls; one had a
LRTI; and one a skin infection.
6.8 Distribution of patients by primary dischargediagnosis
Table 6.8 shows the number and percentage of patients by primary discharge
diagnosis grouped into 14 disease categories. Seventy-seven per cent of the
primary discharge diagnoses fell within just five of the 14 ICD9 categories:
diseases of the genitourinary system (23%); diseases of the digestive system
(16.9%); neoplasms (14.5%); complications of pregnancy, childbirth and
puerperium (10.3%), and diseases of the musculoskeletal system and
connective tissue (12.5%).
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Table 6.8:The number and percentage of patients by primary discharge
diagnosis grouped Into 14 diseases categories
ICD8dis.... Number of Percentage of
Study
categories patients within patients within
disease
Included In TItle of Categories each of 1he 14 each of the 14
categories
study dis.... dis....
1-14
categories categories category
1 I nfectious and parasitic disease 13 0.5
2 II ~eoplasms 357 14.5
3 III ~ndocrlne, nutrItionel and metaboUcdiseases and 24 1.0
mmunlty disorders
4 IV Plseases of blood and blood forming organs 3 0.1
5 VI Plseases of the nervous system and sense organs 2 0.1
6 VII DIseases of the circulatory system 150 6.1
7 VIII Dlsea... of the respiratory system 6 0.2
8 IX piseases of the digestive system 418 16.9
9 X 1D1se .... of the genitourinary system 569 23.0
10 XI jeompllcatlone of pregnancy, chlJdbirth and 254 10.3
"......" .........
jcertaJn condltions originating In the perinatal period
11 XII piseases of the skin and subcutaneous tIseue 31 1.3
12 XIII plseases of the musculoskeletal system and 309 12.5
!connective tIseue
13 XVII njury and Poisoning 187 7.6
14 XVI lSymptoms. signs and 1ft.. defined conditions 146 5.9
V
XIV ~ental di80rders
Congenltal abnormalities
All groups 2469 100.0
6.9 Numberof co-morbidities
The majority (66.5%) of patients had no co-morbidities; 23.4% had one; 7.0%
two and 3.1% three or more co-existing conditions. Table 6.9 shows the
number of co-morbidities by specialty.
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Table 8.9: The number and percentage of patients by number of co-morbidities
and admission specialty
Admission spec:lalty
.pec:lalty
General
Orthopedic Urology Gynaecology Obstetrics Alispec:lalties
surgery
n % n % n % n % n % n %
~on8 492 55.7 365 722 361 76.5 322 83.4 102 45.1 1642 86.5
One 263 29.8 64 16.8 77 16.3 54 14.0 100 44.2 578 23.4
Two 79 8.9 41 8.2 27 5.7 8 2.1 18 8.0 173 7.0
rnveeormore 50 5.7 11 22 7 1.5 2 0.5 6 2.7 76 3.1
6.10 Characteristics of patients who had one or more operative
procedures
1.10.1 Number of patients who had one or more operations
Of the 2469 patients included in this study 2041 (82.7%) had one or more
operations. Of these 2041 patients, 1999 (97.9%) had one operation, 40 (2.0%)
had two operations, and two (0.1%) had three operations.
1.10.2 Day of surgery
Data on day of operation were available for 1910 patients. Ninety-five per cent
of patients for whom data were available had surgery within 5 days of admission
to hospital: 11.8% had surgery on the day of admission; 77.1% on day two;
4.0% on day three; 2.1% on day 4 and 1.4% on day five.
Characteristics of patients who underwent one or more
operations
Table 6.10 presents the results of the analysis that examined the percentage of
patients who underwent one or more operations by age, sex, admission
specialty, diagnosis, and number of co-morbidities.
6.10.3
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Table 8.10:The number and percentage of patients who had one or more
operations
PadentJ who had one or
lPatient characteristic n more operation. Pvalue
No• %..
Male 1003 815 81.3 0.126
Female 1466 1226 83.6
~group
18-34 514 416 80.9 0.298
35-54 673 570 84.7
55-74 951 787 82.8
75+ 331 268 81.0
ISpecialty
General surgery 884 682 77.1 <0.001
Orthopaedics 501 433 86.4
Urology 472 373 79.0
Gynaecology 386 327 84.7
Obstetrics 226 226 100.0
~.Iontype
Elective 1629 1559 95.7 <0.001
Emergency 840 482 57.4
~Ischarge dlagnosl. group
InfectioUs & parasitic diseases 13 3 23.1 <0.001
Neoplasms 357 322 90.2
Endocrine, nutritIon.1 & metabolic dlseasas & Immunity disorders 24 24 100.0
OIaesses of blood & blood forming organs 3 1 33.3
OIaeases of the nervous system & sense organa 5 0 0.0
OIaeasas of the circulatory system 150 131 87.3
OIaeasas of the respiratory system 8 5 83.3
OIaea.. of the digestive system 418 327 78.2
0Iaeasas of the genitourinary system 589 493 86.6
Complications of pregnancy, chDdblrth& puerperium & certain 254 241 M.9
conditions originating In the perinatal period
0Iaeasas of the skin & IUbcutaneoua tls8ue 31 25 80.8
OiSeasas of the musculoskletalaystem & connective tls8ue 309 287 92.9
Injury & PoIsoning 187 142 75.9
Symptoms, aigna & ill-defined conditione; mental disorders & 148 40 27.4
congenital abnormalltlas
.... ""'''''itIes
None 1642 1396 85.0 <0.001
One 578 452 78.2
Two or more 2.. 9 193 17.5
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The proportion of patients who had one or more operations varied little with sex
or age category: 81.3% of males and 83.6% of females had one or more
operations and for all age categories at least 80% had one or more operations.
There was some variation with admission specialty. The observed variation
was Significant (p=<0.001). As expected, 100% of patients admitted to the
obstetric specialty had an operation. The study was limited to patients who had
a caesarean section. In the other specialties the proportion of patients who had
an operation varied from 77.1% (general surgery) to 86.4% (orthopaedics). A
Significantly higher proportion of elective admissions (95.7%) than emergency
admissions (57.4%) had one or more operations (p=<0.001). The proportion of
patients who had one or more operations varied with primary discharge
diagnosis and varied slightly with number of co-morbidities.
American Society of Anaesthesiologists scores (ASA) scores were reported for
1556 patients. Of these patients 699 (25.6%) had a score of one; 667 (42.9%)
had a score of two; 174 (11.2%) had a score of three, nine (0.6%) had a score
of four and seven (0.4%)had a score of five.
6.10.4 Types of surgery performed
The analysis of types of procedure performed was based on the Office of
Population Census and Survey dassification of operative procedures system
(fourth addition)231and limited to the frequency of the first procedure reported.
It was assumed that the first reported procedure represented the primary
operative procedure undertaken. The research assistants were instructed to
report the primary procedure first. and in those cases where data on procedure
group had been derived direct from the Patient Administration System database
it was usual practice to report the primary procedure first. Of the 2025 initial
operations for which data on procedure were available, 1414 (69.8%) involved
one procedure, 388 (19.2%) involved two procedures, 163 (8.0%) involved
three, 45 (2.2%) involved four, nine (0.2%) involved five, and six (0.3%)
involved six procedures.
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Table 6.11 provides details of the number and overall percentage of primary
procedures, classified within the broad operation categories, performed. The
results reported in Table 6.11 indicated that almost 80% of operations involved
primary procedures classified within six broad operation categories: operations
involving bones and joints (18.5%); urinary system (17.6%), upper female
genital tract (12.00/0), lower digestive tract (11.1%), female genital tract
associated with pregnancy and childbirth (11.1%) and soft tissues (8.8%).
Further details of the specific types of procedures performed are presented in
Appendix 11.
Table 6.11:The number and percentage of patients undergoing primary
procedures classified according to the OffIce of Population
Censusesand SUlVeyS listed categories
No. &% of patients whoM
opcsoperation category primary procedure fell within
each category
No. %
A Nervoua system 10 0.5
B endocrine system and breast 104 5.1
C eye 0 0.0
0 ear 0 0.0
e Respiratory tract 1 0.0
F Mouth 7 0.3
G Upper digestive tract 23 1.1
H Lower digestive tract 225 11.1
J Other abdominal organa· principally digestive 80 4.0
K Heart 0 0.0
L Arterie8 and Veins ee 2.8
M Urinary 3ee 17.6
N Male genital orga.,. 26 1.3
P Lower female genital 60 3.0
Q Upper ternal. genital 242 12.0
R Femal. genital tract eseooIatedwith pregnenoy and childbirth 224 11.1
S Skin 23 1.1
T Softtiaaue 179 8.8
V Bones and joints of skull and spine 15 0.7
W Other bones and joints 375 18.5
X Miscellaneous operatlOll8 10 0.5
Y Subsidiary cteaaificatlon of methods of op.ratlon 8 0.•
Z SubsidIary classification of sitae of operatloll8 1 0.0.Note. _lysis was baud on 2025 patients for whom data on primary procedure was avaHable•
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6.11 In-patientdeaths
Twenty-one patients (0.9%) died during the in-patient period. Eleven patients
were female, ten patients male. Overall 14 (66.7%) were surgical patients and
the remaining seven orthopaedic patients. Eighty-eight per cent of deaths
occurred in patients who had one or more operations. The mean age was 74
years with a minimum age of 32 and maximum age of 93 years. Four (19%)
had no co-morbidities; six (28.6%) had one co-morbidity; two (9.5%) had two
co-morbidities and nine (42.9%) had three or more co-morbidities. Eight
(38.1%) patients had an HAl identified during their hospital stay. Of these one
had a UTI, two a LRTI, one a BSI, one an infection at a site not classified
elsewhere, one a BSI and an infection at a site not specified elsewhere and one
a LRTI and an infection at another site. Overall patients who acquired an
infection while in hospital were 4.3 (95% Cl: 1.6, 11.2) times more likely to die
than uninfected patients.
6.12 Dischargedestinationandfollow up care
The majority (97.6%) of patients were discharged home. Table 6.12 provides
details of the discharge destination.
Table 8.12: Distribution of patients by discharge destination
Discharge destination n %
Home 2410 97.6
Other ward>1week 7 0.3
Other werd <1 week 2 0.1
Other hospital> 1 week 13 0.5
Other hospltal<1 week 2 0.1
Hospice 2 0.1
ConvaIesc:enthome 1 0.0
NursIng home 2 0.1
Reietives 9 0.4
Died 21 0.9
Total 2469 100
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6.13 Services organized on discharge from hospital
6.13.1 Transport.
Of the 2469 patients recruited into the study 42 (1.7%) required an ambulance
to take them home and 32 (1.3%) required a hospital car. The remaining 2395
(97%) patients did not require transport. Table 6.13 shows the age distribution
of patients who utilised this service and table 6.14 the specialty distribution.
The use of hospital transport (ambulance or car) was found to increase with
increasing age and be highest for patients admitted to the orthopaedic specialty.
Table 6.13: The number and percemage of patients requiring NHS
transport home by ase group
Transport
Ambulance Hospital car
Ate8roup n % n %
18-34 (n- 51~) 0 0.0 1 0.2
35-54 (n-673) 2 0.3 0 0.0
55-7~ (n- 951) 17 1.8 18 1.9
75+ (n- 331) 23 7.0 13 3.9
~patienbJ (n-2~69) 42 1.7 32 1.3
Table 6.14: .The number and percentage of patients requiring NHS transport
home by admission specialty
Specialty Transport
Ambulance Hospital car
n % n %
~eneral surgery (n - 884) 9 1.0 8 0.7
pr1hoPaedics (n· 501) 28 5.2 23 4.6
~rology (n -472) 7 1.8 3 0.8
~yna.colgy (n - 386) 0 0.0 0 0.0
Obstetrics (n - 226) 0 0.0 0 0.0
All apecialtles (n -2489) 42 1.7 32 1.3
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6.13.2 Follow up care
In a number of cases follow-up care was organized for patients prior to
discharge. Tables 6.15 and 6.16 shows the number and percentage of patients
for whom follow up care was arranged by type of care and admission speCialty.
Table 6.1S: The number and percentage of patients for whom community
based follow-up care was organized by type of care and specialty
General surgery Orthopaedics Urology Gynaecology Obatetrica All patients
( .... 884' (.... 101' (...-472) (....., (n- 226, (....2489'
n % n % n % n % n % n %
pl8trlct I1UI1Ie 97 11.0 55 11.0 96 20. 5 1.3 0 0.0 253 10.2
3
_ ...... practitioner 25 2.8 11 2.2 11 2.3 5 1.3 0 0.0 52 2.1
Practice nurse 1 0.1 0 0.0 0 0.0 0 0.0 0 0.0 1 0.0
Elderty support team 2 0.2 12 2.4 1 0.2 0 0.0 0 0.0 15 0.6
eTT 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 1 0.0
Continence advisor 2 0.2 2 0.4 6 1.3 0 0.0 0 0.0 10 0.4
Macmillan I1UI1Ie 6 0.7 0 0.0 4 0.8 0 0.0 0 0.0 10 0.4
Stoma I1UI1Ie 1 0.1 1 0.2 1 0.2 0 0.0 0 0.0 3 0.1
Oiabetic I1UI1Ie 1 0.1 0 0.0 0 0.0 0 0.0 0 0.0 1 0.0
~Iathom. 0 0.0 17 3.4 0 0.0 0 0.0 0 0.0 17 0.7
eam
ptas1IC surgery 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 1 0.0
r-v_ .. cUnic
Physiotherapy 0 0.0 12 2.4 0 0.0 0 0.0 0 0.0 12 0.5
Occupational therapy 0 0.0 3 0.6 0 0.0 1 0.3 0 0.0 4 0.2
SocIal worker 10 1.1 13 2.6 7 1.5 2 0.5 0 0.0 32 1.3
Home help 5 0.6 3 O.S 6 1.3 1 0.3 0 0.0 15 0.6
~I& on wheels 5 0.6 1 0.2 10 2.1 0 0.0 0 0.0 16 0.6
err - communtty therapy team
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Table 6.16: The number and percentage of patients for whom hospital based
follow-up care was organized by type of care and specialty
OeneraisUfI8I'Y Orthopedics Urology Gynecology Obsf8trics All patients
( na884) (... 101) (... 472) (na388) (n-228) (na2_)
n % n % n % n % n % n %
Out-patient 588 66 439 87. 347 73.5 274 71.0 1 0.4 1649 86.8
[appointment 8
~CG 2 0.2 2 0.4 2 0.4 1 0.3 0 0.0 8 0.2
~copy 1 0.1 0 0.0 1 0.2 0 0.0 0 0.0 2 0.1
rrwOC 2 0.2 0 0.0 49 10.4 13 3.4 0 0.0 64 2.6
l.iIhotripsy 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 1 0.1
Day hospital 8 0.9 3 0.6 9 1.9 0 0.0 0 0.0 9 0.4
0Iher 9 1.0 3 0.6 13 2.8 0 0.0 1 0.0 30 1.2
ECG - electro-cardlogram; TWOCC - Trial WIthout catheter
6.14 Conclusion
In this chapter the results of the analysis that explored the general characteristic
of the data set have been presented. The distribution of patients by age, sex,
specialty, admission type, admission specialty, primary discharge diagnosis
group and number of co-morbidities have been presented, as has the mortality
rate observed and the follow up care organised for these patients. The
following chapter will examine the incidence of HAls occurring in this sample of
patients.
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CHAPTER7
THE INCIDENCE OF AND RISKS FACTORS FOR HAl: RESULTS
7.1 Introduction
This chapter presents the results of the descriptive analysis of the incidence of
HAls occurring in surgical patients and the results of the multivariable analysis
that identified independent risk factors for HAl. The analysis is limited to those
infections that presented during the in-patient period. The chapter begins with
an exploration of the overall incidence of HAl as defined by two alternative
definitions of incidence, and how the incidence varies with selected patient
characteristics (section 7.2). Data on the day the primary infection presented
are then presented in section 7.3. The results of the analysis that explored
independent risk factors for HAl are presented in section 7.4and sections 7.5-
7.6 present the results of the analysis that explored the incidence of specific
types of HAl, and the day different types of infections presented. Finally
sections 7.7-7.9 present the results of the analysis that examined how the
incidence of the three most frequent types of infections, urinary tract, surgical
wound and lower respiratory tract infections, varied with selected patient
characteristics and the results of the analysis that explored independent risk
factors for these infections.
7.2 The incidence of HAl
The incidence of HAl was assessed according to two alternative definitions:
• the number of patients who presented with one or more HAls expressed
as a percentage of the number of patients discharged
• the number of primary HAls that presented during the in-patient
period/1000 patient days at risk
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The estimates of the incidence used only HAls which were both acquired and
identified during the hospital stay. Patients admitted with an HAl who did not
acquire a second infection were excluded from the numerator and included in
the denominator. There were nine patients in this category. In a further seven
cases data on the day of presentation were not available. In these seven cases
it was assumed that the patient acquired their infection at some point during
their admission and that they were not admitted with the infection. This
assumption was based on the fact that it is likely that if the patient had been
admitted with an infection related to a previous admission the research
assistant would have entered this information on the data collection sheet at the
time of recruitment.
7.2.1 Thenumber of patients who presented with one or more HAls
expressed asapercentage of the number of patients discharged
One hundred and eighty-four patients presented with one or more HAls during
the in-patient period: an incidence rate of 7.5% (95% Cl: 6.4, 8.6). Table 7.1
shows how the incidence of HAl varied with key patient characteristics. The
incidence of HAls presenting during the in-patient period was higher in female
patients, increased with increasing age, was higher in patients classified as
emergency admissions when compared to elective admissions, and was
highest in patients admitted to the gynaecology specialty, followed by patients
admitted to the obstetric, orthopaedic, urology and surgical specialties. The
incidence of HAl also varied with primary discharge diagnosis, although the
confidence intervals around many of the disease categories were wide, and was
higher in patients with co-morbidities than in those patients with no co-
morbidities. The incidence of HAl was higher in patients who had diabetes
mellitus listed as a co-morbidity although this was not found to be significant (p=
0.620), and was significantly higher in patients who had one or more operations.
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Table 7.1: The Incidence of HAis presenting In surgical patients during the
ItaUsed h b I ted h terl tihospl pi ase ,y se ec c arac s cs
HAl IR PvakHI
Characteristic n No Yea (9I%CI)
lex
Male 1003 952 51 5.' (".3 to 7.3) <0.001
Female 1466 1333 133 9.1 (7.6to 10.6)
Age
18-34 51.. 486 28 5." (3.9 to 8.0) 0.017
35--54 673 631 ..2 6.2 (".5 to 8.3)
55-7 .. 951 8n 79 8.3 (16.8 to 10.5)
75+ 331 296 35 10.8 (8.0to 15.1)
Admiuion type
Elective 1629 1520 109 6.7 (5.9 to 8.1) 0.040i
Emergency &40 765 75 8.9 (7.1 to 11.1)
Specialty
General surgery 888 815 53 6.' (".6 to 7.9) <0.001
Orthopaedics 501 464 37 7." (5.2 to 10.")
Urology ..72 448 24 5.1 (3.9 to 8.")
Gynaecology 388 337 ..9 12.7 (9.9 to 16.8)
Obstetrics 226 205 21 9.3 (6.2 to 1..... )
Primary diagnosis
Infectlous & parasitic 13 12 1 7.7 (0.2 to 36.0) O.OOS
Neoplasms 357 329 28 7.8 (5.3 to 11.1)
Endocrine, nutritional & metabolic dIaeaaea & 24 20 4 16.7 (4.7 to 37.")immunitYdisorders
Oiae .... of blood & blood forming organs 3 3 0 o (0.0 to 0.0)
Oiaeaaea of the nervous systam & sense organs 2 2 0 o (0.0 to 0.0)
Oiaeasea of the circulatory system 150 ' ..2 8 5.3 (2.3 to 10.2)
Diseases of the respiratory sywtam 6 .. 2 33.3 (4.3 to 77.n
DIae .... of the dlgeative aystam 418 397 21 5.0 (3.1 to 7.6)
Oiaeaaea of the genitourinary aystem 569 521 48 8." (8.6to 11.")
Complications of pregnancy, chiIdbIr1h &
9.1 (8.1 to 13.7)puetperium & certain conditions originating in the 254 231 23
Pennatal period
DIae .... of the skin & subcutaneous tissue 31 28 3 9.7 (2.5 to 26.9)
Oiaeasea of the muacutoskIetat system & 309 297 12 ..2 (2.6to 7.1)connective tissue
lnjury&poi8oning 187 164 23 12.3 (9.7 to 20.3)
Symptoms, signs & RI- defined condillona; mental 146 135 11 7.5 (3.8to 13.1)disorders & cOngenital abnormalities
of co- morbidities
None 1642 1538 104 6.3 (5.2 to 7.6) <0.001
One 578 530 ..8 8.3 (6.4 to 11.1)
Two 173 159 ,.. 8.1 (4."to 13.1)
Three of more 76 58 18 23.7 (13.8 to 33.8)
Diabetes mellitus listed as a CCH'I'IOI'bIdity
No 2378 2202 176 7." (6." to 8.5) 0.620
Yea 91 83 8 8.8 (3.9to 16.6)
One or mort operations
No 428 409 19 4.4 (2.7 to 6.8) 0.009
Yea 2041 1876 165 8.1 (6.9 to 9.3)
IR -Incidence rate; CI-confidence inteMIl
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The results presented in Table 7.2 show how the incidence of HAl varied with
primary operative procedure classified according to the Office of Population
Census and Surveys Operation Classification System (fourth edition).231The
results presented show how the incidence varied with primary procedure
classified according to the broad body system groups. The variation in
incidence rates observed for the different procedure categories was highly
Significant (p=<0.001). The analysis was limited to 2024 patients for whom data
on primary operative procedure were available. The number of patients in
some of the subgroups was small and as such it is difficult to draw strong
conclusions. However, if categories which include more than 20 patients are
considered, it can be seen that the highest incidence rates were observed in
patients who had operations involving the upper digestive tract (IR 34.8%,95%
Cl: 16.4%, 57.3%), the lower female genital tract (IR 18.3%, 95% Cl: 9.5%,
30.4%), the skin (IR 13%, 95% Cl: 2.8%, 33.6%) and the upper female genital
tract (IR 12.0%, 95%CI: 8.2%, 16.8%).
More detailed analysis examined how the HAl incidence rate varied with the
specific type of primary procedure performed. The results are presented in
Appendix 11. Amongst patients who had a primary procedure involving the
upper digestive tract, the incidence of HAl was highest in patients whose
primary procedure involved the ileum in the form of surgery such as the excision
of the ileum or creation of an artificial opening in the ileum (57.1%) and in
patients who had a total or partial excision of the stomach and/or oesophagus
(37.5%). Amongst those patients whose surgery involved the lower female
genital tract, the highest incidence was observed in patients whose primary
procedure involved a repair of a vaginal prolapse (19.3%). In those patients
whose surgery involved the upper female genital tract, the highest incidence
was observed in patients whose primary procedure was a hysterectomy
(14.9%).
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Table 7.2: Incidence of HAl by primary ooeratlve ~rocedure category
HAl
operation category
IR(%)
n No Ves ('I%CI)
A Nervous system 10 10 0.0 0.0 (0.0 • 30.8)
B endocrine system and breast 104 100 4.0 3.8(1.1.9.6)
C Eye 0 0 0.0 0.0 -
0 Ear 0 0 0.0 0.0 -
E Respiratory tract 1 0 1.0 100.0 (2.5. 100.0)
F Mouth 7 6 1.0 14.3(0.4.57.9)
G Upper digestive tract 23 15 8.0 34.8(16.4.57.3)
H lower digestive tract 225 211 14.0 8.2 (3.4. 10.2)
J Other abdominal organa - principally digestive 80 75 5.0 8.3(2.1.14.0)
K Heart 0 0 0.0 0.0-
l Arteries and Veins 5& 51 5.0 8.9 (3.0. 19.6)
M Urinary 355 334 21.0 5.9 (3.6. 8.9)
N Male genital organs 28 28 0.0 0.0(0.0.13.2)
p lower female genital 60 49 11.0 18.3(9.5.30.4)
Q Upper female genital 242 213 29.0 12.0(8.2.16.8)
R Female genital tract associated with pregnancy and 224 205 19.0 8.5 (5.2. 12.9)chIIdbiI1h
S Skin 23 20 3.0 13.0(2.8.33.6)
T Soft tissue 179 168 11.0 6.1 (3.1. 10.7)
V Bones and joInta of skull and spine 15 15 0.0 0.0 (0. 21.8)
W Other bones and joints 375 352 23.0 6.1 (3.9. 9.1)
X MiseeRaneous operations 10 7 3.0 30.0(6.7.65.2)
V Subaidlary cIesaifIcation of me1hods of operation 8 8 0.0 0.0(0.0.36.9)
Z Subaidlary cIesaifIcation of sites of operations 1 1 0.0 0.0(0.0.98.0)
Note: Based on 2024 patlen1s for whom operation data available.
IR - incidence rate; Cl -confidence interval
Further analysis examined whether the incidence of HAl varied with Body Mass
Index (BMI). This aspect of the analysis was limited to 1588 patients for whom
data on both height and weight were available. Patients were classified into
three groups: patients with a BMI of less than 20; patients with a BMI of 20-29;
and patients with a BMI of greater than 30. The incidence of HAl was found to
vary with BMI category as follows: 10.3% (95% Cl: 5.5 to 17.4) of the 115
patients who had a BMI of less than 20 acquired one or more infections,
compared to 6.0% (4.7 to 7.4) of the 74 patients who had a BMI of 20-29 and
6.4% (3.0 to 8.7) of the 280 patients with a BMI of 30 or more. The variation in
rates was not found to be Significant (p=0.149)
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7.2.2 Thenumber of primary HAlsl1000patient days at risk
The number of days at risk was calculated as the number of days from
admission to either the day prior to the day the primary infection was identified,
or date of discharge, depending on which came first.
As previously indicated 184 patients acquired and presented with an infection
during their admission. Of these seven did not have a date of onset recorded.
These seven patients were excluded from this analysis. The remaining 177
infected patients had a total of 1,280 days at risk and uninfected patients had
15,149 days at risk. The overall number of days at risk was therefore 16,429
days, giving an incidence density of 10.8 (95% Cl: 9.2, 12.5) infections per 1000
patient days at risk.
Table 7.3 shows how the incidence of HAl per 1000 patient days at risk varied
with key patient characteristics.
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Table 7.3 The number of patients presenting with one or more HAis In hospital
1000 ti d ri kper pa ent aysat s
No. of days at risk Total No. No.ofpts lnc::idenGe density
Pta with Pta with of days at with one of (IRCI,
an HAl no HAl risk montHAIs Pva"'"
Patient characteristic n Ca' (b) (a+b). Cc) (d, (d1c)·1000
Sex
Male 1001 430 5636 6066 49 8.1 (5.9 10.7) 0.0093
Female 1461 850 9513 10363 128 12.4 (10.3,14.7)
_aroup
18-34 514 156 2921 3077 28 9.1 (6.0, 13.2) 0.7924
35-54 672 215 3477 3692 41 11.1 (8.0 15.1)
55-74 946 600 5981 6581 74 11.2 (8.8,14.1)
75+ 330 309 2770 3079 34 11.0 (7.6, 15.4)
Admission saeclaltv
General suraerv 984 499 4481 4980 53 10.6 (8.0,13.9) 0.0001
Orthopaedics 496 286 4768 5054 32 6.3 (4.3, 8.9)
Urology 472 153 2304 2457 24 9.8 (6.3,14.5)
Gvnaecology 384 236 2068 2304 47 20.4 (15.0 27.1)
Ob8f.e1rics 226 106 1528 1634 21 12.9 (8.0 19.6)
Admission type
Elective 1627 613 9126 9739 107 11.0 (9.0, 13.3) 0.7505
Emergency 835 667 6023 6690 70 10.5 (8.2 13.2)
Primary dl8anosis
InfectioUB and parasitic 13 2 46 48 1 20.8 (0.5,116.1) 0.0009
Disease
Neoplasms 357 206 2192 2398 28 11.7 (7.8 16.9)
Endocrine, nutritional & metabolic 24 12 97 109 4 36.7 (10.0,93.9)
diseases & immunity disorders
Diseases of blood & blood 3 0 13 13 0 0.0 (0.0,283.7)
forming organs
Diseases of the nervous system 2 0 7 7 0 0.0 (0.0, 526.8)
& sense organs
Diseases of the circulatory 150 129 706 835 8 9.6 (4.1,18.9)
smem
Diseases of the respiratory 6 19 28 47 2 42.6 (5.2,153.7)
system
Diseases of the dlaestive sYStem 418 127 1937 2064 21 10.2 (6.3 15.6)
Diseases of the genitourinary 568 260 2799 3059 47 15.4 (11.3,20.4)
system
Com~of~~n~, 254 114 1681 1795 23 12.8 (8.1,19.2)
childbirth & puerperium & certein
conditions originating in the
perinatal period
Diseases of the skin & 31 23 126 149 3 20.1 (4.1, 58.8)
subcutaneoua tiseue
Diseases of the muaculoakletal 309 91 3122 3213 12 3.7 (1.9,6.5)
SYStem& connective tissue
IrlJu,y & 181 171 1616 1787 17 9.5 (5.5, 15.2)
Symptoms, signs & ill- defined 146 126 779 905 11 12.2 (6.1,21.7)
conditions; mental disorders &
conaenital abnormalities
ities
None 1637 550 9568 10118 99 9.8 (8.0, 11.9) 0.0042
One 576 378 3690 4068 46 11.3 (8.3, 15.1)
Two 173 203 1378 1581 14 8.9 (4.8, 14.9)
Three or more 76 149 513 662 18 27.2 (6.1,43.0)
DiabetU listad as a co-morbidlty
No 2371 1179 14370 15549 169 10.9 (9.3,12.6) 0.6119
Yes 91 101 779 880 8 9.1 (3.9.17.9)
Cl ~nfidence interval
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7.3 Dayof presentation
Table 7.4 shows the number and percentage of primary infections by the day
the infection was identified, and Figure 7.1 provides a graphical presentation of
the proportion of infections presenting by day of admission. Data on the day the
HAl presented was available for 177 of the 184 patients who were not admitted
with an HAl, but acquired one or more infections whilst in hospital which
presented during the in-patient phase. The results presented in Table 7.4
indicate that over 50% of the infected patients presented with their primary
infection within six days of admission and 75% within nine days of admission.
Tabla 7.4: Tha day the primary HAl presented*
Day primary HAl Number of HAts %ofHAIs Cumulative %
presented
2 4 2.3 2.3
3 21 11.9 14.1
4 27 15.3 29.4
5 22 12.4 41.8
6 19 10.7 52.5
7 19 10.7 63.3
8 13 7.3 70.6
9 8 4.5 75.1
10 6 3.4 78.5
11 4 2.3 SO.S
12 7 4.0 84.7
13 2 1.1 85.9
14 1 0.6 86.4
15 5 2.S 89.3
16 4 2.3 91.5
17 3 1.7 93.2
18 1 0.6 93.8
19 2 1.1 94.9
20 1 0.6 95.5
21 2 1.1 96.6
22 1 0.6 97.2
23 0 0.0 97.2
24 1 0.6 97.7
25-27 0 0.0 97.7
28 1 0.6 98.3
29 0 0.0 98.3
39 1 0.6 98.9
40-44 0 0.0 98.9
45 1 0.6 99.4
47-49 0 0.0 99.4
50 1 0.6 100.0
Total 177 100.0
-The analysis waallmlted to 177 or 1he 184 HAIa preHntIng during !he In-patIent ph ....
In seven cases data on day of presentation wae not avaDable.
214
Figure 7.1: The day the primary HAl presented
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7.4. Independent risk factors for HAl
The preceding sections have presented the results of the analysis that
examined how the incidence of HAl varied with different incidence measures
and with selected patient characteristics. In this section the results of the multi-
variable logistic regression analysis that identified independent risk factors for
infection are presented. The factors included in the analysis were those listed
in Tables 7.5 and 7.6. Details of the methods used can be found in section
5.5.2 of Chapter 5.
Table 7.5 presents the results of the single variable analysis and Table 7.6 the
results of the multivariable analysis. The results of the single variable analysis
indicate that with the exception of diabetes, the odds of acquiring an HAl whilst
in hospital vary significantly with all the factors included in the analysis.
Females were found to be at greater risk of acquiring an infection than males;
the risk increased with age and increasing number of co-morbidities; emergency
admissions were at higher risk than elective admissions; the risk was greatest
amongst gynaecology patients and higher amongst patients who had received
antibiotic prior to the onset of an infection. The results of the multivariable
analysis indicted that this pattern remained, and with the exception of sex,
antibiotics and diabetes the odds of acquiring an infection varied significantly
with all the factors included in the analysis.
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Table 7.5: The odds of acquiring a HAl by key patient characteristics
(single variable analysis)
HAl Odds ratio
Patient characteristic (95% Cl)
n No Yes Pvalue
Sex
Male 1003 952 51 1.0 0.0002
Female 1466 1333 133 1.9 (1.3,2.6)
~group
18-34 514 486 28 1.0 0.0076
35-54 873 631 42 1.2 (0.7,1.9)
55-74 951 872 79 1.6 (1.0,2.5)
75+ 331 296 35 2.1 (1.2,3.4)
~dml •• 1on type
Eleo1Ive 1629 1519 110 1.0 0.003
Emergency 840 766 74 1.4 (1.0,1.9)
Specialty
General surgery 884 831 53 1.0 0.0003
Orthopaedics 501 484 37 1.3 (0.8,1.9)
Urology 472 448 24 0.9 (0.5,1.4)
Gynaecology 386 337 49 2.3 (1.5,3.4)
Obstetrics 226 205 21 1.8 (1.0,2.7)
~umber of co-morbidltlea
None 1642 1538 104 1.0 0.0018
One 579 531 48 1.3 (0.9,1.9)
Two or more 249 235 14 2.2 (1.4,3.3)
~blotlcs pre HAl- any I'OUt8
No 1002 948 54 1.0 0.0074
Yes 1467 1338 129 1.7 (1.2,2.4)
Diabetes
No 2378 2202 176 1.0 0.6289
Yes 91 83 8 1.2 (0.6,2.5)
Operation
No 428 409 19 1.0 0.0056
Yes 2041 1876 165 1.9 (1.2,3.1)
Cl - confidence mterval
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Table 7.6: The odds of acquiring a HAl by key patient characteristics
(multlvarlable analysis)
HAl
Patient characteristic No Ves
Odds ratios
n (t5%CI) Pva""
Sex
Male 1003 952 51 1.0 0.061
Female 1466 1333 133 1.5 (1.0,2.3)
Age group
18-34 514 486 28 1.0 <0.0001
35-54 673 631 42 1.7 (1.0,3.1)
55·74 951 872 79 3.4 (1.9 , 6.3)
75+ 331 296 35 4.2 (2.1 ,8.1)
IAdmisslon type
Elective 1629 1519 110 1.0 <0.0001
Emergency 840 766 74 2.3 (1.8,3.4)
Specialty
General surgery 664 831 53 1.0 <0.0001
Orthopaedics 501 484 37 0.9 (0.8 , 1.5)
Urology 472 448 24 0.9 (0.5 I 1.8)
Gynaecology 386 337 49 3.0 (1.8 , 4.8)
Obstetric. 226 205 21 1.9 (0.9 , 3.9)
Number of co-morbidlties
None 1642 1538 104 1.0 0.0118
One 579 531 48 1.3 (0.9 , 2.0)
Two or more 249 235 14 2.1 (1.3,3.4)
Diabetes
No 2378 2202 176 1.0 0.4601
Yes 91 83 8 0.7 (0.3,1.7)
!Antibiotics pre HAl- any route
No 1002 948 54 1.0 0.1340
Ves 1487 1338 129 1.3 (0.9,1.8)
OperatIon
No 428 409 19 1.0 0.0002
Ves 2041 1878 185 2.7 (1.5,4.7)
Cl - confidence mterval
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7.5 The incidence of specific types of HAl
Whilst 184 patients acquired and presented with one or more HAls during the
in-patient phase, overall 208 infections were identified during this time period.
UTls were the most frequent type of infection accounting for 48.1% of the
infections observed, followed by SWls and LRTls (Table 7.7).
Table 7.7: The number, percentage and Incidence of HAl by site of Infection
Number of
Proportion of
incidence of HAl (%)
Type of HAl Infections
Infections (91% Cl)
identified (%)
UTI 100 48.1 4.1 (3.3, 4.9)
LRTI 23 11.1 0.9 (0.6, 1.4)
SWI 40 19.2 1.6 (1.2, 2.2)
BSI 4 1.9 0.2 (0.0, 0.4)
Skin 16 7.7 0.6 (0.4, 1.1)
Other 25 12.1 1.0 (0.7. 1.5)
tITI - unnary tract infection; LRTI -lower rcspnatory tract infection; SW! • surgical wound infection; BSI· bloodstream infection
CI- confidence interval
7.6 Day of presentation of different types of Infection
Table 7.8 shows the number and percentage of infections by the day the
infection was identified. Data on the day the HAl presented was not available
for all HAls. Details of the number of infections included for each site specific
analysis are presented at the bottom of the table. The results presented in
Table 7.8 indicate that for all sites of infection at least 50% of the infections
identified presented within eight days of admission, and with the exception of
skin infections 75% or more of each type of infection presented within two
weeks of admission.
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7.7 The incidence of UTls and identification of risk factors
7.7.1 TheIncidenceof UTls
Of the 2469 patients involved in this study, 100 patients acquired and presented
with a UTI during the in-patient period: an incidence rate of 4.1% (95% Cl: 3.3
to 4.9), with 13 patients presenting with an infection at one or more additional
sites. Of these 13 patients, in eight cases the UTI was the primary infection.
The incidence density was 5.7(95% Cl: 4.7, 7.0) UTls per 1000 patient days at
risk, and 17.4 utisl1000 catheter days at risk.
Table 7.9 shows how the incidence of UTls varies with selected patient
characteristics. The characteristics included in this analysis included both
intrinsic and extrinsic risk factors for hospital acquired UTls identified from the
literature and for which data were available (see section 2.8.3 for a discussion
of risk factors for UTls).
The incidence of UTls was found to be significantly higher in women (p=<0.001)
and varied with admission specialty (p<0.001), being highest in patients
admitted to the gynaecology and obstetric specialties. The incidence of UTI
was also found to vary significantly with discharge diagnosis, being highest in
patients with a primary discharge diagnosis classified as 'Diseases of the
genitourinary system', and was considerably higher in patients who had a
catheter in situ prior to their infection. Urinary tract infection rates were 2.3
times higher in patients who had a catheter inserted compared to patients who
did not have a catheter inserted. Finally, the incidence of UTI was found to be
significantly higher in patients who had an operation and in those patients who
received antibiotics prior to the infection, compared to those who did not, a
factor which suggests that administration of antibiotics is a marker for another
risk factor. That is prophylactic antibiotics are administered to patients thought
to be at greater risk of acquiring an infection than those not given prophylactic
antibiotics. With respect to the other variables included in this analysis, whilst
the incidence of UTI was found to vary with age group, admission type and
number of co-morbidities, the observed variation was not found to be
statistically significant at the 5% level.
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T bl 79Th i Id fUTI I tI tsa e . e nc enceo s n sur g!ca pa en. .
Patient characteristic
UTI IR(%) Pvaluen
No Ves (91% Cl)
Sex
Male 1003 985 18 1.8 (1.1 ,2.8) <0.001
Female 1466 1384 82 5.6 (4.5,6.9)
Age group
18-34 514 498 16 3.1 (1.8,5.0) 0.203
35-54 673 646 27 4.0 (2.7 , 5.9)
55-74 951 914 37 3.9 (2.8. 5.3)
75+ 331 311 20 6.0 (3.7,9.0)
Admission type
Elective 1629 1563 66 5.2 (4.0,6.6) 0.826
Emergency 840 807 34 4.0 (2.8 , 5.6)
Specially
General surgery 884 869 15 1.7 (1.0, 2.8) <0.001
Orthopaedics 501 488 13 2.6 (1.4,4.4)
Urology 472 455 18 3.8 (2.3, 6.0)
Gynaecology 386 344 41 10.6 (7.7,14.1)
Obstetrics 226 213 13 5.8 (3.1 ,9.6)
Discharae dIaGnosis arouD
Infectious & parasitic disease 13 12 1 7.7 (0.2,36.0) 0.005
Neoplasms 357 341 16 4.5 (2.6,7.2)
End0c:e, nutritional and metabolic diseases and 24 24 0 0.0 (0.0,14.2)immun disorders
Diseases of blood & blood forming organa 3 3 0 0.0 (0.0 •70.8)
Diseases of the nervous system & sense organs 2 2 0 0.0 0.0, 84.2)
Diseases of the circulatory system 150 146 4 2.7 (0.9,7.1)
Diseases of the respiratory system 6 6 0 0.0 (0.0. 45.9)
Diseases of the digestive system 418 410 8 1.9 (0.8,3.7)
Diseases of the genitourinary system 569 530 39 6.9 (4.9. 9.3)
CompRcations of pregnancy, chHdbirth& puerperium & 254 239 15 5.9 (3.3, 9.6)certain conditiona orlamatlna in the Derinatal period
Diseases of the skin & subcutaneous tlasue 31 31 0 0.0 (0.0 , 11.2)
Diseases of the muaculoskletalsystem & connective 309 305 4 1.3 (0.4 •3.3)tIasue
Injury & poisoning 187 178 9 4.8 (2.4 •8.9)
Symptoms, signs & iJI.. defined conditiona; mental 146 142 4 2.7 (0.8.7.1)disorders & conaenital abnormalities
Number of co-morbldlties
None 1641 1578 63 3.8 (3.0. 5.0) 0.862
One 579 553 26 4.5 (3.0 , 6.5)
Two or more 249 238 11 4.4 (2.2,7.8)
Antibiotics prior to UTI- any route
No 972 944 28 2.9 (2.1 .4.4) 0.04
Ves 14M 1425 71 4.7 (3.7,6.0)
Antibiotics prior to un -IVIIM
No 1210 1171 39 3.2 (2.3, 4.4) 0.083
Ves 1258 1198 60 4.8 (3.7,6.1)
Catheter present prior to UTI
No 1757 1714 43 2.4 (1.9,3.4) <0.001
Ves 711 655 58 7.9 (6.0,10.1)
Operation·
No 428 421 7 1.6 (0.6 , 3.4) 0.002
Yes 2041 1948 93 4.8 (3.7 , 5.6)
UTI -. unnary tract infection; IR - 1nCldence rate • In the absence of data on day of operation for all 2041 patients who had an
opera~ve procedure the assumption was made that patients acquired their un after their first operative procedure. Note: With the
exception of the antibiotic and catheter variables this analysis is based on all 2469 patients. The analysis examining how un rates
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7.7.2 Independentrisk factors for UTls
In order to assess which factors were independently associated with an
increased risk of acquiring a UTI, a logistic regression analysis was carried out.
The analysis included all the variables listed in Table 7.9 with the exception of
primary discharge diagnosis group, which was omitted from this analysis. The
confidence intervals for the odds ratios of acquiring a UTI for the different
primary discharge diagnosis group were very wide and as such the inclusion of
this variable had little value. Table 7.10 presents the results of the single
variable analysis, and Table 7.11 the results of the multivariable analysis.
It can be seen from Table 7.11 that after controlling for a range of factors the
presence of a urinary catheter at some point prior to the infection and female
sex were associated with the greatest increases in risk. The odds of acquiring a
UTI were 2.6:1 in catheterised patients compared to non-catheterised patients
and 2.8:1 in females compared to male patients. The odds of acquiring a UTI
were also found to increase with increasing age category, and varied
significantly with admission specialty. The odds of acquiring a UTI were higher
for gynaecology and obstetric patients, compared to patients in the other
specialty groups. The odds of acquiring a UTI were also greater in patients who
had one or more co-morbidities. However there was no evidence that the odds
increased with increasing number of co-morbidities. The odds of acquiring a
UTI were higher for emergency patients, and were similar in patients who had
antibiotics prior to a UTI and in those who had not, although the upper
confidence intervals suggest that in some case patients who received
prophylactiC antibiotics were at greater risk of acquiring a UTI. This outcome
suggests that the administration of prophylactic antibiotics is perhaps a maker
for another risk factor not included in this model.
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Table 7.1O:The odds of acquiring a UTI key patient characteristics
(single variable analysis)
Patient characteristic
un Odds ratios Pva .....
n No Ves (91% Cl)
Sex
Male 1003 985 18 1.00 <0.0001
Female 1. 1384 82 3.24 (1.9 , 5.4)
Age group
1844 514 498 16 1.00 0.2331
35-M 673 646 27 1.30 (0.7 I 2.4)
55-74 951 914 37 1.26 (0.7,2.4)
75+ 331 311 20 2.00 (1.0 , 3.9)
Admission type
Elective 1629 1563 66 1.00 0.8233
Emergency 840 807 34 0.95 (0.6 I 1.5)
Specialty
General surgery sa.. 869 15 1.00 <0.0001
Orthopaedics 501 - 13 1.54 (0.7 , 3.3)Urology 472 454 18 2.16 (1.1 14.4)
Gynaecology 386 345 41 7.07 (3.9 , 12.9)
Obatetrica 226 213 13 3.54 (1.7,7.5)
Number of co-morbidlties
None 1841 1579 63 1.00 0.8634
One 579 553 26 1.11 (0.7 , 1.8)
Two or more 249 238 11 1.16 (0.6,2.2)
DIabetes listed as a co morbidity
No 2378 2283 95 1.0 0.4977
Ves 91 88 5 1.4 (0.6 , 3.5)
Antibiotics p... UTI- any route
No 972 944 28 1.00 0.0266
Ves 1496 1425 71 1.62 (1.1 ,2.3)
Antibiotics pre UTI-IVIIM
No 1210 1171 39 1.00
Ves 1258 1198 60 1.47 (1.0,22) 0.0636
Cathetw pNlent prior to UTI
No 1757 1714 43 1.00 <0.0001
Ves 711 855 56 3.41 (2.3,5.1)
Operation
No 428 421 7 1.00 0.002
Ves 2041 1948 93 2.9 (1.3 , 6.2)
UTI- unnary tract infection, Cl - Contldence interval
Note: The analysis limited to 2468 patients for whom complete data sets were available
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Table 7.11: The oddI of acquiring a un by selected factors after controlling
for all other factors lilted (multlvariable analysis,.
Variable Odd. Ratio SigofLog
(tAC ••) likelihood ratio
!Sex
Male 1.0 0.0027
Female 2.8 (1.4 , 5.6)
~9rouP
18-34 1.0 0.0154
35-54 1.8 (0.8 , 3.9)
55-74 2.6 (1.1,6.0)
75+ 4.2 (1.7 , 10.4)
!Admi•• ion type
Elective 1.0 0.0132
Emergency 2.0 (1.2 3 ,.5)
IBpeclalty
General surgery 1.0 <0.0001
Orthopaedics 1.2 (0.5 ,2.7)
Urology 1.9 (0.8 ,4.3)
Gynaecology 5.2 (2.8 , 10.6)
Obstetrics 3.1 (1.1 ,8.5)
~umber of co-morbidlties
None 1.0
One 1.2 (0.7 ,2.0) 0.8292
Two or more 1.2 (0.5 ,2.5)
"'a"" IlstacIas • co-morbidity
No 1.0 0.5242
Yes 1.4 (0.5 ,4.0)
IAnUbiotics (any route) admlnlstenld pnt Nun,
No 1.0 0.8362
Yes 1.1 (0.5,2.3)
[Antibiotics (IVIIM, aclmlnlstenld pnt Nun
No 1.0 0.9205
Yes 1.0 (0.5 , 2.0)
1"""" r pntsant prior 10un
No 1.0 <0.0001
Yes 2.6 (1.6 ,4.1)
IOperation
No 1.0 0.0181
Yes 2.7 (1.1,8.5)
CI- Confidence interval
Note: The IUUIlysislimited to 2468 patients for whom complete data sots were available
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7.8 Incidenceof SWlsand the identification of risk factors
7.8.1 Overall incidence of SWis
Of the 2469 patients recruited into the study 44 presented with a SWI with 40
(1.6%, 95% Cl: 1.2, 2.2) acquiring and presenting with a SWI during their
admission to hospital. Twelve patients acquired one or more infections at other
sites as well. The incidence density was 2.3 (95% Cl: 1.6, 3.1) SWls per 1000
patient days at risk.
Table 7.12 shows how the incidence varied with key patient characteristics.
There was little variation in the incidence of SWI by the factors listed in Table
7.12.
7.8.2 The incidence of SWis occurring in patients who had one or
more operative procedures.
Of the 2469 patients recruited into the study 2041 had one or more operative
procedures. Of these 2041 patients, 38 acquired a SWI: an incidence rate of
1.9% (95% Cl: 1.3, 2.5). Table 7.13 shows how the incidence varied with
selected patient characteristics. As with the analysis that included all patients,
there was little variation in the incidence of SWls with the patient characteristics
included in the analysis.
7.8.3 Independent risk factors for SWI
In order to assess which factors were independently associated with an
increased risk of acquiring a SWI, a logistiCregression analysis was carried out.
Since SWls by definition can only occur in patients who had one or more
operations, the analysis was limited to patients who had one or more operative
procedures (n=2041). Table 7.14 presents the results of the single variable
analysis, and Table 7.15 the results of the multivariable analysis. The analysis
included all the variables listed in these tables.
There was little variation in the odds of acquiring a SWI with the factors included
in the analysis. The only Significant variation was with wound drain status.
Patients who had one or more wound drains in place were 2.2 (95% Cl: 1.0,
5.0) times more likely to acquire a SWI than those who did not.
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Table 7.12: The Incidence of SWis In surgical patients
SWI IR (Oh) Pvaluen
No Ves (11% Cl)
Sex
Male 1003 989 14 1.4 (0.8 , 3.3) 0.465
Female 1466 1«0 28 1.8 (1.2,2.8)
Age group
18-34 514 508 6 1.2 (0.4, 2.5) 0.236
35-54 873 666 7 1.0 (0.4,2.1)
55-74 951 932 19 2.0 (1.2,3.1)
75+ 331 323 8 2.4 (1.0 ,4.7)
Spedalty
General surgery 884 868 16 1.8 (1.0,2.9) 0.162
0rth0paedic:6 501 489 12 2.4 (1.2,4.1)
Urology 472 470 2 0.4 (0.1 , US)
Gynaecology 386 379 7 1.8 (0.7 ,3.7)
Obstetries 226 223 3 1.3 (0.3 , 3.8)
Admission type
elective 1629 1604 25 1.5 (1.0 ,2.3) 0.555
Emergency 840 825 15 1.8 (1.0 , 2.9)
Diagnosis group
Infectious & parasitic disease 13 13 0 0.0 (0.0 , 24.7)
0.239
Neoplasma 357 350 7 2 (0.8 ,4.0)
Endocrine. nutritional & metabolic diseases & 24 23 1 4.2 (0.1 ,21.1)
Immunity disorders
OIseases of blood & blood forming organs 3 3 0 0.00 (0.0 •70.8)
OIseases of the nervoua system & sense organs 2 2 0 0.0 (0.0 •84.2)
Oisea.e. of the circulatory system 150 147 3 2 (0.4,5.7)
OIseases of the respiratory system 6 6 0 o (0.0 , 45.9)
OIseases of the digestive system 418 414 4 1.0 (0.3 , 2.4)
OIseases of the genitourinary system 569 563 6 1.1 (0.4,2.3)
Compllcatlona of pragnency, chiIdbIr1h & 1.2 (0.2 , 3.4)puerperium & certain conditions originating In the 254 251 3
Derirlatal Deriod
0Iseases of the akin & subcutaneous tissue 31 30 1 3.2 (0.1 ,16.7)
Oiseases of the mU8cul08ldetalsystem & 309 305 4 1.3 (0.4 , 3.3)
connective 1Is8ue
Injury & poisoning 187 178 9 4.8 (2.2 , 8.9)
Symptoma. signa & III- defined conditions; mental 146 144 2 1.4 (0.2 •4.9)disorders & conaenltalabnorma_
CcHnorbIdIties
None 1642 1622 20 1.2 (0.7 ,1.9) 0.083
One 578 564- 14 2.4 (1.3 ,4.0)
Two or more 249 243 6 2.4 (0.9 , 5.2)
Antibiotics (any route) admlnlsteNd pre SWI
No 968 956 12 1.2 (0.6 , 2.2) 0.188
Vea 1501 1473 28 1.9 (1.2 , 2.7)
Antibiotics (IVIIM) administered pre SWI
No 1213 1199 14 1.2 (0.6,1.9) 0.105
V .. 1256 1230 28 2.1 (1.4,3.1)
SWI- surgical wound infections, IR -Incidence rate, 01- Confidence inteMIl
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Table 7.13:The Incidence of SWI occurring In patients who had one or more
doperative proce ures
Patient charac18rlstlc
SWI IR (%) Pvalue
n No Vea (95%CI)
sex
Male 815 799 16 2.0 (1.1,3.2) 0.7823
Female 1226 1204 22 1.8 (1.1,2.7)
AaearouD
18-34 416 410 6 1.4 (0.5,3.1) 0.1665
35-54 570 564 6 1.1 (0.4, 2.3)
55-74 787 769 18 2.3 (1.4, 3.6)
75+ 268 260 8 3.0 (1.3,5.8)
Specialty
General surgery 682 666 16 2.3 (1.3,3.8) 0.3083
Orthopaedics 433 422 11 2.5 (1.3,4.5)
Urology 373 370 3 0.8 (0.2,2.3)
Gynaecology 327 322 5 1.5 (0.5, 3.5)
Obstetrics 226 223 3 1.3 (0.3,3.8)
Admlaaion tYDe
Elective 1559 1536 23 1.5 (0.9,2.2) 0.0202
Emergency 482 467 15 3.1 (1.8,5.1)
Dlaal'lDlSia arouo
Infectious & parasitic disease 3 3 0 0.0 (0.0, 70.8) 0.328
Neoplasms 322 315 7 2.2 (0.9, 4.3)
Endocrine, nutritional & metabolic diseases & 24 23 1 4.2 (0.1,21.1)
immunity disorders
Diseases of bIoocI & blood forming organs 1 1 0 0.0 (0.0, 97.5)
Diseases of the nervous system & sense organs 0 0 0 -
Diseases of the Circulatory system 131 128 3 2.3 (0.5,6.5)
Diseases of the respiratory system 5 5 0 0.0 (0.0, 52.2)
Diseases of the digestive system 327 323 4 1.2 (0.3,3.1)
Diseases of the genitourinary system 493 428 5 1.0 (0.3, 2.4)
Complications of pregnancy, childbirth & puerperium 241 238 3 1.2 (0.3, 3.6)& certain conditions orlalnatlrg in the oemetal ceriod
Diseases of the skin & subcutaneous tissue 25 24 1 4.0 (0.1, 20.4)
L)li8ases of the musculoskletalsystem & connective 287 282 5 1.7 (0.6,4.0)tis8Ue
Injury & poisonirg 142 135 7 4.9 (2.0,9.9)
Symptoms, signs & ill- defined conditions; mental 40 38 2 5.0 (0.6, 16.9)disorders & conaenltal abnormalities
eo-morbldltlea
None 1396 1376 20 1.4 (0.9, 2.2) 0.0998
One 452 440 12 2.7 (1.4,4.6)
Two or more 193 187 6 3.1 (1.1,6.6)
Dlabetee listed as • co-morbldlty
No 1971 1935 36 1.8 (1.3,2.5) 0.8332
Yes 70 2 2 2.9 (0.3, 9.9)
AntIblotica (anv rou18T administered or. SWI
No 720 708 12 1.7 (0.9,2.9) 0.63012
Yes 1321 1295 26 2.0 (1.3, 2.9)
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Table 7.14:The odds of acquiring a SWI by key patient characteristics
(single variable analysis)
SWI Odds Ratio Pvalue
Patient characteristic (11% Cl)
n No Yes
Sex
Male 815 799 16 1.0 0.8973
Female 1226 1204 22 1.0 (0.5,2.1)
~gegroup
18-34 416 410 6 1.0 0.2789
35-54 570 564 6 0.7 (0.2,2.3)
55-74 787 769 18 1.5 (0.6, 3.9)
75+ 268 260 8 1.8 (0.6, 5.5)
!specialty
General surgery 682 666 16 1.0 0.1514
Orthopaedics 433 422 11 1.0 (0.4, 2.2)
Urology 373 370 3 0.2 (0.1,1.0)
Gynaecology 327 322 5 0.6 (0.2, 1.8)
0b8tetrIce 226 223 3 0.6 (0.2, 1.9)
!Admission type
Elective 1559 1536 23 1.0 0.0896
Emergency 482 467 15 1.9 (0.9,3.7)
~... ,_...~Iti..
None 1396 1376 20 1.0 0.0659
One 452 440 12 2.1 (1.0,4.4)
Two or more 193 187 6 2.5 (1.0, 6.3)
Diabetes listed ... co-morbldlty
No 1971 1935 36 1.0 0.5147
Yes 70 2 2 1.7 (0.4,7.1)
Antibiotics {any route, admlnlatenld pna SWI
No 720 708 12 1.0 0.2682
Ves 1321 1295 26 1.5 (0.7,3.1)
~blotics (IVAM)adminlstenMl pre SWI
No 904 891 13 1.0 0.0885
Ves 1137 1112 25 1.8 (0.9, 3.7)
PNound drain prior to SWi
No 1921 1894 28 1.0 0.0071
Ves 548 539 12 2.5 (1.3, 4.9)
SWI - surgical wound InfectiOl'l8
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Table 7.1S:The odds of acquiring a 8W1by key patient characteristics
(multl·varlable analysis)
Patient characteristic Odd. RatioSWI (95% Cl) Pvalue
n No Ves
Sex
Male 815 799 18 1.0 0.6812
Female 1226 12CM 22 0.8 (0.4 1.9)
Aaearoup
18-34 416 410 8 1.0 0.3978
35-54 570 584 6 0.8 CO.2, 2.8}
55-74 787 769 18 1.7 (0.5 5.3)
75+ 268 260 8 1.9 (0.5 6.6)
General surgery 682 866 16 1.0 0.3536
OrthopaediCla 433 422 11 0.6 0.3 1.5}
Urology 373 370 3 0.3 0.1 1.4}
G 327 322 5 1.2 0.4 4.0)
Obstetrics 226 223 3 0.7 0.1 ,3.S}
IAdmisslon tvDe
Elective 1559 1536 23 1.0 0.1CM3
Emergency 482 467 15 1.9 (0.9 ".1)
CcHnorbIdities
None 1396 1378 20 1.0 0.2893
One 452 <440 12 1.9 (0.8 ".n
Two or more 193 187 8 1.8 (0.6 5.1)
Diabe1u listed as • eo-morbldltv
No 1971 1935 36 1.0 0.820
Ves 70 2 2 0.8 (0.2 3.9)
Mtlbioticl (anv route) administered DraSWI
No 720 708 12 1.0 0.5136
Ves 1321 1295 26 0.5 (0.1 4.3T
Antibiotics OVIIM)administered DI'8 SWi
No 9(M 891 13 1.0 0.3396
Yea 1137 1112 25 2.4 (0.3 18.6)
Wound drain prior to SWI
No 1921 1894 28 1.0 0.0501
Vea 548 539 12 2.2 (1.0 , 5.0)
SWI- 8Urglcal wound infections, Cl - Confidence Interval
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7.9 The incidence of LRTls and Identification of independent risk
factors
7.9.1 The incidence of LRTls
Of the 2489 patients involved in this study 23 (0.9%: 95% Cl: 0.6, 1.4) acquired
and presented with a LRTI during the in-patient period. The incidence density
was 1.3 (95%CI: 0.8,1.9) per 1000 days at risk. Table 7.16 shows how the
incidence of LRTI varied with selected patient characteristics. The results
indicated that the incidence was higher in males than females; increased with
increasing age; was highest in surgical patients; was higher in emergency as
compared to elective admissions; was highest in patients whose primary
discharge diagnosis was classified as a neoplasm; increased with increasing
number of co-morbidities; was higher in patients who had diabetes listed as a
co-morbidity, patients who had surgery, patients with a naso-gastric tube and/or
endotracheal or tracheostomy tube in place prior to the onset of infection, and
higher in patients who received antibiotics prior to infection. However, the only
significant variation was with age group, number of co-morbidities, presence of
a naso-gastric and/or endotracheal or tracheostomy tube prior to the onset of
infection and increasing age.
7.9.2 Independent risk factors for LRTls
To assess which factors were independently associated with an increased risk
of acquiring a LRTI, a logistiC regression analysis was conducted. Tables 7.18
and 7.19 present the results of the single and multivariable logistic regression
analysis. In the Single variable analysis significant variation was observed with.
respect to age, the number of co-morbidities, and presence of an NG tube
and/or endotracheal or tracheostomy tuoe, However, the results of the
multivariable analysis indicated that the only significant variation in the odds of
acquiring a LRTI was with the presence or absence of an endotracheal or
tracheostomy tube. The odds of acquiring a LRTI were found to be 44.4 (95%
Cl: 8.8, 288.0) times higher in patients who had an endotracheal or
tracheostomy tube than those who did not.
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Table 7.16: The Incidence ofLRTIs in surgical patients
LRn IR%
Patient characteristic n No Ves (t8%CI) Pvalue
Sex
Male 1003 990 13 1.3 (0.7 ,2.2) 0.119
Female 1466 1456 10 0.7 (0.3 1.3l
Age group
18-34 514 513 1 0.2 (0.0,1.1) 0.024
35-54 673 669 4 0.6 (0.2, 1.5)
55·74 951 940 11 1.2 (0.6,2.1)
75+ 331 324 7 2.1 (0.9 4.3)
S
General surgery 884 871 13 1.5 (0.8 ,2.5) 0.299
Orthopaedics 501 497 4 0.8 (0.2, 2.0)
Urology 472 470 2 0.4 (0.1 ,1.5)
Gynaecology 386 383 3 0.8 (0.2 •2.3)
Obstetrics 226 225 1 0.4 (0.0. 2.4)
Admission type
Elective 1629 1616 13 0.8 (0.4, 1.4) 0.338
Emergency 840 830 10 1.2 (0.6.2.2)
Diagnosis groUp·
Infectious & paresilIc disease 13 13 0 0.0 (0.0 .24.7) 0.0387
Neopiesms 357 351 6 1.7 (0.6.3.6)
Endocrine, nutritional & metabolic dIse_ & Immunity 24 23 1 4.2 (0.1,21.9)
disorders
DIseases of blood & blood forming organs 3 3 0 0.0 (0.0, 70.8)
DIseases of 1he nervous system & sense organs 2 2 0 0.0 (0.0, 45.9)
Diseases of 1he circulatory system 150 149 1 0.7 (0.0.3.7)
Dise_ of the respiratory system 6 5 1 16.7 (0.4,84.1)
Diseases of 1he dIgnttve system 418 414 4 1.0 (0.3. 2.4)
DIseases of 1he genitourinary syetem 569 566 3 0.5 (0.1,1.5)
Complications of pr~=nc:y. c:hiIdblrth & puerperium & 254 253 1 0.4 (0.0, 2.2)
certain conditions ori stina In 1he oerIn8ta1 ~
Oiae_ of the IkIn & aubcutaneoua ti8Iue 31 31 0 0.0 (0.0, 11.2)
Diaenes of the rnusculoakletal system & c:onnec:tIve ti8Iue 309 307 2 0.6 (0.1 , 2.3)
Injury & poieonIng 187 185 2 1.1 (0.1,3.8)
Symptoms, ligna & NI- defined c:ondItions; mental dllordera 146 144 2 1.4 0.2, 4.9)
& abnorma_
Co-mOrbIdItie.
None 1842 1832 10 0.6 (0.3,1.1) <0.001
One 578 573 5 0.9 (0.3, 2.0)
Two armore 249 241 8 3.2 (1.4 6.2)
Diabetes listed as. co-morbIdlty
No 2378 2357 21 0.9 (0.6 1.3) 0.214
Ves 91 89 2 2.2 (0.3,7.7)
NO tube present pre- LRn
No 2376 2380 18 0.7 (0.4,1.1) <0.001
Vea 93 86 7 7.5 (3.1 14.9
Tracheostomy or eT tube pre LRn
No 2449 2433 16 0.7 CO.4 1.1) <0.001
Ve. 20 13 7 35.0 (15.4,59.2)
Antibiotics In LRn - any route
No 1002 995 7 0.7 (0.3, 1.4) 0.467
Vea 1467 1451 16 1.1 (0.6 1.8)
Antibiotics In LRn - tntravanous route onlv
No 1228 1220 8 0.7 CO.3 1.5) 0.228
Vea 1241 1226 15 1.2 (0.7 1.9)
Operation
No 428 428 2 0.5 (0.1 ,1.7) 0.096
Ves 2041 2020 21 1.0 (0.6,1.6)
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Tabl.7.17: Th. odds of acquiring a LRTI (singI. variabl. analysis)
LRTI Odd. Ratio
n (tI%CI) Pvalue
No Ves
Sex
Male 1003 990 13 1.0 0.1231
Female 1486 1456 10 0.5 (0.2 1.2)
lAaearouD
18-34 514 513 1 1.0 0.0223
35-54 673 669 4 3.1 (0.3 37.5)
55-74 951 940 11 6.0 (0.8 46.S)
75+ 331 324 7 11.1 (1.4 ao.sf
SD8C1a1ty
General surgery 884 871 13 1.0 0.2919
Orthopaedics 501 497 4 0.5 (0.2 1.7l
Urology 472 470 2 0.3 (0.1 1.3)
Gyn.~logy 366 383 3 0.5 (0.1 1.9)
Obstetrics 226 225 1 0.3 (0.0 2.3l
IAdmlssion type
Elective 1629 1616 13 1.0 0.3450
Emergency 840 830 10 1.5 (0.7 ,3.4)-
Co-morbIdities
None 1842 1632 10 1.0 0.0047
One 578 573 5 1.4 (0.5 , 4.2)
Two or more 249 241 8 5.4 (2.1 13.9)
Diabetes listed as a co-morbIdltV
No 2378 2357 21 1.0 0.2723
Ves 91 89 2 2.5 (0.6 10.9)
NO tube Pf'8 LRTI
No 2376 2360 16 1.0 <0.001
Yea 93 86 7 12.0 (4.8 29.9)
Endo-tracheal or tracheostomy tube pre LRTI
No 1.0 <0.001
Ves 2449 2433 16 81.9 (28.9 232.n
Antibiotics pre LRTI- any route
No 1002 995 7 1 0.3110
Ves 1467 1451 16 1.6 (0.6, 3.8)
Ipre LRTI-Intravenous route only
No 1228 1220 8 1.0 0.1463
Ves 1241 1226 15 1.9 (0.8 4.4\
No 428 426 2 1.0 0.2323
Ves 2041 2020 21 2.2 (0.5 , 9.5)
LRTI-Iower respiratory tract infection; CI- confidence Interval
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Table 7.18: The odds of acquiring a LRn (multi-variable analysis)
Odd. Ratio
n LRn
Pva .....
No Ves
(l1%CI)
Sex
Male 1003 990 13 1.0 0.1890
Female 1466 1456 10 0.5 (0.2 1.4)
~.group
18-34 514 513 1 1.0 0.0813
35-54 673 669 4 3.9 (0.3 47.sf
55-74 951 940 11 5.1 (0.4 69.3'-
75+ 331 324 7 14.3 (1.0 201.S)
Specialty
General suraery 884 871 13 1.0 0.4609
Orthopaedics 501 497 4 0.8 (0.2 2.9)
Urology 472 470 2 0.4 (0.1 2.1)
Gynaecology 386 383 . 3 2.6 (0.5 , 13.2)
Obstetrics 226 225 1 2.& (0.2 48. 'If
IAdmission type
Elective 1629 1616 13 1.0 0.5128
Emergency 840 830 10 1.4 (0.5 , 4.4)
Co-morbiditia
None 1642 1632 10 1.0 0.0737
One 578 573 5 0.& (0.3 3.4)
Two ormor. 249 241 8 3.7 (1.1,12.of
Diabetes li.meI as a co morblditv
No 2378 2357 21 1.0
Ve. 91 89 2 0.5 (0.1 3.5)
NO tube pre LRTI
No 2376 2360 16 1.0 0.8084
Vea 93 86 7 1.3 (0.2 8.3)
Endotracheal or tracheostomy tube
DreLRTI
No 1.0 <0.001
Vea 2449 2433 16 44.4 (6.6 288.0)
Antibiota pre LRTI- anv route
No 1002 995 7 1.0 0.6549
Yea 1467 1451 16 0.6 (0.1 ,5.4)
Antibiota pre LRTI- intravenous
route only
No 1228 1220 8 1.0 0.8358
Yes 1241 1226 15 1.3 (0.1 10.9\
Operation
No 428 426 2 1.0 0.4022
Yea 2041 2020 21 2.0 (0.4,10.8)
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7.10 Conclusion
In this chapter the results of the analysis that examined the incidence of HAl
and how it varied with selected patient characteristics have been presented. Of
the 2469 patients included in this analysis 7.5% acquired and presented with an
infection during their hospital stay. UTls were the most frequent type of
infections, followed by surgical wound and lower respiratory tract infections.
Independent risk factors for these infections varied with site. The following two
chapters consider the impact these infections had on resource use and costs
incurred by the hospital sector. Chapter 8 presents the results of the analysis
that examined the impact these infections had on costs incurred by the hospital
sector and Chapter 9 the results of the analysis that examined the impact these
infections had on length of hospital stay.
235
CHAPTER8
THE IMPACT OF HAIS ON HOSPITAL IN·PATIENT COSTS: RESULTS
8.1 Introduction
The results of the analysis that assessed the impact that hospital acquired
infections (HAls) occurring in surgical patients, had on hospital costs incurred
during the patients' hospital stay are presented in this chapter. The results of
the single variable analysis that explored how costs varied with HAl status and
a range of other patient characteristics are presented first (section 8.2). This is
followed by the results of the multivariable analysis and the results of the
analysis that looked at the distribution of the costs incurred by infected and
uninfected patients (sections 8.3 and 8.4). Further details of the methods used
can be found in section 5.5 of Chapter 5.
8.2 Resultsof thesinglevariableanalysis
Table 8.1 presents the results of the single variable analysis that assessed how
hospital costs varied with selected patient characteristics. The mean, standard
deviation, median, 251h and 75th percentiles and minimum and maximum values
are presented. The median figure in all cases is lower than the mean costs and
the standard deviations, in most cases, are larger than the mean costs,
indicating that the hospital cost data are highly skewed in the positive direction.
On average inpatient costs amounted to £1,845 per patient. Costs were found
to vary with patient characteristics: women, on average, incurred higher hospital
costs than men; hospital costs increased with increasing age group after the
age of 35; hospital costs varied with admission specialty, with obstetric patients
on average incurring the highest costs; mean hospital costs also varied with
diagnosis group; increased with increasing number of co-morbidities; were
higher for emergency admissions compared to elective admissions and were
~igher in infected compared to uninfected patients. Infected patients on
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average incurred costs that were 2.5 times those incurred by uninfected
patients.
The significance of the variation in costs incurred by patients of differing sex,
age groups, admission specialty, diagnosis groups, number of co-morbidities
and HAl status was assessed using the non-parametric Mann-Whitney and
Kruskal-Wallis tests and found to be highly significant in all cases (p=<O.001).
Because of the large samples the Significance of the observed variation in the
mean costs incurred by patients with differing patient characteristics was also
tested using the parametric t test. Similar results were obtained. The variation
in arithmetic means was found to be highly significant (p=<O.001).
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Table 8.1: Hospital costs Incurred during the In-patient hospital stay by key
patient characteristics
The eo&t of hospital in-D8tient ca.. El
Patient characteristic
Percentile
Minimum Maximumn Mean Median SO 25th 75th
Sex
Male 1003 1635 11..3 1891 750 1847 247 21269
Female 1466 1989 1n3 2074 993 2243 247 39179
Aaearoup
18-34 514 1788 1588 1655 870 2115 247 15937
35-54 673 1846 1391 2043 800 1948 255 39179
55-74 951 1824 1379 1871 860 2201 247 21269
75+ 331 2398 1800 2636 939 2722 292 21881
SPeCialty
General surgery 884 1628 939 2475 671 1534 247 23688
Orthopaedk;a 501 2422 2157 2403 1282 2711 358 39179
Urology 472 1404 1159 1085 853 1573 292 12901
GynaecoloaY 386 1732 1815 726 1481 2043 334 5412
Obatetrica 226 2528 2121 1480 1872 2535 922 12072
~1s.1on tvoe
Elective 1629 1887 ,..30 1460 750 1847 247 23688
Emergency 840 2191 1510 2748 993 2243 297 39179
Discharge diagnosis aroup
Infectious & paraaltlc 13 872 845 452 514 1114 396 2074
diseases
Neoplasms 357 1992 1393 2201 952 2169 276 21158
Endocrine,nuUWonal& 24 1484 1278 764 1155 1484 594 4389
metabolic diseases &
Immunity dlaordera
Diseases of blood & blood 3 992 922 688 342 1713 342 1713
forming organs
Diseases of the nervoua 2 712 712 461 386 1038 386 1039
avstem & sense oraans
Diseases of the circulatory 150 1719 753 3514 597 1065 247 21881
avatem
Diseases of the respiratory 6 5596 2098 6230 1488 12038 1086 15937
eystem
Diseases of the digestive 418 1346 933 1781 670 1373 288 23688
avstem
Diseases of the genitourinary 569 1568 1587 936 963 1938 292 11253
SYIIem
Complications of pregnsncy, 254 2405 2104 1473 1857 2392 504 12072
childbirth & puerperium &
certain condItiona originating
In the oerlnatal oeriod
DIseases of the ekIn & 31 1389 828 2384 611 1173 452 13839
subcUtaneous tissue
Diseases of the 309 2215 2216 1184 1268 2681 356 8520
muscuJoakletalsyetem &
connective tissue
Inlury & Poisonina 187 2634 1941 3356 1258 2781 431 39179
Symptom., signa & l-defined 146 1479 844 2018 663 1517 299 15731cor::; mental disorders &
con I abnormalities
lCo-morbidttles
None 1642 1699 1407 1763 833 2089 247 39179
One 578 1946 1499 2197 851 2181 288 23688
Two 173 2315 1718 2338 1029 2579 398 15937
Three or more 76 3158 1916 3509 936 3828 254 18987
HAl
No 2276 1656 1360 1420 815 2073 247 23688
Yes 193 4081 2430 4745 1624 4014 688 39179
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It should be noted the effects of HAl confound the results presented in Table
8.1. As reported in Chapter 7 the incidence of HAl varied with patient
characteristics, and as such the variation in costs incurred by patients with
differing patient characteristics can in part be attributed to the differing incidence
of HAl in the sub-groups examined and the impact that the infections had on
costs. The results presented in Table 8.2 show how hospital costs varied with
both infection status (infected/uninfected) and selected patient characteristics.
The mean costs for both infected and uninfected patients and how these vary
with selected patient characteristics are presented, together with the ratiOSof
the costs for infected compared to uninfected patients and the additional costs
incurred by infected patients.
The mean costs for infected patients were higher than uninfected patients for all
the patient characteristics examined. On average, amongst infected patients,
costs were higher in males than females, increased with increasing age, were
highest for surgical patients, varied with primary diagnosis group and increased
with increasing number of co-morbidities.
Table 8.3 shows how mean costs varied with type of infection. The mean costs
varied with site of infection and for all sites, infected patients, on average,
incurred higher costs than uninfected patients. The observed variation was
found to be significant (p=<O.0001). Of those patients who acquired an
infection in hospital, patients who acquired a urinary tract infection (UTI), on
average, incurred the lowest costs and patients who acquired more than one
infection, on average, incurred the highest hospital costs. The results of the
analysis which considered how costs varied with each type of infection and
selected characteristics are presented in Appendix 12. The results indicated
that whilst, on average, hospital costs were higher in infected than uninfected
patients for all the selected characteristics, the pattern of variation varied with
type of infection. However, it should be noted that the number of patients in
some of the infection groups was small and the results therefore cannot be
safely generalized.
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Table 8.2: Mean In-patient hospital costs by HAl status and key patient
characteristics
Patient characteristic
Mean cost of hospltalln-patlent Extra In-patlentcaret£) Ratio of costs costal patient (I)NaHAl HAl ,'5%CI) (85%CI)
Mean n Mean n
Sex (a) (b) (bla) (1Ma)
Male 1439 948 4889 57 3.• (2.5••. 2) 3450 (2991. 3909)
Female 1810 1330 37.2 136 2.1 (1.6 2.5) 1932 (1579.2285)
""egroup
18-34 1672 485 37., 29 2.2 (1.4 3.0) 2069 (1473 2665
35-54 1509 627 3512 48 2.3 (1.2. 3.5) 2003 (1408.2597
55-74 1636 870 3837 81 2.3 (1.8 2.9) 2201 (1798 2604
75+ 1997 294 5587 37 2.8 (1.8 3.8) 3590 (2772 «08)
.D8Cialty
General surgery 1338 829 6011 55 4.5 (3.3 5.7) 4873 (4071. 5275)
Orthopaedics 2157 482 5558 39 2.6 (1.6, 3.6) 3401 (2672 4130)
Urology 1316 «5 2848 27 2.2 1.4,2.9) 1530 1130 1929)
Gynaecology 1682 336 2073 50 1.2 (1.1 1.4) 391 (178 6(M)
Obstetrics 2508 204 2715 22 1.1 (0.9.12) 207 (-448. 863)
AdmIssion type
Elective 1569 1519 3013 757 1.9 (1.5 2.3) 1«3 (1169 1717)
Emergency 1828 110 5496 83 3.0 (2.3 3.7) 3667 (3095 4240)
diagnosis group
infectious & parasitic diseases 867 12 940 1 1.1 (0.8 1.4) 73 (-1007 1154)
Neoplasms 1714 329 5263 28 3.1 (1.9 4.2) 3549 (2780 431~
Endocrine. nutritional & metabolic 1360 20 2102 4 1.5 (0.4.2.7) 742 (-82. 1566)dlseasas & immunity disorders
Diseasas of blood & blood forming 992 3 - 0 --- --organs
Oiseases of the nervous system & 712 2 - 0 -- --sense orgens
Diseases of the circulatory system 1134 142 12111 8 10.7 (5.1 6.2) 10977 (9180 12774)
Diseases of the 'system 1726 4 13338 2 7.7 (4.1 11.4) 11612 (7071 1615~
Oiseases of the digeetiye IJYI5tem 1249 396 3107 22 2.5 (1.8 3.3) 1859 (1112.2605)
Diseasas of the genitourinary 1501 519 2259 50 1.5 (1.3,1.7) 758 (493.1023)system
Complications of pregnancy,
childbirth & puerperium & certain
2362 230 2616 24 1.1 (0.9,1.3) 234 (-389.856)conditions originating In the perinatal
period
Diseaees of the skin &
951 28 5483 3 58 (-3.0, 4532 (2060, 7005)subcu1aneoU8 tl88ue . 14.5)
Diseaees of the muecuIoskIetal 2176 296 3106 13 1.4 (1.4.10.1) 930 (1783,7282)system & connective tIasue
Injf.Jl'Y_& PoIsoning 2136 160 5586 27 2.6 (1.2 4.0) 3450 (2163 4736)
Symptoms, ligns & I- defined
conditions; mental disorders & 1189 135 5050 11 42 (1.6, 6.9) 3861 (2779, 4943)
congenital abnormalities
Number of co-rnorbiditi ..
None 1562 1532 3332 110 2.1 (1.5,2.7) 1750 (1419 2081)
One 1723 528 4304 50 2.5 (1.8 3.2) 2582 (1979,3185)
Two 2012 216 6236 33 3.1 (2.3, 3.9) 4224 (3350 5097
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Table 8.3: Hospital In-patientcosts by type of HAl
Cost of hospital in-patIant care (I)
Percentile
Irype of HAl n Mean Median 80 25th 71'" Minimum Maximum
No HAl 2276 1656 1360 1420 815 2073 247 23888
UTI only 88 2856 2322 2665 1753 2718 668 19781
SWlonly 32 4315 3032 3310 HM9 4988 1254 12382
LRTlonIy 15 3182 2366 2308 1675 3852 714 9762
BSlonIy 3 8953 8263 6665 2660 2660 15937
Skin only 13 3603 2898 1954 2348 5603 953 7247
Otheronly* 18 3410 2138 3731 1655 3138 782 13839
Multiple 24 9n4 5161 9315 2340 16253 916 39179
UTI - urinary tract Infection, SWI- surgical wound infection, LRTl- lower respiratory tract Infection, 8SI- bloodstream
Infection
-single alte infections at altes not classified elsewhere I.e. Infections at a altes other than tha urinary tract, surgical
wounds, lower respiratory tract, skin, or bloodstream
8.3 Resultsof the multivariableregressionanalysis
This section presents the results of the multivariable regression analysis. For
the purposes of this analysis it was assumed that the dependent variable
'hospital costs' had a Gamma distribution. Based on this assumption a
generalised linear model of the impact of HAlon hospital costs after controlling
for age, sex, specialty, admission type and number of co-morbidities was
constructed using a maximum likelihood approach and a) an identity link and b)
a log link. Details of the methods employed can be found in section 5.5 of
Chapter 5
As detailed in Chapter 5, the identity link assumes additive effects and enables
estimates of the mean additional costs incurred by infected patients to be
deduced directly from the model, whereas using a log link assumes
multiplicative or proportional effects and thus gives estimates of the ratio of
costs incurred by infected and uninfected patients. to be taken directly from the
model. The results of the generalised linear model that used an identity link are
presented in Section 8.3.1 and the results of the model that used a loglink are
presented in section 8.3.2.
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8.3.1.1
Results of the generalised linear model that used an Identity
link
Estimates of the cost of HAl
8.3.1
The results of the generalised linear model, which assumed that the dependent
variable 'hospital cost' had a Gamma distribution and used a maximum
likelihood approach and an identity link, are presented in Table 8.4.
Table 8.4: Results of the generalised linear model which assessed the Impact
of HAl on hospital costs using an Identity link
Coet 95%CI Pvalue
Low High
Constant 759.02 607.02 911.01
Sex Males REF 0.0055
Females 213.21 79.36 347.06
Age Group 18-34 REF <0.0001
35-54 278.98 128.41 429.56
55-74 467.M 318.03 617.68
75+ 650.33 424.31 876.34
Speclalty General surgery REF <0.0001
Ot1hopaedlcs 741.46 549.64 933.27
Urology 17.20 -126.85 161.25
Gynaecology 336.82 153.37 520.28
Obetetrlcs 1253.73 935.94 1571.51
Type of admission Elective REF 0.0118
Emergency 179.01 51.48 306.53
Number of co-morbldlties None REF 0.0203
One 90.02 -47."" 227.48
Two or more 351.26 101.80 600.73
HAlstatua No HAl REF <0.0001
HAl 2254.21 1738.361 2770.05
REF - reference category
The results presented in Table 8.4 indicate that on average HAls cost the
hospital sector an additional £2,254 (95% Cl: £1,738, £2,770) per case.
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8.3.1.2 Testing for interactions
The above model presents a relatively simple model of the impact of HAlon
hospital costs. A more detailed model was fitted allowing for the effects of
interactions. All two-way interactions between HAl and the other independent
variables were assessed. All interaction terms were entered into the model and
the least significant term was subsequently removed and the model re-run.
This process was repeated until only significant interaction terms remained
(p=<O.05). Significant interactions were found between HAl and specialty.
8.3.1.3 Specialty specific estimates of the impact of HAlon hospital costs
Specialty specific estimates of the additional costs incurred by infected patients
derived from the generalised linear model, which incorporated an interaction
term for HAl and specialty, are presented in Table 8.5 together with the mean
costs incurred by infected and uninfected patients.
Table 8.6: Specialty specific estimates of the additional costs Incurred by
infected patients
Mean In-patient coats (£) Mean Mldltlonal costs (£)
(mode, .. timate: 9'" ClaY
No HAl HAl
General surgery 1338 6011 4673 (4368:2992, 57....)
Orthopaedlca 2157 5558 3401 (3357:1821,4894)
Urology 1316 2846 1530 (1474:534.2414)
Gynaecology 1682 2073 391 (375:·145,895)
Obstetrics 2508 2715 207 (185:-841,1211)
*
l
,
Estimates were derived from the generalised linear model assuming 1hat the outcome varieble hospital costs
has a Gemme c:IIatributionend UIIing a maximum lilcellhoocl approach and Identity Hnk. The model comrolltd for
the effecIB of ege, sex. ednllalslonepecialty, edmlsslon type. end number of co-morbidltlea end Incorporated an
interaction term for HAl and specialty
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With the exception of HAls occurring in gynaecology and obstetric patients the
estimated additional costs incurred by infected patients were significantly higher
than those incurred by uninfected patients from the same specialty (p=<O.01).
Infections occurring in surgical patients on average cost the hospital sector an
estimated £4,368 (95% Cl: £2,992, £5,744) per case, in orthopaedic patients an
estimated £3,357 (95% Cl: £1,821, £4,894) per case; in urology patients an
estimated £1,474 (95% Cl: £534, £2,414) per case; in gynaecology patients an
estimated £375 (95% Cl: -£145, £895) per case and in obstetric patients an
estimated £185 (95% Cl: - £841, £1,211) per case.
8.3.1.4 Site specific estimates of the impact of HAlon hospital costs
The preceding tables have presented the results of the analysis that assessed
the average costs of HAl. Table 8.6 presents the results of the analysis that
assessed the costs of specific types of infection. As before estimates were
derived using generalised linear modelling statistical techniques. The model
assessed the impact of different types of infection on hospital costs after
controlling for age, sex, specialty, admission type and number of co-morbidities.
The impact of the following types of infection was assessed: urinary tract, lower
respiratory tract, surgical wound, bloodstream, an infection at a site not
classified elsewhere, and multiple infections. Since the preceding model
identified an interaction between HAl and specialty, the model also included this
interaction term. However, the interaction term was not found to be significant
in this model and as such was dropped from the analysis. The model identified
highly significant variation in costs incurred by patients with different types of
infection. However, at the level of each category of infection the significance of
the variation in costs incurred compared to uninfected patients varied.
Bloodstream and skin infections costs were not found to be significantly
different from the costs incurred by uninfected patients, whereas the cost of all
other infections were (p=<O.01). However, the number of patients in some of the
subgroups were small and thus the study sample is unlikely to have had
sufficient power to identify a significant difference in costs in these patients if
present.
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Table 8.6: Estimates of the additional costs Incurred by Infected patients by site
of Infection
Infection status Mean costs (I) Mean additional costs Incumld by
Infeeted patients (£)
(model estimate: '1% Cis)
No HAl 1656
UTI 2856 1200 (944: 441,1446)
LRTI 4315 2659 (2672: 753, 4592)
SWl 3182 1526 (1497: 548, 2447)
BSI 8953 7297 (6953: -1652, 15558)
Skin 3603 1947 (1567: -110, 3245)
Other single site infection 3410 1754 (1871: 279, 3064)
MultIple infections 9774 8118 (7930:4551,11310)
UTI - urinary tract infection, LRTI -lower respiratory tract infection, SWl- surgical wound infection,
BSI- bloodstream Infection, Cl - confidence interval
The results presented in Table 8.6 indicate that UTls were the least expensive
infections, and multiple infections the most expensive. On average UTls were
estimated to cost the health service an additional £944 (95% Cl: £441, £1,446)
per case, whereas multiple infections were estimated to cost the health service
an additional £7,930 (95% Cl: £4,551, £11,310) per case.
8.3.2 Results of the generalised linear model that used a logllnk
8.3.2.1 Estimates of the ratio of costs incurred by infected and uninfected
patients
The results of the generalised linear model which assumed that the dependent
variable 'hospital cost' had a Gamma distribution and used a maximum
likelihood approach and a log link are presented in Table 8.7.
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Table 8.7: Results of the generalised linear model which as.e •• ed the Impact of
HAlon hospital costs using a log link
Model .. timatu
of the ratio of
IRCI Pvalue
costs
Coef(exp)
Low High
Sex Males REF 0.0468
Females 1.1 1.0 1.2
~geGroup 18-34 REF <0.0001
35-54 1.2 1.1 1.4
55-74 1.4 1.2 1.5
75+ 1.8 1.4 1.8
Specialty General surgery REF <0.0001
Orthopaedics 1.5 1.4 1.7
Urology 1.0 0.9 1.1
Gynaecology 1.2 1.1 1.4
Ob8tetrlca 2.0 1.7 2.3
Type of admisaion Elective REF 0.002
Emergency 1.1 1.1 1.2
Number of co-morbidilies None REF
One 1.1 1.0 1.2 0.006
Two or more 1.2 1.1 1.4
HAl status No HAl REF <0.0001
HAl 2.3 2.0 2.8
REF - reference category
The results presented in Table 8.7 indicate that on average hospital costs
incurred by infected patients are 2.3 (95% Cl: 2.0, 2.6) times that of uninfected
patients.
8.3.2.2 Testing for Interactions
As with the model that used an identity link, the above model presents a
relatively simple model of the impad of HAlon hospital costs. A more detailed
model was fitted allowing for the effects of interadions. All two-way interadions
between HAl and the other independent variables were assessed. All
interadion terms were entered into the model and the least significant term was
subsequently removed and the model re-run. This process was repeated until
only significant interaction terms remained (p=<0.05). Significant interactions
were found between HAl and specialty.
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8.3.2.3 Specialtyspecificestimatesof the impactof HAlon hospitalcosts
Specialty specific estimates of the ratio of costs incurred by infected and
uninfected patients derived from the generalised model allowing for possible
interactions between HAl and admission specialty are presented in Table 8.8.
Table 8.8: Specialty specific estimates of the ratio of costs Incurred by Infected
and unlnfected patients
Mean In..patient coats (£) RatIo of costs Incurred by Infect8d and unlnfect8d patients
(model estimate: 95% CIs)·
No HAl HAl
General surgery 1338 6011 5.5 (3.9: 3.0,4.9)
Orthopaedk:a 2157 5558 3.8 (2.4: 1.8, 3.3)
Urology 1316 2848 3.2 (2.1: 1.5, 2.9)
Gynaecology 1882 2073 2.2 (1.2: 0.9, 1.8)
Obstetrics 2508 2715 2.1 (1.1: 0.7,1.6)
*Estimates were derived from the generalised linear model which asseased the impact of HAl on hospital costs allowing
for the effects of age, sex, admission type, admission specialty, and number of co-morblditiea and allowing for possible
interactions between HAl and admiuion specialty and which used a log link.
The results presented in Table 8.8 show that infected general surgical patients
on average incurred the greatest proportional increases in cost. The results of
the generalised linear model indicated that, on average, infections occurring in
general surgical patients were estimated to increase hospital costs by a factor
of 3.9 (95% Cl: 3.0, 4.9). The model estimates of the ratio of costs were similar
for orthopaedic and urology patients. On average, infected patients incurred
costs that were twice those of uninfected patients. In contrast estimates of the
impact of infections occurring in gynaecology and obstetric patients on hospital
costs indicated that infections occurring in these patients resulted in a slight
increase in costs. On average costs were 1.2 (95% Cl: 0.9, 1.6) times higher in
infected gynaecology patients than uninfected patients from the same specialty
and 1.1 (95% Cl: 03.7,1.6) in obstetric patients compared to uninfected patients
from the same specialty. However, it should be noted that the confidence
intervals for these estimates included zero and as such there was some
uncertainty as to whether HAls occurring in these patients increased costs.
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8.3.2.4 Site specific estimates of the impact of HAlon hospital costs
The preceding tables have presented the results of the analysis that assessed
the ratio of costs incurred by patients with one or more HAls at any site
compared to the costs incurred by uninfected patients. Table 8.9 presents the
results of the analysis that assessed the costs of Specific types of infection. As
before, the generalised linear model assumed a Gamma distribution and used a
log link to assess the impact of different types of infection on hospital costs after
controlling for age, sex, specialty, admission type and number of co-morbidities.
Since the preceding model identified an interaction between HAl and specialty,
the model also included this interaction term. However, the interaction term
was not found to be highly significant in this model (p = 0.054) and as such was
dropped from the analysis. The results presented in Table 8.10 are limited to
the estimates of the ratio of costs incurred by patients acquiring specific types of
infection compared to uninfected patients derived from the generalised linear
model.
Table 8.9: Estimates of the ratio of costs Incurred by Infected compared
to unlnfected patients by site of Infection
Infection staIua Mean costa Cl) Ratio of costa incurred by infected compared
to uninfected patients
(model estimate: 11% ct.).
NoHAI 1656
UTI 2856 1.7 (1.6: 1.3. 1.9)
LRTI 4315 2.6 (2.8: 1.8. 4.3)
SWI 3182 1.9 (1.9: 1.... 2.6)
BSI 8953 5.4 (6.0: 2.2. 16.2)
SIdn 3603 2.2 (2.0: 1.2. 3.2)
Other single site Infection 3410 2.1 (2.0: 1.3. 2.9)
Multiple Infections 9774 5.9 (5.8: 3.9. 7.9)
UTI- urinary tract Infection, LRTI -lower re8plf'atory tract infection, SWI- eurgicalwound Infection.
BSI- bloodstream infection, CI- confidence Interval
* Estimates were derived from the generalised 1inear model which assessed the impact of HAl on hospital COllis allowing for
the effec1ls of age, sex, admlaalon type. admission specially, and number of co-morbIdItiea and allowing for possible
interactionsbetween HAl and admi8tion apacIaIty and which used a log link.
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The results presented in Table 8.9 show that UTls were estimated to have the
lowest impact on hospital costs. Patients who acquired a UTI were estimated to
incur hospital costs that were 1.6 (95% Cl: 1.3, 1.9) times those incurred by
uninfected patients. Surgical wound infections, skin infections and infections at
sites not classified elsewhere were all estimated to increase hospital costs by a
factor of about 2, whereas bloodstream infections were estimated to increase
hospital costs by a factor of 6.0 and multiple infections by a factor 5.8
8.4 Thedistribution of hospital costs Incurredby infectedand
uninfectedpatients
This section presents the results of the analysis that explored how hospital
costs and the distribution of these costs differed between infected and
uninfected patients. Table 8.10 presents the mean costs for infected and
uninfected patients, the additional costs incurred by infected compared to
uninfected patients, and the contribution each category of costs makes to the
overall additional costs incurred by infected patients. Model estimates 'of the
additional costs incurred by infected patients allowing for the effects of age, sex,
admission specialty, admission type and number of co-morbidities, are also
presented in the table. It should be noted that whilst a significant interaction
between HAl and admission specialty was identified, for the purposes of this
analysis this has been ignored and the average impact of HAl across all
specialties on the various cost categories assessed.
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The results present in Table 8.10 show that in all cost categories the costs
incurred by infected patients were higher than in uninfected patients. The cost
categories that accounted for the majority of the additional costs were those
linked to time in hospital. The costs of hospital overheads, directorate
management, capital charges and medical time were all assigned to individual
patients on the basis of their length of hospital stay. When these categories are
taken together it follows that 38.4% of the additional costs were directly linked to
time in hospital. This combined category represents the second largest
contributor to additional costs, the largest being nursing care accounting for
40.46% of the additional costs incurred. The cost of antimircrobials and
microbiology tests were over four times higher in infected than uninfected
patients. However, anti-microbial costs only accounted for 1.52% of the
additional costs incurred by infected patients and the cost of microbiology tests
just 0.88% of the additional costs incurred.
The results of the analysis that examined the distribution of additional costs
incurred by infected patients for each type of infection are presented in
Appendix 13. For all cost categories, costs incurred by infected patients were
higher than uninfected patients and in most cases costs linked to LOS
represented a substantial proportion of the additional costs incurred by infected
cases. The exception was BSls, where costs directly linked to time in hospital
accounted for just 1.13% of the additional costs incurred. The cost of nursing
care represented the greatest proportion of additional costs accounting for
59.98%, and drugs other than anti-microbials the second largest contributor
accounting for 13.49%. The cost of drugs other than antibiotics was 30.9 times
that of uninfected patients. However, it should be noted that there were only
three patients who acquired a BSI and no other infection.
Antibiotic costs varied with site of infection. Overall, patients who acquired an
infection in hospital on average incurred antibiotic costs amounting to £48.60
per patient. However, antibiotic costs ranged from a low mean cost of £13.41
per patient with a UTI to a relatively high average cost of £141.06 per case for
patients with multiple infections.
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Similarly, when looking at the costs of microbiology tests, a cost category which
is directory relevant to the detection and management of infections, whereas on
average infected patients incurred costs amounting to £26.90 (4.7· times the
costs incurred by uninfected patients); the cost varied with site, from a low of
£11.92 per patient with a skin infection to a relatively high average cost of
£78.25 for patients with multiple infections.
8.5 Conclusion
This chapter has presented the result of the analYSisthat assessed the impact
of HAls on hospital costs. These results, to be discussed in detail in Chapter
11, clearly demonstrate the substantial burden HAls place on the hospital
sector. It is also clear from the distribution analysis, that whilst mean costs
incurred by infected patients are in all categories higher than the mean costs
incurred by uninfected patients, a large proportion of the additional costs
incurred are linked to a prolonged hospital stay. This impact on length of
hospital stay is explored in more detail in the next chapter.
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CHAPTER9
THE IMPACT OF HAIS ON LENGTH OF HOSPITAL STAY: RESULTS
9.1 Introduction
The results of the analysis that assessed the impact of HAls on length of
hospital stay (LOS) are presented in this chapter. Section 9.2 presents the
results of the single variable analysis and sections 9.3 - 9.5 the results of the
multivariable analysis. Further details of the methods used can be found in
section 5.5 of Chapter 5.
9.2 Resultsof thesinglevariableanalysis
Table 9.1 presents the results of the single variable analysis which assessed
how LOS varied with key patient characteristics. The mean, standard deviation,
median, 25th and 75th percentiles and minimum and maximum values are
presented. The median LOS in almost all cases is lower than the mean LOS
and the standard deviations in most cases are larger than the mean LOS
indicating that the LOS data is highly skewed.
The mean length of hospital stay was 7.4 days. On average women remained
in hospital longer than men; LOS increased with increasing age; orthopaedic
patients on average remained in hospital longer than patients in the other
specialty groups; LOS varied with diagnosis group; was longer in emergency
compared to elective admissions; increased with increasing number of co-
morbidities, and was longer in infected than uninfected patients.
The significance of the variation in LOS by patients of differing sex, age group,
admission Specialty, admission type, number of co-morbidities and HAl status
was first assessed using the non-parametric Mann-Whitney and Kruskal-Wa"is
tests. The observed variation was significant (p=<O.001). The variation in
median LOS by all the factors listed in Table 9.1 was also found to be highly
significant (p=<O.001).
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The significance of the observed variation in the mean LOS was also tested
using the parametric t test. Parametric tests are based on the assumption that
the data for each group has an approximately normal distribution.232 In this
case it clearly was not; however, the t test is fairly robust to non-normality. The
variation in arithmetic means was found to be highly significant (p=<O.001).
Table 9.2 presents the results of the analysis that explored in more detail how
LOS stay varied with HAl status. The mean LOS for both infected and
un infected patients are presented and how this varies with selected patient
characteristics, together with the ratios of the LOS for infected compared to
un infected patients and the number of additional days infected patients
remained in hospital. The mean LOS for infected patients was higher than for
uninfected patients for all the patient characteristics examined. On average
infected males remained in hospital longer than females, the LOS amongst
infected patients increased with increasing age, was highest for infected
surgical patients, varied with primary diagnosis group and increased with
increasing number of co morbidities.
Table 9.3 shows how the mean LOS varied with type of infection. The mean
LOS varied with site of infection and for all sites was greater than uninfected
patients. The observed variation was found to be significant (p=<O.0001). Of
those patients who acquired an infection in hospital, patients who acquired a
UTI, on average, had the shortest length of stay and patients who acquired
more than one infection on average had the longest length of stay.
Further analysis examined how for each type of infection the length of stay
varied with selected characteristics. The results are presented in Appendix 14.
The results showed that whilst the length of hospital stay for all the selected
characteristics was higher in infected than uninfected patients the pattern of
variation varied with type of infection. However, it should be noted that the
number of patients in some of the infection groups was small and as such the
results cannot be safely generalized.
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Table 9.1: Length of hospital stay by key patient characteristics
Lendt of hospltal.my (davs}
n Mean Madian SD Percentile Minimum MaximumPatient characteristic 25th 75V1
Sex
Male 1003 6.5 4 7.1 2.0 8.0 1 88
Female 1466 7.9 6 9.3 4.0 9.0 1 153
Age group
18-34 514 6.4 5 8.6 3.0 6.0 1 124
35-54 673 5.9 5 5.1 3.0 7.0 1 78
55-74 951 7.6 5 7.6 3.0 9.0 1 88
75+ 331 11.2 8 13.7 3.0 13.0 1 153
Specialty
Surgery 884 6.5 4 9.9 2.0 7.0 1 153
Orthopaedics 501 11.3 9 10.1 5.0 13.0 1 97
Urology 472 5.6 4 6.3 3.0 6.0 1 88
Gynaecology 386 6.4 6 3.7 5.0 8.0 1 34
Obstetrics 226 7.5 6 5.5 5.0 8.0 1 45
Admission type
Elective 1629 6.4 5 7.2 3.0 8.0 1 153
Emergency 840 9.2 6 10.4 4.0 10.0 1 97
Primary discharge diagnosis group
Infectious and parasitic diseases 13 3.8 3 1.6 2.0 5.0 2 6
Neoplasms 357 7.5 5 7.6 3.0 9.0 1 68
Endocrine, nutritional and metabolk: 24 5.2 5 2.4 4.0 6.0 1 13diseases and immunitY disorders
Diseases of blood and blood 3 4.3 5 3.1 1.0 6.0 1 7forming organs
Diseases of the nervoua system 2 3.5 3.5 2.1 2.0 5.0 2 5and sense oroans
Diseases of the circulatory system 150 7.7 3 18.6 2.0 5.0 1 153
Diseases of the respiratory system 6 9.2 9.5 ".3 5.3 12.0 3 15
Diseases of the digestive system 418 5.3 3 5." 2.0 6.0 1 51
Diseases of the genitourinary 669 5.7 6 3.8 3.0 7.0 1 38.YStem
Complications of pregnancy,
childbirth and puerperium & certain 254 7.4 6 5.8 5.0 7.0 1 45conditions originating in the
Derinatal period
Diseases of the skin and 31 7.8 .. 16.9 2.0 6.0 2 97subcUtaneous tissue
Diseases of the muaculoskletal 309 10.7 10 7.7 5.0 13.0 1 52Svstem and connective tissue
Injury and Poisoning 187 11.6 8 11.6 5.0 14.0 1 78
Symptoms, signs & IB- defined
conditions; mental disorders & 146 7.2 4 10.5 3.0 7.0 1 88
congenital abnormalities
Co-morbidities
None 1642 6.6 5 6." 3.0 8.0 1 97
one 578 8.1 5 11.5 3.0 8.0 1 153
Two 173 10.3 7 11.1 3.5 12.0 1 75
Three or more 76 11.8 8 12.0 4.0 15.0 1 80
HAl
No 2276 6.6 5 6.6 3.0 8.0 1 12..
Yes 193 16.1 10 18.1 7.0 17.0 3 153
Cl - confidence interval
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Table 9.2: The mean length of stay by HAl status and key patient characteristics
Mean length of hospital stay
.dava) Ratio of days No. of additional
No HAl HAl daysPatient characteristic (91% Cl) (91% Cl)
Mean n Mean n
(a' (b) (b/a) (b-a,
Sex
Male 5.9 946 17.1 57 2.9 (2.2. 3.6) 2.9 (9.5.13.0)
Female 7.1 1330 15.6 136 2.2 (1.7.2.7) 2.2 (6.9,10.1)
Age group
18-34 6.0 485 12.6 29 2.1 (1.0 ,3.2) 2.1 (3.4,9.8)
35-54 5.5 627 11.1 46 2.0 (1.4, 2.6) 2.0 (4.1 ,7.1)
56-74 6.8 870 15.6 81 2.3 (1.8. 2.7) 2.3 (7.1,10.4)
75+ 9.4 294 26.0 37 2.8 (2.0, 3.5) 2.8 (12.3,21.0)
Specialty
Surgery 5.4 829 22.8 55 4.2 (3.0, 5.5) 4.2 (14.9,19.9)
OrIhopaedk:8 10.3 462 22.9 39 2.2 (1.6, 2.8) 2.2 (9.5,15.7)
Urology 5.1 445 14.0 27 2.7 (1.8,3.7) 2.7 (6.5,11.2)
Gynaecology 6.1 336 8.0 50 1.3 (1.1 , 1.5) 1.3 (0.7,2.9)
Obste1rk:a 7.5 204 8.3 22 1.1 (0.9,1.3) 1.1 (-1.8,3.3)
Admission type
elective 6.0 1519 12.4 110 2.1 (1.6, 2.8) 2.1 (5.1,7.8)
Emergency 7.9 757 20.9 83 2.7 (2.1 ,3.2) 2.7 (10.9,15.2)
Primary discharge
diagnosis arouo*'
Infectious and parasitic 3.8 12 3.0 1 0.8* 0.8· O.S* -0.8·diseases
Neoplasms 6.7 329 17.2 28 2.6 (1.9, 3.2) 2.8 (7.8,13.3)
Endocrine, nutrItIonal.nd
metabolic diseases .nd 4.9 20 7.0 4 1.4 (0.9, 2.0) 1.4 (-0.4, 4.7)
Immunity disorder8
Oleeases of blood and 4.3 3 0.0 0.0 - -blood formlna oroan. - -
Olee.... of the nervous 3.6 2 0.0 0.0 --swtem and sense oroane --
OIeeases of the circulatory 5.0 142 55.9 8 11.2 (3.8, 18.6) 11.2 (40.4,61.6)SVIItem
OIeeases of the respiratory 7.0 4 13.5 2 1.9 (1.0,2.9) 1.9 (-0.6, 13.6)SYStem
OIeeases of the digestive 4.9 396 12.2 22 2.6 (1.S, 3.2) 2.6 (6.1 ,19.6)SYStem
OIee.... ofthe 5.4 519 9.3 60 1.7 (1.4,2.1) 1.7 (2.9,6.0)aenltourinery sYStem
CompUcations of
pregn.ncy. chHdblrth .nd
puerperium & certain 7.3 230 8.1 24 1.1 (1.0,1.2) 1.1 (-6.4,7.1)
conditions originating In the
oertnatal periOd
Oleeeses of the skin .nd 4.5 28 37.0 3 8.2 (6.0, 10.5) 8.2 (29.7,35.3)subcutaneous ti8aue
OIeeases of the
muaculoakletal aystem and 10.6 296 16.2 13 1.5 (1.4, 1.7) 1.5 (1.5, 10.0)
connacllve ti8aue
Injury and POisoning 9.9 180 22.0 27 2.2 2.2 (1.6 •3.0) 2.2 (7.7,16.6)
Symptoms, signa and ill-
deftned conditions; mental 5.8 135 24.6 11 4.3 (1.4,7.1) 4.3 (13.1 ,24.6)disOrders & congenital
.bnormallti ..
Number of co.morbidlties
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Table 9.3: Length of hospital stay by Infection status
Length of hospital stay (days)
N Mean Median SO Percentile Minimum Maximum
Type of HAl 25th fr
No HAl 2276 6.6 5.0 6.6 3.0 8.0 1.0 124.0
UTI 88 11.5 8.0 10.0 6.0 12.8 3.0 56.0
SWI 32 14.6 11.0 10.8 9.0 17.0 3.0 45.0
LRTI 15 14.5 13.0 9.4 7.25 18.8 4.0 45.0
BSI 3 8.7 9.0 3.5 5.0 12 5.0 12.0
SkIn infection 13 18.8 16.0 11.8 8.0 32 4.0 38.0
Other single site Infection 18 20.0 8.0 27.4 6.0 21.3 4.0 97.0
not ctassitled elsewhere
Multiple Infectiona 24 32.S 20.5 33.7 9.0 34.8 4.0 153.0
UTI - urinary tract mfectlon, LRTI - lower respiratory tract infection, SWI- surgicalwound infection,
BSI - bloodstream infection
9.3 Resultsof themultivarlableanalysis
This section presents the results of the multivariable analysis. In this model the
dependent variable 'LOS' was assumed to have a Gamma distribution and a
generalised linear model of the impact of HAlon LOS after controlling for age,
sex, specialty, admission type and number of co-morbidities was constructed
using a maximum likelihood approach and a) an identity link and b) a log link.
Details of the methods employed can be found in section 5.5 of Chapter 5.
As detailed in Chapter 5, and referred to in Chapter 8, the identity link assumes
additive effects and consequently enables estimates of the mean additional
costs incurred by infected patients to be taken directly from the model. In
contrast the log link assumes multiplicative or proportional effects and as such
gives estimates of the ratio of costs incurred by infected patients and uninfected
patients. The results of the generalised linear model that used an identity link
are presented in Section 9.3.1 and the results of the model that used a log link
are presented in section 9.2.
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9.3.1 Results of the generalised linear model that used an identity link
9.3.1.1 Estimates of the impact of HAlon length of hospital stay
Table 9.4 presents the results of the generalised linear model to assess the
impact of HAlon LOS after contrOlling for the effects of age, sex, admission
specialty, admission type and number of co-morbidities. The model assumed
that the dependent variable ChospitalLOS' had a Gamma distribution and used
a maximum likelihood approach and an identity link.
Table 9.4: Results of the generalised linear model which assessed the Impact of
HAlon length of hospital stay using an Identity link
Coef H%CI Pvalue
Low High
Constant 2.64 1.99 3.29
Sex Malee REF 0.0001
Femal.. 1.20 0.822 1.78
Age Group 18-34 REF <0.0001
35-54 0.59 -0.64 1.23
55-74 1.72 1.045 2.40
75+ 2.90 1.81 4.00
Specialty Surgery REF <0.0001
Orthopaedlo8 4.3<4 3.37 5.31
Urology 0.10 -0.50 0.70
Gynaecology 0.98 0.21 1.76
0batetric8 1.97 0.88 3.07
Type of admiaaion Elective REF <0.0001
Emergency 1.57 0.99 2.15
Number of co-morblditiee None REF 0.0007
One 0.81 0.19 1.43
Two or more 1.64 0.51 2.78
HAlstatua No HAl REF <0.0001
HAl 7.83 5.67 10.00
REF - reference category
The results indicate that on average infected patients remain in hospital 7.83
(95% Cl: 5.67 to 10.00) days longer than uninfected patients.
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9.3.1.2 Testing for interactions
The above model presents a relatively simple model of the impact of HAlon
LOS. A more detailed model was fitted allowing for the effects of interactions.
All two-way interactions between HAl and the other independent variables were
assessed. All interaction terms were entered into the model and the least
significant term was subsequently removed and the model re-run. This process
was repeated until only Significant interaction terms remained (p=<0.05).
Significant interactions were found between HAl and specialty (p=<0.001).
9.3.1.3 Specialty specific estimates of the impact of HAlon length of hospital
stay
Table 9.5 presents the specialty specific estimates of the average number of
additional days infected patients remained in hospital, derived from the
generalised linear model that incorporated an interaction term for HAl and
specialty, together with the mean LOS of infected and infected patients.
Table 9.S: Specialty specific estimates of the Impact of HAlon length of hospital
stay
Mean LOS (days)
Number of extra days Infectad patientS ntmaIned in hospital
(model estimate '5% Cl.)·
No HAl HAl
Surgery 5.4 22.8 17.4 (15.26: 9.49, 21.03)
Orthopaedlc:a 10.3 22.9 12.6 (11.73: 4.70, 18.75)
Urology 5.1 14 8.9 (7.88: 2.85, 12.93)
[Gynaecology 6.1 8 1.9 (1.79: -0.43, 4.01)
~Iut 7.5 8.3 0.8 (0.60 -2.87, 4.07)
LOS .Iength of stay
*The model estimates were derived from a generalised linear model1hat used an lden1lty link and controlled for age,
sex, admi88lon specialty, admission type, number of co-morbldltles, and Included an Interaction term for HAl and
specialty
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The results presented in Tables 9.5 indicate that HAls occurring in surgical
patients had the greatest impact on LOS in terms of the number of extra days
patients were estimated to remain in hospital as a result of acquiring and
infection. On average HAls occurring in surgical patients were estimated to
prolong the in-patient stay by an additional 15.3 (95% Cl: 9.5, 21.0) days. In
contrast infections occurring in gynaecology patients were estimated to increase
the patients LOS by just 1.8 days (95% Cl: -.04, 4.0) days and in obstetric
patients the presence of one or more HAls was estimated to increase the LOS
by just over half a day (0.6 days, 95% Cl: -.3,4.1). Estimates of the impact
HAls occurring in the other specialty groups had on LOS varied. HAls occurring
in orthopaedic patients were, on average, estimated to extend the in-patient
stay by 11.7 (95% Cl: 4.7, 18.8) days; and HAls occurring in urology patients
were estimated to extend the hospital stay by 7.9 (95% Cl: 2.9, 12.9) days.
9.3.1.4 Site specific estimates of the impact of HAlon length of hospital stay
The preceding tables have presented the results of the analysis that assessed
the average costs of HAl. Table 9.6 presents the results of the analysis that
assessed the costs of specific types of infection. As before the generalised
linear model assumed a Gamma distribution and used a maximum likelihood
approach and identity link. The model assessed the impact of different types of
infection on hospital LOS after controlling for age, sex, specialty, admission type
and number of co-morbidities. The impact of the following types of infection
were assessed: urinary tract, lower respiratory tract, surgical wound,
bloodstream, infections at a site not classified elsewhere, and multiple
infections. Since the preceding model identified an interaction between HAl and
Specialty, the model also included this interaction term. However, the
interaction term was not found to be significant in this model and was dropped
from the analysis. The results of this analYSisare given in Table 9.6, together
with the mean costs incurred by infected and uninfected patients by infection
group.
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Table 9.6: Estimates of the impact of specific types of HAl on
length of hospital stay
lTypeofHAI n Mean
Number of additional days
(model •• tlmate: 91% Cl)·
~oHAI 2276 6.6
~lonIy 88 11.5 4.9 (3.27: 1.25,5.28)
~W1 only 32 14.6 8.0 (7.18: 2.M, 12.02)
~Sl only 3 8.7 2.1 (2.21: -7.08,11.49)
~T1 only 15 14.5 7.9 (8.01: 0.62,15.37)
~kln only 13 18.8 122 (9.85: 0.37, 19.33)
ptheronly 18 20.0 13.4 (11.59: 2.97,20.21)
Multiple 24 32.5 25.9 (24.01: 11.14,36.18)
CI- confidence interval
-Model estimates obtained from generalised Bnear modeling that controlled for the effects of age, sex, admission
specially, admission type, number of co-morbldltles, and included a variable denoting type of infection.
The results presented in Table 9.6 indicate that on average multiple infections
have the highest impact on LOS. Patients who acquired more than one
infection in hospital were estimated to remain in hospital an estimated 24 (95%
Cl: 11.9, 36.2) extra days. In contrast BSls were estimated to increase the in-
patient stay by just 2.2 (95% Cl: -7.1, 15.37) days. However, it should be noted
that there were just three patients who acquired a BSI and no other infections,
two of whom died in hospital. As evidenced by the Cis there was considerable
uncertainty about this finding, and as such the results cannot be safely
generalised. UTls had the second lowest impact on LOS. On average UTls
were estimated to prolong the patients stay by 3.3 (95% Cl: 1.3, 5.3) days.
SWls, LRTls, skin infections and infections at other sites were estimated to
increase the average LOS by 7 - 12 days, with the estimate of increase varying
with site.
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9.3.2 Results of the generalised linear model that used a logllnk
9.3.2.1 Estimates of the ratio of LOS incurred by infected and uninfected
patients
The results of the generalised linear model which assumed that the dependent
variable 'hospital cost' had a Gamma distribution and used a maximum
likelihood approach and a log link are presented in Table 9.7.
Table 9.7: Results of the generalised linear model which assessed the Impact of
HAlon length of hospital stay using a log link
Model estimates t""CI Pvalue
of the ratio of
LOS
Coef(exp)
Low High
Sex Males REF 0.0008
Females 1.2 1.1 1.3
jAge Group 18-34 REF <0.0001
35-54 1.1 1.1 1.3
55-7" 1.4 1.2 1.5
75+ 1.6 1.4 1.9
Specially General eurgery REF <0.0001
Orthopaedios 1.7 1.6 1.9
Urology 1.0 0.9 1.1
Gynaecology 1.2 1.0 1.3
1.4 1.2 1.6
rrype of admiaaion Elective REF <0.0001
Emergency 1.3 1.2 1."
Number of co-morbkliliee None REF
One 1.2 1.0 1.3 0.0001
rrwo or more 1.3 1.1 1.5
HAl status No HAl REF <0.0001
HAl 2.1 1.8 2.5
REF - reference category
The results presented in Table 9.7 indicate that on average infected patients
have a hospital LOS that is 2.1 (95% Cl: 1.8, 2.5) times that of uninfected
patients.
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9.3.2.2 Testing for interactions
As with the model that used an identity link, the above model presents a
relatively simple model of the impact of HAlon LOS. A more detailed model
was fitted allowing for the effects of interactions. All two-way interactions
between HAl and the other independent variables were assessed. All
interaction terms were entered into the model and the least significant term was
subsequently removed and the model re-run. This process was repeated until
only significant terms remained (p=<O.05). Significant interactions were found
between HAl and specialty.
9.3.2.3 Specialty specific estimates of the impact of HAlon LOS
Specialty specific estimates of the ratio of the LOS incurred by infected and
uninfected patients derived from the generalised model allowing for possible
interactions between HAl and admission specialty are presented in Table 9.S.
Table 9.8: Specialty specific estimates of the ratio of costs
Incurred by Infected and unlnfected patients
Mean LOS (days)
Ratio of days
(model eatimate: 95% Cls)-
No HAl HAl
Surgery 5.4 22.8 4.22 (3.4: 2.6, 4.4)
Or1hopaedic8 10.3 22.9 2.22 (2.0: 1.4, 2.7)
Urology 5.1 14 2.75 (2.5: 1.7, 3.6)
Gynaecology 6.1 8 1.31 (1.3: 1.0, 1.7)
Obstetrica 7.5 8.3 1.11 (1.1: 0.7, 1.6)
CI- confidence interval
*Eltlmates were derived from the generalised Inear modal which assessed the Impact of
HAl on LOS allowing for 1I1eeffects of age, aex, admia810ntype, admlsaion specialty, and
number of c:o-molbldltle8 and allowing for poaslble interactions betWeen HAl and admlsaion
.specialty and which used a log Ink.
The results presented in Table 9.8 show that infected general surgical patients
on average incurred the greatest proportional increases in LOS. The results of
the generalised linear model indicated that, on average, infections occurring in
general surgical patients were estimated to increase the patients LOS by a
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factor of 3.4 (95% Cl: 2.6, 4.4). Infections occurring in urology patients were
estimated to result in an average LOS that was 2.5 times that of uninfected
patients from the same specialty, and infections occurring in orthopaedic
patients were estimated to result in an average LOS that was twice as long as
uninfected patients from the same specialty. HAls occurring in gynaecology
and obstetric patients were not estimated to have a substantial impact on LOS.
Infections occurring in gynaecology patients were estimated to increase the
LOS by a factor of 1.3, and infections occurring in obstetric patients were
estimated to have a LOS that was just 1.1 times that of uninfected patients from
the same specialty.
9.3.2.4 Site specific estimates of the impact of HAlon LOS
The preceding tables have presented the results of the analysis that assessed
the average increase in LOS incurred by patients who acquired one or more
infections in hospital. Table 9.9 presents the results of the analysis that
assessed the impact of specific types of infection on LOS. As before the
generalised linear model assumed a Gamma distribution and used a log link to
assess the impact of different types of infection on hospital LOS after controlling
for age, sex, specialty, admission type and number of co-morbidities. The
impact of the following types of infection were assessed: urinary tract, lower
respiratory tract, surgical wound, bloodstream, an infection at a site not
classified elsewhere, and multiple infections. Since the preceding model
identified an interaction between HAl and specialty, the model also included this
interaction term. However, the interaction term was not found to be significant
in this model (p = 0.138) and as such was dropped from the analysis.
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Table 9.9: Estimates of the ratio of LOS Incurred by Infected patients
compared to uninfected patients by site of infection
rrypeofHAI Mean
Ratio of LOS
n
(model •• tImate: 91% CI)*
No HAl 2276 6.6
UTI only 88 11.5 1.7(1.5:1.13, .1.9)
SWlonIy 32 14.6 2.2 (2.0: 1.5,2.9)
BSlonIy 3 8.7 1.3 (1.5: 0.5, 4.4)
RTl only 15 14.5 2.2(2.3: 1.4,3.8)
Skin only 13 18.8 2.8(2.5: 1.5,4.2)
Other only 18 20.0 3.3(2.7: 1.7,4.2)
Multiple 24 32.5 4.9(4.4: 2.9,6.5)
UTI - urinary tract infection, LRTI-Iower respiratory tract infection, SWI - surgical wound Infection,
BSI- bloodstream Infection, Cl - confidence interval
• estimates were derived from ttl. generalised linear model which assessed ttl. Impact of HAlon hoapItal LOS anowing
for the effects of age, sex, admission type, admieaion specialty, and number of c:o-morbiditles and sHowing for possible
Interactions between HAl and sdmieaion apecially and which used a log link.
The results presented in Table 9.9 show that BSls were estimated to have the
lowest impact on LOS. Acquisition of a BSI was estimated, on average, to
increase the LOS by a factor of 0.5. However, as noted in section 9.3.1 there
were just three patients in this infection group, two of whom died as in-patients
thus curtailing their length of hospital stay. The acquisition of a UTI was also
estimated to increase the LOS by a factor of 0.5. SWls, LRTls, skin infections
and infection at sites not classified elsewhere were estimated to result in a LOS
that on average was twice that of uninfected patients, whereas multiple
infections were estimated to result in a LOS that on average was 4.4 times that
of uninfected patients.
9.4 Conclusion
In this chapter the results of the analysis that explored the impact of HAlon
length of hospital stay were presented. Whilst the results of this analysis will be
discussed in detail in Chapter 11, it is clear from the preceding sections that
HAls have a substantial impact on hospital length of stay. The following chapter
will consider how the estimates of both the impact of HAlon LOS and also the
impact on hospital cost can be used in models to assess the benefits of
investment in prevention.
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CHAPTER10
THE POTENTIAL BENEFITS OF INVESTMENT IN INFECTION
PREVENTION AND CONTROL
10.1 Introduction
The results of this study clearly demonstrate that hospital acquired infections
(HAl) place a substantial burden on health care resources. This chapter will
explore how the results of this analysis, and indeed estimates taken from other
studies, can be used to assess the magnitude and distribution of the potential
benefits of investment in infection control. Estimates of the gross benefits of
investment in prevention and control activities and a framework for assessment
of net benefits are presented.
10.2 The potential benefits of prevention
The estimates of the economic burden of HAls derived in this study and
presented in Chapters 8 and 9, may be considered to represent the gross
benefits of prevention, as measured by costs avoided if an infection is
prevented. The net benefits will depend on the cost and effectiveness of
infection control practices.
10.3 The gross benefits of prevention
As indicated above the results of this analysis represent the gross benefits of
prevention, as measured by the average costs that may be avoided if an
infection is prevented. The magnitude of these gross benefits within a particular
clinical setting will depend on both the number and types of infections
prevented.
Estimates of the proportion of HAls that are preventable vary. As mentioned in
Chapter 1, perhaps the most widely quoted estimate of the proportion of
infections that could be avoided through improvements in infection prevention
and control is that derived as part of the SENIC study conducted in the US in
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the mid 1970s and early 1980s. The study estimated that 30% of infections
could be prevented." It is not known how applicable this estimate is to the
situation in NHS hospitals in England. The results of a recent National Audit
Office survey of infection control teams indicated that many of the teams felt
that this was an overestimate of the proportion that were preventable. Infection
control teams were asked to estimate the proportion of HAls they considered
preventable. The estimates varied, ranging from a low estimate of 5% to over
35%. The bed weighted average was 15%.3 Whilst it is acknowledged that this
estimate is a subjective assessment of the proportion of HAls that can be
prevented, for the purpose of exploring the potential benefits of prevention, the
more conservative estimate of 15% will be used to explore the potential gross
benefits of prevention at the level of the study hospital and also at the national
level.
10.3.1 Methods used to derive estimates of the potential gross benefits
of a 15% reduction In Infection rates
Estimates of the potential gross benefits of a 15% reduction in rates were
derived from estimates of the number of patients acquiring one or more
infections and the burden these infections imposed on the hospital sector.
These latter estimates were derived from data on the observed incidence of
HAls presenting during the in-patient period; the estimated ratio of the hospital
costs and LOS incurred by infected compared to uninfected patients obtained
from the generalised linear modelling analysis; the mean hospital costs and
mean LOS incurred by uninfected patients; and data on the number of adult
admissions to the specialties covered in this study at a) the study hospital in
1994/5 and b) NHS hospitals throughout England in 199415.
Estimates of the number of patients acquiring one or more infections were
derived by applying the observed incidence of HAl to the number of patients
admitted to the specialties covered in this study at a) the study hospital in
1994/5 and b) NHS hospitals throughout England in 1994/5.
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Estimates of the burden these infections imposed were derived as follows. If N
is the number of patients admitted to the specialties covered in this study at the
study hospital in 1994/5 (or NHS hospitals throughout England in 199415), C the
baseline cost of treating uninfected patients, i the estimated incidence and r the
estimated ratio of costs incurred by infected compared to uninfected patients,
NiC(r-1) provides an estimate of the national burden.
Ninety-five per cent confidence intervals were derived as follows. The
estimates of the incidence of HAl and the ratio of costs incurred by infected
compared to uninfected patients used to determine the burden of HAl were
those derived from this study. The true population values are unknown. The
sampling error of these estimates was measured by their standard errors sei
(standard error - incidence) and ser (standard error - ratios of costs (LOS».
Using these values, the variance of the estimated burden of HAl was estimated
as follows: N2C2[fser2+(r-1)2 sef]. This estimated variance was then used to
obtain 95% confidence intervals for the estimates of the annual burden of HAls,
on the assumption that the sampling error in such an estimate would be
approximately Normal. The square root of the estimated variance was derived
and this figure multiplied by 1.96 and the resultant figure added to the estimate
of the cost (and number of additional days) to derive an estimate of the upper
confidence limit, and subtracted from this estimate to derive an estimate of the
lower limit.
Having derived estimates of the number of patients who acquired one or more
infections and estimates of the burden these infections imposed both in terms of
costs and the number of additional days spent in hospital, estimates of the
potential gross benefits of a 15% reduction in rates were derived.
The same methodology was subsequently used to derive site and specialty
specific estimates of the burden of HAl and the potential benefits of a 15%
reduction in rates, utilising site and specialty specifiC estimates of the incidence
of HAl and the ratio of costs and LOS as appropriate.
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10.3.2 The potential gross benefits of a 15% reduction In Infection
rates at the level of the study hospital
Tables 10.1 to 10.3 present the results of the analysis that estimated the
potential benefits of a 15% reduction in HAl rates at the level of the study
hospital. The estimates are limited to infections occurring in adult, non-day
case patients admitted to the surgical specialties covered in this study. Table
10.1 provides details of the number of patients estimated to have acquired an
infection in 1994/5. Table 10.2 presents the results of the analysis that
estimated the cost of these infections and the gross benefits of a 15% reduction
in rates, and Table 10.3 estimates of the number of bed days utilised as a result
of infection and the number that would be released if infection rates had been
15% lower.
In 1994/5 (the year in which the study was conducted) an estimated 579 (950/0
Cl: 500, 665) adult patients admitted to the general surgical, orthopaedic,
urology, gynaecology and obstetric specialties acquired one or more HAls.
These infections were estimated to have cost the hospital sector, an additional
£1,224,044 (95% Cl: £898,408, £1,549,680) and affected patients were
estimated to have utilised an estimated 4,308 bed days (95% Cis: 3,059,
. 5,558). If the infections rates had been 15% lower in 1994/5 then the crude
estimates presented in Tables 10.2 and 10.3 suggest that resources valued at
£183,607 (95% Cl: £134,761, £232,452) may have been available for
alternative use, and the same reduction in rates might have resulted in the
release of 646 bed days (95% Cl: 459 , 834 bed days).
The estimated cost of HAl, and the estimated benefits of a 15% reduction in
rates varied considerably with site. Whilst multiple infections were estimated to
impose the greatest burden, if infections occurring at just one site are
considered, the results presented in Tables 10.2 and 10.3 show that UTls,
which had the lowest cost per case, were the most expensive type of infection.
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Specialty specific estimates suggested that relative to the other surgical
specialties the general surgical and urology specialties incurred the greatest
costs from HAl, and the benefits of a 15% reduction in rates potentially could be
substantial.
It should be stressed that the estimates presented in Table 10.2 represent the
gross benefits of prevention: that is they represent the level of resources that
might be released for alternative use. They do not represent the value that
affected individuals and society as a whole place on prevention.
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10.3.3 National estimates of the potential gross benefits of a 15%
reduction In Infection rates
Tables 10.4 - 10.6 present site and specialty specific estimates of the potential
benefits of a 15% reduction in infection rates occurring in adult non-day case
patients admitted to the surgical specialties, covered in this study at NHS
hospitals in England in 1994/5. Overall an estimated 154,920 (95% Cl:
134,024, 177,943) adult non-day case patients admitted to the specialties
covered in this study at other NHS hospitals in England acquired one or more
HAls in 1994/5, at a cost to the health sector of £327.78 million (95%CI:
£240.58, £414.98) (in-patient costs only). Overall an estimated 1,153,726 (95%
Cl: 819,019, 1,488,434) additional bed days were utilised as a result of patients
acquiring one or more HAls. The magnitude of the burden imposed varied with
site and specialty.
Estimates of the gross benefits of a reduction in rates indicated that a 15%
reduction in rate would result in resources valued at £49.17 million (95% Cl:
£36.09, £62.25 million) released for alternative use. The same level of
reduction in the rate would have released an estimated 173,059 bed days (95%
Cl: 122,853,223,265) for alternative use. Estimates the magnitude of the level
of resources released varied with site and with specialty, as indeed they did for
the study hospital.
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10.4 Thenet benefits of Investmentin infection control
The preceding sections presented estimates of the gross benefits of investment
in infection control that may result if a 15% reduction in rates were achieved.
No attempt was made to take into account the costs of prevention and control
activities and their actual effectiveness. The above examples simply highlight
the magnitude of the level of resources that might be released if a reduction at
the 15% level was achieved. This section explores how the results of this study
may be incorporated into simple economic models to demonstrate the net
benefits of investment in infection control practices.
Models of the net benefits of investment in prevention activities can be derived
from information on infection rates;
the cost of the infection control practice to be evaluated and its
• efficacy (assuming 100% compliance);
the cost of alternative strategies which would need to be introduced to maximise
compliance and the level of compliance they are expected to achieve; and
the magnitude, nature and distribution of the economic burdens that may have
resulted had the HAls not been prevented.
Data on infection rates can be obtained from a variety of sources including
hospital records, the literature and national surveillance schemes. Data on the
cost of selected infection control practices and the cost of strategies to enhance
compliance with a given practice can generally be relatively easily estimated,
and data on the cost of the burden that may have resulted had the HAls not
been prevented can be obtained from studies such as this. However, data on
the efficacy of interventions and strategies that aim to enhance compliance and
hence effectiveness are a little more difficult to obtain. Whilst a number of
studies have demonstrated the effectiveness of surveillance and feedback of
results to the appropriate personnel,1M 233 with the exception of studies that
have assessed the efficacy of specific antibiotics there is a marked lack of
information on the efficacy of specific infection control activities. Lack of
information on the effectiveness of infection control practices was highlighted by
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Thames Valley University. when drafting infection control guidelines for the
prevention of HAls.2a.. When drafting these guidelines prevention activities
were categorised according to the quality of the supporting evidence.
Category 1 included activities where there were generally consistent findings
from a range of evidence derived from well designed experimental studies.
Category 2 included activities for which evidence of effectiveness was based on
a single acceptable study. or a weak or inconsistent finding in multiple
acceptable studies. Category 3 included those activities for which there was
limited scientific evidence that did not meet all the criteria of 'acceptable
studies'. or an absence of directly applicable studies of good quality. This
included published or unpublished expert opinion. The majority of the activities
fell within category three.235
In the absence of rigorous data on the efficacy of a particular intervention
models can be developed which assess the potential benefits of prevention
assuming different levels of effectiveness. Information on the break-even point
given different levels of effectiveness can subsequently be derived from these
models. That is the point at which the potential benefits cover the cost of the
intervention and any further reduction in rates result in net benefits. This
information can subsequently be used to inform decision marking regarding
investment in the activity assessed.
The following presents a worked example of how this could be achieved. The
example looks at the problem of catheter related UTls; it represents a re-
working of a study by Plowman et 8/215 but incorporates data from the work
presented here. A copy of the paper by Plowman et al215can be found at the
back of this thesis.
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An economic model to assess the cost and benefits of the
routine use of silver alloy coated urinary catheters to reduce
the risk of urinary tract Infections In catheterised patients
As reported in Chapter 2, prevalence studies have generally found urinary tract
infections (UTls) to be the most common type of hospital acquired infection
accounting for between 21 and 45% of all HAls identified.119 2022Studies which
10.4.1
have assessed the incidence of urinary tract infections in patients admitted to
both medical and surgical specialties suggest that between 1 and 3% acquire a
urinary tract infection,478182whilst a study that was limited to the incidence of
infections occurring in surgical, urology,' gynaecology and orthopaedic patients
who had an operative procedure found that 6.3% acquired a UTI.1. In this study
the overall incidence of UTls in patients admitted to the general surgical,
orthopaedic, urology, gynaecology and, if the patient had a caesarean section,
the obstetric Specialties was 4.1 % (95% Cl: 3.3, 4.9).
These infections may result in additional morbidity82125131144145and in some
cases mortality,112122a prolonged hospital stay and additional costs incurred by
the hospital sector as a result of additional in-patient care.1• 69 172207236 The
results of this study indicated that on average UTls cost the hospital sector an
additional £944 (95% Cl: £441, £1446) per case and prolonged the LOS by 3.27
(95% Cl: 1.25. 5.28) days. Further costs are borne by the secondary and
primary health care sector following discharge from hospital, and by patients
and their carers.
A key risk factor for these infections is the presence of a urinary catheter,1. 134
137138143with an estimated 80% of hospital acquired UTls being associated with
the presence of this device.237 In an endeavour to reduce the infection risk
associated with urinary catheters, silver alloy coated catheters have been
developed. A number of trials have found these catheters to reduce the
infection risk.238-244The silver alloy coating prevents the adherence of microbes
to the catheter wall and this reduces the risk of infections being established.
However, whilst these trials indicate that silver alloy coated catheters appear to
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be effective at reducing the patients risk of acquiring a UTI, the level of
effectiveness has been found to vary, this perhaps reflecting variations in case
mix and the underlying infection rate. A meta-analysis of eight clinical trials
found that silver alloy coated catheters, when compared to non-coated
catheters, had a preventive effect, and this effect was over and above other
coatings such as silver oxide coatings,240that have been removed from the
market in the US. One trial demonstrated that up to 48% of hospital acquired
UTls may be prevented through the use of silver alloy coated urinary
catheters.241
Whilst studies have demonstrated the effectiveness of these catheters their
routine use has cost implications. Silver alloy coated catheters are more
expensive that the catheters routinely used in hospitals in England and Wales:
in 1994/5 silver-alloy coated catheters cost an additional £9 each.245 As such
before routine use can be advocated the potential costs and benefits associated
with their routine use in a particular clinical setting needs to be assessed.
The following sections present a model for assessing the potential costs and
benefits of the routine use of silver alloy coated catheters. This is followed by
an illustrative model of the potential costs and benefits of their routine use in
patients admitted to the specialties covered in this study at the study hospital in
1994/5.
10.4.2 Alms and objectives of the economic model
The model aims to assess the following:
i. the number of hospital acquired UTls occurring in catheterised patients
admitted to the specialties of interest at one or more hospital.
ii. the economic burden these infections impose on the hospital sector as a
result of additional in-patient care
iii. the number of extra days infected patients remain in hospital.
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iv. the potential benefits of the routine use of silver alloy coated catheters
estimated as the value of resources and bed days released for
alternative use.
10.4.3 Thestructure of the economic model
Figure 10.1 illustrates the structure of the model. The starting point is the
number of admissions to the specialties of interest (cell 1). These patients are
then sub-divided into the specialty groups of interest (cells 2-6). Figure 10.1
shows 5 surgical specialties, however this could be adapted to reflect the needs
of the user. The patient groups of interest are then further subdivided into those
who are catheterised and those not catheterised (cells 7-16). The estimated
number of hospital acquired UTls that might occur in these catheterised patients
are then determined based on the specialty specific incidence of UTls (cells 17-
26). Estimates of the economic impact these infections place on the hospital
sector are then derived by multiplying the number of UTls by an appropriate
estimate of the additional cost of these infections (cells 27-31) and the number
of extra days patients remain in hospital (cells 32-36).
Specialty specific estimates of the additional costs associated with the routine
use of silver alloy coated catheters, as compared to non-coated catheters, are
then derived by multiplying the additional cost of the catheter by the number of
patients catheterised (cells 7,9,11,13,15). The potential gross benefits (value
of resources and the number of days released for alternative use) are then
derived for varying levels of effectiveness (0%-100%), and the net benefits
derived by subtracting the cost of the intervention from the estimated gross
benefits. Finally, the costs of the intervention can be plotted against the
benefits that might accrue assuming different levels of effectiveness and the cut
off point where potential benefits are equal to the costs of the intervention
identified. Any further reduction in rates would result in net benefits.
Sensitivity analysis can subsequently be conducted to assess the impact that
varying the incidence of UTls and the cost per case has on the results obtained.
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In order to operationalise this model the following information is required:
i. Number of admissions to the specialties of interest at one or more
hospitals.
ii. Of those patients selected, the number (or proportion) of patients within
the particular group of interest. For example, the number of patients
admitted to specific specialties. In Figure 10.1 the patients have been
subdivided into five surgical specialties.
iii. The number (or proportion) of patients in the selected groups of interest
who are catheterised.
iv. The number or estimated incidence of hospital acquired UTls occurring
in these catheterised patients.
v. Estimates of the cost of hospital acquired UTls to the hospital sector.
vi. Estimates of the average number of additional days catheterised patients
with a hospital acquired UTI remain in hospital.
vii. The cost and estimated effectiveness of the intervention.
The model produces five main outputs:
i. The number of catheter related UTls that might occur in a pre-defined
patient group.
ii. The value of hospital resources used by catheterised patients who
acquire a UTI
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iii. The number of additional bed days utilised as a result of patients
acquiring a UTI.
iv. The net financial benefits associated with the routine use of sliver alloy
coated catheters assuming different levels of effectiveness.
v. The number of bed days released for alternative use assuming different
levels of effectiveness
10.4.4 Illustrative model
A model to assess the costs associated with catheter associated hospital
acquired UTls occurring in adult (~ 18 years of age) non-day case admissions
to five surgical specialties at the study hospitals in 1994/5 (Figure 10.2), and the
potential benefits of introducing the routine use of silver alloy coated urinary
catheters (Table 10.7) was developed. The model utilises data obtained from
the study hospital together with the results of this work. Details of the data
sources used and the output of this model are given below.
Number of admissions (cel/1)
Data on the number of adult (~ 18 years of age), non-day case admissions to
the surgical specialties of the study hospital were obtained from the study
hospital's database. In 1994/5 there were 7763 admissions that met this
criteria.
Number of patients admitted to the different surgical specialties (eel's 2-6)
Data on the number of patients admitted to the five surgical specialties included
in this model were obtained from the study hospital's database. In 1994/5 2994
(38.6%) of the 7763 adult non-day case admissions to the surgical specialties
listed were general surgical admissions, 1672 (21.5%) were orthopaedic
admissions, 1067 (13.7%) urology admissions, 1702 (21.9%) gynaecology
admissions and 328 (4.2%) obstetric admissions who underwent a caesarean
section.
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The number of patients catheterised (cells 7-16)
Estimates of the number of patients catheterised were derived by applying
estimates of the proportion of patients catheterised at some point during their
admission to the number of admissions. Data on catheterisation rates were not
routinely collected at the study hospital and as such the model utilises data
obtained in this study. Of those patients recruited into this study 17.6% of
surgical patients; 6.9% of orthopaedic patients; 47.0% of urology patients;
19.5% of gynaecology patients and 9.0% of obstetric patients were catheterised
at some point during their admission to hospital.
Number (or percentage) of catheterised patients who acquire a UTI
(cells 17-26)
Estimates of the number of patients who acquired a UTI were derived using
specialty specific estimates of the incidence of UTls in catheterised patients
derived from this study. The incidence of UTls in catheterised general surgical
patients was 7.2% (95% Cl: 3.3, 13.2), in orthopaedic patients 6.1% (95% Cl:
1.2, 16.9), in urology patients 4.5% (95% Cl: 2.5, 7.3), in gynaecology patients
18.0% (95% Cl: 12.0,25.4) and in obstetric patients 6.3 (95% Cl: 1.7, 15.2).
The value of resources used as a result of additional in-patient care
Estimates of the value of resources used as a result of additional in-patient care
were derived by multiplying the estimated cost per case derived in this study by
the number of infections. Estimates derived from the generalised linear
modelling analysis indicated that, on average, UTls cost the hospital sector an
additional £944 (950/0 Cl: £441, £1,446) per case as a result of additional in-
patient care.
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Thenumber of additional days catheterised patients with a UTI remain In
hospital
Estimates of the number of additional days catheterised patients with a UTI
remained in hospital were derived by applying the model estimates of the
impact of UTls on LOS derived in this study, to the number of infections
estimated to have occurred. Estimates derived from the generalised linear
modelling analysis indicated that, on average, patients who acquired a UTI
remained in hospital an additional 3.3 days (95% Cl: 1.3, 5.3).
Estimating the potential benefits of the routine use of silver alloy coated
catheters
Having identified the number of patients who acquired a UTI, and the estimated
impact these infections have on hospital sector resource use, the final stage
was to identify the potential savings that might result from the routine use of
silver alloy coated catheters. In order to estimate these benefits information on
the cost of the intervention and its estimated level of effectiveness is required.
As indicated above, in 1994/5 the additional cost of silver alloy coated catheters
compared to non-coated catheters was £9.245 Estimates of the cost of this
intervention ean therefore be derived by applying this figure to the number of
catheterised patients within each speCialty (cells 7,9,11,13 and 15 in Figure
10.2). Table 10.7 presents Specialty specific estimates of the costs that would
be incurred if silver alloy coated catheters were in routine use.
Estimates of the potential gross and net benefits of prevention were
subsequently derived for varying levels of effectiveness ranging from 0%-100%
(Table 10.7). Finally the costs and potential benefit were plotted against each
other (Figures 10.3 - 10.7).
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Figure 10.3: Estimated costs and benefits of the routine use
of silver alloy coated catheters in adult, non-day
case patients admitted to the general surgical
specialty of an NHS hospitals in England
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Figure 10.4: Estimated costs and benefits of the routine use of
silver alloy coated catheters in adult, non-day case
patients admitted to the orthopaedic specialty of an
NHS hospitals in England
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Figure 10.5: Estimated costs and benefits of the routine use of
silver alloy coated catheters in adult, non-day case
patients admitted to the urology specialty of an NHS
hospitals in England
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Figure 10.8: Estimated costs and benefits of the routine use of
silver alloy coated catheters in adult, non-day case
patients admitted to the gynaecology specialty of an
NHS hospitals in England
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Figure 10.7: Estimated costs and benefits of the routine use of silver
alloy coated catheters In adult, non-day case patients
admitted to the obstetric specialty of an NHS hospitals in
England
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10.4.5 Results of the illustrative model
If the assumptions detailed above are accepted, the model suggests that 129
surgical patients acquired a catheter related UTI in 1994/5 (Figure 10.2).
General surgical patients were estimated to cost the hospital sector an
additional £35,815, orthopaedic patients an additional £6,643, urology patients
£21,303, gynaecology patients £56,395, and obstetric patients who underwent a
caesarean section an additional £1,756. In terms of the number of additional
days patients remained in hospital surgical patients were estimated to remain in
hospital an additional 125 days, orthopaedic patients an additional 23 days,
urology patients 74 days, gynaecology patients 197 days, and obstetric patients
who underwent a caesarean section 6 days.
The additional costs of the routine use of silver alloy coated catheters was
balanced against these costs assuming different levels of effectiveness at
preventing UTls (Table 10.7). If the routine use of silver alloy coated catheters
were adopted at an additional cost of £9 per catheter then, in order for the
benefits to outweigh the costs, 13.2% of infections occurring in general surgical
patients would need to be prevented to cover the costs, 15.6% in orthopaedic
patients, 21.2% in urology patients, 5.3% in gynaecology patients and 14.4% in
obstetric patients who underwent a caesarean section (Figures 10.3 - 10.7).
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The results of one clinical trial suggest that up to 48% of hospital acquired UTls
can be prevented.2"1 Clearly at this level of effectiveness the benefits of the
silver alloy coated catheters significantly outweigh the costs.
10.4.8 Sensitivity analysis
Tables 10.8 and 10.9 show the results of the sensitivity analysis, which
assessed the impad that varying the incidence of UTls and the cost per case
had on the results.
Table 10.8: The effect of varying un incidence rates on the proportion of
Infections that need to be prevented to cover cost of silver alloy
coated catheters·
Incidence rate (%)
Proportion of infectIona that need to be pnmnted to cover cost
of silver alloy coaled catheters· (%)
2 "7.7.. 23.8
6 15.9
8 11.9
10 9.5
12 7.9
1.. 6.8
16 6.0
18 5.3
20 ".8
..
Table 10.1: The effect of varying the cost per un on the proportion of
Infections that need to be prevented to cover cost of silver alloy
coated catheters*
Proportion of infectIona that need to be pnaventad to cover cost of silver
alloy coaled cath ... ,.* (%)
eo.tpercaH General surpry OrthopIIedica Urology Gynaecology Obstltric:s
150% of cost uaed 26.6 31.3 "2." 10.6 30.3
100% of cost uaed 11.2 15.6 21.2 5.3 1.....
150% of coets uaed 8.8 10." 12.1 3.5 10.1..- All other llSSumptloIla (additional cost of catheter, cost per case) n:mam 'mcbanged
As the individual parameters are decreased the intervention needs to be more
effective for the benefits to cover the costs. As they are increased the
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intervention needs to be less effective to cover the costs. For example, if the
incidence of UTls in catheterised general surgical patients was just 2%, rather
than 7.20/0as assumed in the model, then providing all the other assumptions
are thought to be valid, 47.7% of the expected UTls occurring in catheterised
general surgical patients would need to be prevented if the costs of the
intervention were to be covered. However, if the specialty specific incidence
rates are higher than that assumed in the model, then providing the other
assumptions are accepted, a lower percentage of infections would need to be
prevented to cover the cost of the intervention. For example, if the incidence of
UTls in catheterised general surgical patients was 12%, rather than the 7.2%,
as assumed in the model, a 7.9% reduction in the incidence of UTls in
catheterised surgical patients would be needed to cover the cost of the
intervention.
The effects of altering more than one parameter at a time were not explored in
this model.
10.4.7 Validityof the model
The validity of this model is dependent on how realistic the structure of the
model is and how accurately the estimates of the parameters used reflect what
is happening in the patient group of interest. The illustrative model presented
was baaed on information derived from this study. It should be noted that the
specialty specific incidence rates derived had wide confidence intervals and this
should be taken into account when interpreting the results. However, it should
also be noted that this particular model is for illustrative purposes. If the results
were to be used to inform decision making, the impact of varying the incidence
should be taken into consideration.
10.4.8 Interpretingthe lUults of themodel
The model provides information on the number of UTls occurring in catheterised
patients; the number and cost of extra bed days utilised as a result of UTls; and
the net financial benefits associated with the routine use of silver alloy coated
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catheters. Studies that have assessed the effectiveness of the use of this type
of catheter suggest that up to 48% of infections can be prevented.2<t1 However,
the validity of some of the published estimates has been questioned,243and as
mentioned earlier, to some extent the level of effectiveness achieved depends
on the scope for reducing the incidence of this type of infection. Nevertheless
the evidence to date does appear to suggest a preventative effect, and the
results of this model demonstrate that even at relatively low levels of
effectiveness the cost of their routine use can be recouped.
However, the results of the sensitivity analysis demonstrate that if the specialty
specific incidence rates used in this model are an overestimate of the actual
incidence rates, then the routine use of these catheters may be an expensive
option unless a high proportion of infections can be prevented. The routine use
of silver alloy catheters in patients in which the infection rate is just 2% would
necessitate a 47.7% reduction in rates if the costs were to be recouped.
However, with the exception of obstetric patients the lower confidence rate was
above 2% for all specialties.
When relatively conservative estimates of the additional costs resulting from
HAl were introduced into the model, the results indicated that with the exception
of the urology specialty, the catheters would need to be effective at preventing
between 11% and 23% of infections if the cost of the catheters were to be
covered, the precise level varying with specialty. The level of effectiveness
needed for urology patients was somewhat higher - 42%. However, if the
estimates used are underestimates of the value of resources that might be
released, then the catheters would only have to be effective at preventing
between 3.5 and 12.1% of infections, if the costs of the catheters were to be
covered, again the actual level of effectiveness needed varying with specialty.
It should be noted that the sensitivity analysis did not consider the impact of
varying more than one parameter at a time. If the incidence of UTls and the
additional cost per case used in this model are both thought to overestimate the
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situation in a given setting, the benefits may no longer outweigh the cost of the
intervention.
However, the model did not assess the benefits associated with a reduction in
secondary bactereamias, a known sequela to UTls. Studies indicated that
between 1% and 5% of patients with a UTI will develop a secondary
bacteraemia.81 82 144 Acquisition of a BSI following a UTI may further prolong
the patients length of hospital stay and represent an additional burden to the
health sector. As such the benefits of preventing hospital acquired UTls may
have been underestimated in the illustrative model. If the use of silver alloy
coated catheters are effective in preventing UTls in patients who in the absence
of this intervention would have acquired both a UTI and a bacteraemia, the
benefits of preventing UTls through the routine use of this intervention will
increase.
When interpreting the benefits the user should be aware that the cost of the
infection, if avoided, will not all be realised as a cash saving. Many of the
costslbenefits are fixed costs and expenditure on these resources is committed
at the beginning of a time period and cannot be recovered. However, the
variable costslbenefits (for example drugs, and other consumable items), which
represent a smaller proportion of the total costs, would show as cash savings
and as such expenditure that could be avoided.
While the fixed costs avoided will not all be realised as cash savings, they do
represent economic benefits as these resources could be deployed to produce
other outputs (instead of treating the infection). NHS resources are severely
limited and so there is almost certainly an opportunity cost associated with
using fixed resources to treat hospital acquired UTls. This implies a positive
value for the fixed resources freed up by prevention control activities. It is
therefore justified to use the full cost data (fixed plus variable costs) to represent
the benefits.
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10.4.9 Potentialapplications
The model described represents a flexible tool which could easily be adapted to
the specific needs of the user. It may be of particular interest to infection control
nurses and doctors who wish to demonstrate the magnitude of the burden of
this type of infection and the benefits associated with the routine use of silver
alloy coated catheters. The information derived from the model may be used to
justify the additional expenditure associated with this intervention, and to
change policy regarding infection control practice.
While the model presented focuses on UTls occurring in catheterised patients
and the routine use of silver alloy coated catheters as a means of reducing this
type of infection, the model could equally be adapted to assess the benefits of
an altemative infection prevention intervention.
10.5 Conclusion
In this chapter estimates of the gross benefits that might result if a 15%
reduction in infections rates in adult non-day case patients admitted to the five
surgical Specialties covered in this study, at the study hospital or at the national
level were achieved, have been presented. Estimates of both the value of
resources that might be released for alternative use and the number of bed
days released have been presented. The results demonstrate that the
magnitude of these benefits, should this reduction be achieved, is likely to be
substantial. However, achieving such a reduction is not cost free. As such the
net benefits will be dependent on the costs of achieving such a reduction in
rates. With the exception of studies that have assessed the costs and benefits
of surveillance, and prophylactic antibiotics, few studies have assessed the cost
and benefits of selected infection control practices. In the absence of such
studies, economic models can be developed, utilising data from a variety of
sources, and the information derived used to inform decision making regarding
resource allocation and practice. An illustrative model that assessed the cost
and benefits of the routine use of silver alloy coated catheters was presented
and the results discussed. The use of models together with the findings of this
study will be discussed further in the following chapter.
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CHAPTER 11
DISCUSSION AND CONCLUSIONS
11.1 Introduction
In this chapter the results of this study will be discussed. The chapter begins
with an overview of the main results and how they compare to those derived in
earlier published studies. The strengths and limitations of this research are
then discussed in sections 11.3 and 11.4, followed by a discussion of
methodological issues in section 11.5. The implications of the study findings for
policy and practice are discussed in section 11.6, areas for future research
identified in section 11.7and conclusions drawn in section 11.8.
11.2 Overviewof results
This study provides important data on the incidence of HAls occurring in adult
non-day case patients admitted to selected surgical specialties of a district
general hospital in England, independent risk factors for these infections, and
estimates of the economic burden these infections place on the hospital sector
as a result of additional in-patient care.
11.2.1 IncidenceofHAl
Of the 2469 patients included in this study 7.5% (95% Cl: 6.4%, 8.6%) acquired
and presented with one or more HAls during their in-patient stay. Twenty-nine
per cent of infections presented within the first four days of admission, over 50%
within the first six days, and 75% within nine days of admission.
The incidence of HAl varied with admission specialty. The incidence of HAl in
gynaecotogy patients was 12.7% (95% Cl: 9.9%, 16.8%); 9.3% (95% Cl: 6.2%,
14.4%) in obstetric patients who had undergone a caesarean section; 7.4%
(95% Cl: 5.2%, 10.4%) in orthopaedic patients; 6.10/0(95% Cl: 4.6%, 7.9%) in
general surgical patients and 5.1% (95% Cl: 3.9%, 8.4%) in urology patients.
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The incidence of specific types of infection also varied. Urinary tract infections
(UTls) were the most frequent type of infection accounting for 48.1% of
infections identified; surgical wound infections (SWls) accounted for 19.2%;
lower respiratory tract infections (lRTls) 11.1%; skin infections 7.7%;
bloodstream infections (BSls) 1.9%; and infections at other sites 12.1%.
Valid comparisons of the incidence rate observed in this study with those
observed in other studies are difficult. Important differences exist between this
and other studies with respect to the definitions used, surveillance methods
employed, the case-mix studied and the treatment patterns followed in the
different clinical settings. As discussed in Chapter 2 these differences will
inevitably influence the reported incidence rates. Inability to control for these
differences renders meaningful, valid comparisons difficult. A study conducted
in a similar type of NHS hospital in England in 1992, using the same definitions
and surveillance methods used in this study, observed a higher incidence rate
amongst surgical patients than that observed in this study: 9.7% of in-patients
admitted to the general surgical, gynaecology and orthopaedic specialties of an
NHS hospital acquired and presented with an infection whilst in hospital...7
Without further details about the case mix and treatment patterns present it is
difficult to interpret these findings. The different infection rates could reflect
differences in practice, with the study hospital performing better with respect to
infection control. Alternatively they could reflect important case-mix differences,
with the study hospital treating patients at lower risk of infection than patients
involved in the study by Glenister et s/ (1992).47 The most likely explanation is
that there was a combination of factors at play.
Whilst precise comparisons of the incidence rates observed in the various
studies cannot be made, it is interesting to note that studies have found similar
patterns with respect to the frequency of the different types of HAl. As in this
study, other incidence studies have reported UTls, SWls, and lRTls be the
most frequent types of HAl with UTls being the most frequent.48 ..7
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11.2.2 Risk factors for HAl
The results of the multivariable logistic regression analysis indicated that the
odds of acquiring an HAl were higher in females than males; increased with
increasing age category and increasing number of co-morbidities; were higher
in patients who had diabetes mellitus fisted as a co-morbidity; were higher in
emergency as compared to elective admissions; varied with admission specialty
being highest in gynaecology patients; were greater in patients who had
received antibiotics prior to the onset of an infection; and were higher in patients
who had one or more operations. With the exception of sex, and diabetic
status, the variation identified above was significant at the 5% level. The results
of a separate analysis limited to 1,588 patients for whom data on body mass
index (BMI) were available found that the incidence did not vary significantly
with BMI.
11.2.2. 1 Urinary tract infections
The results of the multivariable logistic regression analysis, undertaken to
assess independent risk factors for UTls, indicated that female patients and
patients who had been catheterised prior to the onset of this type of infection
were at greater risk of acquiring a UTI than male and non-catheterised patients.
The odds of acquiring a UTI were 2.6 (95% Cl: 1.6, 4.1) times higher in
catheterised patients compared to non-catheterised patients and 2.8 (95% Cl:
1.4, 5.6) times higher in female compared to male patients. The odds of
acquiring a UTI were also found to increase with increasing age category, and
varied significantly with admission specialty. The odds of acquiring a UTI were
higher for gynaecology and obstetric patients, compared to patients in the other
specialty groups and were higher in patients who had an operative procedure
(Odds ratio 1.1 95% Cl: 1.1, 6.5). The odds increased with increasing number of
co-morbidities, and were higher in patients who had diabetes mellitus listed as a
co-morbidity, however these increases were not significant at the 5% level.
Similarly whilst the odds of acquiring a UTI were higher for emergency patients,
this was not found to be significant at the 5% level. The odds of acquiring a UTI
were similar both in patients who had antibiotics prior to a UTI and in those who
300
had not, although the upper confidence intervals suggest that in some case
patients who received prophylactic antibiotics were at greater risk of acquiring a
UTI. This outcome suggests that the administration of prophylactiC antibiotics is
perhaps a marker for another risk factor not included in this model.
11.2.2.2 Surgical wound infections
The results of the multivariable logistic regression analysis undertaken to
assess independent risk factors for SWls identified just one independent risk
factor that was significantly associated with the risk of acquiring a SWI at the
5% level. The presence of one or more wound drains was found to increase the
risk of acquiring this type of infection by a factor of 2.2:1 (95% CI:1.0, 5.0).
11.2.2.3 Lower respiratory tract infections
The results of the multivariable logistic regression analysis undertaken to
assess independent risk factors for LRTls also identified just one factor that was
significant at the 5% level. The presence of an endotracheal or tracheostomy
tube was found to increase the risk of acquiring a LRTI by a factor of 77: 1 (950/0
Cl: 27.4, 216.9).
To a degree the results of this study are consistent with the findings of earlier
studies. For example, a number of earlier studies have identified urinary
catheters and female sex to be key risk factors for UTlS,1134137138143144whilst
others have identified the presence of an endotracheal or tracheostomy tube as
key risk factors for lower respiratory tract infections.1 147However, unlike some
earlier studies, this study did not find a significant associated between diabetes
mellitus and infection or a significant association between body mass index and
infection risk.11ee 74138141142 However, it should be noted that only 3.4% of
patients studied had diabetes mellitus and data on BMI was only available for
63% of the patients studied, thus limiting the ability of this work to identify an
association if present.
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11.2.3 Economicburden
Generalised linear modelling statistical techniques were used to determine how
much of the observed variation in costs and LOS could be attributed to the
presence of an infection. The analysis controlled for the potentially confounding
effects of age, sex, number of co-morbidities, admission type, and admission
specialty and used both an identity and a log link. Models that incorporate an
identity link assume additive effects, and as such its use enabled estimates of
the mean additional costs incurred by infected patients, and the mean number
of additional days infected patients remained in hospital, to be taken directly
from the model. In contrast models incorporating a log link assume
multiplicative or proportional effects, thus providing estimates of the ratio of
costs and LOS incurred by infected compared to uninfected patients.
It is not clear which approach most accurately reflects the impact of HAlon
costs and LOS. Whether HAls on average have an additive or a proportional
effect will to some extent vary with specialty and type of infection.
Consequently, since it is impossible to establish that either is the correct way to
assess the impact of HAl on costs, estimates of both the average costs of HAl
and the average proportional increase in costs incurred by infected compared to
uninfected patients, after controlling for a number of potential confounding
factors, have been reported in this thesis. However, it is worth noting that the
ratios of the costs incurred by infected compared to uninfected patients, derived
from the additional cost estimates, taken from the identity link model, are very
similar to the ratios obtained directly from the model using a log link and vice-
versa.
11.2.3.1 Estimated cost to the hospital sector as a result of additional in-
patient care
The results indicate that acquiring an infection, on average, increased hospital
costs by a factor of 2.3 (95% Cl: 2.0, 2.6). Estimates of the additional costs
attributable to infection indicated that on average HAls cost the hospital sector
an additional £2,254 (95% Cl: £1,738, £2,770) per case.
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Estimates of the impact of HAlon hospital costs were found to vary with
specialty. Estimates of the proportional increase in hospital costs incurred by
infected compared to uninfected patients from the same specialty indicated that
infections occurring in general surgical patients, on average, increased costs by
a factor of 3.9 (95% Cl: 3.0, 4.9), whereas infections occurring in orthopaedic
patients were estimated to increase costs by a factor of 2.4 (95% Cl: 1.8, 3.3);
in urology patients costs were estimated to increase by a factor of 2.1 (95% Cl:
1.5, 2.9); in gynaecology patients costs were estimated to increase by a factor
of 1.2 (95% Cl: 0.9, 1.6); and in patients who had a caesarean section, costs
were estimated to increase by a factor of 1.1 (95% Cl: 0.7, 1.6). As evidenced
by the confidence intervals, there was some uncertainty about the estimates
relating to both obstetric and gynaecology patients.
Estimates of the additional costs incurred, indicated that on average HAls
occurring in general surgical patients cost the hospital sector an additional
£4,368 (95% Cl: £2,992, £5,744) per case; this compared to an additional
£3,357 (95% Cl: £1,821, £4,894) per case in orthopaedic patients; an additional
£1,474 (95% Cl: £534, £2,414) per case in urology patients; an additional £375
(95% CI:-£145, £895) per case in gynaecology patients and an additional £207
(95% CI:-£841, £121) per case in patients who had undergone a caesarean
section. Again, as shown by the confidence intervals, there was some
uncertainty about the estimates relating to both obstetric and gynaecology
patients.
Cost estimates also varied with site of infection. The results indicated that
multiple infections were the most costly and that UTls were the least costly.
The acquisition of more than one HAl was estimated to result in hospital costs
almost six times higher than uninfected patients (model estimate: 5.8 95% Cl:
3.9, 7.9). In contrast, UTls, on average, were estimated to increase costs by a
factor of just 1.6 (95% Cl: 1.3, 1.9), With the exception of BSls, infections
occurring at the other sites were estimated to result in a two to three fold
increase in costs. Acquisition of a BSI and no other infection was estimated to
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increase costs by a factor of 6.0 (95% Cl: 2.2, 16.2). However, as evidenced by
the confidence interval there was considerable uncertainty about this estimate.
Only three patients acquired a BSI and no other infection, two of whom died as
in-patients.
Estimates of the additional costs incurred indicated that on average, multiple
infections cost the hospital sector an additional £8,118 (95%CI: £7,930,
£11,310) per case, whereas UTls, on average, were estimated to cost £944
(95% Cl: £441, £1,446) per case. The average cost of infections occurring at
other sites were as follows: SWls £1,497 (95% Cl: £548, £2,447); infections at
sites not elsewhere classified £1,671 (95% Cl: £279, £3,064); skin infections
£1,567 (95% Cl: -£110, £3,245); LRTls £2,672 (95% Cl: £753, £4,592) and
BSls £6,953 (95% Cl: -£1,652, £15,558).
The estimates derived in this study are considerably higher than those derived
in other studies. For example, the most recent UK based study that estimated
the economic burden of HAls occurring in surgical patients (general surgical,
gynaecology and orthopaediC patients), indicated that on average HAls costs
the hospital sector £1,041 per case.14
A number of factors could account for the higher cost estimate derived in this
study. Firstly the infections identified in this study may have been more
resource intensive and thus more costly to treat. However, this is unlikely to
explain all the cost differences observed. Other factors which might in part
explain the considerable difference in the estimates derived in this study I and
those reported in the study by Coello et ./ include inflation (the study by Coello
et ./ was conducted in 1988), the more detailed approach to identifying and
valuing resources used in this study, and differences with respect to the
attribution methods employed which in tum could impact on the estimates
derived.
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Whilst the precise estimates derived in earlier studies differ markedly to those
obtained in this study, the pattern of increase is similar. For example, as in this
study, Coello et a 14 found UTls to be the least costly infections and multiple
infections the most resource intensive. A number of other studies that have
examined the relative costs of different types of HAl have also found UTls to be
the least resource intensive.171 11 69
11.2.3.2 Estimated number of additional days infected patients remain in
hospital
HAls were, on average, estimated to increase the patients LOS by a factor of
2.1 (95% Cl: 1.8, 2.5). Estimates of the number of extra days patients remained
in hospital indicated that on average HAls extended the in-patient stay by 7.8
days (95% Cl: 5.7 to 10.0).
As with costs, the estimates of the number of extra days patients remained in
hospital varied with specialty. Infections occurring in general surgical patients
were estimated to result in a three fold increase in LOS (model estimate 3.4,
95% Cl: 2.6, 4.4), whereas infections occurring in orthopaedic and urology
patients, on average, were estimated to double the in-patient stay. HAls
occurring in orthopaedic patients were estimated to increase the LOS by a
factor of 2.0 (95% Cl: 1.4, 2.7) and in urology patients by a factor of 2.5 (95%
Cl: 1.7, 3.6). Infections occurring in gynaecology and obstetric patients were
estimated to have a relatively small impact on LOS. HAls occurring in
gynaecology patients were estimated to increase the LOS by a factor of 1.3
(95% Cl: 1.0, 1.7) and infections occurring in obstetric patients were estimated
to increase LOS by a factor of 1.1 (95% Cl: 0.7, 1.6).
Estimates of the number of extra days attributable to HAl indicated that, on
average, infections occurring in general surgical patients prolonged the in-
patient stay by 15.3 (95% Cl: 9.5, 21.0) days, whereas HAls occurring in
orthopaedic patients were estimated to extend the LOS by 11.7 (95% Cl: 4.7,
18.8) days; in urology patients by 7.9 (95% Cl: 2.9,12.9) days, in gynaecology
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patients by 1.8 (95% CI:-O.4, 4.0) days and in patients who had undergone a
caesarean section LOS, on average, was extended by 0.6 (95% CI:-2.8, 4.1)
days. As with costs, as shown by the confidence intervals obtained, there was
considerable uncertainty about the estimates of the number of additional days
infected obstetric and gynaecology patients remained in hospital.
Estimates of the impact HAl had on LOS also varied with site of infection. The
results indicated that acquiring more than one infection resulted in the greatest
proportional increase in LOS: on average, multiple infections were estimated to
increase LOS by a factor of 4.4 (95% Cl: 2.9, 6.5). In contrast BSls were
estimated to increase LOS by a factor of just 1.5 (95% Cl: 0.5, 4.4). This might
appear a rather surprising finding. However, as mentioned above only three
patients acquired a BSI and no other infection, two of whom died whilst in
hospital thus curtailing their length of hospital stay. As shown by the confidence
interval, there was considerable uncertainty around this estimate. It is
interesting to note that whilst the LOS of patients who acquired a BSI and no
other infection was not markedly prolonged, as mentioned in section 11.2.3.1
the costs incurred were considerable. On average, acquiring a BSI was
estimated to result in a six-fold (95% Cl: 2.2, 16.2) increase in costs. Whilst, as
evidenced by the wide confidence intervals, there was some uncertainty
surrounding this estimate, the results suggest that whilst LOS is not markedly
increased costs are, thus indicating that the time in hospital is resource
intensive.
Acquisition of a UTI was also found to have a relatively small impact on LOS.
UTls were estimated to extend the LOS by a factor of 1.5 (95% Cl: 1.3, 1.9).
Infections occurring at the other sites on average were estimated to result in a
two fold increase in LOS.
Site-specific estimates of the number of extra days patients remained in hospital
indicated that, on average, multiple infections extended the in-patient stay by 24
days (95% Cl: 11.8, 36.4), whereas BSls and no other infection were estimated
306
to extend the in-patient stay by just 2.2 (95% Cl: -7.1, 11.5) days. UTls were
estimated to prolong the in-patient stay by 3.3 (95% Cl: 1.3, 5.3) days, SWls
were estimated to extended the LOS by 7.2 (95% Cl: 2.3, 12.0) days, LRTls by
8.0 (95% 0.6, 15.4) days; skin infections by 9.9 (95% Cl: 0.4, 19.3) days, and
infections at sites not elsewhere classified by 11.6 (95%CI: 3.0, 20.2) days.
11.2.3.3 Distribution of additionsl costs
This study took a detailed approach to assessing the cost of resources used by
both infected and uninfected patients. The resources used were categorised
under a number of headings (hospital overheads, directorate management,
capital charges, medical time, nursing care, paramedics and specialist nurses,
physiotherapy, surgical interventions, consumables used for specific
procedures, antimicrobials, non-antimicrobial drugs, microbiology tests, other
pathology tests, endoscopies, radiology and other tests) and the distribution of
the additional costs incurred by infected patients subsequently assessed. The
results indicated that for all cost categories, the costs incurred by infected
patients were higher than for uninfected patients. The cost of nursing care was
the largest contributor to the additional costs incurred accounting for 40.5% of
the additional costs. Cost categories that were directly linked to time in hospital,
taken together, were the second largest contributor accounting for 38.4% of the
additional costs incurred by infected patients. Costs that were considered to be
directly linked to time in hospital included the costs of hospital overheads,
directorate management, capital charges and medical time. These costs were
all assigned to individual patients on the basis of their LOS.
The distribution of costs varied with site of infection reflecting the different
resource requirements of different types of HAl. For example, nursing care
accounted for a varying proportion of the costs attributed to infection. Nursing
care accounted for 60% of the cost of BSls; 46% of the costs of multiple
infections and LRTls; 34% of the cost of UTls, 33% of cost of SWls, just 25% of
the cost of skin infections and 28% of the costs associated with infections at a
range of other sites.
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11.3 Strengthsof study
11.3.1 Inclusion of a number of surg/cal specialties
One of the strengths of this study was that it assessed the incidence and
economic burden of HAls occurring in adult, non-day case patients admitted to
surgical specialties common to all district general hospitals: general surgery,
orthopaedics, urology, gynaecology and obstetrics (caesarean sections only).
Nationally patients admitted to these specialties accounted for 35% of all adult
non-day case admissions in 1994/5.221 The results of this study are therefore
relevant to a substantial proportion of NHS patients.
This study provides important data on the incidence of, and risk factors for HAls
occurring in adult non-day case patients admitted to the specialties listed above
and the economic burden they impose on the hospital sector. Few studies have
assessed the incidence of HAl occurring in such a broad case mix of patients.
Three notable exceptions are the SENIC study conducted in the US in 1975
which assessed the incidence of HAl occurring in 6,449 medical and surgical
patients;·9 a study by Glenister et a/,7 which assessed the incidence of HAl
occurring in 3,326 adult medical, surgical, orthopaediC and gynaecology
patients; and an audit study involving 81,218 adult patients admitted to the
medical, surgical, orthopaediC and gynaecology speCialties of 19 hospitals in
England and Wales conducted in 1993/4.1 The majority of incidence studies
have focussed on the incidence of HAls occurring in a narrower group of
patients defined by specialty or operative procedure. For example, a number of
studies have focussed on the incidence of HAls occurring in patients who had a
caesarean section.51-56
Studies that have assessed the economic burden of HAl also vary in scope.
Many studies are limited to the economic burden of HAls occurring in patients
admitted to a particular specialty or the burden associated with a particular type
of infection occurring in a selected patient group. The most recent UK study
that involved a broad case-mix of patients was a study in 1988 by Coello et 8/
(1993)1. that assessed the economic burden of HAls occurring in adult patients
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admitted to a similar range of specialties: general surgery, orthopaedics and
gynaecology. The results reported in this thesis provide a more timely
assessment of costs resulting from infections occurring in adult patients
admitted to specialties common to most hospitals.
11.3.2 Use of previously validated definitions of Infection and
surveillance methods
The study used previously validated definitions of infection and surveillance
methods thus enhancing the validity of the results obtained. The definitions and
surveillance methods used were developed and validated in an earlier study by
Glenister et s/ (1992).77 The surveillance method adopted involved reviewing
patient records (patient notes, drug charts, observations charts and
microbiology records) and liaising with ward staff to identify signs and
symptoms that were indicative of a possible infection. Those patients who had
signs and symptoms that met the criteria for infection as detailed in the
validated definitions were classified as having an infection.
11.3.3 A detailed approach to costing resource use
In marked contrast to other studies this study took a very detailed approach to
the estimation of the economic burden HAls place on the hospital sector as a
result of additional in-patient care. Studies reported in the literature have
generally limited their assessment of costs to a few areas considered to be
directly linked to infection. For example, some studies have limited their
assessment of costs to those associated with an extended length of stay, whilst
others have adopted a Slightly more detailed approach, including the cost of
specific resources considered directly linked to infection such as the cost of
antibiotics, in addition to those costs associated with an extended stay.1314189
In this study no assumptions were made as to what types of resources might be
used in greater quantity by infected patients as a consequence of having
acquired an infection in hospital. As far as possible data on all resources used
by both infected and uninfected patients were collected and subsequently
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valued. This included the costs of all drugs prescribed, investigations
undertaken, procedures performed, care administered by nurses, doctors and
personnel from the professions allied to medicine, and the costs associated with
an extended hospital stay. Estimates of the value of these resources were
subsequently made and statistical modelling techniques employed to determine
how much of the observed variation in costs between infected and uninfected
patients could be attributed to the presence of an HAl.
The methods derived to estimate the value of these resources were also very
detailed. Earlier studies have tended to value resources by applying an
average cost to the resources used. For example, in many cases estimates of
the cost of an extended hospital stay have been derived by first deriving an
estimate of the average cost per bed day and then applying this to the number
of extra days infected patients were estimated to remain in hospital. Such an
approach fails to take into account that costs may vary markedly with day of
admission. Hollingsworth et s/ (1993) found that patients admitted to hospital
with a fractured neck of femur incurred relatively high daily costs during the first
few days in hospital, after which they decreased.198 Similar pattems are likely
to be present for other types of patients undergoing emergency surgery,
whereas for elective patients, depending on the day of surgery, costs may
initially be relatively low on admission to hospital, rising on the day of surgery,
and then decreasing over time as the patient recovers and becomes less
dependent on nursing and medical care. The use of an average cost also fails
to take into account that complications such as an infection may cause daily
costs to increase, the level of increase depending on the type and severity of
the infection and how it interacts with the patients other co-morbidities.
In this study, detailed data were collected on the types and quantities of
resources used. As such, wherever possible, the estimates of the cost of
resources used reflect consumption by individual patients. Unit costs were
derived for laboratory and radiology tests, drugs, operations and procedures
performed, and subsequently allocated to individual patients based on the
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amount consumed. The methods developed to derive unit costs aimed to take
into account all resources used. For example, the cost of administering an
intramuscular drug not only included the cost of the drug. but also the cost of
the syringe, needle and, if applicable the cost of the solution used in the
preparation of the drug for administration. The cost of the time and skills
involved in preparing the drug and subsequently administering it were included
in the pharmacy overhead costs allocated on a cost per bed day, and the
nursing care costs allocated on the basis of the amount of nursing care
individual patients received on a daily basis. The algOrithms used to derive
nursing costs took into account the number and types of drugs administered on
a daily basis.
As indicated above, estimates of the cost of nursing care took into account the
level of nursing care administered to patients on a daily basis. Patients were
categorised into one of seven nursing care groups based on the intensity of the
nursing care received. Care group one denoted patients who needed very little
nursing care, whereas at the other end of the spectrum, care group seven
denoted patients requiring 24 hour nursing care. Using a previously validated
care group weighting system, nursing care costs for individual wards were
allocated to patients based on their daily care group.
Estimates of the costs of care administered by physiotherapists, occupational
therapists, nutritionists and other health personnel from the professions allied to
medicine, were derived from activity data and employment costs, and allocated
on the basis of the number of contacts individual patients had with these health
care professionals. Unfortunately it was not possible to adopt a similar
approach for medical care. Resource constraints prohibited the assessment of
the amount of care individual patients received from medical staff. As such an
average cost per bed day was derived for medical costs and allocated to
patients on the basis of the number of days they remained in hospital.
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Similarly it was beyond the scope of this study to assess individual patient
consumption of the services provided by the various overhead directorates. As
such estimates of the cost of the hospital overheads were attributed to patients
on the basis of an average cost per day, having first allowed for consumption of
the various overhead directorates by the overheard directorates themselves.
For example, the allocation model developed did not simply apportion the costs
of heating to individual patients based on their LOS, but through the use of a
series of simultaneous equations first allowed for consumption of heating by the
'Estates Directorate' itself and the other overhead directorates. Once this had
been taken into account the remaining costs were allocated to patients on the
basis of an average cost per day.
This detailed approach to identifying and estimating the cost of resources used
by both infected and uninfected patients was both time consuming and complex
to undertake. However, the approach offered a number of advantages over
limiting estimates to the number and cost of extra days patients remained in
hospital and the use and cost of a few specific resources considered to be
linked to infection. The approach used enabled a more accurate assessment of
the costs of resources used by individual patients, from which estimates of the
ratio of costs and the additional costs incurred by infected compared to
uninfected patients could be derived. Since the methods employed did not
make any assumptions as to what categories of costs were likely to be higher in
infected than uninfected patients, the approach enabled a detailed assessment
of the distribution of additional costs to be made, thus providing information
which may be of use to those involved in decision making regarding the
allocation and use of scarce hOSpitalresources.
11.3.4 Attribution methods
As discussed in Chapter 3, the majority of studies that have assessed the
economic burden of HAl have adopted one of three methods to attribute
resource use and costs to infection: the concurrent method which involves the
subjective assessment of the resources used by infected patients as a result of
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their infection, the comparative method, and the comparative method with
matching of cases and controls. As detailed in Chapter 3 all three approaches
have their limitations.
In this study an alternative approach to the attribution of resource use and costs
to HAl was taken. A large cohort of patients was followed and patients who
acquired an infection in hospital identified. Generalised linear modelling
statistical techniques were then used to assess the impact of HAlon hospital
resource use and costs by comparison of the HAl group and remainder of the
cohort. The modelling took into account a range of factors that, in addition to
the presence of an HAl, were considered to influence resource use and costs
(age, sex, admission specialty, admission type, and number of co-morbidities).
Two methods of describing the impact of HAlon resource use were used.
Estimates of the proportional increase in costs and LOS incurred by infected
patients compared to uninfected patients were derived through the use of a log
link, and estimates of the additional costs and extra days in hospital attributable
to HAl were derived through the use of an identity link.
This alternative approach to attribution has a number of strengths. The
approach is considerably more rigorous that the concurrent approach, the
validity and reliability of which has been questioned in the Iiterature.187 It has
been suggested that physician reviewers may be hesitant to attribute resources
to the presence of an HAl and as such the resulting estimates of costs may be
underestimates of the resources and costs that are attributable to the presence
of an infection.48 The approach adopted in this study did not involve subjective
assessment of resources used by Infected patients. The resources used by
both infected and uninfected patients were identified and costed and
generalised linear modelling statistical techniques applied to determine how
much of the observed variation in resource use and costs could be attributed to
infection.
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This approach also has a number of strengths when compared to the
comparative approach. The comparative approach without matching simply
involves assessing resource use and costs incurred by infected and uninfected
patients and attributing any cost differences to the presence of an infection.
The approach does not take into account any other factors that might differ
between the two groups of patients (infected and uninfected) that in turn might
influence resource use and costs. For example, infected patients even in the
absence of an infection may have utilised more resources than uninfected
patients and as such only a proportion of the additional costs incurred can be
justly attributed to the infection. Thus failure to control for important differences
between infected and uninfected patients that in tum might influence resource
use and costs, may result in an overestimate of the economic burden of HAl.
Haley et s/ (1980) compared three alternative methods for the attribution of
resources and costs to HAl and concluded that studies which attributed
resource use and costs to HAl using the comparative approach resulted in
overestimates of the costs attributable to infection.48 The analysis used in this
study controlled for a number of factors that might influence resource use and
costs.
The comparative approach with matching of cases and controls does take into
account factors that may influence resource use and costs. Infected patients
are matched with controls on the basis of factors such as age, sex, diagnosis
and number of co-morbidities. However, studies frequently encounter
difficulties finding suitable controls for infected patients, resulting in infected
patients being lost from the final analYSis. As detailed in Chapter 3, the
proportion of infected patients for whom suitable controls can be found varies
considerably with study. Haley et s/ (1980)48 in a review of matched studies
conducted between 1953 and 1975, found the proportion of infected patients
who were successfully matched with uninfected ·controls' varied considerably
from a low of 32% to 100%. Scheckler et s/ (1978)171 in a study to assess the
economic burden of HAls occurring in 104 patients admitted to a community
hospital in the US between January and March 1978 were unable to find a
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sufficient number of suitable controls and therefore had to abandon this
approach to attribution of costs. A more recent study, conducted in the UK,
successfully matched 67 (85%) of the 79 infected surgical patients for whom
medical records were available for review.14 A study by Kappstein et s/
(1992),182 which assessed the excess costs and LOS resulting from ventilator
associated pneumonia occurring in patients admitted to the intensive care unit
of a university teaching hospital in Germany, found that after excluding cases
that died during their admission, suitable controls could only be found for 34
(60%) of the 57 cases, and a study conducted in Turkey in 1994 involving
general surgical patients successfully matched only 67% of their 225 infected
patients.61
In those cases where suitable controls are found this approach provides
valuable estimates of the economic burden imposed. However, the estimates
derived represent the economic burden imposed by infections occurring in a
limited set of patients. Frequently it is the sicker, more resource intensive
patients for whom suitable controls cannot be found. Thus the estimates
derived may underestimate the average costs of HAls occurring in the wider
population from which the infected patients were identified. The strength of the
approach adopted in this study was that it included all infected patients. By
utilising all the available data it was possible to control for a similar range of
factors as have been used in comparative-with-matching studies, yet include all
infected patients. As such a broader understanding of the average costs of
infections occurring in surgical patients was derived. Whilst some of the
infections may have imposed a relatively small burden and others may have
been considerable more expensive, the approach allows for an overall average
estimate to be derived.
11.3.5 General/sabilityof results to other health care settings
A major strength of this work is the perceived generalisability of the results to
other health care settings. The results of this study were derived from data
relating to adult non-day case patients admitted to five surgical specialties of
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one NHS hospital in England. The inclusion of just one hospital inevitably
represents a limitation of the study design. Ideally patients would have been
recruited from a number of hospitals randomly selected, however funding
constraints prohibited the inclusion of more than one hospital site. However,
despite this limitation for a number of reasons it would appear justifiable to
assume that the results may be taken to represent what occurs in patients
admitted to the same clinical specialties in other health care settings.
The hospital selected was an NHS district general hospital not dissimilar to
other district general hospitals in England in terms of the types of care offered,
its size, and a range of financial indicators2 and, as already mentioned, patients
were selected from specialties common to all district general hospitals. It is
acknowledged that the cost of resources will inevitably vary to some extent from
one hospital to another, depending on a number of factors such as the suppliers
to the hospital. However, the cost of specific resources within any given setting
will be the same for both infected and uninfected patients. As such, if it can be
assumed that clinical practice at the study hospital is similar to that occurring in
other health care facilities, it is likely that the ratios of costs incurred by infected
compared to uninfected patients derived from the statistical analysis, reflect
those occurring in adult non-day case patients admitted to the same specialties
at other NHS hospitals. Additionally, since the study hospital was not dissimilar
to other district general hospitals it is also likely that the estimates of the
additional costs of HAls are also broadly generalisable to other health care
settings.
If it is accepted that the results are generalisable to other settings this
represents a major strength of the study design facilitating the wider application
and use of the study results. For example, they can be used in economic
models to assess the burden of HAl occurring in a specified population of
patients from similar speCialties, and when used together with data on the cost
and effectiveness of infection control practices, the results can be used to
estimate the potential benefits of investment in infection control. Predictive
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models can be developed and the results of such models can subsequently
contribute towards decisions about the allocation of resources to infection
prevention and control and the nature of infection control programmes.
11.4 Limitations
Whilst recognising the strengths of the study, the results should be interpreted
in the context of the limitations of the methods used. These limitations relate to
a number of factors that are discussed below.
11.4.1 Thestudy was limited to one hospital
As acknowledged above in section 11.3.5 the study was limited to one hospital.
Inevitably this potentially has implications for the generalisabily of the results.
Ideally a number of randomly selected hospitals would have been included
allowing for inter-hospital comparisons to be made and the generalisability of
the main results to be assessed. Resource constraints prohibited such an
approach. Nevertheless it should be noted that the hospital selected was not
dissimilar to other district general hospitals in England and as such, whilst the
inclusion of a number of hospitals would have been preferable, the limitations of
just one study site are not as marked as they might have been.
11.4.2 Limited to adult non-day case patients admitted to selected
surgical specialties
The estimates derived in this study reflect the incidence and economic burden
of HAls occurring in adult non-day case patients admitted to five surgical
specialties of a district general hospital. The burden imposed by infections
occurring in excluded patient groups may differ from these estimates. In some
cases the costs may be considerably higher than those estimated here. For
example, the cost of HAls occurring in patients who have received cardiac
surgery may be considerably higher. Other excluded groups include neonates;
paediatrics; day cases; and patients admitted to bums, oncology, dialysis, and
neurosurgical units. Whilst focussing on this patient group represents a
limitation of the study, it should be noted that the speCialties included are
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common to most NHS hospitals and that patients admitted to these specialties
account for a substantial proportion of NHS admissions. In 1994/5 patients
admitted to the five surgical specialties covered in this study accounted for 35%
of all adult non-day case admissions.221
11.4.3 Potentialpatient selection bias
Selection bias occurs if patients successfully recruited into the study are
systematically different from those who were not recruited.246 In this study
failure to invite all eligible patients to partiCipate in the study and patient refusal
are two areas that potentially may have introduced some bias.
As far as possible the research assistants attempted to invite all eligible patients
(i.e. patients who met the inclusion criteria) to participate in the study.
However, for a number of practical reasons this was not always possible.
Time constraints were a key limiting factor. The research assistants were
required to collect a vast amount of data on each patient successfully recruited
into the study. In order to ensure a complete data set was obtained for all those
recruited it was not possible to attempt to recruit all eligible patients. Another
constraint was that at times it was not possible to identify a suitable time to
approach eligible patients and invite them to participate.
Failure to recruit all eligible patients is not in itself a problem, providing that the
cohort of patients not invited to partiCipate, are similar to those who were invited
to partiCipate. However, the risk is that those patients not invited to participate
in the study differ from those invited in some important respect. For example
due to time pressures it is possible that the research assistants may have
consciously, or subconsciously, elected to recruit patients who were perhaps
not as acutely ill, in preference to those who were acutely ill. Such patients are
likely to have been easier to recruit and, following recruitment may have
resulted in less data collection that the sicker patients. Furthermore, it is likely
that the less acutely ill patients are more readily available for recruitment than
those who are acutely ill. Many of the sicker patients may have been engaged
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with medical and nursing staff when the research assistants were trying to
recruit patients, thus prohibiting recruitment at that time. However, it should be
noted that if these and/or other differences were present they are not likely to
have major implications unless the differences are unequally distributed
between infected and uninfected patient groups. If those patients who were not
invited to participate in the study differed in important respects to those who
were invited, and these differences were concentrated in what would have been
the 'infected' or the 'uninfected' patient group had they been recruited, failure to
recruit all 'eligible patients will have implications for the representativeness of
the results. However, if these differences are equally distributed between the
intended 'infected' and 'uninfected, patient groups had all eligible patients been
recruited, the implications for the representativeness of the results obtained are
likely to be minimal.
It is possible that many of the anticipated differences between patients invited to
participate in the study and those not invited may have had impact on the level
of resource use and in tum may have been unequally distributed between
infected and uninfected patients. For example, it is possible that patients who
were acutely ill on admission, may in some cases have utilised more resources
than the less acutely ill, and may also have been at greater risk of infection.
Had they been recruited these patients may have been concentrated in what
would have been the 'infected' group. Consequently, failure to recruit these
patients may have introduced bias into the results obtained.
Refusal to participate in the study may also have introduced some bias. Overall
5.6% of patients refused to participate. Their reasons for doing so varied.
Some patients had an inherent distrust of research studies and simply did not
want to be involved. Others were concerned about the time implications for
themselves as partiCipants (the underlying study required a proportion of
patients to complete a post-discharge questionnaire). Again if differences were
present and these were unequally distributed between what would have been
the 'infected' and 'uninfected' patient groups, then this again would have
introduced some bias into the results.
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A number of steps were taken to minimise and monitor this risk of selection
bias. The importance of minimising this risk was discussed with the research
assistants prior to the start of data collection; appropriate recruitment training
was given and the research assistants were required to record base line data
on those patient they were unable to recruit. This included details of age group,
admission specialty and type of admission. The age group, admission specialty
and admission type distributions of recruited patients and eligible patients who
for practical reasons were not invited to participate and patients who refused
participation were subsequently compared. Whilst some differences were
observed, these were not marked. As such it can be concluded that on the
basis of these factors the recruited sample was fairly representative of the wider
eligible population group at the study hospital. However it is possible that there
may be other systematic differences between those invited to participate and
those who were not invited or refused partiCipation, which are not accounted for
in this analysiS.
11.4.4 Limited to the assessment of the Incidence of HAis presenting
during the In-patient period
This thesis was limited to the estimation of the incidence of HAls presenting
during the in-patient period. Infections acquired in hospital but presenting
following discharge were not included. As such the results presented are
inevitably an underestimate of the 'true' incidence of HAl. The results of the
study to which this work is linked suggest that infections presenting in the
community are a considerable problem.2 The study found that 19% of patients
who, at the time of discharge were classified as not having an infection.
reported signs and symptoms suggestive of an infection occurring within four
weeks of discharge from hospital. Of those patients who had an infection
identified in hospital 30% reported signs and symptoms suggestive of an
infection occurring within four weeks of discharge. It was not clear whether
these infections represented a new problem or a continuation of the infection
first identified in hospital. Other studies have also highlighted this problem.
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Studies examining the incidence of SWls presenting post-discharge indicate
that anything from 20 -86% of SWls present post-discharge.98 99 65 100-102247 57 74
103-105
When considering the magnitude of the problem of HAl the fact that the
incidence of HAl observed in this study was limited to infections presenting
during the in patient period and that more infections may have presented post-
discharge should be borne in mind.
11.4.5 Strict crlterla for Identifying surgical wound Infections
As indicated above in section 11.3.2 one of the strengths of this study was the
use of previously validated definitions of infection. However, it should be noted
that the definition for SWI was rather strict. The definition used stated that there
needed to be a purulent discharge from the wound plus or minus a range of
symptoms. Whilst this definition probably ensured that there were few false
positives, it also probably led to a number of false negatives and as such an
under-estimation of the incidence of SWls. The need for a purulent discharge
to be present is likely to have resulted in a number of patients being
misclassified as uninfected patients. The research assistants reported that in a
number of cases patients who were pyrexial, and had a red and inflamed wound
area were treated as if they had an infection with initiation of antibiotic therapy.
The surgical team did not wait for a purulent discharge to develop before
prescribing antibiotics. This was particularly noticeable amongst orthopaedic
patients where the consequences of an infected wound can be particularly
severe. For example, a SWI following a total hip replacement could quickly
develop into an infected prostheSiS requiring revision of the hip replacement.
Thus, as indicated above, the research assistants reported that antibiotics were
frequently prescribed prior to the development of purulent discharge.
Consequently, the incidence of SWI in this study is likely to be an underestimate
of the 'true' incidence of this type of infection, and as such the overall estimate
of the incidence of HAl is also likely to be an underestimate. The cost estimates
may also be underestimated. If a proportion of infected patients were
misclassified as uninfected, and resource use amongst these incorrectly
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classified patients was higher than uninfected patients, then the effect would
have been to increase the average cost of uninfected patients and reduce the
ratio of increase in costs amongst infected patients and the estimates of the
additional costs incurred.
11.4.6 Incomplete data on the pathogens Involved.
The results of the underlying study indicated that data on pathogens involved
were only available for 50% of infections identified.2 Given the paucity of data,
it was realised at the outset that an analysis of the impaet infections involving
specific pathogens or groups of pathogens had on hospital costs was likely to
be beyond the scope of this thesis. This was borne out by the data: less that
50% of infections occurring in surgical patients had a pathogen identified. The
study's inability to estimate the incidence of specific types of infection defined
by causative pathogen, and the impact they have on resources used,
represents a limitation of this study, and is an area requiring further study. It is
likely that the cost of infections will vary depending on the pathogen involved,
with the greatest costs resulting from infections involving antibiotic resistant
pathogens. If this is considered to be the case, future work should perhaps
focus on this.
11.4.7 Incomplete data on risk factors for HAl
This study is linked to a wider study of the socio-economic burden of HAl in
adult non-day case patients admitted to both medical and surgical specialties of
a district general hospital. The underlying study, was primarily concerned with
the economic burden infections imposed, and not the identification of risk
factors for these infections. However, at the outset it was acknowledged that if
possible it would be desirable to collect data on risk factors for HAls. At the
same time, the need not to over burden the research nurses with excessive
data collection requirements was appreciated. However, since the decision was
taken to adopt a very detailed approach to identifying and costing resources
used by infected and uninfected patients, it transpired that the planned
collection of data on resource use also represented data on risk faetors. For
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example, data on the use of intravenous lines and urinary catheters not only
provided data on the resources used but also the presence of two important risk
factors for HAl. Similarly data on case-mix (age, sex, diagnosis, number of co-
morbidities), which was essential for the attribution process also provided
important risk factor data. However, the collection of some of the planned data
caused problems for the research assistants. The volume of data required was
considerable and the availability of some of the data varied. Whilst the research
assistants encountered few problems when collecting data on case-mix, and
key items of resource use (e.g. catheters and drains), problems were
encountered when collecting operation data. The collection of data on
operations undertaken did not present any problems. However more detailed
information such as the length of time on the operating table, the grade of the
surgeon who performed the surgery, and the ASA grade proved more difficult to
obtain. The research assistants were instructed to obtain this information from
the operating directorates audit data collection form. During the first few
months of the data collection period no major problems were encountered. The
form was readily available and generally well completed. However, over time
the availability and the completeness of these forms decreased. A change of
management may in part have been responsible for this decline. At the outset
the manager of the Operations Directorate had an active interest in the data
recorded on these forms that was subsequently used for audit purposes.
However, this interest declined follOwing a change in management. The
resulting effect was incomplete data for a number of variables, which in tum
reduced the ability to conduct risk factor analysis.
As such, when considering the results of the analysis that examined how the
incidence of HAl and specific types of HAl varied with selected risk factors, it
should be borne in mind that the range of factors included in the analysiS were
out of necessity limited to those for which data had been collected in the
underlying study and for which there were complete data sets. Incomplete data
particularly affected the analysis examining how SWls varied with selected
factors. Ideally additional factors would have been included in the analysis such
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as data on the time the patient was on the operating table, grade of surgeon
and ASA score. Thus whilst the results clearly show how the incidence varied
with the factors included in the analysis, there may be other factors not included
in the analysis which represent a more substantial risk factor for these
infections.
11.4.8 Theuse of average costs
As detailed in section 11.3.3 this study adopted a very detailed approach to
valuing resources used. As far as possible the costs allocated to individual
patients reflect individual resource use. However, for some components of cost
it was not possible to adopt such a detailed approach. For example. the cost of
medical care did not reflect the actual amount of care administered to individual
patients every day. An average cost per day was derived and allocated to
patients on the basis of the number of days they remained in hospital.
Resource constraints prohibited a more detailed approach. A more detailed
approach to costing medical care, resulting in cost estimates which reflected the
amount and type of medical care individual patients received on a daily basis
would have required detailed time and motion studies: an approach that was
beyond the scope of this study.
11.4.9 Attribution of resources used and costs to HAl
This study utilised statistical modelling techniques to assess how much of the
observed variation in resource use and costs could be attributed to the
presence of one or more HAls. The strengths of this approach have been
discussed in some detail above (section 11.3.4). In this section some of the
limitations of the approach are described.
One of the immediate problems encountered is deciding what factors in addition
to HAl status should be included in the analysis. The following were selected:
age, sex, type of admission, admission specialty, and number of co-morbidities.
These factors were considered to be influential in determining resource use.
Single and multi-variable analysis indicated that total costs and LOS varied with
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all these factors. However, whilst these variables were considered to be key,
the possibility exists that there may be other factors that were excluded from
this analysis which are better predictors of LOS and costs and this may have an
impact on the estimates of the impact of HAlon total costs and LOS derived
from the modelling analysis. However, unless these factors existed and
influenced either the 'infected' or 'uninfected group' more than the other they will
not have eaused systematic biases.
11.4.10 Thestudy was limited to the estimation of the costs to the
hospital sector
This thesis has focussed on the economic burden HAls place on the hospital
sector as a result of additional in-patient treatment and eare. No attempt has
been made to assess the economic burden placed on the health sector (primary
and secondary) post-discharge; on the patient concerned and their family and
friends; or on the economy as a whole. These latter areas represent important
cost centres. Focusing on the hospital alone inevitably ean only provide a
partial picture of the full costs that result from HAls. In some eases patients
identified as having acquired an infection, may be discharged from hospital and
followed up in the community, imposing costs on the primary, and in some
eases secondary, health eare sector, if a greater number of out-patient visits
than would have been the ease in the absence of infection are required, or if the
patient requires re-admission. Patients and earers may also experience
increased costs. In other cases patients may not present with an HAl until after
they have been discharged from hospital. Over recent years patient admissions
have decreased in length, with patients discharged into the community at an
earlier point in their recovery. Whilst in some respects this reduces the risk of
acquiring an infection (the patient is not in hospital so long) it is not clear by how
much the risk is reduced. The patient may have been exposed to many of the
key risk factors during their short admission. In this study 29% of patients
acquired an infection within the first four days of their admission and over 50%
within the first six days. Consequently, it would appear that many of the major
risks are encountered during the first few days. As such a policy of early
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discharge may result in an increased likelihood of the infection presenting post-
discharge. In such cases this may result in additional cost to the health sector
in the community, and family and friends. In other cases, where costs are not
increased, it may represent unmet need.
Estimation of the burden to these other areas was beyond the scope of this
work. When considering the results of this work and their implication for the
health service, costs falling on these other areas should be borne in mind.
11.4.11 Thestudy was limited to the estimation of the economic burden
of HAl
This study was primarily a cost of illness study and as such represents what
Drummond refers to as a partial economic evaluation.162 Estimation of the
benefits of investing in activities that are directed towards preventing these
infections was beyond the scope of this study. As such the results cannot be
used to directly inform policy on the level of investment in infection control that
should be made. However, the results do serve to highlight the magnitude of
the burden these infections place on scarce hospital resources, and the gross
benefits of prevention should these infections be prevented, in terms of the
average value of resources that would be released if an infection was
prevented. Furthermore, as detailed in Chapter 10 simple models can be
developed from which estimates of the burden of HAl in a defined population,
and the estimated gross benefits that would arise if a proportion were
prevented, can be derived. More detailed models which utilise additional data
on the cost and effectiveness of prevention activities, can subsequently be
developed to estimate the net benefits of prevention. The results of such
models can be used to inform and contribute to decision making regarding the
allocation of resources to infection control and the nature of infection control
programmes.
326
11.5 Methodologicalconsiderations
The methods employed in this study raised a number of practical difficulties,
some of which are discussed in the following sections.
11.5.1 Recruitment
The recruitment of patients into this study presented a number of difficulties.
Patients were recruited into the study by a research assistant, who adopted the
following procedure. The research assistant would explain the study to the
patient, ask the patient if they would be willing to participate in the study, and
subsequently leave them with an information sheet and retum at a convenient
time to see if they were willing to participate. The main problem associated with
this procedure was the fact that the research assistant had to introduce the
topic of HAl at a time when frequently patients were anxious about their
admission and proposed treatment. Many patients were unaware of the
problem of HAl, and as such were rather alarmed to hear that whilst in hospital
they might acquire an infection. This recruitment 'problem' was acknowledged
at the outset and first experienced when conducting the pilot study. In order to
overcome this and reduce the anxiety that patients may experience a number of
steps were taken. Measures were taken to ensure that all ward staff and
medical staff were aware of the study; posters were placed in aU wards
informing patients and relatives that a study was taking place; the study
received some media coverage at its official launch, thus raising awareness of
the issue; and the research assistants all received training in communication
skills and recruitment procedures from myself and importantly from a trained
communication expert. The aim was to equip the research assistants with the
necessary skills to manage the recruitment process in a way that minimised
anxiety yet kept patients informed of all relevant factors. It was important that
all steps were taken to ensure that patients could make an informed choice
about whether to partiCipate in the study, whilst at the same time not causing
undue anxiety and stress. These procedures appeared to be effective. Whilst it
did not eliminate the difficulties associated with this procedure, the measures
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were successful in helping and equipping the research assistants with the skills
necessary to carry out this task.
11.5.2 Difficulties associated with conducting research In a clinical
context
Conducting research in a clinical context presented a number of practical
difficulties. These difficulties primarily related to the relationship between the
patient and research assistant. All the research assistants were qualified
nurses. a factor that whilst helping them to fulfil their role. also presented its
own difficulties and conflicts.
As discussed in section 11.5.1 there were a number of difficulties associated
with recruiting patients. in particular problems relating to raising the issue of the
possibility that the patient might acquire an infection in hospital. The most
recent UK prevalence study indicated that at anyone time an estimated nine
per cent of hospital in-patients have an infection that they acquired whilst in
hospital.7 For many patients this proved to be quite an alarming statistic.
In addition to these problems. there was the issue of confidentiality. Patients
were assured that any information that they provided would be treated as
confidential. A standards document was drafted which outlined procedures with
respect to the handling and storage of patient data which all the research
assistants and other members of the team were required to read and sign up to
prior to the start of data collection (see Appendix 2). However. occasionally
situations arose when a patient would tell the research assistant something
directly relevant to their condition and circumstances. which ideally medical and
nursing staff needed to know. This placed the research assistant in a difficult
position. The research assistant was obliged to maintain the patients
confidentiality. However. at the same time the research assistant was acutely
aware of the need to inform nursing and medical staff. Such situations had to
be handled with great care and sensitivity. In all cases the research assistant
successfully persuaded the patient through reasoned discussion that they
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should inform a member of medical or nursing staff. Additional training was
given to the research assistants to help with situations such as these.
As indicated above the research assistants were all qualified nurses, a fact
which undoubtedly helped them in their role. However, from their perspective,
this often gave rise to conflict between their previous nursing role and their
newly acquired research role. Support was given to help them to adapt to this
different role, and develop boundaries that enabled them to fulfil the
requirements of their research assistant role.
11.5.3 Quantity of data required.
The data requirements of this study were large. The research assistants were
required to recruit patients into the study, obtain base line case-mix and
demographic data, and then collect detailed data on the resources used by
individual patients each day, whilst at the same time undertaking surveillance
for all types of infection. In addition to this, although not related to the analysis
presented in this thesis, they were also required to collect data from primary
health care records. In order to collect this data successfully and ensure
complete data sets, the research assistants were unable to recruit as many
patients as they had wished. This trade off between data quality and number of
patients recruited was discussed on many occasions. At all times the priority
was to ensure full data sets.
11.6 Implicationsof resultsfor policy
The results of this study have important implications for policy and practice.
The results reinforce the findings of earlier studies that these infections affect a
considerable number of people and place a substantial burden on scarce
hospital resources. Whilst it is acknowledged that inclusion of just one hospital
may be viewed as a limitation of the study design, for the reasons discussed in
section 11.3.5 the results of this study are likely to adequately reflect the ratio of
increase in resource use and costs incurred by infected compared to uninfected
adult patients admitted to similar specialties within other NHS facilities, the
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additional costs incurred and number of extra days infected patients remain in
hospital, and to some extent the incidence of HAl.
The results of this study not only provide important data on the incidence of
HAls and the burden infections place on limited health sector resources, but
also the gross benefits that might result if infections were prevented: that is the
value of resources that might be released for alternative use if infections are
prevented. Whilst not all HAls are likely to be preventable, there being what
Ayliffe163 described as an 'irreducible minimum' it is clear that a proportion can
be prevented. The results of a National Audit Office survey provide some
insights into the proportion of infections that infection control teams consider
could be prevented through improvements in infection control. The proportion
of infections considered preventable varied between hospitals from a low of 5%
to over 35%, with a bed weighted average of 15%.3 The results presented in
Chapter 10 indicate that if the results of this study are extrapolated to aUadult
non-day case patients admitted to the specialties covered in this study at the
study hospital, it follows that a 15% reduction in rates would result in the
prevention of 87 (95% Cl: 75, 100) HAls and the release of resources valued at
£183,607 (95% Cl: £134,761, £232,452) for alternative use. These released
resources would include 646 (95% Cl: 459, 834) bed days freed up for
alternative use. Applying the results to a wider population of all adult non-day
case patients admitted to similar specialties at other NHS hospitals throughout
England in 1994/5, indicated that a 15% reduction in rates would result in the
prevention of 23,238 (95% Cl: 20,104, 26,691) HAls and the release of
resources valued at £49.17 million (95% Cl: £36.09, £62.25 million) for
alternative use. This estimate includes 173,059 (95% Cl: 122,853, 223,265)
bed days released for alternative use.
These results clearly demonstrate that prevention of infections would result in
the release of considerable hospital resources for alternative use. These
benefits may be considered to be the gross benefits of prevention, with net
benefits dependent on the cost of achieving a reduction in rates. Estimation of
330
the net benefits of investment in infection control was beyond the scope of this
work. However. as indicated in Chapter 10. the results of this study can be
incorporated into economic models. together with data on the cost of infection
control practices. to derive estimates of the net benefits of investing in infection
control given various levels of effectiveness. The information generated by
these models can subsequently be used to assist decision making regarding the
allocation of resources to interventions to prevent and control infection. Models
can be developed for a range of different activities. For example, models can
be developed that assess the net benefits of investing in a comprehensive
infection control programme, employing an additional infection control nurse, or
investing in a particular piece of equipment thought to reduce the risk of
infection. These models may relate to the prevention of all types of HAl or
specific types of a HAl in a selected patient group or a wider patient population.
The results of the analysis that examined independent risk factors for HAl also
have important implications for policy and practice. The results indicated that
the risk of acquiring an HAl varied with both intrinsic and extrinsic risk factors.
For example, the results of the analysis that examined independent risk factors
for UTls indicated that there were a number of intrinsic risk factors including sex
(women had a greater risk of acquiring a UTI than men) and increasing age (the
risk increased with age). The analysis also identified an extrinsic risk factor: the
presence of a urinary catheter prior to the onset of infection. The presence of a
urinary catheter was found to increase the risk of acquiring a UTI by almost
three fold. Whilst it is acknowledged that the analysis was limited to a few
selected potential risk factors for which data were available, the results still have
important implications for policy and practice.
Information on independent intrinsic and extrinsic risk factors provides important
data about which patients might be at greater risk of acquiring an infection. This
information can be used by nursing and medical staff when planning and
implementing care. For example. as indicated above the presence of a urinary
catheter was found to significantly increase the risk of acquiring a UTI. thus
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reinforcing the findings of earlier studies.1 134 137138 143144 In terms of their
implications for policy and practice, the results point to the need to question the
need for catheterisation in individual patients. The results of an audit of
infection control policies and practices in 19 hospitals in England and Wales
indicated that catheterisation rates in patients admitted to similar specialties at
these 19 hospitals varied considerably.1 For example, amongst gynaecology
patients, the catheterisation rate varied from 21% to 72%. Whilst some of this
variation in rates may reflect case mix differences, such differences are unlikely
to account for all the variation observed. Thus since catheterisation is a
significant risk factor, the decision about whether to catheterise a patient should
be taken carefully. When in use, care should be taken to minimise the risk of
infection through the use of an appropriate catheter and appropriate catheter
care. Where this involves additional resources, models can be developed that
can provide important data on the costs and benefits of investment in a
particular strategy and the results used to inform decision-making. In Chapter
10 an illustrative model was presented which demonstrated that investment in
silver-alloy coated catheters resulted in positive retums at relatively low levels of
effectiveness. Finally the results can be used to stimulate further research into
the prevention of infections. That is the identification of key risk factors may be
used to focus research into areas that can reduce the risk of these key
independent factors.
The results of this study therefore have a number of implications for policy and
practice. The results highlight the magnitude of the problem of infection in
terms of the number of patients affected and the costs that fall on the hospital
sector; they represent the potential gross benefits of prevention and when used
in conjunction with data on the cost of prevention strategies they can be used to
estimate the potential net benefits of investment in infection control.
These findings are of relevance to policy makers and health care professionals
working at different levels in the health service. By demonstrating the
magnitude of the problem, the results may help to keep the problem of HAlon
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the Department of Health's policy agenda and through various initiatives also on
the agenda of hospital trusts and health care professionals. The results may be
used to raise awareness of the problem and when used in conjunction with data
on the cost of prevention strategies may be used to inform decisions about how
much should be invested in infection prevention and control and the nature of
the programmes themselves.
11.7 Areasfor future research
Several areas for future research were identified which would enable a more
comprehensive understanding of the burden imposed by HAls occurring in
surgical patients. The focus of this study was the incidence of HAls occurring in
adult non-day case patients admitted to five surgical specialties common to
most hospitals, and the economic burden these infections placed on the
hospital sector as a result of additional in-patient care. Further work is now
needed to assess the incidence of HAls presenting after discharge from hospital
and the economic burden infections presenting during the in-patient period
and/or post-discharge place on the primary and secondary health care sector
following discharge from hospital.
Another area for future research concerns the estimation of the benefits of
investment in infection control activities. The research reported in this thesis
was limited to the assessment of the economic burden HAls placed on the
secondary health sector as a result of additional in-patient care. As such the
results presented represent the gross benefits of prevention. Net benefits will
be dependent on the cost of effective infection control activities. Assessment of
the net benefits of investment in specific infection control activities was beyond
the scope of this study. However, a framework for assessing the net benefits of
investment in specific prevention activities was presented in Chapter 10. This
modelling framework needs to be further developed to establish the benefits of
investment in various infection control activities, the results of which may be
used to inform decisions regarding the allocation of funding and the nature of
infection prevention activities.
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Other areas for future research include the assessment of the incidence and
cost of infections involving specific pathogens or groups of pathogens and the
incidence of HAls occurring in omitted patient groups and the economic burden
imposed. Omitted surgical groups include patients admitted to the renal,
cardiac, plastiCS, paediatrics, neonates and bums specialties; and day cases.
The burden imposed by HAls occurring in some of these omitted groups is likely
to be substantial.
11.8 Conclusion
The problem of HAl has attracted considerable research interest in recent
years. The results of this study add to the current body of knowledge providing
detailed data on the incidence of HAl occurring in adult patients admitted to five
surgical specialties common to most hospitals, risk factors for these infections
and the economic burden these infections place on the hospital sector as a
result of additional in-patient care. Overall 7.5% (95% Cl: 6.40/0, 8.6%) of adult
patients admitted to selected surgical specialties of a district general hospital
acquired one or more HAls that presented in hospital. Independent risk factors
for these infections were found to vary with site of infection. These infections
were found to increase resource use. On average infected patients had a LOS
2.1 (95% Cl: 1.8, 2.5) times that of uninfected patients and utilised resources
valued at 2.3 (95% Cl: 2.6, 3.0) times those used by uninfected patients. HAls
were estimated to prolong the hospital stay by 7.8 days (95% Cl: 5.7, 10.0) and
increase hospital costs by £2,254 (95% Cl: £1,738, £2,770) per case. Whilst
the results of this study reflect the experience of patients admitted to just one
hospital site, for reasons discussed in section 11.3.5 it is likely that the results
are generalisable to other heath care settings in the UK.
The results of the analysis that estimated the burden of HAls occurring in
patients admitted to the specialties covered in this study at other NHS hospital
in England, provide important data on the magnitude of the problem at the
National level. An estimated 154,920 (95% Cl: 134,024 to 177,943) adult non-
day case patients admitted to the Specialties covered in this study at other NHS
hospitals in England acquired one or more HAls in 1994/5, utilising 1,153,726
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(95% Cl: 819,019 to 1,488,434) additional bed days and, as a result of
additional in-patient care, cost the health sector an additional £327.77 million
(95%CI: £240.58 to £414.98) with further costs borne by the primary health care
sector, patients and carers.
The results of this study have important implications for policy and practice.
The estimates demonstrate both the substantial burden these infections place
on limited heath sector resources and at the same time the gross benefits of
prevention. It is acknowledged that not all HAl can be prevented. However a
proportion can. The results of a recent NAO survey of ICTs suggested that a
15% reduction in rates could be archived through improvements in infection
control. If this were achieved then at the National level resources valued at an
estimated £49.17 million (95% Cl: £36.09 to £62.25 million) and 173,059 bed
days (95% Cl: 122,853 to 223,265) may be released for alternative use. These
estimates represent the potential gross benefits of prevention. The net benefits
will depend on the cost and effectiveness of infection control activities.
Estimation of these net benefits was beyond the scope of this study. However a
framework for assessing net benefits was presented and it is concluded that
after taking into account the costs of prevention activities it is likely that in many
cases a considerable level of resources would be released for alternative use.
The results of this study thus demonstrate that a substantial number of surgical
patients acquire an infection in hospital and that these infections place a
considerable burden on limited heath sector resources. The findings are of
relevance to health care professionals and policy makers. They serve to raise
awareness of the magnitude of the problem of HA" and the potential benefits of
prevention, and when used in conjunction with data on the costs of prevention
strategies may be used to inform decisions about how much should be invested
in infection prevention and control and the shape of infection control
programmes. If improvements in infection control, and a reduction in rates
follow, this is likely to result in the release of considerable resources for
alternative use and most importantly improved patient outcomes.
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APPENDIX 1
Research assistant training and seminar programme
Ai.i Introduction
This appendix contains details of the research assistants' training and seminar
programme.
Ai.2
Ai.2.i
Training programme
Aim
To enable the research assistants to futfill their role in the study by providing
them with the necessary information and enabling them to develop the
appropriate skills
Ai.2.2 Learning outcomes
At the end of the indudion programme the research assistant will;
1. Understand the epidemiology of HAls, how the cost of HAl has been
studied in the past and some principles of infection control including the
surveillance of HAl.
2. Understand the study methods and how the data colledion will be
organised.
3. Be able to discuss the project with patients and ask for their consent to
be included in the study.
4. Be able to coiled relevant information from clinical records and complete
the data colledion forms.
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s. Be able to use the surveillance methods to identify patients with an
infection.
6. Know how to enter data onto the database and validate some of the
information.
7. Know who they should contact, and how to contact them if they
encounter difficulties or need advice.
8. Understand the principles of the Data Protection Act and the standards of
record keeping expected of them.
9. Understand their terms and conditions of service.
10.Be familiar with the areas they will be working in, and emergency
procedures.
A.1.2.3 Areascovered:
Over the course of three weeks the following areas were covered:
1. Personnel issues: terms of service, disciplinary procedures.
2. The study site: the layout of the study hospital; hospital policies; library
services.
3. Emergency procedures: fire; cardiac arrest and security procedures.
4. Aims and objectives of the study and envisaged benefits.
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5. Study methods: recruitment, informed consent, patient confidentiality, the
Data Protection Act and Standards for record keeping, surveillance methods,
other data collection procedures (in-patient and post discharge phase), data
coding, data entry, filing systems.
6. Basic health economics: costs arising from HAls; valuing the cost of
resources used; methods used to attribute resource use to the presence of
an HAl.
7. Organisational issues: wards responsible for; introduction to ward areas;
organisation of workload; time management; who to contact if there is a
problem; where to find information of relevance to study; how to order
stationary and other supplies.
8. Importance of accurate data collection.
9. Adapting to a new role and ethical issues
• What to do if asked to help out on a ward.
• What to do if you see something being done that you believe to be
wrong or unethical.
• What to do if a patient tells you something in confidence that you
believe a member of the medicaVnursing staff should be aware of.
• What to do if a patient does not want to take part in the study - how
to make them feel comfortable with their decision not to participate.
10. Importance of the Research Assistant's role in the study,
The programme commenced on the 14" March 1994 and was delivered over a
three-week period. Much of the training was delivered by the project c0-
ordinator, with specialist sessions given by experts in the relevant field. For
example, Helen Glenister (member of the steering Group) ran a one day
workshop on surveillance of HAl. The Senior Infection Control Nurse from the
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study site discussed infection control issues and the organistation of infection
control services within the Trust. Nick Graves (research economist) gave a
couple of sessions on the economies of HAl. Jennie Wilson (Member of the
steering Committee) assisted in a couple, of sessions that considered the
research assistant's new role and ethical issues that might arise over the course
of the study. A Mental Health Services Manager ran a session on
communication skills, and obtaining informed consent. The Trust's Community
Liaison Nurse Manager ran a session which discussed the organisation of
district nursing services in the area. Lynda Taylor (Steering Committee
Member) provided an overview of the Public Health Laboratory Services. Over
the course of the three week programme the research assistants visited the
wards they would be working on, met with ward staff and familiarised
themselves with the ward setting. The research assistants also visited a local
GP practice. Finally the research assistants went on a weekend team building
training programme. The latter was an outward-bound training programme that
encouraged team building skills.
The programme was accompanied by a reader, which contained copies of key
papers and a list of additional recommended references and journals. Papers
addressing the following topies were included: incidence and prevalence of HAl;
surveillance; risk factors for HAl; infection control; and the economic burden of
HAl.
A1.2 SeminarProgramme
The seminar programme covered the following areas: epidemiology of HAl,
surveillance and infection control; financing and health care; research methodology;
research and health policy; and health care evaluation. The programme was as
follows.
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Dr Rachael Joce
12.7.94 Dr Dianna Barry
26.7.94 Dr Barry Cookson
9.8.94
Flnanclna a !1d•• ... Health Ca,.
23.8.94 Financing health care - the alternatives RosPlowman
6.9.94 The NHS and the NHS reforms Dr Jenny Roberts
20.9.94 Contracting in the NHS Jane Bandcroft
4.10.94 Recent Reforms and Primary Care - The District nurse
District Nurses Perspective
18.10.94 The project - NHS applications Nick Graves
Re.earch Methodology
1.11.94 Research methods Dr Mike Rowland
15.11.94 Costing Methodology Nick Greves
29.11.94 Statistics made easy - part 1 Mark Griffin
13.12.94 Statistics made easy - part 2 Mark Griffin
- .L altd • I ....... - .1'
28.2.94 Does research affect policy? If 10 how? DrAZwi
31.1.95 Research, Polley and the DOH perspective Dr E Meerabeau
I~::g:::
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APPENDIX2
Standards for Reeords and Record Keeping. Socio-economic Burden of
Hospital Acquired Infeetlon
1. Introduction
1.1 This paper sets out the standards to be applied to ensure confidentiality of
patient centred data for the Socio-economic Burden of Hospital Acquired
Infection study.
1.2 Nurses have a responsibility to adhere to the United Kingdom Central
Council for Nursing. Midwifery and HeaHh Visiting 'Code of Professional
Conduct for the Nurse, Midwife and HeaHh Visitor' Standards for records
and Record Keeping and abide by the following principles:
"As a registered nurse, midwife or heaHh visitor you are personally
accountable for your practice and, in the exercise of your professional
accountability. must:
1. act always in a manner as to promote and safeguard the interests
and well-being of patients and clients;
2. ensure that no action or omission on your part, or within your sphere
of responsibility, is detrimental to the interests, condition or safety of
patients and clients"
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2. Maintaining Patient Confidentiality
2.1 Each patient that participates in this study will be identified by a unique
study number. This number will be the only form of patient identification
included in the computer held database.
2.2 Access to these patient data record files will be restricted to individuals
named in Appendix A.
2.3. Personal details such as a patient's name, address, telephone number and
hospital number will be stored in a separate file held on computer and on
paper stored in a locked filing cabinet. within a locked room at the study
hospital, or at the LSHTM or CPHL. CPHL has a secure perimeter fence
and 24 hour security. The LSHTM has 24-hour security. Access to this file
will be restricted to the individuals listed in Appendix B.
2.4 It will not be possible to access records held on computer without the use
of a password. (Separate passwords will be required to gain access to the
patients data record files and the patient personal detail files). Passwords
will be changed periodically.
2.5 The project computers will be held in a locked room. Only individuals listed
in Appendix A will be allowed access to the project computer.
2.6 Data exported for analysis will be entered onto designated computers at
(LSHTM). Colindale has a secure perimeter fence and 24 hour security.
The LSHTM has 24 hour security.
2.7 Access to the computers held at CoIindale and the LSHTM will be
restricted to individuals listed in appendix A.
2.8 Access to data held on these computers will be through the use of a
password which will be changed periodically.
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2.9 After completion of the research or its formal abandonment the key to the
identities of all persons involved in the research and all personal data no
longer required will be destroyed unless the Secretary of State directs
otherwise in writing. The certificate of the Secretary of State to this effect
shall be conclusive.
3. Patients Access to Records
3.1 In accordance with the Data Protection Act 1984 and the Access to Health
Records Act 1990, participants in the study have the right to see their
records. Information will only be withheld if in the view of the patients
medical practitioner its release might cause serious harm to the physical or
mental health of the patient or it would identify a third party.
3.2 If a patient requests access to their records, the request must be passed to
the project co-ordinator, who will facilitate access.
3.3 When necessary advice regarding release of data will be sought from
members of the Project Group.
4. Training of Research Assistants
4.1 The research assistants will receive training on the Data Protection Act and
their professional responsibility for record keeping during their induction
programme.
4.2 The project co-ordinator will provide additional training jf the standards of
record keeping described in this document are not being maintained.
4.3 Each research assistant will receive a copy of this document which they
should read and sign.
Slgnature .
08_ .
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APoendlxA
Individuals permitted to have access to patient records held on paper and
on computer, the room where the study computer Is held, the study
computer and the computers to be used for analysis.
Project co-ordinator
Project economist
Project statistician
Research assistants
Project secretaries
Data entry derk
Programme leader in surveillance and infection control
Statisticians from Steering Committee
Health economist from Steering Committee
ApoendixB
Individuals allowed access to the patient personal details flle
Project co-ordinator
Project economist
Project statistician
Research assistants
Project secretaries
Data entry clerk
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APPENDIX3
Presentations concerning the Socio-economic Burden of Hospital Acquired
Infection Study
Date Pre.entatlon
Sept 1993 - A number of seminars were held for clinical staff at the study hospital and
April 1994 also for district nurses within the community. The seminars provided an
opportunity to discuss the alms and objectives of the socia-economic
burden of HAl study and the methods we wished to employ. and provided
staff at the study site with an opportunity to ask questions about the
study.
Nov. 1994 Council of Europe. Strasbourg
'Economic and social aspects of hospital acquired infection. '
March 1995 Canadian Nosocomial Infection Surveillance Programme - Semi-annual
Meeting. cmawa. Canada
'Estimating the costs of hospital acquired infection. '
June 1995 University of Hertfordshire Research Leaders Forum
'The socio-economic burden of hospital acquired infection. '
Sept. 1995 Public Health Laboratory Service 20th Annual Scientific Conference
'Socio-economic burden of hospital acquired infection - An extensive
follow up survey. '
March 1996 European Infection Control Seminar, London.
'Hospital acquired Infection - how much does It cost?'
March 1996 The London Hospital Medical College. London.
'The economics of infection. '
June 1996 University of Hertfordshire.
'The socio-econom/c burden of hospital acquired infection'
July 1997 Diploma in infection control nursing - London.
'The cost of hospital acquired Infection'
Sept 1997 Infection control nurses association annual conference Swansea .
•Hospital-acqulred infection - How much does It cost and why do we
need to know?'
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Date Presentation
June 1998 Infection Control Nurses Association, Wessex Regional Group Seminar.
~n expensive business - The real cost of hospital-acquired infection'.
July 1998 The NHS Confederation 50th Anniversary Conference: The NHS: All our
tomorrows. The Public Health Laboratory Service and hospHal-acquired
infection.
'The Economic challenge of hospital-acquired infection. '
Nov. 1999 Nosocomial Infection National Surveillance Scheme, Surgical Site
Infection Annual Meeting.
'The cost of surgical site infections'
April2000 Kelsey Lecture 2000, Central Sterilising Club.
'Hospital -acquired infection - Where is the Czar?'
June 2000 Infection Control Nurses Association - London Branch.
•The socio-economic burden of hospital acquired infection'.
June 2000 North Thames (East) Microbiology Consultants Meeting.
'The price of !J9J..washingyour hand'
July 2000 The first conference of the Economics of Infectious Disease. London
School of Hygiene and TropiCal Medicine.
'The burden of hospital acquired infection'
Nov.2000 The Infection Control Nurses Association Intemational Conference.
Edinburgh
'The economic burden of hospital acquired Infection'
March 2001 Risk and Responsibilities. A conference on hospital acquired infection.
North Staffordshire Hospital NHS Trust.
'The socio-economic burden of hOSpital acquired Infection'
March 2001 Intemational Conference on The Economics of Infectious Disease,
London School of Hygiene and Tropical Medicine.
'Cost infonnation infonning policy and practice - A case study of hospital
acquired Infection'
June 2001 Infectious Diseases and Hospital Acquired Infection Guidelines - The
implementation challenge. A conference organised by the Health Studies
Department at Oxford Brooks University. and held in London.
'Socio-economic benefits of better control of h o. I aeaulred Infection'.
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APPENDIX4
Wards Involved in the Socio-economlc burden of Hospital Acquired
Infection Study
A4.1 Introduction
The Socio-economic Burden of Hospital Acquired Infection study involved the
assessment of the incidence and economic burden of hospital acquired
infections (HAls) occurring in patients admitted to eight clinical specialties,
common to most general hospital. Six research assistants were responsible for
recruiting patients admitted to these specialties and subsequent data collection.
For practical reasons it was not possible to recruit all patients admitted under
the eight clinical specialties. As such, 14 study wards were selected. Each
research assistant was responsible for the recruitment of patients admitted to
the selected study wards. This appendix provides details of the number of
wards included, their primary clinical specialty and the number and type of
wards each research assistant was responsible for.
A4.2 Wards Involved in the aocio-economlc burden of hospital acquired
infection study.
Table A4.1 provides details of the wards involved, their clinical specialty and the
number of beds on each ward. It should be noted that whilst each ward had a
primary clinical interest, in practice patients admitted under other specialties
were admitted to these study wards. Consequently, in addition to recording the
ward, the research assistants recorded the clinjcal specialty and the consultant
patients were admitted under.
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Table A4.1 Number of wards Involved In the Soclo-economlc Burd.n of HAl
study
Clinical specialty Number of ward. Total number of beds
General medicine 3* 15
General surgery 2 60
Orthopaedics 2 60
Urology 1 15
Gynaecology 1 20
Elderlv care 2 56
ENT 1 15
Obstetrics" 2 50
one ward included a 5bed coronary C8f'e unit
*0nIy those patients who had a caesarean section were eligible for reoruItment.
A4.3 Number of wards each research assistant was primarily responsible for
Table A4.2 provides details of the number of wards each research assistant
was primarily responsible for. The allocation of wards took into account both
the number of beds available on each ward and the types of patients admitted
to each of the selected wards, and the implications this might have for
recruitment and subsequent data collection.
Table A4.2 Th. allocation of wards to re•• arch a,,'stant
Research Ward. allocated Total number of beds
assistant
1 2 care of the elderfy wards 60
Obstetrics· 50·
2 , surgical ward 30
I medical ward 15
3 , gynaecology ward 20
1 surgical ward 30
4 1 uroloav ward 15
1 medical ward 30
5 2 orthoDaedic wards 60
1 ENTward 15
6 I medical ward 30
*Only those patients who had • c.... rean aection wert eligible for recruitment.
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APPENDIX5
Patient information sheet, consent forms and decline to participate form
AS.1 Introduction
This appendix contains a copy of the following documents:
a) The patient study information form.
b) The consent form administered to patients who agreed to participate in
the study.
c) The consent form administered to relatives of patients who were unable
to give their own consent to participation in the study.
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INFORMATION SHEET
COSTING INFECTIONS
A small number of patients develop an infection following hospital treatment; this can
occur whilst in or shortly after leaving hospital. The study hospital is involved in a study,
funded by the Department of Health, looking at how many patients develop such infections
and the cost of these to the health service and the patients concerned. We would be
grateful if you would take part in this study.
We would like to gather information about your condition and the treatment you receive.
This will involve looking at your medical and nursing records. After you have left hospital
we may need to contact your GP.
You may also be contacted about a month after you have left hospital to find out how you
are feeling and how you have been since leaving hospital. Any information you give us
will be kept strictly confidentiaL
Since the information we obtain from you will be treated in total confidence, and will not
be reported to your doctor or nurse, it is important that you also mention any concerns you
might have about your health and treatment to them.
We would appreciate your help with this study. If you are willing, would you please sign
the attached consent form. If you do not wish to participate, it will not affect the treatment
you are given in any way.
If you have any questions or require any further information about the study please do not
hesitate to ask (insert name) your research nurse or contact Rosalind
Plowman the Project Co-ordinator. (insert name of research nurse) will visit
the ward daily but can also be contacted on Ext. XXX at the study hospital. Rosalind
Plowman can be contacted either on Ext XXX at the study hospital or at the Central Public
Health Laboratory, London, Tel 081 200 4400 ext 4234.
Thank you for your help.
Central Public Health Laboratory, 61 Colindale Avenue, London NW9 SHT
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COSTING INFECTIONS
CONSENT FORM
I
of ------------------------------------------
agree to take part in this study looking at the extent of and cost of hospital infections. I
have read the study information sheet and understand that Ihave given my consent to the
collection of data on my condition and the treatment I receive. Whilst in hospital this
information will be obtained from my medical and nursing notes. After leaving hospital
my GP may be contacted to obtain this information.
Ialso understand that taking part in this study may involve my completing a questionnaire
one month after leaving hospital.
I understand that any information obtained from my medical and nursing notes and any
information given will be kept strictly confidential.
Patient's signature Date
Research Assistant's signature Date
Central Public Health Laboratory, 61 Colindale Avenue, London NW9 SDF
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COSTING INFECTION
CONSENT FORM
I
of
give consent that:
of
may take part in this study looking at the extent of and cost of hospital infections. I have
read the study information sheet and understand that Ihave given consent to the collection
of data on condition and the treatment he/she receives. Whilst in
hospital this information will be obtained from my medical and nursing notes. After
leaving hospital his/her GP may be contacted to obtain this information.
I also understand that taking part in this study may involve _
completing a questionnaire one month after leaving hospital.
I understand that any information obtained from my medical and nursing notes and any
information given will be kept strictly confidential.
Relative's signature Date
Relationship to patient
Research Assistant's signature Date
Central Public Health Laboratory, 61 Colindale Avenue, London NW9 SDF
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• •~----------------------------------~Ql StudyNumber ~ ---,
PATIENT DECLINES TO
PARTICIPATE IN THE
STUDY OR IS EXCLUDED
FROM STUDY
Q2 Date of admission:
o , I ,
III II··· T • •..... I " I II
Q3 Day of attempted ncndtment:
o 1 I , ••• T •• MU U
I I I II I I I I I " I
o 1 I I • • • T • •
11111111111
• tiS • • • T • •
I I I I I I I I I I I"
I I I I I I I I I I I'
Q4 Meode:
• t • • • • • T • •
I I I I I I I I I I I"
I I I I I I I I I 1It
Q5 0 Pt declines partidpation
0 Unable to recruit pt due to lack of time
0 Unable to find a suitable time to recruit pt
0 Pt too sick/next ofldn·unavaUablelinapproprlate to uk next of kin
D Pt admitted on a non-recruiting day
0 Weekend admission
Q6 Apvoup: Q7 Spedalty: Q8 Sex:
18-30 0 Surpry D Male 0
31-40 D Medicine 0 Female D
41-50 0 Care of the elderly 0
51-60 0 Orthopaedics 0
Q9 Type of admission:
Elective 061-80 0 UrololY 0
81·100 D Obs&Gynae 0
Em'l'Iln&:y 0
over 100 D ENT 0
III
SlIMly: 1 PIOtl:1
1111111111111111111111111• SCiMing by Formic Ltd, London, (+44) 0111241130 •
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APPENDIX6
Definitions of Infections presenting during the patient's hospital stay
A6.1 Introduction
The definitions of hospital acquired infections used in this study, with the exception
of the definition of a chest infection, are those developed and used in the recent
study. 'A Study of Surveillance Methods for Detecting Hospital Infections.' n
A6.2 Hospital acquired infection (HAl)
An infection found to be adive (or under adIve treatment at the time of survey)
which was not present or incubating on admission to hospital.6 Where doubt exists,
infections appearing at 72 hours or more after admission should be classified as
hospital acquired.248 249 A patient readmitted with established infection resulting
from an earlier admission is recorded as having a HAI.23 Transfers admitted from
another hOSpital with a nosocomial infection acquired there will be coded
separately.
A6.3 Community Acquired Infection (CAl)
An infedion found to be adive (or under adIve treatment) at the time of survey,
which was present or incubating on admission to hospital.250
A6.4 Criteria for Diagnosing the Presenceof Infection
There must be clinical evidence of infection except in the case of central nervous
system infections where laboratory evidence may suffice. Colonisation should be
excluded.
A6.4.1 Clinical evidence.
This includes the cardinal signs and symptoms as defined in this document which
are presented. or have been present during the patient's stay in hospital. Some
signs and symptoms may include fever E!37.aoc.261 where infection is the only
known cause, inflammation (i.e. redness, swelling. pain, heat) and the produdion of
pus.
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A6.4.2 Laboratory evidence
This is present if the results of specimens meet the criteria defined in this
document. With some infections, a clinician's diagnosis of infection based on
clinical signs and symptoms with or without laboratory evidence will be
accepted.
AS.S Dateof onset
This is the date the first dinical evidence of infection appeared, or if no signs and
symptoms are present, the date the specimen used to make or confinn the
diagnosis was collected, whichever comes first.
AS.S Urinarytract infection
AS.6.1 Patients without a urinary catheter in situ
A urinary tract infection is present if the patient has two or more of the following
signs and symptoms:
• Fever ?;37.8oC with no other recognised cause
• Urgency
• Frequency
• Dysuria
WITH OR WITHOUT
• A positive urine culture, that has ?;105colonies per ml of urine with no more than
two species of micro-organisms.
• A positive urine culture that has <105 colonies per ml of urine of a single micro-
organism in the presence of an antibiotic being given to treat an urinary tract
infection.
OR
• A positive urine culture with more than 2 species of micro-organisms identified
and the presence of 10 white blood cells or more seen on high power film.
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Note:
• If the patient is unable to communicate the above signs and symptoms a
clinician's diagnosis of urinary tract infection will suffice.
• Surveyor should note whether clinical, or clinical with laboratory evidence is
used to detennine the presence of infection.
• Infections of organs of the urinary tract (kidney, ureter, bladder or urethra)
following surgery to that area should be recorded as surgical wound infection.
A6.6.2 Patients with a catheter in situ
A clinician's diagnosis of a urinary tract infection will suffice.
WITH OR WITHOUT
• A positive urine culture, that has ~105 colonies per ml of urine width no more
than two species of micro-organisms.
• A positive urine culture that has <105 colonies per ml of urine of a single micro-
organism in the presence of an antibiotic being given to treat an urinary tract
infection.
OR
• a positive urine culture with more than 2 species of micro-organisms identified
and the presence of 10 white blood cells or more seen on high power film.
Note:
• The surveyor should note whether clinical, or clinical with laboratory, evidence is
used to detennine the presence of infection.
• Infection of the urethra occurring at the insertion site of a catheter should be
included as an urinary tract infection. The presence of the device (i.e. catheter)
should be noted.
• Infections of organs of the urinary tract (kidney, ureter, bladder or urethra)
following surgery to that area should be recorded as surgical wound infection.
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AS.7 Asymptomatic bacteriuria
AS.7.1 Asymptomatic bacteriuria
This is present if:
• There are two positive urine cultures that have ~ 105 colonies per ml of urine
with repeated isolation of the same micro-organism and no more than two
species of micro-organisms.
• The patient does not have any of the following signs and symptoms: fever
«37.8oC); urgency; frequency; dysuria.
AS.8 Infections of upper respiratory tract and 88r
A clinician's diagnosis of one or more of the following with or without microbiological
evidence of infection:
• Furuncle
• Rhinitis (infective)
• Sinusitis
• Pharyngitis
• Epiglottis
• Tonsillitis
• Otitis media
Note:
• Infection of the anterior nares surrounding the insertion site of a nasogastric
tube should be included as upper respiratory tract infection. The presence of
the nasogastric tube should be noted.
• Infections of the upper respiratory trad (ear, nose or throat) following surgery to
that area should be recorded as surgical wound infection.
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AS.9 Pneumonia
Pneumonia is present if the patient has appropriate chest signs including
consolidation and/or x-ray changes showing new or progressive infiltrate and one or
more of the following:
• New or increased production of sputum
• Fever ~37.8oC)
If the above are not present, a clinician's diagnosis of pneumonia will suffice.
AS.10 ChestInfection
A chest infection is present if the clinician has diagnosed a chest infection and the
patients' symptoms do not meet the definition of pneumonia
AS.11 Otherlower respiratorytract Infection
A clinician's diagnosis of one or more of the following will suffice:
• Empyema
• Lung abscess
• Tracheitis
• Bronchitis
• Mediastinitis
Note:
• Infections of anyone area of the lower respiratory tract (trachea, bronchus,
lung, mediastinum) following surgery to that area should be recorded as a
surgical wound infection.
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A6.12 Woundinfection
A wound is defined as a break in the epithelial surface (skin or mucous membrane)
and the underlying tissue made by some positive act such as an accident or
surgical incision. Bums should be excluded. An ulcer or pressure sore is not a
wound for the purposes of this definition.
All wound infections must have one of the following:
• Purulent discharge in the wound
• Purulent discharge exuding from a wound
• Purulent discharge seen on direct examination at the operative site.
A6.12.1 Major infection
This is present when the wound is broken down, gaping or completely dehisced or
there is evidence of septicaemia, spreading cellulitis and lymphangitis.
A6.12.2 Minor infection
This is present when the wound is not broken down, gaping or completely dehisced
and there is no evidence of septicaemia, spreading cellulitis and lymphangitis.
A6.12.3 Surgical wound infection
This is present if infection occurs at the Incision site or operative site (including
drains) within 30 days after surgical operation if no implant is left in place, or within
one year if an implant is in place. The infection must appear to be related to the
surgical procedure.
A6.12.4 Accidental wound
This is present if infection occurs at or in the accidental wound site.
Note:
• Infections OCCUrringat the entry site of a device which has required an incision
for insertion should be noted as surgical wound infection (e.g. tracheostomy,
intravascular catheters, renal dialysis catheters, suprapubic catheter). The
presence of the device should be noted.
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AS.i3 Skin infection
A skin infection is present if there is inflammation of the skin and infection is the
only known cause. There mayor may not be pus on the skin.
Note:
• Ulcers, pressure sores and otitis externa should be exduded.
AS.14 Bum infection
A bum infection is present if one or both of the following are present:
• Discharge of purulent material
• Graft rejection with clinical (i.e. inflammation and/or pus) evidence of infection.
AS.iS Septicaemia
Septicaemia is present if the patient has at least one of the following signs or
symptoms:
• Fever (::37.SoC) with no other recognised cause
• Chills or rigors
• Hypotension
AND
• Micro-organisms are isolated from one or more blood cuHures taken when the
symptoms were present.
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A6.16 Bacteraemia
Bacteraemia is present if:
• Micro-organisms have been isolated from one or more blood cultures taken on
the one occasion, except in the isolation of a skin contaminant (e.g. diptheroids,
coagulase negative staphylococci), when two or more positive blood cultures
drawn on separate occasions should be obtained.
AND
• The patient does not have any clinical signs or symptoms of infection, i.e. there
is no fever «37.aoC), chills or hypotension.
A6.17 Eye infection
An eye infection is present if there is new purulent discharge or pus within or on the
surface of the eye.
Note:
• Infections of the skin surrounding the eye, e.g. stye, should be noted as skin
infections.
• Infection of the eye following surgery should be noted as a surgical wound
infection.
A6.18 Central nervous system Infection
A central nervous system infection must meet at least one of the following criteria:
• Micro-organisms in cerebral-spinal fluid (CSF), but excluding contaminants, with
or without white blood cells.
• White blood cells in CSF in the absence of micro-organisms if the patient is
receiving antibiotics.
• White blood cells in the CSF In the absence of micro-organisms if there is no
other obvious cause for their presence.
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A6.19 Genital tract infection
Genital tract infections can be divided into post-partum and other genital tract
infections.
A6.19.1 post-partum infection
This requires systemic evidence of infection with a new purulent discharge.
A6.19.2 Other genital infection
This is present if there is new purulent discharge with or without microbiological
evidence of infection.
Note:
• Episiotomy should be classified as a surgical wound and a perineal tear
classified as an accidental wound.
• Infection of any one area of the genital tract following surgery to that area
should be recorded as wound infection.
A6.20 Gastrointestinal infection
A gastrointestinal infection is present if diarrhoea and/or vomiting occurs which is
not as a result of any of the following:
• Diagnostic tests
• Therapeutic regimens
• Other underlying non-infectious causes
Note:
• The presence of a gastrointestinal infection should be supported whenever
possible by microbiological evidence.
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A6.21 Other abdominal infection
Other abdominal infections include a clinician's diagnosis, with or without
microbiological evidence, of the following:
• Intra-abdominal abscess formation
• Peritonitis
Note:
• Appendicitis, cholecystitis, pancreatitis and diverticulitis should not be recorded
as infections unless the presence of pus is noted.
• Infections within the abdomen following surgery to the affected area should be
recorded as surgical wound infection.
A6.22 Bone andJoint infections
These require a clinician's diagnosis of septic arthritis or osteomyelitis, with or
without microbiological evidence.
A6.23 Systemic infection
This requires a clinician's diagnosis, with or without laboratory evidence (including
serology), of generalised bacterial, viral, fungal or parasitic infection without a
definable single site of infection (e.g. measles, mumps, herpes, varicella).
A6.24 Other Infections
These require a clinician's diagnosis, with or without microbiological evidence of
infection, which does not fall into the above categories (e.g. varicose ulcers, rectal
abscesses, pressure sores, otitis externa, oral thrush and non-therapeutic related
hepatitis). This includes clinical symptoms of infectious hepatitis (A,B, Non A and
Non B) and serum positive for hepatitis B antigen without symptoms.
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APPENDIX7
Examples of data collection forms used
A7.1 Introduction
This appendix contains examples of some of the data collection forms
used. The following forms are Included:
i) General data collection form. Information relating to the type of admission,
reason for admission, the patients' social circumstances, formal and informal
care received prior to admission, ward transfers, discharge diagnosis and
care organised on discharged were recorded on this form.
ii) Drug data collection forms. Infonnation on drugs and infusions administered
were recorded on a number of different data collection fonns. The enclosed
examples were used to record infusions and drugs administered by the
intravenous, intra-muscular and/or subcutaneous route during the patients'
hospital stay. Similar forms were available to record, tablets, topical drugs
and other drugs administered.
iii) Investigations data collection form. Information on investigations undertaken
(e.g. cardiac tests, endoscopies and x-rays) were recorded on this form,
together with information on devices in place (e.g. intravenous lines, wound
drains and urinary catheters); care provided by health care professionals
allied to medicine (e.g. physiotherapists, occupational therapists and
dieticians); and nursing care administered to patients during their hospital
stay.
iv) Operation data collection form. Operation details, including the type of
anaesthetic, procedures performed and duration of surgery were recorded
on this form.
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v} Laboratory tests data collection form. Information on laboratory tests
performed were recorded on this form. Specimens taken either at the pre-
assessment clinic or in the accident and emergency department were
recorded in the appropriate columns. If the test was performed out of normal
working hours the test was recorded in the 'oIc' (on call) column.
vi} Infections data collection form. Information on both hospital and community
acquired infections were recorded on this form. Where possible, the date of
onset, site of infection, devices in situ and pathogens involved were
recorded.
With the exception of the general and the laboratory tests data collection forms,
the forms contained within this appendix apply to the first two weeks in hospital.
The laboratory tests data collection form only applies to the first week in hospital.
Additional forms were available for patients who had a length of stay that
exceeded these time-periods.
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•
GENERAL Ql Study Number
Ql RA _
o 1 2 3 4 6 • 7 • •
I I I I I I I I I I 110
I I I I I I I I I I 11
Q3 Day recruited:
(9!I - p.....dIIIlI.loa cUDIc)
o 1 2 a 4 5 • 7 • •
I I I I I I I I I I 1'0
I I I I I I I I I I I'
•
o Yes o Yes o No
Q5 If yes - II tbll admlSllon linked to tbe last admlSllon?Q4 Readmission - last admission within the last month?
o No
Q7 Type of admlSllon:
o elective via pre-admission clinic:o elective direct to wardo urgent direct to wardo emergency via A+Eo emergency via OPDo emergency GP referal direct to wardo transfer from another wardo via day hospitalo transfer from another hospital
Other 0' 2 3 4 I • 7 • •
I I I I I I I I I I I'
Qti What Is the link between tbe current and previous
admlsslon
Q9 Date seen to pre-admlSllon clinic If applicable.
Q8 Previous study number
o , 2 , 4 • • 7 • •
I I I I I I I I I I 1'000
I I I I I I I I I I 1'00
I I I I I I I I I I 1'0
I I I I I I I I I I I'
o , 2 3
I " 114 I • 7 • •..... 111111 QI0 Dateofadmlsslon:
o , 2 3 • I • 7 • • 10 11 12
1111111111111
o , 2 3 • S e 7 • •
11111111111
o 1 2 3
I " II· I • 7 • •..... I I I II
o 1 2 3 4 I e 7 • • 10 11 12
1111111111111
o 1 23. • • 7 • •
""1111111
Ql1 Admission speciality:
o General medicineo General surgeryo OrtbopaediCio Urologyo Gynae
0
0 clo elderly
ENTo Obs
Ql1 Ward admitted to:
o 1 2 I • • • 7 • •
I I I I I I I I I I 1'0
I I I I I I I I I I I'
Survey:2 PIIgtI:1
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Q13 Admitting Consultant _ Q14 Joint care on admission - consultant
01234587"
I I I I I I I I I I 1'0
I I I I I I I I I I l'
o 1 234 • 1 7 • •
I I I I I I I I I I 1'0
I I I I I I I I I I I'
Q15 Sex OMale OFcmale
Q16 GP _
o 1 23' I e 7 1 •
I I I I I I 1'00
I I I I I I 1'0
I I I I I I I'
Q17 Age
01234.17 ••
I I I I I I I I I I I lOO
I I I I I I I I I I 1'0
I I I I I I I I I I I I
Q1' Wellht (kp)
o 1 2 3
I " 114 1 8 7 • •..... I II I I I
012341.7 ••
I I I I I I I I I I 1'00
I I I I I I I I I I 1'0
I I I I I I I I I I II
Q19 DOD
Q10 Bellht (ft)o , 2 S 4 1 e 7 • •
I I I I I I I I I'
10.1
~*~~*~~=il 0.01
o I 2 3 4 1 8 7 • • 10 11 12
1111111111111
01234587 ••
""11111"
QU Reason for admission: Qll Diagnosis on admission:
01234187 ••
I I I I I I I I I I 1'000
I I I I I I I I I I 1'00
I I I I I I I I I I 1'0
I I I I I I I I I I I'
L....L.....L......I.-J'-I......I-.L-I-l...J1 0 1
o I 234 • 8 1 • •
I I I I I I I I I I 1'000
I I I I I I I I I I I lOO
I I I I I I I I I I 1'°I I I I I I I I I I I'
L-£. ......................_._ ................_.I o. I
Q13 Co-morbidities 1 Q14 Co-morbidities 1 Q15 Co-morbidities 3 Q16 Co-morbidities 4
II
Survey: 2 Page:2
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• Q27 Marital status
o singleo married living with husband/wifelpannero married not living withhusband/wifeo widowedo divorced
Household Size
Q18 Number of adults In household Includlnl patient •
o I 2 3 • • I 7 • • >18 yn
I I I I I I I I I I I I
Q29 Number of children In household
0123 •• 17 ••
I I I I I I I I I I I I <18 yr.
Q30 How many children have you got?
o I 23. 5 • 7 • a
I I I I I I I I I I I' all Illes
Q31 How many children under 5 yean old
0123 •• 171.
I 1 I I 1 1 1 1 1 1 I'
Q31 How mllny children under 16 yean old
0123.587 ••
I 1 1 1 1 1 1 1 1 1 I'
Q33 How mllny children under 11 yean old
o I 23. a .71 a
1 1 1 1 I I I I 1 I I'
Q34 How many children under 18 yean old
o , 23. 5 • 7 • •
1 I I I 1 I I I 1 I I'
Q35 Currently living in Residential home 0 Nursing home 0 Sheltered accomodation 0
Hostel 0 Hospice 0 Own Home 0 Relatives Home o
-------------------------------------------------------------------------
CHILD CARE
Q36 Have you had to IIrrange any addditional care for
your children whilst In hospital?
Yes 0 NoD
Q37 If yes from whom? o Husband/wlfflpartnero other relative <I>o friend/neighbour <s>o nanny/c:hlldmlnder
900 Is a half day
other:
Q38 Husband/wife partner· day. caring for chn
0123.517 ••
1 I I I 1 I I 1 I I 1'00
I I I 1 1 I I I I I 1'0
I I I I I I I I 1 I I'
Q39 Husband/wife partner· day. off work
0123.5., ••
I 1 I I 1'00
I I 1 I 1'0
1 I I I I'
Q40 Relative 1·day. caring for chn
0123.aI7 ••
I 1 I 1 1 1 1 1 1 1'00
I I I 1 I I 1 1 I 1'0
1 1 I 1 1 I 1 I 1 I'
Q41 Relative 1· day. off work
0123.aI7 ••
1 1 1 1 I I I I I I 1'00
I I 1 I 1 1 1 I I I 1'0
1 I I 1 1 I 1 I I I I'
Q42 Occupation
I
Q43 Relative I· day. carinI for ehn
0123.517"
I 1 I 1 1 I I I I 1'00
1 I I I 1 I I I I 1'0
1 I I I I I I I I I'
Q44 Relative 2· day. off work
0123.aI7 ••
1 I I 1 I I I I 1 1 1'00
1 I I I I I I I I I 1'0
I 1 I 1 1 I I I I 1 I'
Q45 Occupation
I
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Q46 Relative 3- days caring for ehn
01234587 ••
I I I I I I I I I I I lOO
I I I I I I I I I I 1'0
I I I I I I I I I I I'
FreindslNeiebbours
Q49 FIN 1- daysc:aring for ebn
01234587 ••
I I I I I I I I I I 1'00
I I I I I I I I I I 1'0
I I I I I I I I I I I'
Q51 FIN 1- days caring for chn
o I 234 5 8 7 • •
I I I I I I I I I I 1'00
I I I I I I I I I I I ID
I I I I I I I I I I I'
Q55 FIN 3 - days caring for chn
01234587 ••
I I I I I I I IlOO
I I I I I I I IID
I I I I I I I I'
AddfUQna) paid cllOdeare
Q47 Relative 3- days off work
01234517 ••
I I I I I tOO
I I I I IID
I I I I I'
900 Is a half day
Q50 FIN 1- daynff work
0123.587 ••
I I I I I I I I I I I lOO
I I I I I I I I I I 1'0
I I I I I I I I I I I'
Q53 FIN 1- days off work
o I 23' 587 • •
I I I I lOO
I I I I I I I I I I IID
I I I I I I I I I I I'
Q56 FIN 3 • days off work
o I 234 587 • •
I I I I I I I I I I I lOO
I I I I I I I I I I Ito
I I I I I I I I I I I'
Q58 III days
01234587 ••
I I I I I I I ID
I I I I I I I I I I I'
•
Q48 Occupation
Q51 Oc:c:upatlon
I
Q54 Occupation
I
Q57 Occupation
I
Q59 Full day.
o I Z 3 • • • 1 • •
I I I I I I ID
I I I I I I I I I I I'
Other De,pendents
Q60 Other dependents? (Elderly defined al over 70 yean)
oNone 01elderly R 0 elderly R 0 pets Ciusbandlwifo'partner
o elderly FIN [PIN (not elderly) other
o,ther relative (not elderly)
o No
Q61 Whilst In hospital have you had to arranle for anyone to care for thue dependents?
[Oatery etc SocCServcspetsoHusbandlwifo'partner liilher relative Iliendlneighbour []espite care
Survey: 2
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Q64 Relatlvel- days earing for D Q6S Relative 1- day. off work ~ Occupation0 , 2 3 ~ 5 I 7 • • 0 , 2 3 • • • 7 • •I I I I I I I I I I 1'00 I I I I I I I I I I 1'00
I I I I I I I I I I I'D I I I I I I I I I I I'D
I I I I I I I I I I I' I I I I I I I I I I I'
Q67 Relative 1-days earlng for D Q68 Relative 1- days off work
Q69 Occupation0 , 2 3 ~ • • 7 • • 0 , 2 3 ~ • I 7 • •I I I I I I I I I I 1'00 I I I I I I I I I I 1'00
I I I I I I I I I I I'D I I I I I I I I I I I'D
I 1 I I I I I 1 I I I' I I I I I I 1 I I I I'
Q70 Relative 3· days earlng for D Q71 Relative 3 - day. off work
Q71 Occupation0 , 2 3 ~ • • 7 • • 0 , 2 3 • • • 7 • •I I I I I I I I I I 1'00 1'00
I I I I I I I I I I I'D I'D
I I I I I I I I I I " "
•
RELATIVES
Q61 Husbandlwifelpartner caring for D
O'23~.'7"
I I I I I I I 1'00
I I I I I I I I'D
I I I I I I I I'
FRIENDstNEIGfJBOUBS
Q73 FIN 1 - days earing for D
o , 2 3 ~ • • 7 • •
I I I I I I I I I I 1'00
I I I I I I I I I I I'D
I I I I I I I I I I I'
Q74 FIN 1 - days off work
o , 234 I • 7 • •
I I I I I I I I I I 1'00
I I I I I I I I I I I'D
I I I I I I I I I I I'
Q76 FIN1days earlng for D
O'23~1'7"
I I I I I I I I I I 1'00
I I I I I I I I I I 1'0
I I I I I I I I I I I'
Q77 FIN 1- days off work
o , 2 3 ~ • • 7 • •
I I I I I I I I I I 1'00
I I I I I I I I I I I'D
I I I I I I I I I I I'
Q7!1 FIN 3- days earlng for D
0'23."7"
I I I I I I I I 1'00
I I 1 I I I I I I'D
I I I I I I I I I'
QaO FIN 3- days off work
O'23~1'7"
I I I I I I I I I I 1'00
I I I I I I I I I I I'D
I I I I I I I I I I "
•Q63 Day. off work
0'23 ••• 7 ••
I I I 1'00
I I I I'D
I I I I'
Q7S Occupation
Q78 Occupation
Qal Occupation
II
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Q81 OPHetc
0'23.'87 ••
I I I I I I I I I I 1'0
I I I I I I I I I I I'
Q83 Self financed ~NHS
Local Auth (no contr,)
Local Auth (contr.)
Local Auth (not lure)
Q84 Co.t per day In a catterylkennel. (t)
o , 23. • 8 7 • •
I I I I I I I I I I 1'0
I I I I I I I I I I I'
SERVICES RECEIVED PRE- ADMISSION
Q85 Community/social Q86 Dayslweek Q87 Weeks Q88 Monthsservices received
pre-admission:
0 , 2 3 • • 8 7 • • 0 , 2 I • • e 7 • • 0 , 2 3 • • 8 7 • •District Nune 0 I I I I I I I I I I I' I I I I I I I I I I I' I I I I I I I I I'0 , 2 , • • • 7 • • 0 , 2 , • 5 • 7 • • 0 , 2 , • • 8 7 • •Home help 0 I I I I I I I I I I I' I I I I I I I I I I I' I I I I I I I I "0 , 2 , 4 I • 7 • • 0 , 2 , • • e 7 • • 0 , 2 , • • • 7 • •MOW 0 I I I I I I I I I I I' I I I I I I I I I I " I I I I I I I I0 , 2 3 4 , • 7 • • 0 , 2 , • • • 7 • • 0 , 2 , • • • 7 • •Con. advisor 0 I I I I I I I I I I I' I I I I I I I I I I I' I I I I I I I I0 , 2 , 4 5 • 7 • • 0 , 2 , • • e 7 • • 0 , 2 , • • • 7 • •Mac.Nune 0 I I I I I I I I I I " I I I I I I I I I I I' I I I I I I I I0 , 2 3 • • • 7 • • 0 , 2 , • , e 7 • • 0 , 2 3 • • 8 7 • •CTT 0 I I I I I I I I I I I' I I I I I I I I I I I' I I I I I I I I I0 , 2 , 4 • • 7 • • 0 , 2 3 • • e 7 • • 0 , 2 , • • • 7 • •OT 0 I I I I I I I I I I I' I I I I I I I I I I I' I I I I I I I I I0 , 2 , • • e 7 • • 0 , 2 3 • I • 7 • • 0 , 2 , • • • 7 • •EST 0 I I I I I I I I I I I' I I I I I I I I I I I' I I I I I I I I I I'0 , 2 3 4 , • 7 • • 0 , 2 S • • • 7 • • 0 , 2 S • 5 • 7 • •Day Hosp D I I I I I I I I I I I' I I I I I I I I I I I' I I I I I I I I I I'
D0 , 2 , 4 5 • 7 • • 0 , 2 , 4 • • 7 • • 0 , 2 , 4 • • 7 • •Other: I I I I I I I I I I I' I I I I I I I I I I I' I I I I I I I I I I I'
Q89 Help received from famlly and friends pre-admlnion? Q90 Q91
Daulhter Partner Friend Other Weeks Months
son etc. neichbour
0 , 2 , . • • 7 • • 0 , 2 , • • • 7 • •ShoppinC 0 0 0 0 I I I I I I I I I I I' I I I I I I I I I I I'
0 , 2 3 • • • 7 • • 0 , 2 , • • • 7 • •Cleanlnl 0 0 0 0 I I I I I I I I I I I' I I I I I I I I I I I'
WashlnglDressinl 0 0 0 0 0 , 2 S • • • 7 • • 0 , 23. • • 7 • •I I I I I I I I I I I' I I I I I I I I I I'
0 0 0 0 0
, 2 , . • • 7 • • 0 , 2 S • • • 7 • •Cooklnl I I I I I I I I I I I' I I I I I I I I I I'
0 , 2 ,. 5 e 7 • • 0 , 2 3 4 • • 7 • •Dally check 0 0 0 0 I I I I I I I I I I I' I I I I I I I I I ),
0 , 2 , • I • 7 • • 0 , 2 3 • 5 • 7 • •Twice weekly meck 0 0 0 D I I I I I I I I I I I' I I I I I I I I I I'
0 , 2 ,. 5 • 7 • • 0 , 2 , • • e 7 • •Weekly meck 0 0 0 0 I I I I I I I I I I I' I I I I I I I I I I l'
Q91 Live In carer - friend0 Live In carer - relative 0
• I II II II II II II I I I I II I I I • IScMning by FonnIc Lid. London. (...... 10171112 .. 1130
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OCCUPATION/EMPLOYMENT
Q93 Employment status prior to admission to hospital.
o employed full timeo employed part timeo employed but temporary laid offo unemployed looking for worko unable to work because of ilIhealth(disabled)o Housewife!house husbando student (FT)o retiredo other • please specify
Q94 Job description
o Self employed with employeeso Self employed without employeeso Employed· manalero Emplyed. foreman/supervisoro Employed. normal employee/apprentice
Q95 Social Class
o I 2 I 4 • • 7 • •
I 1 1 1 I I 1 1 1 1 I'
Present or most recent Job?
Q96 Soclo economic IrouP
o I 2 I 4 • • 1 • •
I I I I I I I I I I 1'0
I I I I 1 I I I I I I'
~_'_-'-~L....L.-L....J-J....JI0.1
Q97 Husband/wlfe!partners occupationalltatus?
o NI A single!not living with partnerlhusbandlwifeo employed full timeo employed part timeo employed but temporary laid offo unemployed looking for worko unable to work because of illhealth (disabled)o Housewifethusbando student (FT)o retiredo other· please specify
I
Q98 Job description
o Self employed wltb employeeso Self employed without employeeso Employed. manalero Emplyed • foreman/supervisoro Employed· normal employee/apprentice
Q99 Social Class
o , 2 I 4 • • 7 • •
I I I I I I I 1 I I I'
Present or mosl recenl Job Ql00 Soclo economic croup
0'234'17"
I 1 1 1 1 1 I I I I 1'0
I I 1 I 1 I I I I I I'
~_'_-'-~L....L.-L....J-.L....JI01
S_y:2 PIIIJ4t:7
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Consultant Transfer 1
Consultant transfer 2
Consultant transfer 3
•QI01 Consultant transfer to ~ _
o I 2 , 4 e 8 7 • •
I I I I I I I I I I 1'0
I I I I I I I I I I I'
QI01 Day of transfer:
01234.87 ••
I I I I I I I I 1'0
I I I I I I I I I I I'
QI03 Consultant transfer to ~ _
o , 2 I 4 e 8 7 • •
I I I I I I I I I I 1'0
I I I I I I I I I I I'
QI04 Day of transfer
o , 2 I 4 8 , 7 • •
I I I I I I I I I I 1'0
I I I I I I I I I I I'
QI0S Consultant transfer to ::-:-:- __
o , 2 3 4 • e 7 • •
I I I I I I I I I 1'0
I I I I I I I I I I I'
QI06 Day of tranlfer
o , 2 I 4 5 8 7 • •
I I I I I I I I 1'0
I I I I I I I I I I I'
Ward transfer 1
Ward transfer 2
Ward transfer 3
Ward transfer 4
QI07 Ward transfered to:
o , 234 • 8 7 • •
I I I I I I I I I I 1'0
I I I I I I I I I I I'
QI09 Ward transfered to:
o , 2 I 4 .87 • •
I I I I I I I I I I 1'0
I I I I I I I I I I I'
Ql11 Ward transfered to:
o , 234 .17 • •
I I I I I I I I I I 1'0
I I I I I I I I I I I'
Q113 Ward traD.fered to:
o , 234 .17 • •
I I I I I I I I I I 1'0
I I I I I I I I I I I'
QI08 Day oftraD,fer
o , 234 • • 7 • •
I I I I I I I I I I 1'0
I I I I I I I I I I I'
QUO Day oftran,fer
o , 234 • 8 7 1 •
I I I I I I I I 1'0
I I I I I I I I I I I'
Ql11 Day of transfer
0'234.17 ••
I I I I I I I I 1'0
I I I I I I I I I I I'
Q1l4 Day oftransfer
o , 2 J 4 5 .7. •
I I I I I I I I I I 1'0
I I I I I I I I I I I'
Consultant Referral 1
Nos
Code Day of days
Consultant Referral 2
Nos
Code Day of days
Consultant Referral 3
Nos
Code Day of days
Consultant Referral 4
Nos
Code Day of days
SuMy:2
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405
• •Ql1!.Dlscharged to:
Home
Other ward <I week
Other hosp <I week
Hospice
Nursing home
Relatives
RIP Other L..- -----J
DISCHARGE
QUO Discharge date:
10"12(146 e 7 ••
..... I I I I "
o , 2 3 4 6 e 7 • • 10 11 ,a
1111111111111
0'234517"
11111111111
~
Other ward >1week
Other hosp>lweek
Residential home
Convalescent home
Sheltered aeeem
Q121 DAmbulance
QIZZ Diagnosis on discharge QlZ3 Diagnosis on discharge Q114 Diagnosis on discharge
,..... ,..... ,..... ,.....
f-
l-
I-
l-
I----
I-
L-
Q126 SERVICES ON DISCHARGE
R.O.s (days) 0 1 2 3 ••• 7 ••
I I I I I I I I I I 1'0
I I I I I I I I I I I'
o Hospital Car
Ql15 Diagnosis on discharge .
o Ward OGPsurgery o OPD
o District Nurse 0 A&E
o t 2 I • • • 7 • •
Other I I I I I I I I I I It
QIl7 0 District Nurse Q128 0 , 2 I 4 • 17. •
0 Macmillan Nurse OPA I I I I I I I I It
0 Continence Advisor 0 , 2 I 4 • • 7 • •
0 CTT ECG I I I I I I I I I'
0 EST 0 , 2 I •• .7. •
0 MOW Endoscopy I I I I I I It
0 HH 0 , 2 I • • .7. •
0 Sodal worker TWOC I I I I I I'
0 ~¥SiO
0 , 2 S • , .7. •
0 Lithotripsy I I I I I I'
0 CPN 0 , 2 I • ,.7. •
0 GP follow up Day Hosp I I I I I I l'0 1 2 3 • • • 7 • • 0 , 2 S 4 •• 7 • I
Other I I I I I I I I I I It I I I I I I I I I l'0 , 21.'.7 ••
Other I I I I I I I I I I It0 , 2 I • • .7. •
I I I I I I I I I I l'
weeks
weeks
weeks
weeki
weeks
Days/week
Number of weeks
c:ode
weeki
SurvIY: 2
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• DRUGS SupPLIED
Q129 Dr",1
01234'17"
I I I I I I I I I I 1'000
I , , , I , I , I I ''OO
I , I I I I I I I I 1ID
I I I 1 I I I I I I I'
Supply (d.7I)
01234"7"
I I I I I I I I I I I ID
I I I , I I I I I , II
Ql3l 0l'1li4
01234"7"
I I I I I , , 1'000
I I I I I I I , I I I lOO
I , , , I I I , I , I ID
I I I I I I I I , I I'
Supply (d.7I)
01234'17"
I I , I I I I I I , 1'0
I I I I I I I I I I I'
Q135 0l'1li7
01234"7',
I I I I I I I 1'000
I I I I I I I I I I IlOO
I , I I I I I I I I 1'0
I I I I I I I I I I l'
Supply (dayo)
o 1 234 , , 7 • ,
I I I I I I I I I I 1'0
I I I I I I I I , , I'
Q131 0l'1li10
0123."7',
I I I I I I I I I 1'000
I I I I I I I I I 1'00
I I I I I I I I I 1'0
I , 1 , I , , I I l'
Supply (da7l)
0123 ••• 7,.
I , I I , I , , I , 1'0
I I I I , I , I I , l'
Q141 0l'1li13
01234'17,.
I , , I , , I 1'000
I I I I , I I I I I I lOO
I I , I , I , , , , 1'0
I , I I I I 1 I , I l'
Supply (dI7l)
0123.'17 ••
I , I I , , I I , I 1'0
I , I I , I , I , I I'
QUO DrUl2
0123 •• 17 ••
I I I , , I I 1'000
I I I I I , I , I I I lOO
I , , I I I I I I I I ID
I I I I I I I I , I I'
Supply (da7l)
o I 234 , 1 7 • •
I I , I I I I I I , I ID
I I I I 1 I I I I I I I
Q133 0l'1li5
01234117 ••
I I I I I I I 1'000
I 1 I I I I I I I I IlOO
I I I I I I I I I , I ID
I I , , , , I I , I I'
Suppl)' (da7l)
o I 2 I 4 , • 7 , •
I I I , I , I I I I I ID
I I , I I I I I I I I I
Q13' DrUI'
o I 23. I 1 7 • •
I I I I I I I 1'000
I I , , I I I I I I 1'00
I I I , I I I I I I 1'0
I I I I I I I I I I I'
Supply (da7l)
o I 23. , 1 7 • •
I I , I , I I I , I 1'0
I I I I I I I I I I I I
Q13' DrUlll
o I 234 • 1 7 • •
I I I I I I I 1'000
I I I I I I I I lOO
I I I I I I I 1'0
I , , I I I I I'
Supply (da7l)
o I 23. • 1 7 • •
I I , , , I , , I I 1'0
I I I I , I I I I I I'
Q142 Drlll14
o I 23. • • 7 • •
I I I I I I , 1'000
I I I , I I I I I I I lOO
I , I I I I I I I I 1'0
I I I I I I I , I , I'
Supply (da7l)° I 23. 1 • 7 • •
I I I I I I I I I I 1'0
I I , , I I , I , I I'
•
Q131 Drlll3
01234 •• 7 ••
I I I I I I , 1'000
I I I I I I I I lOO
I I I I I I I 1'0
I I I I " I I I
Supply (d.7I)
01234.17 ••
I I , , , I , , , I 1'0
I I I I I , I I I I I I
QI34 0l'1li'
012'4'17"
I I I I I I I I I 1'000
I I , , I , , I , I "OO
I I I , , I I I , I 1'0
I I I I , I I I , , I I
Supply (day.)
o I 2 , • , 1 7 • •
I I I , , I I , I I I ID
I I I I , I I , , , I I
Q137 DrUI'
o I 23. I • 7 • •
I I I , , , I I1000
I I , , , I I , I I I lOO
I , , I , I , , , I I ID
I , , I , I , I I , I I
Supply (dayo)
o I 23. • 1 7 • •
I " , , I , , I , , I ID
I I I , , , , I I , II
QI40 Drill Uo I 2 , • • 1 , • •
I I I I I I 1",000
I , I I I I I I I 1lOO
I I I I I I I I I 1'0
I I , , , I' "I I
Supply (dayo)
0123 •• 17"I , , , I , I , , I 1'0
I I I I I I I I I I "
QI43 DI'III15
0123 •• 1' ••
I I , , , , I 1'000
I I I I I I I I lOO
I I , I I I I I ID
I I I I , I I I'
Supply (da7l)
0123 •• 1' ••
I I I I I I I I I I 1'0
I , I I I I , I I I I'
Surv.y:2
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•INFUSIONS
Ql Study Number r------------,
m CRYSTALLOID
1 2 3 4 S 6 7 8 9 10 11 12 13 14
N/saline 500mIs xl 0000000 0000000
x2 0000000 0000000
x3 0000000 0000000
x4 0000000 0000000
xS 0000000 0000000
x6 0000000 0000000
N/saline lOOmIsxl 0000000 0000000
x2 0000000 0000000
Q3 1 234 S 6 7 8 9 10 II 12 13 14
D/saline 500mls xl 0000000 0000000
x2 0000000 0000000
x3 0000000 0000000
x4 0000000 0000000
xS 0000000 0000000
x6 0000000 0000000
Q4
123 4 S 6' 7 8 9 10 11 12 13 14
Dextrose 5% 500mls xlO 0 0 0 0 0 0 000 000 0
x2 0000000 0000000
x3 0000000 0000000
x4 0000000 0000000
xS 0000000 0000000
x6 0000000 0000000
Dextrose 10% xl 0000000 o 0 0 000 0
x2 0000000 0000000
Dextrose 20% xl 0000000 o 0 0 0 000
x2 0000000 o 0 0 0 000
Dextrose 50% xl 0000000 0000000
x2 0000000 0000000
•
SUIV.y: 111 Page: I
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•
Q5 I 2 3 " 5 6 7
N/saline + 20ke) 500mls xl 0 0 0 0 0 0 0
xl 0000000
x3 0 0 0 0 0 0 0
x4 0 0 0 0 0 0 0
D/saline + 20kc1 500rnhl
xl
xl
x4
o 0 0 000 0o 0 0 0 000o 0 0 0 000o 0 0 0 000
5% Dexttose + 20kcl500mlul 0 0 0 0 0 0 0
xl 0000000
x3 0000000x" 0 0 0 0 0 0 0
20ke) xl 0 0 0 0 0 0 0
20ke) xl 0 0 0 0 0 0 0
20kc1xl 0 0 0 0 0 0 0
20ke) x4 0 0 0 0 0 0 0
20kclxS 0000000
Q6 1 2 3 " S 6 7
Heparin/saline 500mls xl 0 0 0 0 0 0 0
Hartmanns soln 500mls xl
xl
xl
x4
o 0 0 0 000
000 0 0 0 0o 0 0 0 0 0 0o 0 0 0 0 0 0
8 9 10 II 12 13 14
0000000
000 000 0o 0 0 0 0 0 0
0000000
0000000
0000000
000 000 0
0000000
0000000
0000000
0000000
0000000
000 0 0 0 0
0000000
0000000
0000000
0000000
8 9 10 11 12 13 1"
0000000
o 0 0 0 0 0 0
0000000
0000000o 0 0 0 000
•
SUlVey: 19 PIllll':2
11111111
•
111'11111111111111111.
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m COLLOID
123 4 S 6 7 8 9 10 11 12 13 14
Haemocell SOOmlsxl 0000000 o 0 0 0 000
xl 0000000 0000000
xl 0000000 o 0 0 0 000
x4 0000000 0000000
xS 0000000 0000000
x6 0000000 0000000
Hespan SOOmlsxl 0000000 0000000
xl 0000000 0000000
x3 0000000 0000000
x4 0000000 0000000
xS 0000000 0000000
x6 0000000 0000000
HAS4.S%Xl 0000000 0000000
X2 0000000 0000000
X3 0000000 0000000
X4 0000000 0000000
XS 0000000 o 0 0 0 000
X6 0000000 0000000
HAS20%XI 0000000 0000000
X2 0000000 0000000
Blood xl 0000000 0000000
xl 0000000 0000000
xl 0000000 0000000
x4 0000000 0000000
xS 0000000 o 0 0 0 000
x6 o 0 0 0 0 0 0 0000000
Q8 123 4 S 6 7
0000000
0000000
0000000
0000000
0000000
0000000
8 9 10 11 12 13 14
0000000
0000000
0000000
0000000
0000000
0000000
Platelets UIIils "I
xl
xl
x4
xS
x6
Platelets pooled b.. xl
x2
0000000 0000000
0000000 0000000
Q9 123 4 S 6 7
0000000
0000000
8 9 10 11 12 13 14
0000000
0000000
FFPXI
FFPD
•
Swv.y : 19 PIIge: 3
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Study Number ,....- --,
IV, 1M & se DRUGS
WEEKS 1&2
QZ
1 2 3 4 5 6 7 8 9 10 11 12 13 14
xl 0 0 0 0 0 0 0 0 0 0 0 0 0 0
xl 0000000 0000000
xl 0 0 0 0 0 0 0 0 0 0 0 0 0 0
~ 8888888 8888888
0000000 0000000
0000000 0000000
x~ 8 8 B 8 8 8 8 B B B B B B B
xl 0000000 0000000
xl 0 0 0 0 0 0 0 0 0 0 0 0 0 0
xl 0000000 0000000
x3 0000000 0000000
x4 0 0 0 0 0 0 0 0 0 0 0 0 0 0_._ __ __ -_.._ _ _-----------------------------_ .._-----------_._ ..__ ._ -----_ --_ _---------
Benzyll-penicillin 600mc, BD 0 0 0 0 0 0 0 0 0 0 0 0 0 0
QDS 0 0 0 0 0 0 0 0 0 0 0 0 0 0
BD 0 0 0 0 0 0 0 0 0 0 0 0 0 0
XI
QDS 8 B B 8 8 8 B 8 8 8 8 B 8 B
xl 0000000 0000000
~ 8888888 8B8BB8B
1-6m,Adenosine iv
1 in 1000Adrenaline Bolus
250m, TOS
500mg TOS
S-20iu
AmoxycillinInjection
Argipressin
600mc,Q3 Atropine Sulphate
1.2g
4m,Betamenthazone
-----_ .._-_ - _-------------_ ..-------_.--------_ _------------------_------
0000000
0000000o 0 0 0 0 0 0
BBBBBB8
0000000
0000000
B8B8888
0000000
8888888
0000000
0000000
0000000
BBBB8BB
0000000
0000000
0000000
0000000
8BBB888
0000000
0000000
8888888
0000000
8888888
0000000
0000000o 0 0 0 0 0 0
8888888
0000000
10mg of 10% xl
xl
IOmg xl
xl
2g TDS
750mg TOS
1.5, TOS
19 TDS
2, BD
10mg xl
xl
x3
2Smg-SOmg xl
xl
x3
1.2, TDS
50mg xl
xl
Q<:a1cium ,luconate
Calcium Chloride
Cefotaxime
Cefuroxime
Ceftaxidime
Chlorpheniramine
Qlthlopromazme
Co-Amoxiclav
Cytlizine
..._-_ _ _--._ _-..-_._ .._-_ -_ _ --_ ----_ _--- --_ -_ _---_.-._--.---_ _.._ -..
P-v-:1
11111111
Survey :32
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•
Q6
Dexamethasone 4.8mg xl
xl
Dextrose
Q7 Diazemuls
SO% minijet xl
S-IOmg xl
xl
x4
11-2Omg xl
xl
x4
75mg xl
xl
xl
12SEDCg xl
2SOalcg xl
IOmg xl
Diclofenac:
Digox.in inj
Droperidol
x3
123 4 S 6 7
0000000
0000000
0000000
0000000
0000000
0000000
0000000
BBBBBBB
0000000
0000000
BBBBBBB
0000000
0080000o 0 0 0 0 0
•
8 9 10 II 12 13 14
0000000
0000000
0000000
0000000
0000000
0000000
0000000
BBBBBBB
0000000
0000000
BBBBBBB
0000000
0008000°0000 0---_ .._--_ ....._ ....._-_ ...._-.----_ ...._ .._-_ ..._------_. __ .._ ..--_ ..._-.-_.- ....-._-------.----._--
Q8
Ergometrine SOOalcg xl
xl
QDS
BD
xl
xl
Erythromycin SOOalcg
19
BolusEtomidate
0000000
0000000
0000000
BBBBBBB
0000000
0000000
0000000
0000000
BBBBBBB
0000000
Fleconide 150mg
............... _ .._ ..-- _ _ _ _-- _- ..__ ._._ _- - _._-_ .._ --_ _._.-_ -_._ _ ..__ _-
Q9 Flucloxacillin 2S0mg
SOOalg
xl
xl
xl
QDS
QDS
xl
xl
xl
xl
x.3
x4
xS
x6
Flumazenil
Pruseimid&Omgsl2mls
0000000
0000000
0000000
0000000
0000000
0000000
8888888
0000000
0000000
BB8BBBB
0000000
0000000
0000000
0000000
0000000
0000000
0000000
88BBBBB
0000000
0000000
BBBBBBB
0000000--.--_ _ _ _-_ _ _-..__ -_ .._-_ _---- _ _ __ _ _--_ _ _ _---._ -
QIO Gentamicin 1-80mg BD
TOS
BD
TOS
xl
xl
xl
xl
x3
81-160mg
Goserelin
Glucagon
Glyeopyronium
3.6mg
19m
600mg
0000000
0000000
0000000
BBBBBBB
0000000
0000000
BBBBBBB
0000000
0000000
0000000
BBBBBBB
0000000
0000000
BBBBBBB
...__ -._ _ _ _ _._-_ _ _ - _ __.._ _ _
•
Sut'V.Y : :12
I I I I I II I I I I I II I I I I • II II I
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Qll
Haloperidol Smg xl
xl
BD
TOS
xl
xl
xl
xl
xl
xl
xl
x4
xl
xl
xl
x4
Heparin sic SOOOu
Heparin Infusion
Hydralazine 0-2Omg
Hydrocortisone loomg
200mg
Ql2 Hyocine Butylbromide Buscapan 20mg xl
xl
xl
xl
Hyocine Hydrobromide 600mcg
1 2 l 4 5 6 7
0000000
0000000
0000000
BBBBBB8
0000000
0000000
88888B8
0000000
0800000o 0 0 0 0 0
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
•
8 9 10 11 12 13 14
0000000
0000000
0000000
B8SBB8B
0000000
0000000
8888888
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
Labetolol
...__ .._-_ ...__ .._----_ ...._-_ ..._----------------_.- .._.-_ ...._---_._-- .._.-
Leuprorelin
Lorazepam
SO-lOOmg xl 0 0 0 0 0 0 0
xl 0000000
l.7Smg xl 0 0 0 0 0 0 0
4mg xl 0 0 0 0 0 0 0
0000000
0000000
0000000
0000000
.....__ ...__ ...-.._---_ .._ .._ ......._--_ ...._--_ ..._.__.__ ..__ ..._------------_ ..._------
Metaclopromide lOmg xl
xl
xl
x4
120mg daliyxlMethyl-prednisolone
0000000
0000000
0000000
0000000
0000000
0000000
0000000
8000800000 0 0
0000000
Ql3 - ••----_._._-_._._. • ._. • •• ._. •••__ • ._._. ._••_
Naloxone 400mcg xl 0 0 0 0 0 0 0 0 0 0 0 0 0 0
xl 0000000 0000000
xl 0000000 0000000._._--_ .._---,-------_. __._---_._-----_._----_ ....-
Pabrinex 1&.11
Phenytoin
OD
loo-2S0mg xl
xl
xl
IOmg xl
2g QDS
48 QDS
SOOmg BD
TOS
QDS
PhytDmenadion
Pipcnci11in
Primaxin
0000000
BB8BB8B
0000000
0000000
BBBBBBB
0000000
88BBBB8
0000000
B888888
0000000
0000000
BBBBBBB
0000000
8888888
Page:3
IIIIIIMII i 1""""1"11""1
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•
Q 14 Prochlorperazine 12.Smg
2 3 4 S 6 7
xl 0 0 0 0 0 0 0
x20000000
x30000000
x~ B B B 8 8 8 8
x4 0 0 0 0 0 0 0
xl 0 0 0 0 0 0 0
x~ 8 B B B 8 B B
TDS 0 0 0 0 0 0 0
Tranexamic·acid SOOmg
-----_.------------_ ..----_ .._.._---_------ ..._---
TDS 0 0 0 0 0 0 0
•
8 9 10 11 12 13 14o 0 0 000 0o 0 0 000 0o 0 0 000 0
8888888
0000000
0000000
8BBBBBB
Ranitidine samg
...._-_ ..-_._ -._ _--._----_.-._-_. __ ._ --_.__ .._-_.- --_ __ ._ -
0000000
xl 0 0 0 0 0 0 0
x20000000
x30000000
xl 0 0 0 0 0 0 0
x20000000
x30000000
III
SUlWy:32
1111111111111111111
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....---_ ..__ ._--_ .._--_ _.._._------ ------_._------------------
0000000
Vancomycin SOOmg
Promazine SOmg
0000000
0000000
0000000
0000000
0000000
0000000
Protamine
Promethazine
up to 50mg
2S.SOmg
Verapermil Smg
Pap:4
111I111I •
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•
INVESTIGATIONS
Q2 Cardiac Tests
lECG
2ECGs
3ECGs
4ECGs
SECGs
more than S
24hourtape
exercise ECG
echoc:ardiogram
Q3 Endoscopies
Bronchoscopy
Colonoscopy
ERCP
Gastroscopy
Sigmoidoscopy
Q4 XRay.
Chest X-ray x 1
xl
x3
Q5 XRay.
GroupAx 1
xl
xl
x4
xS
x6
Q6 XRay.
Group Bx 1
x2
xl
x4
xS
x6
•
StudyNumber rrr: _,
8 9 10 11 12 13 14o 0 0 0 0 0 0o 0 0 000 000000000000000o 0 0 0 0 0 0o 0 0 0 0 0 0
0000000o 0 0 0 0 0 0o 0 0 0 0 0 0
8 9 10 11 12 13 14o 0 0 0 0 0 00000000o 0 0 0 0 0 0000 000 0o 0 0 0 0 0 0
8 9 10 11 12 13 140000000o 0 0 0 0 0 0o 0 0 0 000
8 9 10 11 12 13 140000000o 0 0 0 000o 0 0 0 000o 0 0 0 00000000000000000
8 9 10 11 12 13 14o 0 0 0 0000000000o 0 0 0 0 0 0000000000000000000000
PA 1 2 3 4 5 6 7o 0 0 0 0 0 0 0o 0000000o 0 0 000 0 0000 000 0 0o 0 0 0 0 0 0 0000 0 0 0 0 0
00000 0 0 000000 0 0 000000 0 0 0
1234567o 0 0 0 0 0 0o 0 000 0 0o 0 000 0 0o 0 0 0 0 0 00000000
PA 1 2 3 4 S 6 700000 000o 0000000o 0 0 0 0 000
PA 1 2 3 4 S 6 7o 00000000000000 0o 0000000o 0000000o 0000000o 0 0 0 0 0 0 0
PA 1 2 3 4 S 6 7o 0000000o 0 0 0 0 000o 0000000o 0 0 0 0 000o 000 0 000o 000 0 0 0 0
Swv.y: 3 Peg.: 1
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•
Q7 XRay.
1 2 345 6 7
000 000 0o 0 0 0 0 0 0Group C x 1xl
Q8 XRay.
1 2 3 4 5 6 7o 0 0 0 0 0 0o 0 0 000 0o 0 0 0 0 0 0o 0 0 000 0
GroupO x 1
GroupExl
Group F xl
Nuclear Med scan xl
X-Rays that are not found on list
Day _
•
8 9 10 11 12 13 14
0000000
0000000
8 9 10 11 12 13 14
0000000
0000000
0000000o 0 000 0 0
X-Rays that are not found on list
Day _
Test'--- _ Test'-- _
Pregnancy Test
Urine Flow Studies
1 2 345 6 7o 0 0 0 0 0 0o 0 0 0 0 0 0
QIO
Test 1:
Ql1
Test2:
8 9 10 11 12 13 14
0000000
0000000
Ql2
Test3: o , 234 • 8 7 • ,I I I I I I I I I I I'
o , 234 .81 • •
I I I I I I I I I I I'0
I I I I I I I I I I It
o t 234 1 8 1 • •
I I I I I I I I I I It
o , 234 1 , 7 • •
I I I I I I I I I I 1'0
I I I I I I I I I I I'
o , 234 5 8 7 • •
I I I I I I I I I I It
0,2341818'
I I I I I I I I I I Ito
I I I I I I I I I I I'
Day Day
Lines/Drains/Packs
Q13 Una
1234567
Peripheral xl 0000000
xl 0000000
x3 0000000
x4 0000000
Centtalline xl 0000000
xl 0000000
xl 0000000
Tripple lumen xl 0000000
xl 0000000
Hickman 0000000
Swanganz 0000000
Arterial 0000000
Epidural Catheter 0000000
Feeding line 0000000
Q14 Packs etc.
Vaginal pack 0000000
Nasal pack 0000000
Nasal pack splints 0000000
Day
8 9 10 11 12 13 14
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
Survey:3 Page:2
111111' I• 11(: 11111111111111111_ Scanning by Formic Ltd. London, (+44) 01718241730 •
416
Redivacxl
xl
x3
x4
Corrugated drain xl
xl
Robinson Portex Drain xl
xl
x3
x4
Chest Drain xl
xl
xl
x4
NG tube - bile drainage
Ttube
Urinary Catheter
Re-eatheterised
Suprapubic Catheter
Nephrostomy tube
Q16 Other
Tracheotomy Tube
ETTube
Pacing Wire
1234567
0000000
0000000o 0 0 0 000
0000000
0000000
0000000
o 0 0 0 000
0000000
000 000 0
0000000
0000000
0000000
0000000
000 000 0
o 0 0 0 000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
000 0 000
Physiotherapy. OT. Speech Therapy etc
Ql7 Physio - Face to Face contacts
xl
xl
x3
x4
x5
x6
x7
x8
x9
xl0
Q18
Dietician xl
Dietician x 2
Social worker
Speech therapy xl
xl
xl
Spec. stoma nrs
Macmillan Nrs
Diabetic Nrs Spec
Continence Nurse
123 4 S 6 7
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
123 4 S 6 7
0000000
0000000
0000000o 0 0 000 0
0000000
0000000
0000000o 0 0 000 0o 0 0 000 0o 0 0 000 0
8 9 10 11 12 13 14 •
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000o 0 000 0 0o 0 000 0 0
8 9 10 11 12 13 14o 0 0 0 0 0 0
0000000o 0 0 0 0 0 0o 0 0 0 0 0 0o 000 000
000 0 000o 0 0 0 0 0 0o 0 0 0 000o 0 0 0 000
0000000
8 9 10 11 12 13 14
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
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Ql9
OT xl
x2
x3
x4
x5
x6
x7
x8
Q10 OT Home VIsit
Day of Visit 1
012'41.71.
I I I 1 1 1 1 1 1 I 1'0
I 1 I I I I I 1 I I I'
Units supplied 1
012345171'
I 1 I 1 1 I 1 1 1 I I'
1 2 3 4 5 6 7
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
•
8 9 10 11 12 13 14
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
Day of Visit 2o , 2 , 4 I • 7 1 •
I 1 1 1 I I I I 1 I 1'0
I I I I I I I 1 I I I'
Units supplied 2
o 1 2 , 4 I • 7 • •
I I I I I I I I I I I'
Dressingslnursing procedures
Q21 Wound care
o 1 234 I • 7 • •
Number of wounds I I 1 1 I I 1 I I I I'
Q21 Wound care
Wound redressed Xl
X2
X3
X4
XS
>5
Snch~c1ipsranoved
Q23 TractionlPlasterffEDS
Skin traction set up
Check traction
c/o new plaster
Limb plaster renewed
TED stockings
CPMmachine
Nursing Care
21t Pmonal Hygien!
Bed Bath
Assisted wash
PuUbath
Assistancr with dressing
1 2 3 4 5 6 7
0000000
0000000
0000000
0000000
0000000
0000000
0000000
1234567
0000000
0000000
0000000
0000000
0000000
0000000
1234567
0000000
BBBB8B8
0000000
8 9 10 11 12 13 14
0000000
0000000
0000000
0000000
0000000
0000000
0000000
8 9 10 11 12 13 14
0000000o 000 0 0 0
0000000
0000000
0000000
0000000
8 9 10 11 12 13 14
000 0 0 0 0
8BBBB88
0000000
I I ::
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Q1S Elimination
clo urinary incontinence
clo faecal incontinence
clo illeostomy/colostomy
clo bladder irrigation
bladder washout
Assistance to the toilet
Manual evacuation
Peritoneal Dialysis
Q16 Prevention of presure sores,
DVTetc
2-4 hourly change oCposition
Inurse
2-4 hourly change of position -
2 nurses+
Encouragement leducation
deep breathing exercises.
leg exercises
Q17 MobUity
Bedfastichairfast
Assistance needed in
and out of bed
Assistance with walking
Q18 Observations
Post-op obs
Hourly TPRlBP/02 SATIPCA
4 hourly TPR & BP
BDlDaily Obs.
NeuroObs.
Stool Chart
Pain Chart
PV Loss Chart
HourlyBMs
4-6 Hourly BMs
Daily urinalysis
4-6 Hourly Urinalysis
6 Hourly Urinalysis
Fluid Balance Chan
Weight recorded
Peak Flows
Continuous cardiac monitor
Swan ganz studies
Hourly ventilator checks
CVP Readings
Blood gasses 1-5
Blood gasses 6-10
Blood gasses 11-15
Blood gasses 16-20
Blood gasses 21-25
CIOFall
123 4 S 6 7
000 0 0 0 0
0000000
8888888
0000000
0000000
0000000
0000000
I 2 3 4 S 6 7
0000000
0000000
0000000
1234567
0000000
0000000
0000000
1234567
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
8 9 10 11 12 13 14
o 0 0 000 0
0000000
8888888
0000000
0000000
0000000
0000000
8 9 10 II 12 13 14
0000000
0000000
0000000
8 9 10 11 12 13 14
0000000
0000000
0000000
8 9 10 11 12 13 14
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000o 0 0 0 0 0 0
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000o 0 000 0 0
0000000
•
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Q19 Chest physio by nurse etc
ET suction
2.4 hourly chest physio
clo oxygen therapy
cloCPAP
Q30 Special Bed/mattress
Foam/Spenco mattress
Ripple mattress
Low air loss bed
Water/air fluidise bed
Q31 Nutrition
Help with fluids and meals
Food chart maintained
clo ng feed
cloTPN
clo gasttostomy feed line
Nutrison xl
x2
x3
x4
Tuminl
pt/relative education
Q31 Mental state/sensory
defedts
123 4 S 6 7
0000000
0000000
0000000
0000000
123 4 S 6 7
0000000
0000000
0000000
0000000
123 4 S 6 7
0000000
0000000o 000 000
0000000
0000000
0000000
0000000o 000 000
0000000
0000000
1 2 3 4 S 6 7
clo acute confusion 0 0 0 0 0 0 0
emotional support
needed for pt +/or relatives 0 0 0 0 0 0 0
unconcious 0 0 0 0 0 0 0
impaired speccblsightl
hearingllanguage 0 0 0 0 0 0 0
difficulties
Q33 Other
Cardio version
Cardiac arrest
Barrier nursing
Q34 HaemoftltrationlDialysis
Haemofiltration
Set change xl
Set change x2
Set change x3
Dialyisis
0000000o 0 0 0 000o 000 0 0 0
o 000 0 0 0
0000000o 000 000
0000000
o 0 0 0 0 0 0
8 9 10 11 12 13 14
0000000
0000000
0000000
0000000
8 9 10 11 12 13 14
0000000
0000000
0000000
0000000
8 9 10 11 12 13 14
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
8 9 10 11 12 13 14o 0 0 0 000
000 000 0
o 0 0 0 0 0 0
000 0 000
o 0 0 0 000
0000000
0000000
0000000o 0 0 0 0 0 0
0000000o 0 0 0 0 0 0
000 0 0 0 0
•
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OPERATION DATA
Study Number
Operation 1 Q2 Dayo I 2 , • • • 7 • •
I I I I I I I I I I I'D
1 I I 1 1 I I I I I I'
Q3 Location
o , 2 I • • • 7 • •
1 I I I I I Ito
1 I I I I I I I I I I'
QI0 Urgency of Surlery:
DWlthln 1hour
DWlthln 8 hours
DWlthln 24 boun
DWlthln 72 boun
DWlthin 3weeki
D Non-urgent
Q12 Grade oflurgeon:
o I I , • • • 7 • •
I I I I I I I I I I 1'0
I I I I I I I I I I It
IAnaesthetic Section I Q4 Anaesthetist 1 gradeo , 2 , 4 I .7. •
I I I I I I I I I I 1'0
I I I I I I I I I I I'
Q6 ASAgrade
o , 234 6 • 7 • •
I I I I I I I I I I I'
Q7 Anaesthetic type: Q8
D GAonly
D GA&LA
D LA +or-sedation
DSedation only
OEpldural
ISurgical SeCtioS
Q9 Type of case:
DElective
DEmergency
DElective or urgent cases done by spedal
arrangement (I.e. not on a routine list)
Ql1 Procedure 1: _
OPCS4 code:~~~~~~~_
o I 2 J • • • 7 • •
Letten 11111111111'0
1 I I I I I I I I I I'
o , 234 • • 7 • •
I I I I I I I I I I Ito
Numbers 1 I I I I I I I I I I'
I I I I I 10.,
Q5 Anaesthetist 2 grade
0121 ••• 7 ••
I I I I I I I I I I I'D
I I I I I I I I I I I I
D Local Inftltration
D Topical Infiltration
D Motratt'slolutioD
D Peripheral nerve block
D Intravenous regionalo Brachial plexus block
D Intercoltal block
D Spinal
D Caudal epidural
D Lumbar epidural
D Thoracic epiduralo Cervical epidural
Q13 Grade of lupervlslng lurgeon:
o , Z 1 • • • 7 • •
1 I I I I I I I I I 1'0
I I 1 1 I 1 I I I 1 I'
SUIV.y:6
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• •Q14 Procedure 2: _
QIS Grade ofsurgeon:
Letters
OPCS4 code:-:--:--:-:--:-::-:--:-:::-::-_
01234117 ••
I I I I I I I , , , ''D
I , I I I , I I I I "
o I 2 3 • • • 7 • •
I I I , I I I I I I 1'0
I I I I I , , , , I It
Numbers
o I 234 • 1 7 • •
I I I I I I I I I I Ito
I I I I I I I I I I It
I I I lo.t
Ql' Grade of supervising surgeon:
o t 2 , • • • 7 • •
I I I I I I I I I I ID
I I I I I I I I I , I'
Ql. Grade of surgeon:Q17 Procedure 3: _
OPCS4 code:..,_ __ ~~:_::__:_:::-::--
o I 23. I • 7 • •
I I I I I I I I I I ItO
I I I I I I I I I I It
Letters
Numbers
o t 2 a • • • 7 • •
I I I I I I I I I I I to
I I I I I I I I I , It
o t 23. I • 7 • •
I I I I I I I I I I I to
I I I I I I I I I I It
I I I I lo.t
Q19 Grade of supervising surgeon:
o t 23. I • 7 • t
I I I I I I ID
I I I I I I I I I I It
Q20 Procedure4: _
OPCS4 code:~~:-:"-:--:-:::-:"-:-,:",,""_
o I 23. 6 • 7 • •
I I , I I I I I I I I to
I I I I I I I I I I It
Letters
Numbers
Q21 Grade of surgeon: o t 23. • • 7 • •
I I I I I I I I I I I to
I I I I I I I I I I It
Q21 Grade of supervising surgeon:
o I 23. • • 7 • •
I I I I I I I I I I I to
I I I I I I I I I I It
I Io.t
012,.,·7 ••
I I I I I Ito
I I 1 I 1 I I , I I It
Q23 Procedure S: _
OPCS4 code: _
Letters
Numbers
Q24 Grade of surleon:
o t 23. • • 7 • •
I I I I I I I I I I I to
I I I I I I I I I I I'o t 23. • • 7 • •
I I , I I I I I I I Ito
I I I I I I I I I , It
Q25 Grade of supervising surgeon:
o I 23. • • 7 • •
I I I I I I I I ID
I I I I I I I It
I I I I I lo.t
Otl, ••• 7.,
I I I I I Ito
I I I I I I I I I I It
SUlWy:1I P9:2
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•Q26 Procedure 6: _
OPCS4code: ~~---
o , 23' 5 • 7 • •
I I I I I I , I I , 1'0
I , , I I I I I I , "
Letters
o , 2 , , • • 7 • •
I I I I I I I I I I 1'0
Numbers I I I I I I I I I I "
I I I I ,0'
Q29 Procedure 7: _
Letters
OPCS4 code: -..--
o , 23' • • 7 • •
I I I I I I I I I I jlo
I I I I I I , I I , "
o , 2 , , • • 7 • •
I I , I I I I I I I ,'0
Numbers I I I I , , , I , I "
W-L..J...,...L..J.-L..J....:L....L...JI 0.,
•
Q17 Grade of suraeon:
o , 2 S , 5 • 7 • •
I I I I I I I I I I 1'0
I , , , , I I , , , I'
Q28 Grade of supervising suraeon:
o , 2 I 4 • • 7 • •
I , , , I I I , , , '.0
I , I , I I I I I , "
Q30 Grade of surgeon:
o , 2 , • I • 7 • •
I I , I I , , , , , 1'0
I , , , I , I , I , "
Q31 Grade o!supervislng suraeon:
o , 2 , • • • 7 • •I , I , , , , , , , ,'0
I I I I I I I I I , I'
Q32 Time sent for:
o , 2
FER' • I • 7 • •_1111111
Q35 Time entering recovery:
o , 2
RTII · I • 7 • •_"""I
DRUGS IN THEATRE
Q37 Augmentin 1.2 grams
Ccfuroxime 7SOmgs
Cefuroxime l.Sgrams
Erythromycin 1 grams
Gentamicin 80 mgs
Gentamicin 120mgs
Metromidazole sOOmgs
Q33 Time of inducdon:
o , 2
Em' · ·· 7 • •_1111'"
Q34 Time on table:
o , 2
Em' · I • 7 • •rrrrrrrrrn
Q36 Time leaving recovery:
o , 2
Em' · ·· 7 • •_11'"11
0 , 2 , • I 5 7 • •I I I I I I I I I I I'
0 , 2 , • I 5 7 • •I I I I I I I I I I I'
0 t 2 , • I • 7 • •I I I I I I I
0 t 2 , • I • 7 • •I I I I I
0 t 2 , • I • 7 • •I I I I I
0 t 2 , • • 5 7 • •I I I I I
0 t 2 , 4 I I 7 • •I I I I I
Q38 Other Andblodes:
rr- ,......... l- I--- l- I--- l- I--- L.....
l.- I- I-
2
t
o
•
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LAB TESTS: Dayl-Day7
•~----------------------------~
Study Number .....-- --------------.
Ql Biochemistry, Haemotology, Histopathology & Cytopathology
ole 5 ole 6 ole 7 olePIA ME I ole 2 ole 3 ole 4
----------- _---_._-----_._-----_._._----_ .._--
AIAT 0 0
ABHB 0 0
ADNA 0 0
ALBU 0 0
ALKP 0 0
ALT 0 0
AMYL xl 0 0
xl 0 0
ANA 0 0
AST 0 0
ATA 0 0------------
BICA 0 0
BILl 0 0
BJP 0 0
BM 0 0
0000000 0000000
0000000 0000000
0000000 0000000
0000000 0000000
0000000 0000000
0000000 0000000
0000000 00000008888888 0000000
0000000 8888888o 0 0 0 0 0 0 000 0 0 0 0---_ ..._----------_ .._-----------------
0000000 0000000
0000000 0000000
0000000 0000000
0000000 0000000
Q3
CALC 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
CE 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
CHOL 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
CK 0 00000000 0000000
COAGS Xl 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
X2 0 00000000 0000000
X3 0 00000000 0000000
COMP 0 00000000 0000000
CORT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
COULT Xl 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
i; 8 88888888 8888888
X4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0...._------_ __ ..__.__._-_ .._-_._-_. __.__ --_._--_ ..-_.-.- .._ --_ _._-
~~~CL 8 8 B B B B B B B B B B B B 8 8
C~ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0-_ --_._---_ .._._---_ _--_ _---.._ _-------_. __ ._--------------
DIFF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
DIGO 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0_ _----_._------------_._. __.__.__ _ _.._..-_.-._---------_._.---_ _-
ESR 0 00000000 0000000
SlII'Vey:4
P~:1
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Q4 PIA A&.E I ole 2 ole 3 ole 4 ole' ole 6 ole 7 ole
FARA 0 0 0 0 0 0 o 0 0 0 0 0 0 0 0 0
FBC xl 0 0 o 0 0 0 0 0 0 0 0 0 0 0 0 0
xl 0 0 0 0 0 0 o 0 0 0 0 0 0 0 0 0
x3 0 0 0 0 0 0 o 0 0 0 0 0 0 0 0 0
x4 0 0 0 0 o 0 o 0 0 0 0 0 0 0 0 0
FOP 0 0 0 0 o 0 o 0 0 0 0 0 0 0 0 0
FEST 0 0 o 0 0 0 000 0 0 0 0 0 0 0
FLGLU 0 0 0 0 o 0 0 0 0 0 0 0 0 0 0 0
FLPROT 0 0 0 ODD 000 0 0 0 0 0 0 0
FOB 0 0 0 0 0 o 0 o 0 0 0 0 0 0 0 0
FSH 0 0 0 0 0 0 0 o 0 0 0 0 0 0 0 0........ ----_ ....-.._.-_ ..-----_._ .._---_._- ----_ ..----------
GASE 0 0 0 000 0 o 0 0 0 0 0 0 0 0
GF 0 0 0 000 0 o 0 0 0 0 0 00 0
ooT 0 0 0 0 B B B B B B 0 B B 0 0 BGLUe 0 0 o 0 0 0 0
GLUeF 0 0 0 0 0 0 o 0 0 0 0 0 0 0 0 0
GLyeA 0 0 0 0 o 0 DOD 0 0 0 0 0 0 0
GTT 0 0 0 0 0 0 o 0 0 0 0 0 0 0 0 0
GP 0 0 0 0 0 0 o 0 0 0 0 0 0 0 0 0_ ..------_ .._---------------------------- ------------
Q' 1 ole 2 ole 3 ole 4 ole' ole 6 ole 7 ole
HBD 0 0 0 0 o 0 o 0 0 0 0 0 0 0 0 0
HEP xl 0 0 0 0 0 0 0 o 0 0 0 0 0 00 0
xl 0 0 0 0 0 0 0 o 0 0 o 0 0 0 0 0
--------_ ..._------------------_ ...._ .._----_.- .... --------------_ ......-
IGA 0 0 0 000 0 0 0 0 0 0 0 0 0 0
IGE 0 0 0 000 0 0 0 0 0 0 0 00 0
100 0 0 0 DOD o 0 0 0 0 0 0 00 0
IGM 0 0 0 000 0 0 0 0 0 0 0 00 0
IGS 0 0 0 0 o 0 0 0 0 0 0 0 0 00 0
INSU 0 0 0 0 o 0 0 0 0 0 0 0 0 0 0 0
IRON 0 0 0 000 0 o 0 0 o 0 0 00 0
......_-----_ ...__ ..._.._-_ ......._.--_ ......_--_._ .._.----------------------------
Kt 0 0 0 0 0 0 0 0 0 0 o 0 0 00 0-_ .._--._---_ ....------_ ..__ .._-_ ....-_ ...._-....---------------------------_ .._----
LAP 0 0 0 0 o 0 o 0 0 0 0 0 0 00 0
LFT 0 0 0 0 o 0 0 0 0 0 0 0 0 0 0 0
LH 0 0 0 0 0 B o 0 0 B B B B B B BLIB 0 0 0 0 0 o 0 0
LITH 0 0 0 0 0 0 o 0 0 0 0 0 0 0 0 0
----------------------_._---_ .._-_ ...._-----_ .._---------------------_ ..-
QMAGN 0 0 0 0 o 0 o 0 0 0 0 0 o 0 0 0----_ .._-_ .._-_ ..----_ .....__---_ ..._----_ ...-.__ ..._-----------------------
NAIK. 0 0 0 0 0 o 0 0 0 0 0 0 000 0-------_ ......... _--_ ...._ .........__.-..__._....._._._._----_.-. __ .----_._ .._------
OLIGO 0 0 0 0 0 o 0 0 0 0 0 0 o 0 0 0
OSMO 0 0 0 0 0 0 o 0 0 0 0 000 0 0
..-..__ .._--_._-------_._ .._._._---_._-_ .._-_._ ......_-_.---._-_ .....-------------_ .._-----
PHENY 0 0 0 0 0 000 0 0 o 0 0 0 0 0
PRe 0 0 0 0 o 0 0 0 0 0 0 00 0 0 0
PROG 0 0 0 0 0 o 0 0 0 0 o 0 0 0 00
PROl 0 0 0 o 0 o 0 0 0 0 o 0 0 0 0 0
PROT 0 0 0 0 000 0 0 0 0 0 0 0 0 0
PRS 0 0 0 0 000 0 0 0 o 0 0 0 0 0
PS.-\ 0 0 0 0 0 o 0 0 0 0 0 0 0 0 0 0-_ ..._ ........_--_ .._-_ .._---_._ ....._ ..._----_ ..-....._._--_._.---------._---------------_._----_._--
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~7
RA
RC
RCF
RUBILI
RUCREA
RUNAJK
RUOSMO
RUPORP
RUUBG
RUUREA
SB 12
SCFGLU
SFER
• SPE
SSP
PIA A&Eo 0o 0o 0o 0o 0o 0o 0o 0o 0o 0
o 0o 0o 0o 0o 0--------------
1 ole 2 ole 3 olc 4
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
ole S ole 6 ole 7 ole
0000000
0000000BBBBBBBo 0 0 000 0o 0 0 0 0 0 0
0000000
0000000
0000000
0000000
•
._-------------
0000000
0000000
0000000
0000000
0000000-----------_.
Q8
TEST 0 00000000 0000000
TImO 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0~ g g 888 8 8 8 8 B B B 8 B B B
-------- _._._ --_ .._-_ .._-_ _-------------_ ..---_ _..-..- _._-
UCALC 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
UCREA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
UNAJK 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
uo~ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
um~ 0 0 0000000 0000000
U PORP 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
UPROT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
UURAT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
UUREA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
UVMA 0 0 0 0 0 0 0 0 0 000 0 0 0 0
UIE xl 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
xl 0 0 0000000 0000000
x3 0 0 0000000 0000000
......._.- _-._-------_ _--_._._--_ _-------------_ _--_.- _----
Q9 URAT
UREA
o 0 0000000o 0 0000000 00000000000000
------------_---------- ..---------------------_ ..._--_ .._-----_._-- ..._--_ ..
V CORT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0---_._-- _ __ .-_.._-_._---_._-----._. __ ._ - _- _-_.__ _ ..-.__._--_ _ _ .._ _---_.
W~ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
---...._ ......._----_ ....-.._---_ ...._-_ .._-.---_ ......_-- ...--_..----------_._-------
XM xl 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
xl 0 0 0000000 0000000
QIQFS
2FS
2B
3B
4B
SB
6B
7B
8B
9B
lOB
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
8888888o 0 000 0 0
0000000
0000000
0000000
0000000o 0 0 0 0 0 0
I111i
P8p:3
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Microbiology
Qll PIA A&B 1 ole 2 ole 3 ole 4 ole S ole 6 ole 7 ole
AFB 0 00000000 0000000
ASO 0 00000000 0000000
AWO 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0__ ,_._-----. --_._-_.-
BC 0 00000000 0000000 --
0000000
0000000
0000000 ,----
0000000
0000000
--------"------
CAPD
CHLAM
CMV
ooo 0
00000000
000000000000000------,------------DW 0 0 0 0 0 0 0 0 0
DIS 0 0 0 0 0 0 0 0 0
---- ....._._---_._- ----_._-------_----
~ 0 0 0 0 000 0 0
En 0 0 0 0 0 0 0 0 0..__ ._--_. -------,--
FLUID 0 0
FU 0 0
0000000o 0 000 0 0
BB88BBB
,--------
BBBBBBB
o 000 Oo-oo-erO O-oo·-cfb--·----
00000000 0000000
00000000 0000000
GA 0
GENT 0
GNT 0
Q12
0 0 0HAV o 0 0 0 0 0 0 0 0 0 0 0 0
HBSAG 0 0 o 0 0 0 0 0 0 0 0 0 0 o 0 0
HEPC 0 0 B888BB 0 8 8 B B 0 0 0HIV 0 0 0 0 0 0
HOLD 0 0 o 0 0 0 0 0 0 0 0 0 0 0 0 0
HSV 0 0 o 0 0 0 0 o 0 0 0 0 0 0 0 0--_._.__ .._- --------- ............._-----------_-.
ruc 0 0 0 0 000 0 0 0 0 0 0 0 0 0_..__ ._---_.-.-----_. __ ..-.------_ ......_.__._-_ ...._---_._--_.
LEP 0 0 0 o 0 0 0 0 0 0 o 0 0 0 0 0
LP 0 0 0 0 000 0 0 0 0 0 0 0 0 0. -------_ .._-_ .._.__ ._-_ ......
MRSA 0 0 0 0 000 0 0 0 0 0 0 0 0 0
MS 0 0 0 o 0 0 0 0 0 0 0 0 0 0 o 0
---_-------- _--------_ ..._--------_ .._--
NS 0 0 0 0 000 0 0 0 0 0 o 0 0 0~----o·-o·"""d 0 "t]""cj""o- 0-a--·O ..O··-cro"Ef·o···[j""· ..·--··-·····
PEN 000000000 0000000
PLEUR 000000000 0000000
pus 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0-_ ..__._----
SUI'VtI)':4 PIIII':4
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Q13 P/.A AU 1 ole 2 ole 3 ole"
ROTA 0 0 0 0 0 0 0 0 0
RS 0 00000000
RSV 0 0 0 0 0 0 0 0 0----------------------------,
sOD 000 000 0
SP 0 0 0 0 0 0 0 0 0
STS 0 0 0 0 0 0 0 0 0
TlSSUF
TOXO
TS
ooo
00000000
00000000
00000000
•
ole 5 ole 6 ole 7 ole
0000000o 0 000 0 0
0000000,--------------------------
0000000
0000000
0000000
0000000
0000000
0000000
u 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0---------------- -- ----------------VAN 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0VI 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
VS 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
VSER 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
--------------_._----------------- ---
W 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0_.._--.._-----------_ .._.._...._.__---- -------
Surv'V:4
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INFECTIONS
Study Number
•
Infection 1
Ql Date of onset:
(1'121'1. a • 7 ••..... 111111
o 1 2 3 • • • 7 • • 1011 12
1111111111111
o 123 • • • 7 • •
11111111111
QS Patbogen 1:
o 1 2 S • 6 • 7 • •
I I I I I I I I I 1'0
I I I I I I I I I I l'
Q3 Site of infdon:
o 1 2 I • I • 7 • •
1 1 I I I I I I 1'0
I I I I 1 I I I I I l'
Q6 Pathogen 1:
o 1 2 I • I 8 7 • •
I 1'0
I I I I I I I I I I l'
Q8oCAl0HAl• same ward 0HAl· different ward
Q4 Device:
012, ••• 7 ••
I I I I I I 1'0
I I I I I I I I I I l'
Q7 Pathogen 3:
o 1 2 S • • • 7 • •
I I I I I I I I I I 1'0
I I I I I I I I I I l'
DHAl· different hospital
Infection Z
Q9 Date of onset:
o 1 2 I
1I I I I· I • 7 • •..... I II II I
0'2'."7"'01112
1111111111111
o I 21. • • 7 • •
11111111111
Pathogen 1:
o 1 2 , • I • 7 • •
I I I I I I I I I I I to
I I I I I I I I I I l'
Site of lnfeedon:
o 12' • • • 7 • •
I I I I I I I I I I 1'0
I I I I I I I I I I I'
Pathogenl:
o 1 2 , • 6 a 7 • •
I I I I I I I I I I 1'0
I I I I I I I I I I l'
oCAl0HAl· same ward 0 HAl· different ward
Device:
o 1 2 S • • • 7 • •
I I I I I I I 1'0
I I I I I I I I I I l'
Pathogen3:
0121."7"
I I I I I I I I I I 1'0
I I I I I I I I I I It
o HAl· different hospital
Survey:7
I I II I II I I I I I I II II I II I•
PIIgtI:1
Sc:ft1Ing by Formlc Lid. London. (+44)017182<41730
1111111 • •
429
•
Infection 3
Date of onset:
o 1 2 3
111114 • • 1 • 8..... I I I I I I
o 1 2 3 • 5 e 1 • 8 10 " 12
I I " I I I I I I " I
o 1 234 5 • 1 • •
11111111111
Pathogen 1:
o 1 234 5 • 7 • 8
I I I I I I I I 1'0
I I I I I I I I I I I'
Site of infection:
o , 2 3 4 • 81. •
I I I I I I I I I 1'0
I I I I I I I I I I I'
Pathogen2:
o , 234 .81 • •
I I I I I I I I I I 110
I I I I I I I I I I f1
oCAl 0HAl • same ward 0 HAl • different ward
Infection 4
QZ3 Date of onset:
o , 2 3
111114 • • 1 • •..... I I I I I I
Q26 Pathogen 1:
0'23"81.'
I I I I I I I I I I 1'0
I I I I I I I I I I I'
Q24 Site of infection:
o , 2 I 4 • I 7 • •
I I I I I I I I I I 1'0
I I I I I I I I I I I'
QZ7 Pathogen 2:
o , 2 3 4 • 8 1 • •
I I I I I I I I I I 110
I I I I I I I I I I I'
Q29 OCAI OHAI. same ward 0HAl•different ward
•
Device:
o 1 2 a 4 • 81. •
I I I I I I 1'0
I I I I I I I I I I j1
Pathogen3:o 1 2 I 4 8 .,. •
I I I I I I I I 1'0
I I I I I I I I I I J1
o HAl· different hospital
Q25 Device:
o , a I • 8 .7. •
I I I I I I I I I I 1'0
I I I I I I I I I I j1
Q28 Pathogen 3:
o 1 2 I 4 • 8 7 • •
I I I I I I I I I I 110
I I I I I I I I I I I'
OHAI • different hospital
Survey: 7
I I II ! I I II II I II II II I II•
PIIge:2
Sc.nntng by Formic:Lid. London. (+404) 0171 92. 1730 •
430
APPENDIXS
Members of the Socio-economic Burden of Hospital Acquired Infection
Project Team,Steering Committee and Advisory Group
AS.1 Introduction
This appendix provides details of the members of the Socio-economic Burden
of Hospital Acquired Infection Project Team, Steering Committee, and Advisory
Committee.
AS.2 Project Team
Rosalind Plowman BA, MSc, RN
Nicholas Graves, BA, MA
Mark Griffin, BA, MSc
Rachael Dunk, RN
Alison Franklin, BSc, RN
Janette Trevarthen, RN, OHND
Maggie Waters, RN
Jennifer White, RN
Lynda Wright, BSc, RN
Barbara Ayres
Christine Berry
Project Co-ordinator
Research Economist
Statistician
Research Assistant
Research Assistant
Research Assistant
Research Assistant
Research Assistant
Research Assistant
Project Secretary
Administrative support
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A8.3 ProjectSteeringCommittee
Jane Bandcroft RN, ON, HV, FPCert Director of Nursing Practice, Study
Hospital
Barry Cookson MB, BDS, FRCP Path Director of laboratory of Hospital
Infection, Public Health Laboratiry
Service
Helen Glenister BSc, PhD, RN Nursing Director, Medical Devices
Agency. DOH
Bernadette Nazareth MBBS, MSc, Consultant in Communicable Disease
MRCPath Control. Redbridge and Waltham
Health Authority
Jennifer A Roberts MSc Econ, PhD, Reader in Economics of Public Health,
HMPHM London School of Hygiene and
Tropical Medicine, London
Mike Rowland, MBBS, FRCP, FFPHM Consultant Epidemiologist,
Communicable Disease Surveillance
Centre, Anglia and Oxford RHA
Tony Swan.PhD, HMFPHM, C Stat Director, Statistical Unit, Public Health
Laboratory Service
Lynda Taylor, RN, RM Head of Nursing and Infection Control
Unit, Laboratory of Hospital Infection,
Public Health Laboratory Service
Jennie Wilson, BSc, RN Programme Leader Infection Control
and Surveillance, Nursing and Infection
Control Unit, laboratory of Hospital
Infection. Public Health Laboratory
Service
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AS.4 Advisory Committee Members
Kay Butcher
Millie Carter
Sue Dewar RN, DNCert, MA
Georgia Duckworth MSc, FRCP, FRC
Path, FRIPHH
Johanna Finn BSc, MHSM, Dip HSM
Paul Gillett, MRCP, FRC Path
Simon Harding
Jayne Holmes RN
Rosemary Jenkins MSc, OMS, MTD,
RN,RM
Bill Maton-Howarth PhD
Jennifer Mcintyre RN, MSc
Elizabeth Meerabeau BSc, PhD, RN,
RHV,RNT,RHVT
Richard Murray
Elizabeth Tebbs MBBS, ChB
Ann Whittle
Department of Health (to Oct 1995)
Nursing Officer, Department of Health
(to Sep 1994)
District Nurse, Chichester Primary
Care Services Trust.
Regional Epidemiologist, CDSC,
North Thames
Chief Executive, West Suffolk
Hospitals Trust
Consultant Medical Microbiologist,
Stoke Mandeville Hospital
Economic Advisor, Department of
Health (to Sept 1995)
Senior Nurse, Queen Elizabeth II
Hospital, Welwyn Garden City (to Nov
1996)
Nursing Officer, Department of Health
(from Sept 1994 to Sept 1995)
Department of Health (from 1 April
1997)
Nursing Officer, Department of Health
(from Sept -1995)
Department of Health (to Mar 1997)
Economic Advisor, Department of
Health (from Sept 1995)
Senior Medical Officer, Department of
Health
Department of Health (to Oct 1995)
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APPENDIX9
Data variables included In the data analysis
A9.i Introduction
This appendix provides further details regarding the variables included in the
analysis of the incidence of HAl, and the impact HAls had on hospital costs and
length of hospital stay.
A9.2 Explanatory variables used in the regression analysis
A9.2.1 Overview of variables used
Table A9.1 provides details of the explanatory variables used in the data
analysis.
A9.2.2 Admission type classification system
Patients were classified as being admitted via one of nine routes: elective via
pre-admission, elective direct to the ward, urgent direct to the ward, emergency
via the accident and emergency department, emergency via the out-patients
department, emergency GP referral direct to the ward, transfer from another
ward via the day hospital, transfer from another hospital and finally via another
unspecified route. As indicated in Table A9.1, for the purpose of the analysis
these nine admission types were compressed into three main categories:
emergency admissions, elective admissions and transfers. Table A9.2 shows
how the nine admission types were compressed into three main categories.
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Table A9.1: Explanatory variables as used In the data analysis
Eu ..... tory variable CIauUIeatIon mtem
Sex Male
Female
Age 18-34
35-54
55·74
75+
Admission specialty Surgery
Otthopaedics
Urology
Oynaecology
Obstetrics
Admission type- Elective
Emergency
Transfi:Ir
Diagnosis group- PrimaJy discharge diagnosis grouped into one of 14 ICD9
catarories
Nwnber of co-morbidities None
One
Two or DlOI:e
Body Mass Index BMI<20
BMl20-<30
BMI>30
Diabetes Yes. No
ODeration Yes No
Catheter oresent nrior to UTI Yes No
Endotracheal tube oresent orior LRTI Yes. No
Wound drain mor to SWI Yes No
Antibiotics administered orior to each typo of infection Yes No
IVlIM antibiotics administered prior to each typo of infeotion Yes No
HAl status HAl identified during in-patient phase
HAl not identified durinsl the in- oatient Dbase
1'ypeofHAl· HA1s wore classifiod into 8 mutually axclusive groups:
• no HAl
• urinary tract infections
• lursical wounds infections
• lower respiratory tract infections
• blood stream infections• akin infections
• infections at other sites
• multiple infections (infections at more than one
sito)
*Further details of the cla8elflcation system used are preeented below
Table A9.2: Admission type classification system
Admission catagoriea used In the .... lysis Admission types wilhln MCh cagory
Elective Elective via pre-admleslon clinic
ElectIve
Emergency Urgent direct to the ward
Emergency via accident and emergency
Emergency via out patIenta department
GP referral
VIa day hoIpItal
Transfera Trenafer from another ward
Transfer from another hoIpItal
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A9.2.3 Primary diagnosis classification system
The primary discharge diagnosis were coded using the 9th revision of the
International Classification of Diseases system (ICD9). Each primary discharge
diagnosis was allocated either a three or four digit code depending on the
amount of information available. These diagnosis were initially grouped into 19
disease categories according to the ICD9 classification system and then further
compressed into 14 categories. Table A9.3 provides details of the IC09
categories included in each of the 14 study categories.
Table A9.3: Diagnosis group classification system.
Studyd ..... ICD.D..... Title of cat8gories
categories 1·14 c:at.gorle.
InclUded In
study
categories
1 I Infectious and parasitic disease
2 II Neoplasms
3 III Endocrine, nutritional and metabolic diseases. and Immunity disorders
4 IV 0I8easea of blood and blood forming organa
5 VI Dlaeases of tie nervous aystem and eenaa organa
6 V11 Dlaeases of tie oIrcuIatory system
7 VIII Dlaeases of tie respiratory system
8 IX Dlaeases of the digestive system
9 X 0I8easea of tie genitourinary aystem
10 XI Compllcalona of pregnancy, childbirth and puerperium
XV Certain conditione origlna1lng In tie perinatal period
11 XII. Dlaeases of tie skin and IUbcutaneoua tIeIue
12 XIII Diaeases of tie muacuIoakeletaf aystem and connective tIeIue
13 XVII Injury and PoiIonIng
14 XVI Symptorna, 8Igna and III- defined conditione
V Mental diaorders
XIV Congenital abnorma_
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A9.2.4 HAl classification system
HAls identified during the in-patient phase were classified into eight mutually
exclusive infection groups: no HAl, infections of the urinary tract, surgical
wounds, lower respiratory tract, bloodstream, skin, other sites, and in those
cases where patients acquired more than one infection, multiple infections.
Table A9.4 provides details of the sites of infection included in the six single site
infection groups.
Table AI.4: HAl classification system
HAl groups UHd Inthe....,. .. ._ of InfacIacIn Included In the anaIys" No. of Pemtntap
groups- IItfectIoM of~
IdentfI'Ied .. IdentfI'Ied ..
each ... each ...
Urinary tract irtfec:Iion8 unCllnlctl 38 18.8
unCllnlctl and labonItory evidenoe 81 29.3
AtymptoUc BacterIurta 0 0.0
Lower respiratory tract infections Pneumonia 10 ".8
Che8tlnfectlon 13 6.3
Lower reepiI'atoty tract 0 0.0
Surgical wound infectlona MajorSWI 6 2.9
MinorSWI 34 18.3
Bloodstream infecti0n8 .. StptIcMmIe 3 1.4
Bacteraemia 1 0.5
Skin infectione Skin 15 7.2
SkinUlccn 0.0
PmIure IOAII 1 0.5
BII8tered akin 0.0
Infections at other situ Mljor eccIdentaI wound 1 0.5
Minor aocIdentaf wound 0.0
Upper rtepIratoiy tract and .. 2 1.0
EYE 0.0
0IItiI externa 2 1.0
Oralthruah 2 1.0
Upper ...... atory tract • unapecHIc 1 0.5
MouI'I 3 1.4
Other genital tract " 2.9GI 1 0.5
Other abdominal 2 1.0
Other 3 1.4
SyItamic 1 0.5
PerIoardltit 1 0.5
Note: Whet'. more 1han one infection had been acquired thfte were oIueIfIed .. multiple infectione
• Oeflnltiona of the infectione lilted can be foUnd InAppendIx 5
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APPENDIX 10
The age. sex, admission type and specialty distribution of study
participants and eligible patients who were not recruited Into the study
A10.1 Introduction
Between April 1994 and May 1995, 3534 patients admitted to the surgical
specialties covered in this study were eligible for recruitment. Of these patients,
2477 (70.1%) patients were recruited into the study, 197 (5.6%) declined
participation, 851 (24.1%) were not recruited due to practical reasons such as
insufficient time, and in a further nine (0.3%) cases the reason for non-
recruitment was not specified. In order to check how representative the study
sample was of the wider eligible population the following data were recorded for
all eligible patients who were not recruited: sex, age, admission type and
admission specialty. The age, sex, admission type and specialty distributions of
study participants and eligible patients who were not recruited into the study
were subsequently analysed and compared. The results of this analySiSare
presented in this appendix.
A10.2 The distribution of study participants and eligible patients who
were not recruited by .ex
Table A10.1 provides details of the sex distribution of study participants and
eligible patients who either declined participation, or were not recruited due to
practical reasons such as insufficient time. Table A10.2 shows the sex
distribution of study participants and eligible patients who were not recruited,
together with that, which would have been present if all eligible patients had
been recruited.
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Table A10.1: Sex distribution of study patients and eligible patients who
were not recruited
Reuon for not recruiting eI"" piItiMta
Sex
Study Pdentnot R... on for non- AlI.I""Pdent decIiMd
Participant ........... clua1o NCruIImant piItiMta not
participation practical......,.... uMnown recndtad
n. % n. % n % n % n %
Male 1003 40.62 98 48.7 423 48.7 4 28.8 525 411.4
Female 1_ 59.38 97 48.2 425 49.8 5 35.7 527 49.8
Unknown 0 0.0 2 1.0 3 0.4 5 35.7 10 0.9
TOTAL 2488 100 197 851 14 1062
• For example insuffioIent time
Table A10.2: Sex distribution of study participants, eligible patients who were
not recruited, and that which would have been present If all
eligible patients were recruited
Elig" piItiMta Ma... Femalel An patienII ProportIon C'A) (H% Cl) of male pdants p"Sua
Recruited 1003
1_
2488 40.8 (38.7; 42.8) <0.001
Not - recrulted* 525 527 1052 48.9 (48.8; 53.0)
All eligible pa1IentI 1528 1993 3521 43.4 (41.8; 45.1)
•An addltional1 0 patien1l were not recruited however their lex wee not recorded, conaequently they have been excluded
from this analysis
The percentage of male patients In the cohort of recruited patients was 8.3%
higher than in the cohort of patients who were not recruited. This difference was
found to be highly significant. However, the percentage of male patients in the
recruited cohort was only 2.8% less than the intended cohort. This difference is
extremely unlikely to lead to bias in estimates of how those with and without HAl
compare.
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A10.3 The distribution of study participants and eligible patients who
were not recruited by age group
Table A10.3 provides details of the age distribution of study participants and
eligible patients who either declined participation, or were not recruited due to
practical reasons such as insufficient time. Table A10.4 shows the age
distribution of study participants and all eligible patients who were not recruited,
together with that which would have been present if all eligible patients had
been recruited.
Table A10.3: Distribution of study participants and eligible patients who were
ltedbnotrecru tvaae group
Reuon for not NCnIIIIng eligible patIenIa
Study Patient not Reuon for non- AIIeflglble
Ag_Group Patient declined
Participant racn.dted due to racrultment Pdentsnot
participation
prIICticaI ntUOnI· unknown NCn.dted
n % n. % n % n. % n %
18-30 363 14.7 15 7.8 79 8.3 1 11.1 86 8.0
31-40 337 13.8 17 8.6 91 10.7 2 22.2 110 10.4
41-50 336 13.6 13 6.8 127 14.9 1 11.1 141 13.3
51-60 375 15.2 43 21.8 174 20.4 1 11.1 218 20.8
81-60 815 37.1 80 40.8 244 28.7 3 33.3 327 30.9
81-100 143 5.8 28 14.2 60 7.1 1 11.1 88 8.4
Unknown 0.0 1 0.5 76 8.9 0 0.0 77 7.3
TOTAL 2488 100.0 197 100.0 851 100.0 8 100.0 1067 100.0
*For example In8uffIcient time
Tabl. A10.4: Ag. distribution of study participant., eligible patient. who were
not recruited, and that which would have been p..... nt Ifall .llglble
patient. were recruited
1!IIgIbie patIenIa Age ,roup All patIema Proportion (%) of pattenta ... 1NO Pv ......
18-11 10+ (ll%CI)
Recruited 1411 1058
2_
57.1 (85.2; 58.1) 0.8128
Not - recruiteer 584 418 860 57.8 (M.4; 80.7)
All eligible pa1ierda 1975 1474 344. 57.3 (85.8; 58.8)
*An additional 77 patients were noI recruited however their age WIt noIl'ICOrded, ClOr'IMqUentIy they heve been excluded
from this analyala
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The results presented in Table A10.4 indicate that the proportion of study
participants who were over 60 years of age was almost identical to that which
would have been present if all eligible patients were recruited.
A10.4 The distribution of study participants and eligible patients who
were not recruited by admission type
Table A10.5 provides details of the admission type distribution of study
participants and eligible patients who either declined participation, or were not
recruited due to practical reasons such as insufficient time. Table A10.6 shows
the admission type distribution of study participants and aUeligible patients who
were not recruited, together with that which would have been present if aU
eligible patients had been recruited.
Table A10.6: Distribution of study partlclpanta and .lIglble patl.nts who were
not recruited by admission type
Reason for not racndtlng ...... patients
Admiulon Study
Patient not AII.lig"
Ruaon for non-
Patient declined nICfUIIecI due tID P.aentsnotType Participant ntCf'UIIment
recruWparticipation pt'IICdIuI
unIcnown
I'!IIIISOI'IS.
n % n. % n % n % n %
Elective 1629 •. 0 118 59.9 421 49.5 4 44.• 543 51.4
Emergency a.o 34.0 78 39.8 425 49.9 5 55.8 508 48.1
Unknown 0 0.0 1 0.5 5 0.6 0 0.0 8 0.6
100.
TOTAL 2489 100.0 197 100.0 851 100.0 9 100.0 1057
0
•For example, ineufflcient time
Table A10.6: Admission type distribution of study partlclpanta, .llglble patients
who were not recruited, and that which would have been p..... nt If
all eligible patients were recruited
Eligible patients
Admission type AU Proportion (%) of patients who were
Pvalue
Elective Erntrgency patients elective admInlons "1% Cl)
Recruited 1629 840 2489 •. 0 (84.1: 87.8) <0.001
Not-recruited" 543 508 1051 51.7 (48.6; 54.7)
AB eligible patients 2172 1348 3520 81.7 (80.1: 83.3)
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The proportion of patients who were elective admissions differs significantly in
the two cohorts: patients recruited into the study and eligible patients who were
not recruited. However, the proportion of patients in the recruited cohort who
were elective or emergency admissions only differed from the intended cohort
by 4.3%. Again there is no reason to believe that differences of this magnitude
will have led to substantial biases in comparisons of those with and without HAl.
A10.5 The distribution of study participants and eligible patients who
were not recruited by admission specialty
Table A10.7 provides details of the distribution of study participants and eligible
patients who either declined participation, or were not recruited due to practical
reasons by admission specialty. Table A10.8 shows the admission specialty
distribution of study participants and all eligible patients who were not recruited,
together with that which would have been present If all eligible patients had
been recruited.
Table A10.7: Distribution of study participants and eligible patients who were
not recruited by admission SDeCI.tty
Reuon for not nICI'UIIng eligible pMIInts
Admission Study
Patient not RealOnfor AI. eligible
Specialty Participant
PatIent declined recruItIId due non- patlenbnot
partlclpdon to pnICtIcaI recNiIment nlCNIbId
I'MSONJ. unknown
n % n % n % n. % n %
Surgery 884 35.8 73 37.1 488 55.0 3 33.3 544 51.5
Orthopaedics 501 20.3 45 22.8 121 14.2 5 55.8 171 18.2
Urology 472 19.1 80 30.5 188 21.9 0 0.0 248 23.3
Obstetrics &
9.1
Gynaecology
812 24.8 19 9.8 78 8.9 1 11.1 98
TOTAL 2489 100 197 100.0 811 100.0 9 100.0 1057 100.0
•For example, InaufftcIent time
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Table A10.8: Admission specialty distribution of study participants, eligible
patients who were not recruited, and that which would have been
present If all eligible patients were recruited
ElIgible pIItIents
Proportion rAt) recRiited from each
Admission specialty
.peciIIty
Pvalue
Not AU",,,, Not AU........
RecNited RecNited
recRiited pIItIents I'8CRIited patIentI
Surgery 884 s.M 1428 35.' 61.5 40.6 cO.001
Orthopaedic8 501 171 672 20.3 18.2 19.1
Urology 472 246 718 19.1 23.3 20.4
Obstetrics & gynaecology 612 98 708 24.8 9.1 20.1
Allpatlent8 2469 1057 3528 100.0 100.0 100.0
The results presented in Table A 10.6 indicate that there are significant
differences in the proportion of patients from each specialty in the recruited and
non-recruited patient groups. However, in no specialty was there more than a
4.7% difference between the recruited and intended cohort. There is therefore
very little likelihood of these differences causing a substantial bias in the
comparison between those who did and did not have HAls.
A10.6 Conclusion
While the recruits and non-recruits had almost the same proportion of older
patients, there were significantly more female patients and less emergency
patients in the recruited cohort of patients, fewer surgical and urology patients
and more orthopaedic and obstetric and gynaecology patients. However, the
differences between the cohort of recruited patients and the intended cohort
were quite small. Since the HAl and non HAl comparisons were stratified by all
of these factors it is reasonable to assume that the results obtained from those
recruited are generalisable to all eligible patients in the study hospital, despite
the Significant differences between those recruited and those not recruited.
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APPENDIX 11
The incidence of HAl. by primary operative procedure
A11.1 Introduction
This appendix presents the results of this analysis that examined the incidence
of HAls and how this varied with primary operative procedure. Tables A11.1 -
A 11.11 show how the incidence of HAl varied with primary operative procedure
classified according to the Office of Population Census and Surveys operation
classification system (fourth edition)231three-digit code. Where appropriate
similar operations have been grouped together and the incidence of HAl
calculated.
The incidence was found to vary with operative procedure. However the
number of patients undergoing many of the specific procedures were small and
as such, as evidenced by the confidence intervals, there is considerable
uncertainty about the estimate deriVed.
The highest incidence of HAl occurred in patients whose primary procedure
involved the female genital tract: 13.2% acquired one or more HAls. Amongst
these patients the incidence was highest in patients who had a repair of a
prolapse of the vagina (19.3%), and hysterectomy (14.9%).
The second highest incidence rate was observed in patients whose primary
procedure involved the arteries and veins: 8.9% of patients acquired one or
more infections in hospital. Of these patients 33.3% of patients whose primary
procedure involved the aorta and 25.0% of patients whose primary procedure
involved the iliac and/or femoral artery acquired one or more infections that
presented during the in-patient period. However, the number of patients in
these two subgroups was small.
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A similar incidence rate was observed in patients whose primary procedure
involved the digestive tract: 8.9% acquired one or more infections that
presented during the in-patient stay. The highest incidence rate was observed
in patients who had a primary procedure which involved the ileum (57.1%); and
patients who had a total or partial excision of the stomach and lor oesophagus
(37.5%). Again the number of patients within the various sub-groups of
procedures was small and as such strong conclusions cannot be drawn.
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APPENDIX12
Results of the analysis that assessed how hospital costs varied with site
of infection and selected patient characteristics
A12.1 Introduction
The results of the analysis that assessed how hospital costs varied with site of
infection and selected patient characteristics are presented in this appendix.
The results presented in tables A12.1 - A12.7 show that whilst for all sites of
infection hospital costs, on average, are higher in infected than uninfected
patients for all the patient characteristics examined, the level of increase varied
with type of infection. However, it should be noted that in some cases the
number of patients in the infected groups was small and as such the results
cannot be generalized.
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Table A12.1: Mean in-patient hospital costs for patients with a urinary tract
Infection compared with those Incurred by unlnfected patients by
k tt th titley pa en c arac er s cs
Mean hospital costs (£,
Ratio of costs Additional Costs (£)
Patient characteristic No HAl UTlonh'_ (95% Cl, (95% Cl)
Mean n Mean n
(a) ill {bI~ j_b-4&
Sex
Male 1439 946 3148 18 2.2 (1.0 3.4) 1709 (1034 2383)
Female 1810 1330 2781 70 1.5 (1.2, 1.8) 971(612 1331)
Aa_group
18-34 1672 485 2614 15 1.6 (1.3 1.8) 942 (234 1651)
35-54 1509 627 2146 26 1.4 (1.2 1.6) 636(122 1150)
55-74 1636 870 2908 32 1.8 (1.2 2.4) 1272 (736 180n
75+ 1997 294 4218 15 2.1_(0.9 3.::n 2221j_1284, 315~
iSpecialty
General surgery 1338 829 5440 10 4.1 (1.0 7.1) 4102 (2934 52711
Orthopaedics 2157 462 4330 12 2.0 (1.4 2.6) 2173_( 1421 29261
Urology 1316 445 1952 17 1.5 (1.2 1.8) 636(222 10511
Gynaecology 1682 336 2102 36 1.2 (1.1 1.4) 420_(176, 6641
Obstetrics 2508 204 2779 13 1.1(0.51.7) 271 (-648 119Ql
IAdmlssion type
Elective 1569 1519 2061 58 1.3 (1.2 1.4) 492_(178 8~
Emergency 1828 757 4392 30 2.4 (1.6 3.2) 2564_(1873 3255)
plscharge diagnosis group
Infectious & parasitic diseases 867 12 940 1 1.1 • 73 •
Neoplasms 1714 329 2563 14 1.5 (1.1 1.9) 850_(85 161~
Endocrine, nutritional & metabolic
diseases & immunity disorders 1360 20 - 0 - -
Diseases of blood & blood forming
organs 992 3 - 0 - -
Diseases of the nervous system &
sense organs 712 2 - 0 - -
Diseases of the circulatory system 1134 142 19781 1 17.4 • 18647 •
Diseases of the respiratory
system 1726 4 - 0 - -
Diseases of the digestive syStem 1249 396 2007 7 1.6(1.0 2.~ 759 (-505 2023)
Diseases of the genitourinary
1.4_L1.2 1.~ 560 (255 856)system 1501 519 2061 34
Complications of pregnancy,
childbirth & puerperium & certain
conditions originating in the
perinatal period 2382 230 2612 15 1.1(0.8, 1.2}_ 230 (-854, 713)
Diseases of the skin &
subcutaneous tissue 951 28 - 0 - -
Diseases of the musculoskietal
svstem & connective tissue 2176 296 2904 3 1.3 (1.0 1.7) 728_(:-613 2070}
Inlury & Poisoning 2136 160 4806 9 2.2 (1.4 3.1) 2670 _L1674 36661
Symptoms, signs & 10- defined
conditions; mental disorders &
congenital abnormalities 1189 135 4865 4 4.1(1.9 10.11 3676..12127 522~
umber of co-morbldltles
None 1582 1532 247 56 1.6 (1.2 2.0) 894 (552 1232)
One 1723 528 2669 24 1.5 (1.2 1.9) 946 (255 1638)
Two 2012 216 6082 8 3.011.4 4.71 406912590 5548}
UTI- urinary tract infection. "Numerator n=l consequently standard deviation not estimable so confidence limits could not be
estimated.
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Table A12.2: Mean ln-patlent hospital costs for patients with a surgical wound
infection compared with those Incurred by unlnfected patients by
k f t h tel Iey pa len c arac rstcs
Mean hospital costs (£)
Ratio of costs Additional costs
Patient characteristic No HAl SWlonly (95% Cl)
(£)
(9S%CI)
Mean n Mean n
(a' (b) (bla) (N)
!Sex
Male 1439 94Ei 410e 1~ 2.9(1.1 4.6) 2669(974, 4364)
Female 1810 1330 23~E 17 1.3 CO.9 1.8) 556 (·234 1347)
~egroup
18-34 1672 485 378e ' 2.3 (0.8 3.7) 2116 C1050 1868)
35-54 1509 627 207C ~ 1.4 (0.7 2.1) 561 (-747 1868)
55-74 1636 870 286!'i 1Ei 1.8 C1.2 2.3) 1228 (506 1951)
75+ 199 29.. 424" 5 2.1 (1.0 3.30 2245 (876, 3613)
Specialty
General surgery 133e 829 3325 l' 2.5 (1.6, 3.4) 1988 (1000 2796)
Orthopaedics 215 462 361" 11 1.7 (0.9, 2.5) 1455 (658 2252)
Urology 131Ei .... 5 ..525 ., 3.4 (0.1 6.9) 3208(2000 4416)
Gynaecology 1682 336 1473 4 0.9 (O.4, 1.3) -208 (-921 504)
Obstetrics 2508 204 2421 3 1.0(0.7 1.2) -88 (-1840 1665)
IAdmlsslon type
Elective 1569 1519 2715 16 1.7 (1.3, 2.2) 1146 (547,1744)
Emergency 182_8 757 365e 1E 2.0 (1.2 2.8) 1822 (936 2707)
Discharge diagnosis group
Infectious & parasitic diseases 867 12 - C - -
Neoplasms 1714 329 392S 2.3 (1.6 3.0) 2216 (579 3833)
Endocrine, nutritional & metabolic
diseases & immunity disorders 136C 20 116~ 1 0.9· -197·
Diseases of blood & blood forming
99':: 3 C -organs - -
Diseases of the nervous system &
712 2 0-sense organs - -
Diseases of the circulatory system 11_304 142 3451 1 3.0· 2317 •
Diseases of the respiratory system 172Ei .. - 0- -
Diseases of the digestive system 1249 396 3073 4 2.5 (1.0 3.9) 1825 (149 3501)
Diseases of the genitourinary
519 4339 2 2.9 (0.4 6.2) 2838(1571 4104)system 1501
CompHcationsof pregnancy,
childbirth & puerperium & certain
conditions Originatingin the perinatal
2382 230 3 1.0 (0.7 1.3) 38 (-699 1775)period 2421
Diseases of the skin &
subcutaneous tissue 951 28 1656 1 1.7 (1.3 2.2) 706 (-556, 1968)
Diseases of the musculoskletal
system & connective tissue 2176 296 276~ 5 1.3 (0.9 1.6) 586{"'456 1628)
Injury & POisoning 2136 160 310E 10 1.5 (0.5 2.") 972 (·30 1973)
Symptoms, signs & ill- defined
conditions; mental disorders &
4142 (2489 ~795)congenital abnormalities 118S 135 5331 2 4.5J04.4 9.4}
",umber of co-morbidltie.
None 158 1532 2331 18 1.5 (1.0 2.0) 749 (187,1312)
One 172 528 37..S 10 2.2 (1.3 3.0) 2027 (958 3095)
Two 201,.: 216 559E 4 2.8 (1.3 ".2) 3584 (1655 5512)
SWI • surgical wound infection
*Numerator n=1 consequently standard deviation not estimable so confidence limit could not be
estimated.
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Table A1203: Mean In-patient hospital costs for patients with a lower respiratory
tract Infection compared with those Incurred by un Infected patients
bk tl th te°ti)y ay pa en c arac ns cs
Mun hospital costs (£)
Additional Costs
No HAl LRTI Ratio of costs (£)
Patient characteristic (95°,4 Cl) (95% Cl)
Mean n Mun n
(a) (b} (b1a) (b...)
Sex
Male 1439 946 5<450 9 ~.8 (1.3, 6.3) ~011 (1778 62«)
Female 1810 1330 2613 6 1.4 (0.8, 2.1) 80<4 (-<4352042)
IAge group
18-34 1672 485 4693 1 ~.8 • ~022 "
35-5<4 1509 627 2081 2 1.4 (1.1. 1.7) ~72 (-1274, 2418)
55-74 1636 870 5553 7 3.<4 (1.4 5.3) 3917 (2809 5024)
75+ 1997 29<4 3400 5 1.7 (0.8, 2.7) 1403 (41 2764)
Specialty
General surgery 1338 829 5068 10 3.8 (2.0, 5.6) 3730(26304830)_
Orthopaedics 2157 462 2825 2 1.3 (1.1 1.5) 668 (-1106 2442)
Urology 1316 445 1392 1 1.1 • 76·
Gynaecology 1682 336 2313 1 1.4 " 632 "
Obstetrics 2508 204 4693 1 1.9 • 2185 "
Admission type
Elective 1569 1519 4820 8 ~.1 (1.54.6) 13251(2395 4107)_
Eme~ency 1828 757 3738 7 ~.O(0.7, 3.4) 1910 (589 3230)_
Discharge diagnosis group
Infectious & parasitic diseases 867 12 - 0 l- f-
Neoplasms 1714 329 7143 3 ~.2 (1.1, 7.2) ~30 (3746, 7113)
Endocrine, nutritional & metabolic
diseases & immunity disorders 1360 20 4389 1 3.2" ~028 "
Diseases of blood & blood forming
organs 992 3 - 0 - -
Diseases of the nervous system &
sense organs 712 2 - 0 - -
Diseases of the circulatory system 1134 142 - 0 - -
Diseases of the respiratory system 1726 4 10738 1 6.2 • 9013 •
Diseases of the digestive system 1249 396 1891 4 1.5 (1.0 2.0) 843(-1027 2312)
Diseases of the genitourinary
813"system 1501 519 2313 1 1.5"
Complications of pregnancy,
childbirth & puerperium & certain
conditions originating in the
~.O· ~311·perinatal period 2382 230 4693 1
Diseases of the skin &
subcutaneoustiasue 951 28 - 0 l- I-
Diseases of the musculoskletal
system & connective tiasue 2176 296 2825 2 1.3 (1.1 1.5) ~49_(-992 2290)
Injury & Poisoning 2136 160 - 0 l- I-
Symptoms, signs & 111- defined
conditions; mental disorders &
congenital abnormalities 1189 135 3974 2 3.3 (0.9 7.6) ~785 (1150 4421)
Number of co-morbldltie.
None 1582 1532 2788 5 1.8 1.0 2.5) 1206 (149 2263)
One 1723 528 4760 3 2.8 1.6 3.9) ~038(11 06 4970)
Two 2012 216 5215 7 2.6 0.94.3) ~203 (1704 4701)
LRTI -lower respiratory tract Infection
-Numerator n=I consequently standard deviation not estimable so confidence limit could not be
estimated.
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Table A12.4: Mean In·patient hospital costs for patients with a bloodstream
infection compared with those Incurred by unlnfected patients by
hkey patient c aracteristics
Mean hospital costs (£)
Ratio of costs Additional Costs (£1
Patient characteristic
No HAl BSI (95% Cl) (95% Cl)
Mean n Mean n
(a) (b) (b/a) IN)
Sex
Male 1439 946 8953 3 6.2(0.2.12.3) 7514 •
Female 1810 1330 - 0 - -
lAaearoup
18-34 1672 485 15937 1 9.5.. 14265 •
35·54 1509 627 8263 1 5.5.. 6753 ..
55-74 1636 870 2660 1 1.6 .. 1024 •
75+ 1997 2904 - 0 - -
lSP8Ciatty
General suraery 1338 829 8263 1 6.2· 6925 •
Orthopaedics 2157 462 15937 1 7.4" 13779 "
Uroloav 1316 445 2660 1 2.0· 1344 •
Gvnaecoloav 1682 336 - 0 - -
Obstetrics 2508 204 - 0 - -
iAdmission type
Elective 1569 1519 2660 1 1.7.. 1091 •
Emergency 1828 757 12100 2 6.6(2.510.8) 10271 (7818 12724)
Discharge d!aanosis group
Infectious & parasitic diseases 867 12 - 0 - -
Neoplasms 1714 329 - 0 - -
Endocrine, nutritional & metabolic
diseases & immunitY disorders 1360 20 - 0 - --
Diseases of blood & blood forming
oroans 992 3 - 0 - -
Diseases of the nervous system &
sense oroans 712 2 - 0 - -
Diseases of the circulatory system 1134 142 - 0 - -
Diseases of the resolratory system 1726 4 15937 1 9.2• 14211 "
Diseases of the digestive system 1249 396 8263 1 6.6• 7014 •
Diseases of the genitourinary
system 1501 519 2660 1 1.8.. 1160 "
Complications of pregnancy,
childbirth & puerperium & certain
conditions originating in the perinatal
period 2382 230 - 0 - -
Diseases of the skin &
subcutaneous tissue 951 28 0 - -
Diseases of the musculoskletal
system & connective tissue 2176 296 - 0 - -
Injury & POisoning 2136 160 0 - -
Symptoms, signs & ill· defined
conditions; mental disorders &
conoenital abnormalities 1189 135 0 -
!Number of co-morbldlties
None 1582 1532 2660 1 1.7" 1078·
One 1723 528 0 - -
Two 2012 216 12100 2 6.0(2.29.8) 10087(7357,12818)
BSI - bloodstream Infection
*Numerator n=I consequently standard deviation not estimable so confidence limits could not be
estimated.
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Table A12.S: Mean in·patient hospital costs for patients with a skin Infection
compared with those incurred by un Infected patients by selected
characteristics
Mean hospital COlts C£)
Ratio of costs Additional Costs (£)
Patient characteristic
No HAl Skin (95% Cl) (95% Cl)
Mean n Mean n
Ca) (b' (bla' Cb.. ,
Isex
Male 1439 946 3298 5 2.3 (0.8, 3.8) 1859 (276 3441)
Female 1810 1330 3793 8 2.1 (1.1, 3.1) 1983 (774 3193)
~aegroup
18-34 1672 485 2344 1 1.4· 673 •
35-54 1509 627 2797 3 1.9 (0.6 3.1) 1287 (-223 2798)
55-74 1636 870 4031 7 2.5 (1.4 3.5) 2394 (1309 34791
75+ 1997 294 3942 2 2.0 (0.4 3.5) 1945 (1810 6075)
Ispecialty
General surcerv 1338 829 3570 5 2.7 (1.1 4.2) 2232 (710,3754)
Orthopaedics 2157 462 3565 5 1.7 (0.8, 2.5) 1407 (274 25411
Urology 1316 445 5919 1 4.5 • 4603 •
Gynaecology 1682 336 0 -
Obstetrics 2508 204 2621 2 1.0 (0.8, 1.31 113 (-2033 2259)
!Admission type
Elective 1569 1519 3354 7 2.1 (1.3, 3.0) 1784 (882 2686)
Emergency 1828 757 3893 6 2.1 (0.4,3.8) 2065 (634, 3495)
pischarge diagnosis arouD
Infectious & parasitic diseases 867 12 - 0 - -
Neoplasms 1714 329 4339 1 2.5· 2626·
Endocrine, nutritional & metabolic
diseases & immunity disorders 1360 20 1152 1 0.8· ·208 •
Diseases of blood & blood forming -
organs 992 3 0 - -
Diseases of the nervous system &
sense organs 712 2 - 0 - -
Diseases of the circulatory system 1134 142 2352 1 2.1 • 1218·
Diseases of the respiratory system 1726 4 0 - -
Diseases of the digestive system 1249 396 7247 1 5.8· 5999 •
Diseases of the genitourinary
2.9 (0.8 5.0) 2838 (1582 4093)system 1501 519 4338 2
Complications of pregnancy,
childbirth & puerperium & certain
conditions originating in the perinatal
1.1 (0.9 1.3) 239 (·1888 2365)period 2382 230 2621 2
Diseases of the skin &
subcutaneous tissue 951 28 953 1 1.0 • 3·
Diseases of the musculoskietal
system & connective tissue 2176 296 4128 2 1.90.6 3.2) 1952 (302 3601)
Injury & Poisoning 2136 160 4307 2 2.0 (0.7 3.3) 2171 (201 4141)
Symptoms, Signs & ill·defined
conditions; mental disorders &
congenital abnormalities 1189 135 0 - -
Number of co-morbidltles
None 1582 1532 1942 4 1.2 (0.6 1.9) 360 (-820 1541)
One 1723 528 3282 41.9 (1.0 2.8) 1559(-1143233)
Two 2012 216 5187 52.6 (1.8 3.3) 3175 (1458 4892)
*Numerator n=I consequently standard deviation not estimable so confidence limits could not be
estimated.
467
incurred by unln ected patients by key patient characteristics
Mean hos pltal costs (t)
Ratio of costs Additiolllli Costs (£)
Patient characteristic
No HAl Otherslta· (95% Cl) (95% Cl)
Mean n Mean n
(a) (b) (bla) (b.. )
!sex
Male 1439 946 5278 3 3.7 (1.8, 9.2) 3839 (255 7424)
Female 1810 1330 3037 15 1.7 (0.7,2.6) 1227 (29 2425)
lAg_group
18-34 1672 485 6040 3 3.6 (1.0 8.2) 4369/2717 6020)
35-54 1509 627 2410 5 1.6 (0.8 2.4) 901 (-271 2072)
55-74 1636 870 3681 7 2.2 (0.4 4.1) 2040 (940 3150)
75+ 1997 294 1816 3 0.9 (0.2 1.6) -181 (78 3554\
Specialty
General surgerY 1338 829 2474 6 1.8 (1.0 2.7) 1136 (-250 2522)
OrthoDaedics 2157 462 5319 4 2.5 (0.1 5.1) 3162 (1829 4495)
Urology 1316 445 4983 3 3.8(2.1 9.7) 3667 92564 4769)
Gynaecology 1682 336 1957 2 1.2 (0.8 1.5) 276 (-728 1279)
Obstetrics 2508 204 2136 3 0.9 (0.8 0.9) -373 (-2124 1379)
IAdmisslon type
Elective 1569 1519 2440 6 1.6 (0.9, 2.2) 871 (-101 1843)
Emergency 1828 757 3896 12 2.1 (0.7 3.5) 2067 (1026 3109)
plICharae diagnosis group
Infectious & parasitic diseases 867 12 - 0 - -
Neoplasms 1714 329 1607 1 0.0·· -106··
Endocrine, nutritional & metabolic
diseases & immunitY disorders 1360 20 1705 1 1.3" 3045··
Diseases of blood & blood forming
oroans 992 3 0 - -
Diseases of the nervous system &
sense organs 712 2 - 0 - -
Diseases of the circulatory system 11304 142 04804 1 4.2·· 3670··
Diseases of the respiratory system 1726 4 - 0 - -
Diseases of the digestive system 1249 396 1707 2 1.4 (1.1, 1.6) 458 (-1901,2818)
Diseases of the genitourinary
1.0 (0.5 1.6) 65 (-955 1085)system 1501 519 1566 3
Complications of pregnancy,
childbirth & puerperium & certain
conditions originating In the perinatal
0.9 (0.8 1.0) -247 (·1983 1489)Derlod 2382 230 2136 3
Diseases of the skin &
subcutaneous tissue 951 28 13839 1 14.6·· 12888··
Diseases of the musculoskletal
system & connective tissue 2176 296 - 0
IniuIY & Poisoning 2136 160 2480 3 1.2 (0.9 1.5) 3044(·1257 1944)
Symptoms, signs & 111-defined
conditions; mental disorders &
congenital abnormalities 1189 135 5826 3 4.9(1.1 10.1) 4637 (3085 6189)
Number of co-morbldltles
None 1582 1532 3021 11 1.9 (0.5 3.3) 1439 (706 2171)
One 1723 528 4981 4 2.9 (0.1 5.9) 3258 (1555 4962)
Two 2012 216 2746 3 1.4 (0.2 2.9) 734 (1486 2953)
*slngle site infections at sites not ciasslfied elsewhere I.e. Infections at a sites other than the unna tractsur 10iI1
Table A12.6: Mean in-patient hospital costs for patients with a single site
infection at a site not classified elsewhere compared with those
t
ry
wound, lower respiratory tract, skin, or bloodstream
-Numerator n=1 consequently standard deviation not estimable so confidence limit c uld not b
estimated.
g
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Table A12.7: Mean ln-patlent hospital costs for patients with more than one HAl
compared with those incurred by unlnfected patients by key
patient characteristics
Mun hospital costs Il)
Additional Costs(£)Ratio of costs
Patient characteristic No HAl
Multiple (95% Cl) (95% Cl)
Mean n Mean n
(a) Ib) (bla) (b-a)
Sex
Male 1439 946 13044 4 9.1 (4.7 13.5) 11605(10215 12995)
Female 1810 1330 9120 20 5.0 (2.7 7.4) 7310 (6497 81271
IAgearoup
18-34 1672 485 1659 1 1.0· -12"
35-54 1509 627 12923 5 8.6 (0.0 17.6) 11413(9814 13012)
55-74 1636 870 6944 11 4.2 (1.9 6.6) 5307(4354,6260)
75+ 1997 294 13131 7 6.6 11134
Specialty
General surgery 1338 829 13150 11 9.8 (6.8 12.9) 11812110703 12921)
Orthopaedics 2157 462 16096 4 7.5 (0.0 15.0) 13939(12125 1573)
Urology 1316 445 4842 2 3.7 (2.2 5.1) 3526 (2341 4724)
Gynaecology 1682 336 2265 7 1.3 (0.8 1.8) 583 (36 1130)
Obstetrics 2508 204 - 0 - -
Admission type
Elective 1569 1519 6361 14 4.1(1.4 6.7) 4792 (4001 5581)
Emergency 1828 757 14552 10 8.0 (404 11.5) 12723(11423 1402)
Discharge diagnosis group
Infectious & parasitic diseases 867 12 - 0 - -
Neoplasms 1714 329 12051 6 7.0 (3.6 10.4) 10338(8982 11693)
Endocrine, nutritional & metabolic
diseases & Immunitv disorders 1360 20 - 0 - -
Diseases of blood & blood forming
organs 992 3 - 0 - -
Diseases of the nervous system &
sense organs 712 2 - 0 - -
Diseases of the circulatory system 1134 142 16625 4 14.7 (9.2 20.1) 15491 (13509 17472)
Diseases of the respiratory system 1726 4 - 0 - -
Diseases of the digestive system 1249 396 5174 3 4.1 (0.9 7.4) 3926 (1978 5873)
Diseases of the genitourinary
1.5 (0.9 2.1) 764 (91 1436)sYStem 1501 519 2265 7
Complications of pregnancy,
childbirth & puerperium & certain
conditions originating In the
perinatal period 2382 230 - 0 - -
Diseases of the skin &
subcutaneous tissue 951 28 0 -
Diseases of the musculoskletal
syStem & connective tissue 2176 296 3950 1 1.8" 1774"
Injury & Poisoning 2136 160 20145 3 9.4 (0.0 18.8) 18009(1523920779)
Symptoms, signs & iII- defined
conditions; mental disorders &
congenital abnormalities 1189 135 0
Number of co-morbidities
None 1582 1532 8556 15 5.4 (1.9 8.9) 6974 (4936 9012)
One 1723 528 13268 5 7.7 (3.3 12.1) 11546(9913 13178)
Two 2012 216 9971 4 5.0 (2.7 7.2) 7958 (5971 9946)
"'Numerator n=l consequently standard deviation not estimable so confidence limits could not be
estimated.
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APPENDIX 13
The distribution of hospital costs incurred by patients with specific types
of infection
A13.1 Introduction
The results of the analysis that assessed the distribution of the additional costs
incurred by patients acquiring specific types of infection are presented in this
appendix. The results presented in tables A13.1 - A 13.7 show the distribution
of the costs incurred by patients acquiring specific types of infection and how
these costs compare to those incurred by uninfected patients.
Table A13.1: The distribution of hospital costs incurred by patients who
I d tra t l fi d i fe d tI tsacqu re a urmary c m ection corn lare to un n cte .p'a en
Mean hospital costs (£)
No HAl un % contributionRatio of Additional to .ctdltlonal
n-2278 na88 costs costs (£) costs
Hospital overheads 392.89 700.0 1.8 307.08 25.58
Directorate management 47.55 74.9 1.6 27.30 2.27
Capital charges 208.20 350.0 1.7 141.76 11.81
Medical time 150.72 242.1 1.6 91.42 7.61
Nursing care 338.11 746.7 2.2 408.60 34.03
Paramedics & specialist nurses 11.71 24.0 2.0 12.29 1.02
Physiotherapy 16.01 39.7 2.5 23.65 1.97
Consumables used for specific procedures 11.06 33.1 3.0 22.09 1.84
Surgical interventions 335.63 «1.8 1.3 106.16 8.84
Antimicrobials 11.80 13.4 1.1 1.60 0.13
Non-antimicrobial drugs 32.92 46.8 1.4 13.86 1.15
Microbiology tests 5.74 15.2 2.7 9.48 0.79
Other pathology tests 54.59 104.9 1.9 50.33 4.19
Endoscopies 1.71 1.4 0.8 ·0.27 ·0.02
Radiology 33.35 19.1 0.6 ·14.22 ·1.18
Other tests 3.53 3.0 0.9 -0.51 -0.04
Total costs 1655.51 2856.1 1.7 1200.62 100.00
UTI urinary tract infection
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Table A13.2: The distribution of hospital costs Incurred by patients who
acquired a surgical wound infection compared to uninfected
. tspatlen
Mean hospital costs (£) %
No HAl SWI
contribution
Retloof Additional to additional
n-2276 .,...32 costs costs (£, costs
Hospital overheads 392.89 724.87 1.84 331.98 21.74
Directorate rnanaaement 47.55 91.31 1.92 43.75 2.87
Capital ehemes 208.20 386.17 1.85 177.96 11.65
Medical time 150.72 306.47 2.03 155.75 10.20
Nursing care 338.11 837.77 2.48 499.67 32.72
Paramedics & sDecialist nurses 11.71 28.41 2.43 16.70 1.09
Physiotherapy 16.01 40.46 2.53 24.45 1.60
Surgical interventions 335.63 412.12 1.23 76.50 5.01
Consumables used for specific procedures 11.06 45.85 4.15 34.80 2.28
Antimicrobials 11.80 58.82 4.99 47.02 3.08
Non-antimicrobial drugs 32.92 109.25 3.32 76.33 5.00
Microbiology tests 5.74 21.66 3.77 15.92 1.04
Other pathology tests 54.59 81.27 1.49 26.68 1.75
Endoscopies 1.71 4.09 2.40 2.38 0.16
Radiology 33.35 28.57 0.86 -4.78 -0.31
Other tests 3.53 5.40 1.53 1.87 0.12
Total costs 1655.51 3182.49 1.92 1526.98 100.00
SWI - surgical wound Infection
Table A13.3: The distribution of hospital costs Incurred by patients with a
hospital acquired lower respiratory tract Infection compared to
iunlnfected pat ents
Mean hospital cOlts(£, %
No HAl LRTI
contribution
Ratio of Additional to additional
nll2278 n-15 COlts co.ts(£, COlts
Hospital overheads 392.89 754.16 1.92 361.27 13.58
Directorate menaaement 47.55 88.09 1.85 40.54 1.52
Capital charges 208.20 398.99 1.92 190.79 7.17
Medical time 150.72 312.48 2.07 161.76 6.08
Nursing care 338.11 1563.98 4.63 1225.87 46.09
Paramedics & soecialist nurses 11.71 55.63 4.75 43.92 1.65
Ptwsiotherapy 16.01 86.31 5.39 70.31 2.64
Sureical interventions 335.63 538.20 1.60 202.57 7.62
consumables used for specific Drocedures 11.06 34.67 3.14 23.61 0.89
IAntimicrobials 11.80 93.90 7.96 82.10 3.09
Non-antimicrobial drugs 32.92 161.75 4.91 128.83 4.84
Microbiology tests 5.7" 30.82 5.37 25.08 0.94
Other _Qathology tests 54.59 127.64 2.34 73.05 2.75
Endoscopies 1.71 0.00 0.00 ·1.71 -O.OS
Radiology 33.35 52.77 1.58 19.42 0.73
Other tests 3.53 15.69 4.44 12.16 0.46
Total costs 1655.51 4315.07 2.61 2659.56 100.00-LRTI lower respiratory tract infection
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Table Ai3.4: The distribution of hospital costs Incurred by patients who
d feacquire a skin in ction compared to unlnfect8d patients
Mean hospital costs (£) %
Skin contribution
NaHAl infection Ratio of Additional to additional
n:a2276 0=13 costs costs (£) costs
Hospital overheads 392.89 893.77 2.27 50o.a8 25.73
Directorate management 47.55 121.90 2.56 74.35 3.82
!capital charges 208.20 497.92 2.39 289.72 14.88
Medical time 150.72 385.09 2.55 234.36 12.04
!Nursina care 338.11 833.30 2.46 495.20 25.43
Paramedics & specialist nurses 11.71 39.62 3.38 27.90 1.43
IPhysiotherapy 16.01 59.41 3.71 43.40 2.23
!surgical interventions 335.63 478.17 1.42 142.54 7.32
iconsumables used for specific procedures 11.06 105.49 9.54 94.43 4.85
~microbials 11.80 50.17 4.25 38.38 1.97
lNon-antimicroblal drugs 32.92 54.92 1.67 22.00 1.13
Microbiology tests 5.74 11.92 2.07 6.17 0.32
iother pathology tests 54.59 45.17 0.83 -9.42 -0.48
!Endoscopies 1.71 0.00 0.00 -1.71 -0.09
lRadiology 33.35 19.73 0.59 -13.63 -0.70
iother tests 3.53 5.94 1.68 2.41 0.12
trotal costs 1655.51 3602.52 2.18 1947.00 100.00
Table Ai3.5: The distribution of hospital costs incurred by patients who
acquired an infection at a site other than surgical wound,
Ibloodstream, skin, or urinary or respiratory tract
Mean hospital costs (t,
HAl ata site
not %
~lasstfMld In contribution
No HAl ~Is studY" Ratio of Additional to additlona'
.,.2278 .,.18 COlts COlts COlts
Hospital overheads 392.89 962.35 2.45 569.46 32.45
Directorate manaaement 47.55 137.73 2.90 90.18 5.14
Capital charges 208.20 526.88 2.53 318.68 18.16
Medical time 150.72 397.19 2.64 246.46 14.04
Nursing care 338.11 837.59 2.48 499.49 28.48
Paramedics & specialist nurses 11.71 30.85 2.63 19.14 1.09
PhysiotheraDY 16.01 52.58 3.28 36.57 2.08
Surgical Interventions 335.63 216.73 0.65 ·118.90 ..e.77
Consumables used for specific procedures 11.06 25.63 2.32 14.57 0.83
Antimicrobials 11.80 28.43 2.41 16.64 0.95
Non-antimicrobial druas 32.92 80.55 2.45 47.63 2.71
Microbiology tests 5.74 19.46 3.39 13.71 0.78
Other pathology tests 54.59 66.50 1.22 11.91 0.68
Endoscopies 1.71 0.00 0.00 -1.71 -0.10
Radiology 33.35 24.16 0.72 ·9.20 -0.52
Other tests 3.53 3.86 1.09 0.33 0.02
Total costs 1655.51 3410.48 2.06 17504.96 100.00
• single site Infection at a site other than the followin : urlna tract sur Ical wound sldn. lower rei lrato or
bloodstream
g rv g BP rv.
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Table A13.6 The distribution of hospital costs Incurred by patients who
acquired a bloodstream infection compared to unlnfected patients
Mean hospital costs (£) %
No HAl BSI
contribution
Ratio of Additional to additional
n-2276 ".3 costs costs (£) costs
Hospital overheads 392.89 411.54 1.05 18.65 0.26
Directorate management 47.55 65.85 1.38 18.30 0.25
Capital charges 208.20 223.98 1.08 15.78 0.22
Medical time 150.72 180.52 1.20 29.79 0.41
Nursing care 338.11 4715.04 13.95 4376.93 59.98
Paramedics & specialist nurses 11.71 0.00 0.00 -11.71 -0.16
Physiotherapy 16.01 83.28 5.20 67.28 0.92
Surgical Interventions 335.63 849.06 2.53 513.44 7.04
Consumables used for SDecific procedures 11.06 785.73 71.06 774.67 10.62
IAntimicrobials 11.80 120.31 10.20 108.51 1.49
Non-antimicrobial druas 32.92 1017.26 30.90 984.34 13.49
Microbiology tests 5.74 110.14 19.18 104.40 1.43
Other pathology tests 54.59 247.40 4.53 192.81 2.64
Endoscopies 1.71 0.00 0.00 -1.71 -0.02
Radiology 33.35 130.06 3.90 96.71 1.33
Other tests 3.53 13.13 3.72 9.60 0.13
Total costs 1655.51 8953.31 5.41 7297.80 100.00
BSI - bloodstream Infection
Table A13.7: The distribution of hospital costs incurred by patients who
acquired more than one infection compared to unlnfected patients
Mean hospital costs (t) %
Multiple contribution
No HAl Infections Ratio of Additional to additional
... 2276 na24 costs costs (t) costs
Hospital overheads 392.89 1617.61 4.12 1224.72 15.09
Directorate manaaement 47.55 188.92 3.97 141.37 1.74
Capital charaes 208.20 792.85 3.81 584.65 7.20
Medical time 150.72 668.45 04.43 517.73 6.38
Nursing care 338.11 4107.03 12.15 3768.92 46.43
Paramedics & SDecialist nurses 11.71 216.26 18.46 204.55 2.52
Physiotherapy 16.01 147.64 9.22 131.63 1.62
Surgical Interventions 335.63 486.59 1.45 150.96 1.86
Consumables used for specific procedures 11.06 270.60 24.47 259.64 3.20
Antimicrobials 11.80 141.06 11.96 129.26 1.59
Non-antimicrobial drugs 32.92 323.83 9.84 290.91 3.58
Microbiology tests 5.74 78.25 13.62 72.50 0.89
Other pathology tests 54.59 212.52 3.89 157.93 1.95
Endoscopies 1.71 7.12 4.18 5,41 0.07
Radiology 33.35 500.28 Hi.OO 466.93 5.75
Other tests 3.53 14.72 4.17 11.18 0.14
Total costs 1655.51 9773.73 5.90 8118.22 100.00
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APPENDIX 14
Results of the analysis that assessed how length of hospital stay varied
with site of Infection and selected patient characterlatlcs costs and site of
HAl
A14.1lntroductlon
The results of the analysis that assessed how length of hospital stay varied with
site of infection and selected patient characteristics are presented in this
appendix.
The results presented in tables A14.1-A14.7 show that whilst for all sites of
infection the mean length of stay was higher in infected than uninfected patients
for all the patient characteristics listed, the level of increase varied with type of
infection. However, it should be noted that in some cases the number of
patients in the infected groups were small and as such the results cannot be
generalized.
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Table A14.1 Mean length of stay for patients with a urinary tract Infection and
uninfected patients by key patient characteristics
Mean length of hospital stay (days)
Ratio of LOS Additional days
Patient charac:taristic No HAl
UTI only (95% Cl) (95% Cl)
M.. n n Mean n
(a) (b) (b/a) (b-a)
Sex
Male 5.9 946 1H 18 2.1 (1.0 3.2) 6.5 (3.7 9.3)
Female 7.1 1330 11.2 70 1.6 (1.3 1.9) 4.1 (2.3 5.8)
Aa_aroup
18-34 S.O 485 8.2 15 1.4<1.0 1.7) 2.2 (-1.7 s.n
35-54 5.5 627 8.2 26 1.5 (1.3 1.7) 2.7 (1.2 4.3)
55-74 S.8 870 12.0 32 1.8 (1.2 2.3) 5.2 (2.8 7.5)
75+ 9.4 294 19.2 15 2.1 (1.2 2.9) 9.8 (4.9 14.7)
Specialty
General surgerv 5.4 829 18.7 10 3.5 (1.8 5.2) 13.3 (8.9 17.7)
Orthopaedics 10.3 462 24.6 12 2.4 (1.5 3.3) 14.3 (9.4 19.2)
Urolo!JV 5.1 445 7.8 17 1.5 (1.1 1.9) 2.6 (0.5 4.8)
Gynaecolo!JV 6.1 336 8.0 36 1.3 (1.1, 1.5) 1.9 (0.6 3.1)
Obstetrics 7.5 204 8.2 13 1.1 (0.8 1.4) 0.8 (-2.4 3.9)
IAdmission type
Elective S.O 1519 8.0 58 1.3 (1.2 1.5) 2.0 (0.4 3.5)
Emergency 7.9 757 18.2 30 2.3 (1.7, 3.0) 10.4 (7.4 13.3)
pilcharge diagnosis aroup
Infectious & parasitic diseases 3.8 12 3.0 1 0.8" -O.S"
Neoplasms S.7 329 10.7 14 1.6 (1.0 2.2) 4.1 (0.4 7.7)
Endocrine, nutritional & metabolic
diseases & Immunity disorders 4.9 20 0.0 0 - -
Diseases of blood & blood forming
organs 4.3 3 0.0 0 - -
Diseases of the nervous system &
sense organs 3.5 2 0.0 0 - -
Diseases of the circulatory system 5.0 142 45.0 1 9.1" 40.0·
Diseases of the respiratory system 7.0 4 0.0 0 - -
Diseases of the digestive system 4.9 396 10.1 7 2.1 (1.3 2.8) 5.3 (1.6 9.0)
Diseases of the genitourinary
1.5 (1.3 1.7) 2.7 (1.5 3.8)system 5.4 519 8.0 34
Complications of pregnancy,
childbirth & puerperium & certain
conditions originating In the
1.1 (0.9 1.3) 0.7 l-2.2 3.7)perinatal period 7.3 230 8.0 15
Diseases of the skin &
subcutaneous tissue 4.5 2S 0.0 0 0.0 -
Diseases of the musculoskletal
system & connective tissue 10.5 296 15.0 3 1.4 10.8 2.0) 4.S (-4.3 13.3)
Injury & Poisoning 9.9 160 27.8 9 2.811.& 4.0 17.9 ro.e 13.9)
Symptoms, signs & iII- defined
conditions; mental disorders &
congenital abnormalities 5.8 135 13.0 4 2.3 (~O.O 5.2) 7.2 (0.6 13.9)
Number of co-morbldltle.
None 6.2 1532 9.0 66 1.5 (1.2 1.7) 2.8 11.3 4.3)
One 7.0 528 12.4 24 1.811.2 2.4) S.5 (1.9 9.0\
Two B.7 216 25.8 8 2.9(1.4 U) 17.0 (10.9 23.2)
UTI - urinary tract Infection; LOS - len of stay, ·Numcrator n-l consec uen stllndard deviation not.estimable 80
confidence limits could not be estimated. gIh
q tIy
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Table A14.2 Mean length of stay for patients with a lower respiratory tract
infection patients and unlnfected patients by key patient
characteristics
Mean length of hospital stav (davs)
No HAl LRTlonlv
Ratio 0' LOS Additional days
Patient characteristic (91% Cl) (95% Cl)
Mean n Mean n
(a) (b) (b/a) Ib-a)
Sex
Male 5.9 946 16.8 9 2.8 (1.6 4.1) 10.9 (7.1 14.7)
Female 7.1 1330 11.2 6 1.6 (1.0 2.1) 4.0 (-1.7 9.S)
lAaearoup
18-34 6.0 485 17.0 1 2.S" 11.0·
35-54 5.5 627 9.5 2 1.7 (0.3 5.3 4.0 (-1.6 9.6)
55-74 6.S 870 13.7 7 2.0 (1.5 2.5) 6.9 (2.1, 11.6)
75+ 9.4 294 17.2 5 1.8 (0.3 3.4) 7.81-0.2 15.9)
Ispecialty
General surnerv S.4 829 15.9 10 3.0 (1.7 4.2) 10.5 (6.1 14.9)
Orthopaedics 10.3 462 14.0 2 1.4 (1.1 1.6) 3.7 (-7.7 1S.21
Uroloav S.1 445 5.0 1 1.0· -0.1·
Gynaecoloav 6.1 336 9.0 1 1.S" 2.9·
Obstetrics 7.5 204 17.0 1 2.3· 9.5·
Admission type
Elective 6.0 1519 16.9 8 2.8 (1.3 4.2) 10.9 (6.7 15.0)
Emergency 7.9 757 11.9 7 1.5 (1.1 1.9) 4.0 (-1.7 9.7)
Dlscharae diaGnosis group
Infectious & parasitic diseases 3.S 12 0.0 0 - -
Neoplasms 6.7 329 17.0 3 2.6 (1.4 3.7) 10.3(2.7 1B.0)
Endocrine, nutritional & metabolic
diseases & immunity disorders 4.9 20 13.0 1 2.7" 8.2·
Diseases of blood & blood forming -
organs 4.3 3 0.0 0 -
Diseases of the nervous system &
sense oraans 3.S 2 0.0 0 - -
Diseases of the circulatory system 5.0 142 0.0 0 - -
Diseases of the respiratory sYStem 7.0 4 15.0 1 2.1· 8.0·
Diseases of the digestive system 4.9 396 8.S 4 1.8 (1.1 2.5) 3.9 (·1.0 8.7)
Diseases of the genitourinary avstem 5.4 519 9.0 1 1.7· 3.6·
Complications of pregnancy,
childbirth & puerperium & certain
conditions originating in the perinatal
period 7.3 230 17.0 1 2.3· 9.1"
Diseases of the skin & subcutaneous
tiasUe 4.5 28 0.0 0 - -
Diseases of the musculoskletal
3.S (-7.2 14.2system & connective tissue 10.5 296 14.0 2 1.3 (1.1 1.6)
InjuIY & Poisoning 9.9 160 0.0 0 - -
Symptoms, signs & ill- defined
conditions; mental disorders &
conaenital abnormalities 5.8 135 25.0 2 4.3 (-+0.0 11.2) 19.2 (9.9 28.8)
!Number of co-morbidities
None 6.2 1532 10.6 5 1.7 C1.12.4) 4.4 (-0.4 9.2)
One 7.0 528 25.7 3 3.7(0.9 6.4) 1S.7 (S.9 28.8)
Two 8.7 216 12.6 7 1.4 (1.0 1.9) 3.8 (·2.3 9.9)
LRTI-Iower ~e~lr8tory tract Infection, LOS -length of stay, .nwncrator n-I consequently stondard deviation not cstlmobl
so confidence limits could not be estimated.
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Table A14.3: Mean length of stay for patients with a surgical wound Infection
and uninfected patients by key patient characteristics
Mean length of hospital stay (dayS)
Ratio of LOS Additional days
PatientchanKrterist~
No HAl SWlonly (95%CI) (95% Cl)
Mean n Mean n
(a) (b) (bla) (N)
Sex
Male 5.9 946 19.33 15 3.3 (2.2. 4.4) 13.4 (10.4 16.4)
Female 7.1 1330 10.41 17 1.5 (1.0 1.9) 3.3 (-0.2 6.7)
iAaearouD
18 -34 6.0 485 13.14 7 2.2(0.9 3.5) 7.1 (1.4 12.8)
35-54 5.5 627 8.25 4 1.590.92.1) 2.7 (-1.2 6.7)
55-74 6.8 870 14.38 16 2.1 (1.3 2.9) 7.5 (4.3.10.7)
75+ 9.4 294 22.40 5 2.4 (1.2 3.6) 13.0 (5.0. 21.0)
ispeclalty
General suraery 5.4 829 16.67 12 3.1 (1.8 4.4) 11.3 (7.2 15.3)
Orthopaedics 10.3 462 16.27 11 1.6 (1.0 2.2) 6.0 (1.0 11.0)
Urology 5.1 445 5.00 1 1.0· -0.1·
Gynaecology 6.1 336 5.25 4 0.9 (0.5 1.2) -0.9 (-4.5 2.7)
Obstetrics 7.5 204 8.00 3 1.1 (0.6 1.5) 0.5 (6.0 7.1)
IAdmlsslon type
Elective 6.0 1519 12.69 16 2.1(1.5 2.7) 6.713.7 9.6)
Emergency 7.9 757 16.50 16 2.1 (1.2 3.0) 8.6 (4.7,12.5)
Discharge diagnosis group
Infectious & parasitic diseases 3.8 12 0.00 0 - -
Neoplasms 6.7 329 21.00 3 3.2 (1.9 4.4) 14.3 (6.6 27.0)
Endocrine, nutritional & metabolic
diseases & Immunitv disorders 4.9 20 4.00 1 0.8· -0.9·
Diseases of blood & blood forming
oraans 4.3 3 0.00 0 - -
Diseases of the nervous system &
sense organs 3.5 2 0.00 0 - -
Diseases of the circulatory system 5.0 142 17.00 1 3.4· 12.0·
~iseases of the resoiratorv system 7.0 4 0.00 0 - -
Diae8ses of the diaestive system 4.9 396 13.75 .. 2.8 (0.7 4.9) 8.9 (3.9 13.8)
Diseases of the genitourinary
3.4 (-+0.0 7.6) 13.1 (8.4 17.9)system 5.4 519 18.50 2
Complications of pregnancy,
childbirth & puerperium & certain
conditions originating in the
1.1 (0.6 1.6) 0.7 (-5.9 7.3)perinatal period 7.3 230 8.00 3
Diseases of the skin &
subcutaneous tissue 4.5 28 8.00 1 1.8· 3.5·
Oiaeases of the musculoskletal
system & connective tissue 10.5 296 14.00 5 1.3 (0.9 1.7) 3.5 (·3.3 10.3)
Iniury & Poisonina 9.9 160 13.70 10 1.4 (0.6 2.2) 3.8 (-2.2 9.8)
Symptoms. signs & 111- defined
conditions; mental disorders &
congenital abnormalities 5.8 135 26.00 2 4.5 (-+O.O 11.0) 20.2 (10.9 29.5)
Number of co-morbidlties
None 6.2 1532 11.00 18 1.8 (1.1 2.5) U (2.2 7.4)
One 7.0 528 18.00 10 2.6 (1.4 3.7) 11.0 (5.6 16.5)
Two 8.7 216 22.25 .. 2.5 (1.6 3.5) 13.5 (5.4 21.6)
SWI- surgical wound infection, LOS -length of stay. ·nwnerator n=] eonse uently stllndilro dcvioti n not estimable so
confidence limits could not be estimated.
q
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Table A14.4 Mean length of stay for patients with a blood stream Infection and
unlnfected patients by key patient characteristics
Mean length of hospital stay (days)
Ratio of LOS Additional day.
Patient characteristic
No HAl BSlonly (95% Cl) (9&% Cl)
Mean n Mean n
(a) Ib) (b/a) IlHIl
Sex
Male 5.9 946 8.7 3 1.5 (0.8 2.1) 2.8 (-3.7 9.2)
Female 7.1 1330 0.0 0 - -
IAgearouD
18-34 6.0 485 12.0 1 2.0" 6.0"
35-54 5.5 627 5.0 1 0.9" -0.5"
55-74 6.8 870 9.0 1 1.3" 2.2·
75+ 9.4 294 0.0 0 - -
ispecialty
General surgery 5.4 829 5.0 1 0.9" -0.4"
Orthopaedics 10.3 462 12.0 1 1.2" 1.7"
Urology 5.1 445 9.0 1 1.8" 3.9"
Gynaecology 6.1 336 0.0 0 - -
Obstetrics 7.5 204 0.0 0 - -
jAdmission type
Elective 6.0 1519 9.0 1 1.5· 3.0·
Emergency 7.9 757 8.5 2 1.1 (0.3 2.6) 0.6 (-5.8 10.8)
Discharge diagnosis group
Infectious & parasitic diseases 3.8 12 0.0 0 - -
Neoplasms 6.7 329 0.0 0 - -
Endocrine, nutritional & metabolic
diseases & immunity disorders 4.9 20 0.0 0 - -
Diseases of blood & blood forming
organs 4.3 3 0.0 0 - -
Diseases of the nervous system &
sense organs 3.5 2 0.0 0 - -
Diseases of the circulatorv system 5.0 142 0.0 0 - -
Diseases of the resoiratorv system 7.0 4 12.0 1 1.7" 5.0"
Diseases of the digestive sYStem 4.9 396 5.0 1 1.0· 0.1·
Diseases of the genitourinary
system 5.4 519 9.0 1 1.7* 3.S·
Complications of pregnancy,
childbirth & puerperium & certain
conditions originating In the
perinatal period 7.3 230 0.0 0 - -
Diseases of the skin &
subcutaneous tissue 4.5 28 0.0 0 - -
Diseases of the musculoskletal
system & connective tissue 10.5 296 0.0 0 -
Injury & Poisoning 9.9 160 0.0 0 -
Symptoms, signs & iII- defined
conditions; mental disorders &
congenital abnormalities 5.8 135 0.0 0
Number of co-morbldities
None 6.2 1532 9.0 1 U· 2.8·
One 7.0 528 0.0 0 -
Two 8.7 216 8.5 2 1.0 (0.2 1.8) ·0.2(-11.6 11.1)
BSI- bloodstream infection, LOS -length of stay, -numerator n=1 cons ucntJy standard deviation not estimable so confidence
limits could not be estimated.
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Table A14.5 Mean length of stay for patients with a skin Infection and
uninfected patients by key patient characteristics
No HAl
Mean length of hospital stay (days)
n
1.3·
PatientchanKrteristic
Skin only
Ratio of LOS Additional days
(95% Cl) (95% Cl)
Mean n Mean
(b-a)(a) (b) (b/a)
Sex
12.5 (7.5 17.5)Male
12.0 (6.9,17.0)Female
5.9
7.1
946
1330
18.4
19.1
5 3.1 (1.5 4.7)
8 2.7 (1.4 4.0)
lAaearoup
18-34
5.8 (1.2 10.4)
6.0 485 7.0 1.2· 1.0
35-54 5.5 627 11.3 3 2.1 (0.3 3.9)
55-74 6.8 870 22.0 7 3.2 (1.9 4.5) 15.2 (10.3 20.0)
75+ 9.4 294 25.0 2 2.7 (0.6 4.8) 15.6 (3.1 28.2)
12.4 (6.2 18.6)
Isoecialtv
10.1 (2.8 17.4)
General suraerv 5.4 829 17.8 5 3.3 (1.6 5.0)
32.9*
Orthopaedics 10.3 462 20.4 5 2.0 (0.9 3.0)
Uroloav 5.1 445 38.0 7.4·
Gvnaecoloav
Obstetrics
6.1
7.5
336
204
0.0
8.0
o
2 1.1(1.2, 2.0) 0.5 (-3.4, 9.2)
12.0 (7.5 16.4)
iAdmlsslon tvpe
Elective
12.0 (5.7 18.2)Emeraency
Discharge diagnosis group
6.0
7.9
1519
757
18.0
19.8
7 3.0 (1.5 4.5)
14.3'
infectious & parasitic diseases 3.8 12 o.o
329 21.0 1
6 2.5 (1.2 3.8)
Neoplasms 6.7 3.2·
Endocrine, nutritional & metabolic
diseases & immunity disorders H 20 4.0 1 O.S* -0.9·
Diseases of blood & blood forming
organs 4.3 3 b.o P
Diseases of the nervous system &
sense oraans 3.5 2 b.o p
Diseases of the circulatory system 10.0·5.0 142 15.0 1 3.0·
Diseases of the resPiratory system
Diseases of the diaestive system
7.0
4.9
4 b.o p
396 33.0 1 6.8· 28.1·
21.6 (16.9 26.4)
Diseases of the genitourinary
syStem 5.4 519 27.0 2 5.0 (1.0 e.n
Complications of pregnancy,
childbirth & puerperium & certain
conditions originating in the
perinatal period 7.3 230 8.0 2 1.1(0.81.4) 0.7 (-7.3 8.8)
Diseases of the skin &
subcutaneous tissue 1.S·4.5 28 6.0 1
Diseases of the rnusculoakletal
syStem & connective tissue 10.5 296 24.0 2 2.3 (0.2 4.3) 13.5 (2.7 2•. 3)
Inlurv & Poisonina
Symptoms, signs & iII- defined
conditions; mental disorders &
congenital abnormalities
Number of co-morbldlties
9.9
5.S
160 24.0 2
135 0.0 0
2.4 (1.0 3.9) 14.1 (1.2 27.0)
None 6.2 1532 10.0 4 1.6 (0.7 2.6) 3.8 (.1.6 9.2)
One 7.0 528 17.3 4 2.5 (1.0 3.9) 10.3 (1.8 18.8)
Two 8.7 216 27.2 5 3.1(1.8, •. 4) 18.5 (11.1 25.8)
LOS -length of stay, ·numerator n=] consequently standard deviation not estimable so confidene« limits could not be e ti.rntltoo.
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Table A14.6: Mean length of stay for uninfected patients and patients with a
single infection at a site other than the urinary tract, bloodstream,
surgical wound, skin or lower respiratory tract by key patient
characteristics
Mean length of hospitallfay
(daYI)
No HAl HAl"
Ratio of LOS Additional day.
Patient characteristic (95% Cl,
Mean n Mean n (95% Cl)
(a) (b) (b/a) ItHI)
Sex
Male 5.9 946 33.7 3 5.7 (-+ 14.7) 27.8 (20.9 34.7)
133
Female 7.1 0 17.2 15 2.4 (0.7 4.1) 10.1 (6.2 13.9)
AgearouD
18-34 6.0 485 36.3 3 6.0 (-+0.0 15.9) 30.3 (20.9, 39.7)
35-54 5.5 627 12.2 5 2.2 (0.4 4.0) 6.7 (3.1 10.3)
55-74 6.8 870 22.4 7 3.3 (0.6 6.0) 15.6 (10.6 20.6)
75+ 9.4 294 10.7 3 1.1(0.0 2.2) 1.3 (-8.9 11.5)
ispeciaHv
General surgery 5.4 829 14.0 6 2.6 (1.0 4.2) 8.6 (3.0 14.2)
Orthopaedics 10.3 462 35.8 4 3.5 (--+0.0 7.4) 25.5 (16.7 34.2)
6.4 (--+0.0,
27.9 (21.6, 34.2)Uroloav 5.1 445 33.0 3 17.0)
Gynaecology 6.1 336 7.5 2 1.2 (0.7, 1.7) 1.4 (-3.7, 6.4)
Obstetrics 7.5 204 6.0 3 0.8 (--+0.0 1.7) -1.5 (-8.0 5.1)
Admission tvpe
151
Elective 6.0 9 11.0 6 1.8 (0.4 3.2) 5.0 (0.2 9.8)
Emeraencv 7.9 757 24.4 12 3.1 (0.8 5.4) 16.5 (11.6 21.4)
Discharge diagnosil group
Infectious & parasitic diseases 3.8 12 0.0 0 - -
Neoplasms 6.7 329 9.0 1 1.4· 2.3·
Endocrine, nutritional & metabolic diseases &
immunity disorders 4.9 20 7.0 1 1.4· 2.2·
Diseases of blood & blood forming oraans 4.3 3 0.0 0 - -
Diseases of the nervous system & sense
organs 3.5 2 0.0 0 - -
Diseases of the circulatory system 5.0 142 32.0 1 6.4" 27.0·
Diseases of the respiratory system 7.0 4 0.0 0 - -
Diseases of the digestive system 4.9 396 7.0 2 1.4 (0.0 2.8) 2.1 (-U 9.0)
Diseases of the genitourinary system 5.4 519 6.3 3 1.2 (0.6,1.7) 1.0 (-2.8 4.8)
Complications of pregnancy, childbirth &
puerperium & certain conditions originating in
0.8 (->0.0 1.7) -1.3 (-7.9 5.3)the perinatal period 7.3 230 6.0 3
Diseases of the skin & subcutaneous tissue 4.5 28 97.0 1 21.6· 92.5·
Diseases of the musculoskJetal system &
connective tissue 10.5 296 0.0 0
Injury & Poisoning 9.9 160 15.3 3 1.6 (0.8 2.3) S.4 (-5.1 16.0)
Symptoms, signs & ill- defined conditions;
6.8 (0.0 15.3) 33.2 (23.9 42.6\mental disorders & congenital abnormalities 5.8 135 39.0 3
Number of co-morbidities
153
None 6.2 2 17.1 11 2.8 (0.2 5.3) 10.9 (7.4 14.4)
One 7.0 528 30.8 4 4.4 (-+0.0 9.9) 23.8 (14.8 32.7)
Two 8.7 216 16.0 3 1.8 (0.0 3.6) 7.3 (-2.1 16.7)
·stngle infection at a site other than the unnary tract, bloodstream, surgical wound, skin or lower
respiratory tract
lOS -length of stay, ·nwnerator n=I consequently standard deviation not e timable so confidence limits could not be estim lad.
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Table A14.7: Mean length of stay for patients with more than one Infection
(multiple infections) and uninfected patients by key patient
characteristics
Mean length of hospital stay (days)
No HAl Multiple infections
Ratio of LOS Additional days
Patient characteristic
(950,<,Cl) (95% Cl)
Mean n Mean n
(a) (b) (b/a) (b-a)
Sex
Male 5.9 946 23.5 44.0 (2.8, 5.2) 17.6 (12.0 23.2)
Female 7.1 1330 34.3 204.8 (2.5,7.1) 27.1 (23.4 30.8)
jAgegroup
18-34 6.0 485 6.0 11.0 • 0.0·
35-54 5.5 627 29.0 55.3 (0.6, 10.0) 23.5 (19.4 27.6)
55-74 6.8 870 21.3 113.1 (2.2, 4.0) 14,4 (10.6 18.3)
75+ 9.4 294 56.37 0.0 (1.9,10.1) 46.9 (38.3 55.5)
Specialty
General surgery 5.4 829 48.1 118.9 (4.5, 13.4) 42.7 (37.8 47.6)
Orthopaedics 10.3 462 33.5 43.3 (0.4 6.1\ 23.2 (14.8, 31.7)
Urology 5.1 445 25.5 25.0 (~O.O 13.0) 20.4 (13.8, 27.0)
Gynaecology 6.1 336 9.3 71.5 (0.4, 2.6) 3.1 (0.4 2.6)
Obstetrics 7.5 204 0.0 0- -
Admission type
Elective 6.0 1519 26.2 144.4 (1.0, 7.7) 20.2 (16.6 23.8)
Emergency 7.9 757 41.2 105.2 (3.2 7.3) 33.3 (28.2 38.4)
Discharge diagnosis group
Infectious & parasitic diseases 3.8 12 0.0 0- -
Neoplasms 6.7 329 31.2 64.7 (3.7, 5.6) 24.5 (19.0, 30.0)
Endocrine, nutritional & metabolic
diseases & immunitv disorders 4.9 20 0.0 0- -
Diseases of blood & blood forming
organs 4.3 3 0.0 0- -
Diseases of the nervous system &
sense organs 3.5 2 0.0 0- -
Diseases of the circulatory system 5.0 142 84.5 417.0 (5.2 28.8) 79.5 (66.4 92.7)
Diseases of the respiratory system 7.0 4 0.0 0- -
Diseases of the digestive system 4.9 396 18.3 33.8 (1.6, 5.9) 13.5 (7.8 19.1)
Diseases of the genitourinary
71.7 (1.0, 2.5) 3.9 (1.4 6.4)system 5.4 519 9.3
Complications of pregnancy,
childbirth & puerperium & certain
conditions Originating in the
perinatal period 7.3 230 0.0 0- -
Diseases of the skin &
subcutaneous tissue 4.5 28 0.0 0- -
Diseases of the musculoskletal
system & connective tissue 10.5 296 20.0 11.9" 9.5·
Injury & Poisoning 9.9 160 38.0 3 3.8 (~O.O, 7.9) 28.1 (16.7 39.5)
Symptoms, signs & ill- defined
conditions; mental disorders &
congenital abnormalities 5.8 135 0.0 0-
Number of co-morbidlties
None 6.2 1532 21.5 153.5 (1.9 5.0) 15.3 (12.3 18.2)
One 7.0 528 49.2 5 7.1 (~O.O 14.5) 42.2 (33.4, 51.0)
Two 8.7 216 52.8 46.0 (2.7,9.4) 44.0 (35.3, 52.7)
-I n • -LOS e gth of stay, numerator n 1 consequently standard deviation not estimable so confidence bnuts could not be estimated .
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An economic model to assess the cost and
benefits of the routine use of silver alloy
coated urinary catheters to reduce
the risk of urinary tract infections in
catheterized patients
R. Plowman*, N. Graves*,j. Esquivel] and j.A. Roberts*
*London School of Hygiene & Tropical Medicine, Keppel Street, London we IE 7HT, UK and tPrevNiTech Ltd,
Surrey, UK
Summary: Prevalence studies generally find nosocomial urinary tract infections to be the most common
type of nosocomial infection, accounting for between 21% and 45% of all BAIs. The main risk factor
appears to be the presence of a urinary catheter, with an estimated 80°!., of these infections being associated
with their use. This paper describes a model which quantifies the extent of the burden of these infections in
terms of the number of patients affected and the costs incurred by the hospital sector; and identifies the
potential benefits of the routine use of silver alloy coated catheters, as a means of reducing the incidence of
this type of infection. An illustrative model of the annual costs and benefits associated with the routine use
of this intervention in adult, non-day case patients admitted to the medical and surgical specialties of NBS
hospitals throughout England is presented. The results suggest that a 14.6'Yoreduction in the incidence of
urinary tract infections in catheterized medical patients, and a 11.4% reduction in catheterized surgical
patients, would cover the cost of the intervention. Any further reduction in incidence would result in net
positive benefits.
© 200 I The Hospital Infection Society
Keywords: Nosocomial urinary tract infections; urinary catheter; modelling; costs and benefits; infection control; silver
alloy coated urinary catheter.
Introduction
Studies of urinary tract infections in patients
admitted to both medical and surgical specialties
suggest that between 1% and 3'X, acquire a urinary
tract infection (UTI),I-4 whilst a study that was
limited to infections occurring in surgical, urology,
gynaecology and orthopaedic patients who had an
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operative procedure, found that 6.3% acquired a
UTI. 5 Studies suggest that between 1% and 5% of
patients with UTI will develop a secondary bacter-
aemia.I,3,b Prevalence studies generally find UTIs
to be the most common type of nosocomial infec-
tion accounting for between 21% and 45% of all
HAls.7-11 A key risk factor for these infections is
the presence of a urinary catheter6.12-15 with an
estimated 80% of nosocomial UTIs (NUTIs) being
associated with the presence of this device.!"
NUTIs result in additional morbidity3.b,17-19 and
mortality,20.21 and represent a considerable eco-
nomic burden to the health care sector, patients and
their carers.4.5,22-26 This paper presents a model
which quantifies the extent of the burden in terms
© 200 I The Hospital Infection Society
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of the number of catheterized patients who acquire
a UTI and the costs incurred by the hospital sector,
and identifies the potential benefits of introducing
the routine use of silver alloy coated catheters, to
reduce them. An illustrative model of the annual
costs and benefits associated with the routine use of
this intervention in adult, non-day case patients
admitted to the medical and surgical specialties of
National Health Service (NHS) hospitals throughout
England is also presented.
Aims and objectives of the economic model
The model aimed to assess the following:
(1) the number of NUTls occurring in catheter-
ized patients admitted to specialties of interest
at one or more hospitals
(2) the economic burden these infections impose on
the hospital sector in terms of the number of
extra days patients remain in hospital and their
associated value
(3) the potential benefits of an intervention which
aims to reduce the incidence of this type of
infection.
Methods
The literature on the incidence of NUTls, risk fac-
tors for them, their impact on mortality, and the
economic burden imposed was reviewed. Relevant
R. Plowman et al.
papers were identified from the Medline database
and the information obtained used to devise the
model, which was subsequently developed using the
spreadsheet computer package Microsoft Excel 97.
The model was developed as a flexible tool, which
the user could adapt to reflect the patient group of
interest within a particular setting. An illustrative
model of the annual costs and benefits of the rou-
tine use of silver alloy coated catheters in adult,
non-day case patients, admitted to the medical and
surgical specialties of NHS hospitals throughout
England was subsequently constructed.
The structure of the economic model
Figure 1 illustrates the structure of the model. The
starting point for this model is the number of admis-
sions to the specialties of interest. These patients
may then be sub-divided into the groups of interest,
for example categorized by admission specialty.
Figure 1 shows the patients subdivided into two
categories however the model allows subdivision
into as many sub-groups as required. The patient
groups of interest are then further subdivided into
those who are catheterized and those not cathe-
terized. The number of NUTIs that might occur
in these catheterized patients is then determined.
Estimates of the economic impact these infections
have on the hospital sector are then derived by
CELLI
Total admissions
Figure I The structure of the economic model.
I
CELL 11
'-----l~~ DID NOT ACQUIRE A UTI
Use of silver alloy coated catheters
multiplying the number of NUTIs by an appropri-
ate estimate of the number of extra days patients
have to remain in hospital, and multiplying this lat-
ter figure by the relevant estimate of a cost per day
in hospital. Estimates of the benefits of a specific
intervention which aims to reduce the incidence of
NUTIs are subsequently derived. The intervention
considered in this model is the routine use of silver
alloy coated urinary catheters. Estimates of the
number of bed days released for alternative use and
their associated value are derived.
In order to use this model the following informa-
tion is required:
(1) Number of admissions to the specialties of
interest at one or more hospitals.
(2) Of those patients selected, the number (or pro-
portion) of patients within the group of inter-
est, for example, the number of patients
admitted to relevant specialties. In Figure 1 the
patients have been subdivided into medical
admissions and surgical admissions.'
(3) The number (or proportion) of patients in
the selected groups of interest who are
catheterized.
(4) The number or estimated incidence of NUTIs
occurring in these catheterized patients.
(5) The average number of additional days that
catheterized patients with a NUT I remain m
hospital.
(6) The cost of an additional day in hospital.
Results
Medical atients - NUT!
Sur .cal atients - NUT!
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(7) The cost and estimated effectiveness of the
intervention.
A facility, which enabled sensitivity analysis to
be conducted, was also built into the model.
Sensitivity analysis reveals how the varying of one
or more assumptions affects the model. In this
model the sensitivity analysis was used to assess the
effect of changing the estimates of the incidence of
NUTIs in catheterised patients, the effectiveness of
the intervention, the number of extra days patients
remained in hospital as a result of the infection, and
the cost per additional bed day.
The model produces four main outputs:
(1) The number of catheter related NUTIs that
would occur in a pre-defined patient group.
(2) The additional bed days utilized as a result of a
NUTI.
(3) The value of the resources used by catheterized
patients who acquire a NUTI.
(4) The net financial benefits associated with the
routine use of silver alloy coated catheters.
Results of the illustrative model
A model to assess the costs associated with catheter-
associated NUTIs occurring in adult (;:: 18 years of
age), non-day case admissions to the medical and
surgical specialties of NHS hospitals throughout
England (Figure 2), and the potential benefits of
CELLS 7.3~1
I ACQUIRED A UTI 17376
_lCELL4 11.6%
I ICatheterized 236945
ICELL2 49.0o/~1
I CELL9 927~l
-IMedical admissions 2042633 DID NOT ACQUIRE A UTI 219577
I ICELLS 88.4%
INot catheterized 1805688
CELL 1 100~ 1
Total admissions 4181670
CELL 10
7.3~l
I ACQUIRED A UTI 48784
.ICELL6 31.1%
I ICatheterized 665241
ICELL3 510%1 I CELL 11 92.7%:I
-ISurlrical admissions 2139037 DID NOT ACQUIRE A UTI 616678
I JCELL 7 68.9%
INot catheterized 1473796
Figure 2 The economic model of the costs of catheter associated NUTls occurring in adult. non-day case patients admitted to the medical
and surgical specialties of NHS hospitals throughout England.
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Table I The estimated casts and bene~ts of the routine use of silver al/oy coated catheters in adult patients, excluding day cases, admitted to the
medical and surgical spedlaties of NHS hospitals throughout England at different levels of effectiveness
Effectiveness of catheter at preventing NUTls
Surgical patients 1% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Bed days made
available 1756 17562 35124 52686 70248 87811 105373 122935 140497 158059 175621
Gross benefits
(value of bed days) (£ Million) 0.53 5.25 10.50 15.75 21.00 26.26 31.51 36.76 42.01 47.26 52.51
Additional cost of
silver alloy coated
catheter (£ Million) 5.99 5.99 5.99 5.99 5.99 5.99 5.99 5.99 5.99 5.99 5.99
Net benefits (£ Million) -5.46 -0.74 4.51 9.77 15.02 20.27 25.52 30.77 36.02 41.27 46.52
Effectiveness of catheter at preventing NUTls
Medical patients 1% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Bed days
made available 626 6255 12511 18766 25021 31276 37532 43787 SO042 56297 62553
Gross benefits
(value of bed days) (£ Million) 0.15 1.46 2.91 4.37 5.83 7.29 8.74 10.20 11.66 13.12 14.57
Additional cost
of silver alloy (£ Million) 2.13 2.13 2.13 2.13 2.13 2.13 2.13 2.13 2.13 2.13 2.13
coated catheter
Net benefits (£ Million) -1.99 -0.68 0.78 2.24 3.70 5.15 6.61 8.07 9.53 10.98 12.44
introducing the routine use of silver alloy coated
urinary catheters (Table I) was developed. This
model uses real data obtained from a variety of
sources, details of which are given below together
with the output of the model.
Number of admissions (cell ')
The number of adult (~ 18 years of age), non-day
case admissions to the medical and surgical special-
ties of all NHS hospitals throughout England was
obtained from the hospital episodes statistics data-
base.27 In 1994/5 there were 4181670 admissions
that met this criterion. Appendix 1 provides details
of the specialties included in the illustrative model.
Number of patients who were medical
and surgical admissions (cell 2 and 3)
The number of patients admitted to medical and to
surgical specialties was also obtained from the hospi-
tal episodes statistics database.i" In 1994/5 2042633
(49%) of the 4181670 adult, non-day case admis-
sions to the medical and surgical specialties of NHS
hospital in England were surgical admissions and
2139037 (51%) were medical admissions. Appendix 1
contains details of the specialties included in these
two categories.
Number of patients who are catheterized
(cells 4 and 6)
Information on catheterization rates is not routinely
collected and as such the model utilizes estimates
taken from the literature. For the purposes of this
illustrative model estimates taken from the results of
an audit of infection control policies and practices in
19 hospitals in England and Wales have been
applied.j" The audit study provided information on
the proportion of medical, surgical, orthopaedic, and
gynaecology patients who were catheterized at some
point during their in-patient stay. The study was
restricted to adult patients who had a minimum hos-
pital stay of three days. The median values for the 19
sites for each speciality were as follows: medical 11.6'%
(range: 5.0-17.0%); general surgery 34.4'Yo (range:
16.2-50.0%,); orthopaedic 17.3'Yo (range: 10.1-26.0%)
and gynaecology 40.4% (range: 20.9-72.0%). This
model utilizes the median value for the medical
specialties (11.6'Yc,:range 5.0-17.0%) and a weighted
JUse of silver alloy coated catheters
value for all surgical specialties (31.1%: range
16-49'}j,). This latter estimate was derived from the
individual surgical speciality estimates and data on
the number of admissions to these specialties.
Although the case-mix of patients studied in this
earlier study is not directly comparable with the
patient group described in this model, and therefore
it is not clear how accurately these estimates reflect
the actual catheterization rate in the selected patient
group, it was felt that these were the best estimates
currently available.
Number (or percentage) of catheterized patients
who acquire a NUT' (cells 8 and '0)
Data on the incidence of NUTIs in catheterized
patients were not available. In their absence, esti-
mates were derived as follows. A study of the inci-
dence of hospital acquired infections occurring in
3326 adult patients admitted to the general surgical,
general medical, orthopaedic and gynaecology spe-
cialties of a district general hospital, indicated that
83 (2SYo) acquired a UTI.2 Data from the US sug-
gests that 80% of NUTIs occur in catheterized
patients.l" If this assumption is applied to the num-
ber of NUTIs observed it follows that 66.4 of the 83
NUTIs observed occurred in catheterized patients.
In order to obtain an estimate of the incidence of
NUTIs in catheterized patients, this figure was
expressed as a percentage of the number of catheter-
ized patients. In the absence of information on how
many of the 3326 patients involved in the incidence
study2 were catheterized, an estimate was derived
by applying the specialty - specific median catheteri-
zation rates observed in the audit of infection control
at 19 hospitals in England and Wales2M to data on
the number of patients within each specialty, and
the number of catheterized patients was summed.
Overall an estimated 905.47 of the 3326 patients
involved in the incidence study2 were catheterized
at some stage during their admission. If the esti-
mated number of catheter-related NUTIs (66.4
~UTIs) is expressed as a percentage of these 905.47
catheterized patients, then the incidence of NUTIs
in catheterized patients is estimated as 7.3%,
(66.4/905.47) and this figure was used in this model.
The number of additional days that catheterized
patients with a NUT' remain in hospital
The assumption was made that NUTIs occurring in
surgical patients, on average, result in patients
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remammg in hospital an additional 3.6 days. This
estimate was taken from the results of a study which
estimated the cost of NUTIs occurring in adult
patients admitted to the gynaecology, orthopaedic,
general surgery and urology specialties of a district
general hospital.f In the absence of any literature
that exclusively considered the impact of NUTls in
medical patients on hospital sector resources use,
the same estimate was applied to NUTIs occurring
in medical patients.
The cost of an additional days stay in hospital
Estimates of the cost per bed day were derived as
follows. Data were retrieved from the Chartered
Institute of Public Finance Accountants' Health
Service Database/" on total bed days supplied, by
speciality, for as many hospitals as provided data.
Corresponding data were also extracted on expendi-
ture for these bed days. These specialties were
organised into medical and surgical specialties and
the average cost of providing a bed day was derived
for each speciality. To provide an overall figure for
surgical and medical specialities, the sum of the
expenditures was divided by the sum of the bed days
(Table II).
Table II Average value of a bed day by speciality
Medical/surgical category Specialties Mean (£)
Surgical specialties General surgery 266
Urology 263
Orthopaedics 264
Gynaecology 323
Neuro surgery 410
Plastic surgery 358
Cardiothoracic 522
All surgical specialities 299
Medical specialties Geriatrics 125
Cardiology 386
Infectious diseases 275
Medical oncology 327
Neurology 258
Rheumatology 248
Gastroentorology 241
Haematology 299
Thoracic medicine 244
GU medicine 295
Nephrology 276
Rehabilitation 188
General medicine 171
All medical specialties 233
Data source: Chartered Institute of Public Finance Accounts'
Health Service Database, London (1998).
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Estimating the potentia' benefits of the routine
use of silver alloy coated catheters
Having identified the number of patients who
acquire a NUTI, and the estimated impact these
infections have on hospital sector resource use, the
final stage of this model is to identify the potential
savings that might result from the routine use of
silver alloy coated catheters. In order to estimate
these benefits information on the cost of the inter-
vention and its estimated level of effectiveness is
required. The estimated additional cost of silver
alloy coated catheters compared to non-coated
catheters is £9.30 If this figure is applied to all
catheterized patients it follows that the routine use
of this type of catheter in medical patients would
cost an estimated £2 132 509 and in surgical patients
£5987165. Estimates of the effectiveness of the
intervention may be obtained from the results of
clinical trials.31-34 However, it should be noted that
while these trials demonstrate that the intervention
is effective at reducing the incidence of NUTls, the
impact that their routine use has on the incidence of
NUTIs in other settings will depend on the infec-
tion rate and the case-mix of patients involved, and
as such a range of estimates of the effectiveness of
this intervention, (0-100'X,) has been incorporated
into this model.
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Results of the iIIustrotive model
If the above assumptions are accepted, the model
suggests that 17376 medical and 48784 surgical
patients acquire a catheter related NUTI (Figure 2).
Medical patients were estimated to remain in hos-
pital for an additional 62553 days, valued at £15
million, and surgical patients were estimated to
remain in hospital for additional 175621 bed days,
valued at £53 million.
The additional cost of the routine use of silver
alloy coated catheters was balanced against these
costs assuming different levels of effectiveness at
preventing NUTls (Table I). If the routine use of
silver alloy coated catheters was adopted at an addi-
tional cost of £9 per catheter then in order for the
benefits to outweigh the costs 14.6% of infections
occurring in medical patients need to be prevented
(Figure 3) and 11.4% of infections occurring in sur-
gical patients need to be prevented (Figure 4). The
results of some clinical trials suggest that the pro-
portion of infections that could be prevented may
be higher than this.31-H For example, one study
found that the routine use of silver alloy coated
catheters reduced the risk of infection by 32%.34
Clearly at this level of effectiveness the benefits of
the use of silver alloy coated catheters significantly
outweigh the costs.
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Figure 1 Costs and benefits of the routine use of silver alloy coated catheters in adult. non-day case patients admitted to the medical
specialities of NHS hospitals throughout England at different levels of effectiveness.
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Figure 4 Cosu and benefiu of the routine use of silver alloy coated catheters in adult non-day case patienu admitted to the surgical special-
ties of NHS hospitals throughout England at different levels of effectiveness.
Table III The percentage of infections that need to be prevented if the benefits of the rou-
tine use of silver alloy coated urinary catheters are to cover the cost of the intervention and how
this varies when the model parameters are changed
Parameter changed Percentage of infections that need to be prevented if the benefiu
of the intervention are to cover the cost of the intervention
Incidence of NUTls
in catheterized
patients
Medical specialties Surgical specialties
(%) (%)
".0% 26.82 20.90
5.0% 21 ...6 16.72
5.0% 21 ...6 16.72
6.0% 17.88 13.94
7.0% 15.33 11.94
7.3%· 14.63 11.40
8.0% IlAl 10.4S
9.0% 11.92 9.29
10.0% 10.73 8.36
2 26.34 20.52
3 17.56 13.68
3.6* 14.63 11.40
4 13.17 10.26
5 10.53 8.21
6 8.78 6.84
50% of cost used 29.26 22.80
100% of cost used* 14.63 11.40
150% of cost used 9.75 7.60
Average number
of extra days
patients remain
in hospital
Cost per bed day
'"estimates used in the Illustrative model.
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Sensitivity analysis
Table II I shows the results of the sensitivity analy-
sis which assessed the impact that varying the key
as~umptions used in the model had on its resul~s.
The impact of varying the incidence of NUTIs m
catheterized patients, the number of additional bed
days that patients remained in hospital, and the
value of extra bed days were assessed.
As the values of individual parameters are
decreased the intervention needs to be more effective
for the benefits to cover the costs and vice versa. For
example, if the incidence of NUTI in catheteriz~d
patients is only 4% rather than 7.3% as assume~ m
the model, then providing all the other assumptions
are valid, 20.9% of NUTls occurring in catheterized
surgical patients, and 26.8% in medical pa~ients
would need to be prevented if the costs of the inter-
vention are to be covered. However, if the incidence
of NUTI is higher, then providing the other
assumptions are accepted, a lower percentage of
infections would need to be prevented to cover the
cost of the intervention. For example, if the inci-
dence of NUTls in catheterized medical and surgi-
cal patients was 10%, an 8.4'X. reduction in the
incidence of NUTls in catheterized surgical patients
would be needed to cover the cost of the interven-
tion, and a 10.7% reduction in medical patients.
The effects of altering more than one parameter at
a time were not explored in this model. Nor was the
effect of varying the proportion of patients who are
catheterized. Changing the proportion of patients
catheterized will inevitably alter the number acquir-
ing an infection, the number of extra days utilised
by infected patients and the cost of this prol?nged
hospital stay, but will not affect the proportion of
infections that needs to be prevented to cover the
cost of the intervention.
Discussion
Validity of the model
The validity of the model is dependent on how real-
istic the structure of the model is and how accurately
the estimates of the parameters used reflect what is
happening in the patient group of interest. The
illustrative model presented in this paper was based
on information derived from the literature and a
number of assumptions. However, the model has
been developed so that at the level of the individual
hospital, more accurate estimates, which reflect the
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patient group of interest in a particular setting, may
be used. For example, the user may have access to
local information on the number, or proportion of
patients catheterized, the incidence of NUTls in
catheterized patients, and the number and cost of the
extra days infected patients remain in hospital.
Alternatively, the estimates used in the illustrative
model may be replaced by those taken from other
studies, where case mix more closely reflects the
patient group of interest. Equally, the user may con-
sider the routine use of the more expensive silver
alloy coated catheter to be inappropriate and wish to
limit it to patients considered to be at high risk of
acquiring a urinary tract infection. The user would
simply need to substitute data on the number of
admissions, with data on the number of patients in
the high-risk category, and replace the incidence fig-
ures with estimates which reflect the incidence of
NUTls in the high risk group.
Interpreting the results of the model
While a number of studies suggest that the use of
silver alloy coated catheters is an effective means of
reducing the incidence of NUTls,31-34 it should be
noted that the validity of some of the estimates has
been questionedr'" and a study by Thiobon et al."
failed to identify any significant preventative effect.
Concerns relate to factors such as the small number
of patients involved in some of the studies, and
effectiveness being assessed in terms of ability to
prevent bacteriuria rather than symptomatic
NUTls.35,36 However, more recently a relatively
large studv'" assessed how effective these catheters
were at reducing NUTls as defined by Centre for
Disease Control and Prevention criteria.V The
results of this latter study confirmed those of earlier
studies that demonstrated that silver alloy catheters
exerted a preventative effect. The use of silver alloy
coated catheters was found to reduce the risk of
acquiring an infection by 32'X•.34While it may not be
possible to achieve similar levels of reduction in the
incidence of this type of infection in all settings, the
level of effectiveness achieved to some extent
depending on the scope for reducing the incidence
of I\'UTls, the results of this model suggest that the
additional costs associated with the routine use of
silver alloy coated catheters can be recouped at rela-
tively low levels of effectiveness and any further
reductions result in net benefits.
The results of the sensitivity analysis demon-
strate that even when a relatively conservative
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estimates of the incidence of NUTIs, or the number
and value of extra days patients remain in hospital
are applied, the benefits of the routine use of silver
alloy coated catheters continue to outweigh the addi-
tional expenditure. However, it should be noted that
the sensitivity analysis did not consider the impact
of varying more than one parameter at a time.
The model did not assess the benefits associated
with a reduction in secondary bacteraemias and as
such the benefits of preventing NUTIs may have
been underestimated in the illustrative model. An
estimated 1-5% of patients with catheter associated
bacteriuria will develop a bacteraemia'v' which may
further prolong the length of hospital stay and rep-
resent an additional burden to the health sector. If
the use of silver alloy coated catheters is effective in
preventing NUTIs in patients, who in the absence
of this intervention would have acquired both a
NUTI and a bacteraemia, the benefits of prevent-
ing NUTIs through the routine use of this inter-
vention will increase.
It should be understood that the cost of an
infection, if avoided, will not all be realised as a
cash saving. Many of the costs/benefits are fixed
and it is principally the variable costs/benefits (for
example drugs, and other consumable items), which
represent a smaller proportion of the total costs,
that would show as cash savings and as such expen-
diture that could be avoided.
While the fixed costs avoided will not all be
realised as cash savings, they do represent economic
benefits as these costs could be deployed to produce
other outputs other than treating infection. It is
therefore justified to use the full cost data (fixed
and variable costs) to represent the benefits. These
methodological issues are discussed in more detail
elsewhere.f"
Potential applications
The model described in this paper can be adapted
to the particular needs of the user. I t may be of
particular interest to infection control workers who
wish to demonstrate the magnitude of the burden
of this type of infection and the benefits associated
with the routine use of silver alloy coated catheters.
The information derived from the model may be
used to justify the additional expenditure associated
with this intervention, and to change policy regard-
ing infection control practice.
While the model presented in this paper focuses
on NUTIs occurring in catheterized patients and
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the routine use of silver alloy coated catheters as a
means of reducing this type of infection, the model
could also be adapted to assess the benefits of an
alternative intervention and/or the prevention of
infections at other sites.
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Appendix I Number of adult non-day case admissions to seleaed spe-
cialties of NHS hospitals throughout England in 199415
Speciality Number of adult
(~ 18), (non-day
case admissions)
Medical specialties General medicine 1090716
Gastroentorology 17839
Endocrinology 5038
Haematology (clinical) 46626
Clinical pharmacology 5578
Rehabilitation 3706
Palliative medicine 4772
Cardiology 96488
Dermatology 13739
Thoracic medicine 42485
Infectious diseases 12206
Genito-urinary medicine 1985
Nephrology 43531
Medical oncology 37572
Nuclear medicine 151
Neurology 43316
Clinical neuro-physiology 307
Rheumatology 38165
Geriatric medicine 431310
Old age psychiatry 38620
Radiotherapy 56325
Radiology 1575
General pathology 8
Blood transfusion 54
Chemical pathology 495
Haematology 9970
Histopathology 2
Immunopathology 53
Medical microbiology I
Surgical specialties General surgery 804676
Urology 223685
Trauma & orthopaedics 464948
Neurosurgery 37587
Plastic surgery 59060
Cardiothoracic surgery 47686
Gynaecology 501395
Data source: Hospital Statistics Database 1994/5.
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The rate and cost of hospital-acquired
- infections occurring in patients admitted to
selected specialties of a district general hospital
in England and the national burden imposed
R. Plowman. N. Graves*. M.A. S. Griffint.J.A. Roberts*.A.v. Swant. B. Cookson;
and L.Taylor
Infection Control Unit, Laborotory of HO$pitallnfection, Centrol Public Health Laborotory, *Department of Public
Health and Policy. London School of Hygiene & Tropical Medicine, tStotistics Unit, Public Health Laborotory
Service, and tLaborotory of Hospital Infection, Centrol Public Health Laboratory. London, UK
Summary: Between April 1994 and May 1995 4000 adult patient. admitted to selected specialties of a dis-
trict general hospital were recruited to this study. Hospital-acquired infections presenting during the in-
patient Itay were identified using previously validated methods of surveillance, and information on daily
resource use by both infected and un infected patients was recorded and estimates of their cosr derived.
Linear regression modelling techniques were used to estimate how much of the observed variation in
resource use and costs could be explained by the presence of an infection. Complete in-patient data sets
were obtained for 3980 patient •. Of these. 309 patients (7.8%; 95% Cl; 7.0. 8.6) presented with one or more
hospital-acquired infections during the in-patient period. Infected patients, on average, incurred hospital
costs 2.9 (regression model estimate: 2.8; 95% Cl; 2.6, 3.0) times higher than uninfected patients, equivalent
to an additional £3154 (regression model estimate £2917). Both the incidence and the economic impact var-
ied with site of infection and with admission specialty. Estimates of the burden of hospital-acquired infec-
tion. occurring in adult patients admitted to similar speciahies at NHS hospitals in England were derived
from the results of this study. An estimated 320994 (95% Cl; 288071, 353916) patients per annum acquire
one or more infection. which present during the in-patient period, and these infections cost the hospital
sector an estimated £930.62 million (95% Cl; £780.26; £1080.97 million) per annum. The results presented
represent the gross economic benefits that might accrue if these infections are prevented. Further research
is required to establish the net benefits of prevention.
C 200 I Thl Ho.pll., Inloetlon Socii."
K.YWDrdl: Hospital-acquired infection; incidence; economic burden.
Introduction
At anyone time approximately 10% of hospitalized
patients have an infection acquired after admission
to hospital. 1 These infections result in additional
costl to the healthcsre lector, patients and those
who care for them.2 Few studies have estimated the
incidence of these infections OCCUrring in a wide
range of patients. M While a number of .tudi •• ha".
aneased the economic burden imposed by these
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infections, the estimatel derived have generally been
limited to the costa incurred by the hoapital sector,
and little information on the distribution of the
additional costl incurred between the budgetary
centres of the hOlpital hal been provided.5-7 Thil
study providea I more comprehensive laleument of
the incidence of these infectionl and their impact on
resource Ule. The resulta of the analysil examining
the incidence of hospital-acquired infection pre-
senting during the in-patient period and their
impact on ho.pital lector resource use and COSIIare
presented in thil paper.
Method,
Study lICe
Patienta were recruited from a district aeneral hcs-
pital within close proximity of the two institutions
involved in the research. Thil rype of hO'pitll wal
elected in preference to teniary referral centres in
order to facilitlte the generllizability of the atudy
relults to other healthcare aettin ... The hoapital
selected was part of an English NHS Trust provid-
inll lIeneral acute ervicel, elected rellional tertiary
specialist aervicea and primary care services. At the
time of recruitment it had 579 bedl.
A retrospective usessment of how representative
the study hoapital wal of otherl in England wal
undertaken in terml of the number of bed days
produced, number of Itaff employed, the average
COlt per bed day, the average length of Itay and the
expected length of .tay aiven the calC mix of
patient'. Data on the number of bed day. pro-
duced, number of .taff employed and a"erlac coat
per bed day at the Iludy hospital and for hospital.
throughout England were retrieved from the
Chartered Institute of Public Finlnce Accoun-
tantl/He_lthc_re Financial Manaaer. datlbase. s
The Itudy hOlpital valuel for theae three vlriablel
were found to ,lie within the interquartile range of
the distributiona. The Health Senicel Indicator.
databale9 provided information on the lverage
length of Itay, and expected length of Itay given the
c.se mix of pltienll for some of the apecialtiea
involved in thil atudy, at both the study lite and It
other hoapitala throughout England. The atudy
hospital , .. lues for theae variable. fell within the
interquartile rlnlle of the diltributionl. Thele find-
inga luggelt that for the , .. riable. considered, the
•tudy hOlpital wal not atypical of other hOlpilila
throughout England.
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At the time the .tudy was undertaken the study
hospital's infection control team consisted of two
infection control nurse. and a microbiologist who
dedicated approximately 3h to infection control
team activitiel per week. This infection control
team wla responsible for infection control at the
study ho,pital and 60 non-acute beda at two other
hospillls, equivalent to one ICN per 289 scute beds
and 30 non-acute bed •. Thia ratio of infection con-
trol nUries to number of bed. ia higher than the
national averalle of one leN to 535 beds.IO
Adult ( .. t 8 years of age) medical; surgical; ortho-
paedic; urology; gynaecology; ear, nOle and throat;
elderly care; and, if they had had a Caesarean section,
obstetric patienta admitted to elected '\'Irds at the
study hOlpital who had a minimum in-patient Itay of
30h were eligible for recruitment. Day calC patienta
and patient. who remained in hoapital overnight and
were diacharged earl)' the following day were there-
fore omitted from thi. atudy. Resource constrainta
prohibited the inclusiun of these patient&.
Recruitment
Having obtained ethical committee approval,
recruitment began in April 1994 and continued
until May 1995. The informed written consent of
eligible patients waa obtained by one of six research
assistantl, 111 of whom were experienced reaiatered
nurael and trained in recruitment, surveillance and
data collection method •.
From the outaet it was clear that the research
as.iltanta would not be able to invite all eligible
patienta to participlte in thia study. While recruit-
ment itelf did not take up I lot of the available
time, the identification of hospital-acquired infec-
tions (HAIs) Ind the collection of detailed data on
resource ue was time conluming. The relearch
ani,"nta were inatructed to aive priority to the col-
lection of complete data leta rather than recruiting
all elillible patients and were given Ippropriate train-
inllind .upervilion to minimize any election bill.
Information on the realon eliaible pltient. were
not recruited (e.g., the patient declined participa-
tion, or wa. not recruited due to practical reasons
.uch II insufficient time) and the age, sex, admis-
aion Type and admi.aion lpecilhy waa recorded .
Thele data were sublequently analysed to check for
any recruitment bial.
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Dertercollection
Baseline information including age, sex, diagnosis,
co-morbidities and social circumstances was obt-
ained from the patients themselves and their med-
ical and nursing records.
Hospital-acquired infections were identified
using the reference method of surveillance and pre-
viously validated definitions of infections. I I The
reference method of surveillance aims to identify
all HAla presenting durinll the in-patient period. It
involves consulting relevant healthcare records on a
regular basis to obtain evidence of the presence of
one or more infections. If this evidence meet. the
criteria detailed in the definitions used, an HA I is
recorded as being present. The site of the infection,
date of onset, and, if known, the causative path-
ogen are also recorded.
Data on daily resource use, including contacts
with professionals allied to medicine, laboratory
radiological and other diagnostic tests undertaken,
surgical and medical procedures performed, drulls
prescribed, and care administered by nursing staff
were obtained from the patients' medical, nursing,
laboratory and paramedic records.
Development of moneterry ","uOflon.
of re.ource u.e
Estimates of the value of the hospital resources
used by individual patients were made and the
methods used are reported in detail elsewhere.12
The methods were designed to identify the likely
opportunity COltl of the resources used.
The hospital costs incurred by patientl recruited
into this study Were categorized as either costs asso-
ciated with occupying a hospital bed or the cost of
specific care and treatment administered to individ-
ual patients.
The cost of occupying a hospital bed included
the cost of hospital overheads. directorate manage-
ment and capital chargel. The methods used to
attribute these costl were developed from inter-
views with the relevant managera and health care
professionall. A COlt per bed day was derived for
each clinical specialty and this estimate multiplied
by the patient" length of hospital Itay.
COitI associated with Care and treatment adminis-
tered included the cOlt of medicsl time, nuraing
time, the time of other health care profCSlionaia such
u physiotherapists, and the cost of diagnostic inves-
tigations. procedures carried out and consumables
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used. Estimates of the daily cost of medical care
were derived for each specialty and this was allocated
according to the patient's length of hospital stay.
Nursing costs were allocated to patients based on
the amount of nursing care patients received each
day and unit costs were derived for contacts with
professionals allied to medicine and allocated in
accordance with the number of contacts supplied.
Unit costs were also derived for laboratory investiga-
tions, radiological inveerigations, electrocardiograms,
endoscopic procedures, surgical procedures, phar-
maceuticals, dressings and other consumable prod-
ucts supplied to the patient. These costs were
allocated in accordance with the individual patient's
consumption of these resources.
All data on the cost of resources were retrieved
from the finance department of the hospital and the
clinical specialties themselves.
Data analysl.
Checldn, for recrultment/re/ectlon biers
The age, lex, admission type and admission spe-
cialty distributions of patients recruited into the
study were compared to the distributions that
would have been present if all eligible patients were
recruited.
Incidence of ho.plterl-crcqulred Infectlo",
present/n, durin, the In-pOflent p.rlod
The number of patients with one or more HAIs
presenting during the in-patient period was expressed
ua percentage of the number of patients discharged
and 95% confidence intervals derived. Site and
specialty Ipecific estimates were also derived,
Attribution of com to HAl
Factors other than infection may have an impact
on resource use. Z Linear regression modelling
techniques were used to control for a ranlle of
factors that could potentially influence the level
of resource use: age, lex, diallno,is, number of co-
morbidities, admission Bpecialty and admission
type. Since the COlt and length of hospital stay dis-
tributions included I few very high values they
were skewed to the right. For thi.· reason the analy-
si, was performed assuming that the underlying
distribution waBGamma in form (this distribution,
very limilar to the log-Normal, ia appropriate for
skewed data 13). Eltimates of the impact of one Or
The rate and eese of ho.plcal-acqulrod Infactlon.
more HA Is, and of specific types of infection on
resource use, adjusted for the effects of confound-
ing variables were thus obtained from the simplest
regression model that adequately represented the
variation in the costs incurred by infected com-
pared with un infected patients.
Oerlvln, natlonol estimate. of the numbe,
of potlenu who acqu/,. one or mo,. HAl,
National estimates of the number of adult patients
who acquired one or more infections in hospital,
which presented during the in-patient stay, were
derived by applying the observed in-patient inci-
dence rate and 95% confidence interval to data on
the number of adult patients (aged ~ 18), excluding
day cases. admitted to similar specialties, in NHS
provider unit. throughout England in 1994{5
(Table I). The same approach was used to derive
specialty specific estimates of the number of
patients acquiring one or more infections and esti-
mates of the number of patient. acquiring specific
types of infection.
Oerlvln, nOtIonoi estlmotes of the cost
of HAl. to the hOlpltai ,mo,
Estimates of the burden these infections impoaed
on the hospital sector were derived from data on the
observed incidence of hospital.acquired infection.
presenting during the in-patient period (Tables II,
III); the estimated ratio of the hospital costs inc-
urred by infected compared to uninfected patients
TIbIa 1 TIlt _"" .f oduII, non-doy _. __ '" JeIected
IfIK/DIIJft 0(NHS Hotpil" in fnfland in I ,,.,S
Spoclalty Number of"""lc admission ••
",.Iudln, day ..... , In 199415·
Gynaocolol)'
Elderi)' ca..
Ob.1ftrica (... _
NCllonsonly)
Orlhopsedica
Sur,ory
UrololY
Medicine
Ear, no .. and Ihrolt
All spodtlcJll
501395
411110
84089
464941
104676
221685
1411984
I7J 216
.. 11530J
Source: Hospllli opilodllllltIC. dats lit 199415."
• Numbor 01"""" pstiIna. txdudlna day ...... admlttld to ""
lpocilltl .. IImd In Appondbc I It NHS provider .... a In Enaiand In
199415.
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obtained from the linear modelling analysis (Tables
II, III); the mean hospital costs incurred by unin-
fected patients (Tablea II, III) and data on the
number of adult admissions (Table I). If N is the
number of patients admitted nationally, C the base-
line cost of treating uninfected patients, i the esti-
mated incidence and , the estimated ratio of COlts
incurred by infected compared to un infected
patients, then NiCr,-I) provides an estimate of
the national burden.
The variance of this estimate was derived from
the standard deviations of the estimates of the inci-
dence and ratio of costa, sdi and sd, respectively. as
follows: NICI[i1sd,z+(,_I)z sdil].
This estimated variance was subsequently used to
obtain 95% confidence intervals for the estimates of
the national burden of infection, it beinll' assumed
that the sampling error in such an estimate would be
approximately normal. Estimatea of the number of
additional day. patients remained in hospital snd site
and specialty specific estimates of the burden
imposed were made using the same approach.
Results
Sample characteristics
Between April 1994 and May 1995, 5909 patientl
were eligible for recruitment. Of these, 4000 (67.7%)
were recruited, 343 (5.8%) declined participation.
1553 (26.3%) were not recruited due to insufficient
time, and in a further 13 cases (0.2%) information
on the reason for non-recruitmenr was not
recorded. The age, lex, .dmiasion type and admis-
sion specialty of patients recruited into the study
wa. broadly similar to that which would have been
present if all eligible patients had been recruited
(Table IV).
Incidence of HAl.
During the in-patient period, 309 (7.8%; 95% Cli
7.0.8.6) patients presented with one or more HAil.
Site specific estimates indicated that urinary tract
infection. had the highest incidence, followed by
multiple infection. (Table II). Specialty specific
estimates indicated that the incidence varied con-
.iderably with specialty, being lowest amongst ear,
nose and throat patient. and highe.t in gynaecol.
ogy. elderly care and obstetric patients (Table III).
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Table IV The ........ "'*"_ type GIld __ spedCIIIy 0' pc!!len1S recruiUd Into !he Rudy ",,"pored ID rhO!
which would ,.,.. been obIo/IIed if oJ eliJlbIe porlonlS hod be .. roauiIH
Recruited patilnu Alioll&lblopatlonu'
N " N "
Sox M.los 1697 42.6 2669 45.5
Female. 2283 57.4 3i99 54.5
All padonu 3980 iOO 5868t iOO
Aao.roup II-59 1874 47.1 2720 47.2
60+ 2106 52.9 ]040 52.8
All padlnu ]980 100 5760* 100
Adminion typo EloctiYo 174] 4l.8 2332 39.6
Emor.. ncy 2212 55.6 3499 59.4
Unknown 251 0.6 58 1.0
All patllnu ]980 100 5889 100
AdmllSkln 'peelatty Medicine 838 21.1 1438 24.5
Su,.ery 898 22.6 1442 24.6
Orthopaodics 51] i2.9 684 11.7
UrololY 466 11.7 712 12.i
Obstoutcs • lynaecoiOlY 617 15.5 7i3 12.2
Elderly care 582 14.6 787 13.4
ENT 66 1.7 90 1.5
All patients 3980 100 586611 100
• This includes IMUents recruited into the IWdy. patienu who declined partidpatJon and patients who 'Were
11I,lbl. for recruitment but for reasons such II insufficient time the re.larch IlIlstant was unable to invite
them to participate.
t An additional 21 patients we ... noc recruited howlver Eh,ir SIX was not rlcorded, consequently thay hav.
beln excluded from this Inltyall.*An additional 129 patiena were not recruited however their q. was not recorded. consequendy they have
boon o.cluded from this analysis.
§The.o 25 in-padenu _ro tnnsfon from another ward.
'An additional 23 patients were not recruited how• .,.,. th.'r admJllion specialty WlS not recorded.
consequently thoy have boon oxcludod from this Inllysls.
Ertlmot •• of the Impact of HAf on ho.pltof
com ond f.nflh of ho.pftof noy
Estimates of the impact HAl had on length of
stay and hospital costs, and how these varied with
site and specialty are also presented in Tables I I
and III. Patients presenting with one or more HAIs
during the in-patient stay, on average, remained in
hospital and incurred costs almost three times
greater than uninfected patients. The distribution
of the additional costs incurred between the bud-
getary centres of the provider unit is presented in
Table V.
Estimates which only considered the costs of
consumables, such as drugs, dressings and other
pharmaceuticals, indicated that patients who
acquired one or more infections which presented
during the in-patient stay incurred consumable
costs that were 3.7 (regression model estimate 3.8;
95% Cl; 3.3. 4.2) times higher than those incurred
by uninfected patients. equivalent to an increase of
£315 (regression model estimate £325) per patient.
The estimated average increase in costs was low-
est for urinary tract infections. with costs almost
twice as high as in uninfected patients. The greatest
increases were associated with multiple infections:
on average costs were over six times higher than
uninfected patients. With the exception of blood-
stream infections, the impact of specific types of
infection on length of hospital stay followed a simi-
lar pattern. The four patients who acquired a
blood-stream infection and no other infection. had
the lowest increase in length of stay; however. two
of these patients died during the in-patient period.
The results suggest that while these four patients
were not found to have a marked increase in their
length of stay, their hospital stay was highly
resource-intensive. Specialty specific estimates
indicated that HA Is occurring in obstetric patients
who had had a caesarean section resulted in the
lowest increase in length of stay and hospital costs.
whereas infections occurring in surgical patients
resulted in the highest increases.
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Table V Distribution of the hospital cosu: Incurred by infected and unin{ected patients durin, the in-potient phose
COlt clt.iory Me.n COSts (£) Ratio of CDSU Additional Percenuge
costs contribution to
No HAl HAl (£) additional costs (%)
N=3671 N=309
HoSpital overheilds 436.86 1112.58 2.5 675.72 21.43
Directonte mana,ement 49.90 115.07 2.3 65.18 2.07
Capital charles 207.80 499.68 2.4 291.88 9.26
Medical time 153.69 338.09 2.2 184.40 5.85
NUB!n, care 385.40 1721.25 4.5 1335.85 42.36
Paramedics & specialist nurses 17.46 6l.70 l.6 46.24 1.47
Physloth... py 19.02 93.l5 4.9 74.34 2.36
Sur,'cal Interventions 195.20 263.44 I.l 68.24 2.16
Consumable, used specific
procedures· 9.95 118.lS 11.9 108.40 3,44
Antimicrobials IMO 71.07 5.3 57.67 1.83
All other drugs 40.99 150.46 3.7 109.47 H7
Microbiology tests 6.97 n.n 4.8 26.16 0.83
Other pathololY tests 48.26 113.34 2.l 65.08 2.06
Endoscopies 2.59 6.88 2.7 4.29 0.14
Radiology lS.19 7l.13 2.1 37.94 1.20
Other tests 5.70 8.50 1.5 2.80 0.09
Total cosu I628.l8 4782.03 2.9 l153.66 100
• This Includes the cost of items such as dressings. drains. lines.
The natlonal burden of HAl
Estimates of the number of patients who acquired
an infection in hospital which presented during the
in-patient period and of the economic burden these
infections impose on the hospital sector are pre-
sented in Table VI.
An estimated 320994 adult, non-day case admis-
sions to the specialties covered in the underlying
study in 1994/5 acquired one or more infections
that presented during the in-patient period. These
infections were estimated to cost the hospital sec-
tor £930.62 million (95% Cl; £780.26, £1080.97
million).
The estimated burden varied considerably with
the site of infection. While multiple infections,
imposed the highest costs, urinary tract infections,
which on average had a relatively low cost per case
(model estimate £! 122), due to their high inci-
dence, were the most costly single site infection
(£123.89 million: 95% Cl: £80.96, £166.83 mil-
lion). In contrast, bloodstream infections, which had
a relatively high average cost per case (model esti-
mate, £6209), imposed relatively low costs nation-
ally (£25.53 million: 95% Cl; -£6.86, £57.91
million). However, the confidence interval around
this estimate is wide, reflecting the degree of uncer-
tainty in the cost estimates derived.
Specialty specific estimates indicated that H.-\ls
occurring in medical patients resulted in consider-
ably greater costs than infections occurring in
patients admitted to the other specialty groups.
Discussion
This study provides the most comprehensive UK
estimate to date of the incidence and economic bur-
den imposed by HAls occurring in adult patients
admitted to specialties common to most district
general hospitals. At the national level, patients
admitted to these specialties accounted for approxi-
mately 70% of all adult, non-day case admissions in
1994/5.14 The remaining 30% were admitted to spe-
cialties not included in this study. The incidence
and cost of infections occurring in these patients
was not explored in this study.
Estimates of the incidence of HAIs indicated
that 7.8% of patients who were recruited into the
study and for whom complete data sets were
obtained acquired one or more infections which
presented during the in-patient period. As would
be expected. this is less than the most recent preva-
lence figure of 9%15and interestingly is similar to
·the 7.2% incidence rate observed in the only orher
similar recent UK study.)
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The incidence of HAlo varied with the site of
infection. Urinary tract infections, as in other stud-
ies,3.4.15were found to be the most frequent single
site infections followed by respiratory tract infec-
tions and surgical wound infections. Bloodstream
infections were the least frequent type of infection
with only four patients (0.1%) acquiring an infection
at this site in the absence of other infections. With
the exception of the multiple infection category, the
incidence figures presented relate to the incidence of
infections at a single site. If the site-specific inci-
dence figures included both patients who had a sin-
gle infection and those who also had infections at
one or more other sites, the incidence figures would
be higher in some cases. For example, whilst only
four patients solely acquired a bloodstream infec-
tion, a further t t patients acquired a bloodstream
infection and one or more infections at other sites,
giving an overall incidence of 0.4%.
Estimates of the economic burden imposed by
HAh indicate that the)' are a substantial drain on
the hospital sector. Infected patients, on average,
incurred hospital COSII that were almost three times
higher than those of uninfected patients and they
remained in hospital 2.S times longer. The majority
of the additional costs incurred were linked to a
prolonged hospital stay. This finding is consistent
with that found in other studies. S Unlike earlier
studies, however, we have presented detailed infor-
mation on how costs were distributed amongst the
budgetary centres of the hospital.
The additional coste imposed on the health sec-
tor varied considerably with the site of infection.
Patients who acquired a urinary tract infection, and
no other infection, al in other studies, S-7 had the
lowell increases in costa when compared with
patient. having infection at other lites, with costs,
on average, 1.8 times higher than those of the unin-
fected patients. Patients who acquired more than
one infection on average incurred the highest costs
with hospital costs, on average, over six times
higher than for uninfected patients.
In this study, regression analysis was used to
control for a range of factors other than the pres-
ence of an HAl that may have had an impact on
resource use. These were age, sex, admission spe-
cialty, admission type, diagnosis and number of co-
morbiditie •• This approach to attributing costl to
HAl was selected in preference to the frequently
used 'case-control' method.l.S-7 This latter app-
roach involves matching infected patient. with one
or more uninfected patients, on the basis of factors
R. Plowman et al.
thought to influence resource use, and attributing
the difference in costs incurred to the presence of
an infection. It encounters a number of difficulties,
in particular selecting appropriate matching factors
and finding suitable control patients for all infected
patients. '6-'8
The approach taken in this study to attribute
resource use to the presence of an infection i. also
associated with difficulties, in particular whether the
factors included in the regression modelling cov-
ered the major confounding factors. The possibility
exists that factors other than those included in the
analysis may have had an impact on the level of
resource use. Additional analysis explored the
impact of including three additional variables: social
class; the average level of nursing care required
during the period extending from admission to the
time of infection; and a severity of illness measure
(disease stage). This latter variable was derived
from information about the patients' age, sex, diag-
nosis, co-morbidities, operation codes, admission
type, length of in-patient stay and discharge desti-
nation. Previously validated algorithms19 were used
to allocate patients to one of three disease stage
groups (low, medium and high) depending on the
severity of their illness. This work was undertaken
by CHKS Ltd using a specifically designed com-
puter software programme. The inclusion of these
additional variables was found to have very little
effect on the estimated impact of HAlon hospital
costs, once the other explanatory variables used,
had been taken into account.1l
The generalizability of the results of this study
to other hospitals is dependent upon whether the
case mix included in this study was typical of that
which might be found in similar specialties at other
hospitals, and how closely clinical practice, and the
resource use and associated costs that this implies,
reflects that occurring elsewhere.
A retrospective comparison of the study hospi-
tals with other English NHS hospitals indicated
that the atudy hospital was broadly representative
of other hospitals in terms of bed days produced,
number of staff employed and average length of
stay. It waa not possible to assess the representative-
ness of the case mix in any detail, or how typical
clinical practice was of that found in other health-
care setting.. It should be noted, however, that
the specialties included in this study are common
to most di.trict general hospitals, and there was
nothing to sUlLgest that clinical practice would be
markedly different elsewhere.
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It was not possible to recruit an eligible patient •.
There is no reason to believe this may have biased
the sample since a comparison of the age, sex, adm-
ission type and admission specialty distribution. of
the recruited cohort of patients, with that which
would have been present if all eliaible patient. had
been recruited, showed that there were very few
differences. Due to this, and the fact that the infec-
tion group comparison. were made within the
strata defined by these factors, and that these were
not found to vary between strata, it is reasonable
to assume that the results obtained are generalizable
to all patients which this sample was intended to
represent.
The estimates of the national burden of HAl are
based on the observed incidence of HAl and the
estimated economic burden imposed. The nlidity of
the aggregated model i. dependent upon the general-
izability of these results, The analysis allowed for
some variability in the incidence rates and ratios of
costs incurred by infected compared to uninfected
patients, based on the variance observed in the atudy
data. The confidence limits around the national
estimates reflects this. No adjustment was made
for variation in the baseline cost associated with
uninfecred patients, nor for inflation. Although it is
unclear how accurately the cost estimates associated
with uninfecred patients reflect costs at other hospi-
tals, the study hospital, as indicated above, was
found to be broadly representative of others in terms
of the number of bed days produced, the number of
staff employed and the average cost per bed day.
Consequently, it i. likely that the baseline estimates
are a reasonable reflection of the costa elsewhere in
1994/5, when the atudy waa conducted, but are likely
to be higher today aa a result of inflation.
The resultl presented indicate that a substantial
number of adult, non-day case patients admitted to
specialties common to most hospitals acquire one or
more HAls and that these infections are a consider-
able drain on limited hospital resources. In 1994/5
an estimated 320994 patients acquired one or more
HAil costing the hospital sector an estimated
£930.62 million, representing 9.1% of the in-
patient acute, obstetric and geriatric programme
budget in 1994/5,1Uand utilizing an estimated 3.64
million bed days, equivalent to an estimated
"78947 finished consultant episcdes,
Given that these estimates are limited to adult,
non-day case patients admitted to selected special-
ties, the actual burden il likely to be considerably
greater than that indicated here. The incidence of
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HAIa occurring in some of the excluded specialties
may be higher than that observed in this study, and
in lome case. are likely to impose a considerable
additional burden. For example, infections occurring
in patients undergoing renal transplant or cardiac
.urgery are likely to be particularly demanding of
resources.
The estimates of both the number of patients
who acquire one or more infection. and the eco-
nomic burden imposed, presented in thi. paper, are
considerably higher than previously published esti-
mates, For example in 1997, Glyn,' al.lI estimated
that there were at least 100000 HAla annually, and
in 1993 Coello " al.s estimated that HAIa occurring
in surgical patients alone cost the NHS £170 mil-
lion per annum. In this study HAla occurring in
surgical patients (surgical, orthopaedic, gynaecol-
ogy, urology and ear, nose and throat patients) were
estimated to Call the hospital sector £363 million.
The cost estimates derived in thil study repre-
sent the average value of the resources that might
be released if an infection i. prevented, and the
national estimates indicate the value of released
resources if all infections were prevented. The esti-
mates represent the gross benefits of prevention.
Whilst not all HAla can be prevented22 the litera-
ture Buggests that man)' could be prevented
through improved infection control strategies.2.11I.23
Data from the United StateB auggestl that a third of
infections may be preventable.23 However, the
relults of a recent censua conducted by the
National Audit Office reveal that whilst some infec-
tion control practitioners view this frequently
quoted figure to be a realistic target, with some
considering that a higher level of reduction could
be achieved, a substantial proportion consider this
to be rather ambitioul. The average level of reduc-
tion thought to be achievable wall 5%.10
If this modified target were achieved, consider-
able resources would be released for alternative use.
For example, crude national estimatea of the grosl .
benefits of prevention, which take no account of
which infections are prevented, luggelt that a 15%
reduction in HAIa would result in the release of
hospital relourcel in the order of £ 140 million
(95% Cl; £117, £162 million). The majority of
these released resources would be fixed in the COlt
structure of the hospital, with only 1t% in the form
of cash savingl. Any benefits would therefore lie in
their alternative use.
The same level of reduction would result in the
release of an estimated 546000 bed days (95% Cl;
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451500, 640500) In 1994/5 the average length of a
finished consultant episode for the specialties cov-
ered in these estimate. was 7.6 days.14 It therefore
follow. that this ia equivalent to an estimated 71 842
(95% Cl; 59407; 84 276) finished consultant
epiosodes. Given the current length of waiting lists
it appears that the value of these resources, if made
available, would be great.
These models, whilst being gross simplifications
of the complexities of determining the benefits of
prevention, demonstrate that the prevention of
HAla should release considerable resources for
alternative use. However, there are costs associated
with prevention. Further work is now required to
assess the cost and effectiveness of prevention
activities and subsequently the net benefits of .
infection control.
Conclusion
The result. presented in this paper indicate
that HAl is a substantial problem both in terms of
the incidence of this type of infection and the
economic burden imposed on the hospital sector.
Additional costa fall on the health sector post-
discharge. patients and their carers. Estimates
of the magnitude of these costs are reported
elsewhere.1l
The cost estimates presented represent the aver-
Ige value of resources that might be released if
infections are prevented, and the national estimates,
the gro.s benefits of preventing all infections. Not
all infectione are avoidable, however, and there are
colte associated with prevention activitiea. The esti-
mation of the net benefits of alternative prevention
atrategies was beyond the scope of this study.
Further work ie now required to establish the cost
and effectiveness of these activities. This informa-
tion may then be used together with the informa-
tion presented in thie paper to model the net
benefit. of infection control practices, the resulta
of which may be used to inform infection control
programmee.
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Introduction
At anyone time approximately one in 10 patients in acute
hospitals have a hospital-acquired infection (HAl)
(DoH/PHLS, 1995). At the same time, an unquantified
number of patients, discharged from hospital into the
community, have an infection related to their recent hos-
pital admission. These infections impose a burden on the
secondary, tertiary and primary health-care sectors, com-
munity care services, the patients themselves and those
who care for them. These burdens may be both financial
and non-financial.
Studies that have estimated the cost of HAl generally focus
on the burden to the hospital sector. Little is known about
the costs incurred by the primary health-care sector, com-
munity care services, individual patients and their family
and friends. These costs become increasingly relevant as
the length of hospital stay becomes shorter and patients
are discharged home at an earlier point in their recovery.
This change in discharge pattern is likely to result in some
treatment costs being shifted from the secondary health-
care sector to the primary health-care sector and commu-
nity care services, and may result in an increase in the costs
borne by patients, their family and friends.
The aim of this research was to provide a more compre-
hensive assessment of the nature, distribution and mag-
nitude of the costs resulting from HAIs. To achieve this, a
detailed analysis of the resources used in hospital and
post-discharge was undertaken.
The results of this research should be of use to both pur-
chasers and providers of health care, in particular those
involved in the planning and management of infection
prevention and control programmes.
The research was commissioned by the Department of
Health to the Central Public Health Laboratory and the
London School of Hygiene and Tropical Medicine, and
forms part of the Department of Health's Research and
Development Programme.
Aims and objectives
The aim of the study was to assess the burden of HAl in
terms of the costs to the public sector, patients, informal
carers and society as a whole. Specific objectives were to:
1.Determine the overall burden of HAl in terms of the:
• Costs to the secondary and primary health-care
sectors and community care services.
• Impact on the health status of patients.
• Costs to patients, informal carers and the economy.
2. Establish the relative costs of different types of HAl.
3. Determine the type of patients who incur the highest
costs for specific infections.
4. Use the data obtained to construct models to predict the
effects of HAlon the cost categories described above.
Research methods
Adult patients with a minimum in-patient stay of 30 hours
were recruited from the general wards of a district general
hospital over a 13-month period between April 1994 and
May 1995. Information on daily resource use was record-
ed for each patient for the duration of their hospital stay.
Patients who presented with signs and symptoms of infec-
tion which met the definitions of infection used in this
study, and a sample of patients who did not, were fol-
lowed up post-discharge using a structured questionnaire.
This questionnaire provided information on possible sur-
gical wound, chest and urinary tract infections experi-
enced after discharge from hospital; care received from
health and community care services, family and friends;
personal expenditure on items such as drugs and dress-
ings; time of return to normal activities and, if applicable,
employment; and information on the patients' health sta-
tus following discharge from hospital. Information about
care received post-discharge was also obtained from the
patients' health-care records. Estimates of the cost of the
resources used were made and analysed to determine the
extent to which observed variations in costs incurred by
infected and uninfected patients could be explained by the
presence of an HAl.
The in-patient analysis considered how resource use and
associated costs varied between patients with and with-
out an HAl, and how these outcome measures varied
with site of infection. The post-discharge analysis con-
sidered how costs varied between four patient groups:
• Patients who did not have an HAl identified during
the in-patient phase or an infection identified post-
discharge (Group 1).
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o Patients who did not have an HAl identified during
the in-patient phase, but reported symptoms and
treatment that met the study criteria for one or more
infections present post-discharge (Group 2).
o Patients who had one or more HAls identified during
the in-patient phase, but did not report symptoms
and treatment that met the study criteria for one or
more infections present post-discharge (Group 3).
o Patients who had one or more HAIs identified during
the in-patient phase, and reported symptoms and
treatment that met the study criteria for one or more
infections present post-discharge (Group 4).
Patients were classified as having a possible infection post-
discharge if they reported symptoms and treatment which
met the criteria for surgical wound, chest or urinary tract
infections used in this study. It was not possible to deter-
mine whether in all cases an infection was present, or
whether it was acquired in hospital. Furthermore, where
patients presented with an HAl in hospital, it was not clear
whether the symptoms reported post-discharge represent-
ed a new infection or a continuation of a previously diag-
nosed infection.
Since factors other than the presence of an HAl may have
accounted for some of the additional resource use and
costs incurred by infected patients, resource and cost out-
come measures were analysed using regression model-
ling which controlled for a range of potential confounders
(age, sex, diagnosis, number of co-morbidities, admission
specialty, admission type and, where appropriate, time of
return of questionnaire). Estimates allowing for the
effects of these confounders were subsequently derived
from this modelling process.
Results
Recruitment and post-discharge response rates
o Four thousand adult patients were recruited into the
study from the medical. surgical. orthopaedic,
urology, gynaecology, ear, nose and throat (ENT),
elderly care and, if they had a caesarean section,
obstetric specialties.
o Complete in-patient data sets were obtained for 3980
patients.
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o A total of 1449 patients were selected for follow-up
into the community: 215 had an infection identified
during the in-patient phase.
o Of those patients selected for follow-up, 41 died
either before the first questionnaire was sent at four
weeks post-discharge, or between the distribution of
the first and second questionnaires at eight weeks
post-discharge. Four of these patients had an HAl
identified during the in-patient phase. A1l41 patients
were excluded from the response rate.
o Seventy-one per cent of patients returned the
questionnaire after a maximum of two reminders.
o The response rate was similar for patients with and
without an HATidentified during the in-patient phase.
Incidence of HAls
o In-patient phase: 7.8% (95% Cl: 7.0; 8.6) of patients
were identified during the in-patient phase as having
acquired one or more HAls.
o Post-discharge phase: 19.1% (95% Cl: 16.5; 21.9) of
those patients who returned the questionnaire and
who did not have an HAl identified during the in-
patient phase and 30% (95%Cl: 22.8; 38.0) of patients
who had an HAl identified during the in-patient
phase reported symptoms and treatment that met the
criteria for a urinary tract, chest and/or surgical
wound infection used in this stud y.
Impact of HAlon hospital costs incurred
during the in-patient phase
Patients who presented with one or more HAls during
their in-patient stay were found to incur costs that were,
on average, 2.9 times greater than those for uninfected
patients. In these study patients, this represented an
absolute increase of £3154per case. After adjusting for the
effects of potential confounders the ratio was almost iden-
tical (2.8; 95% Cl: 2.6; 3.0), suggesting that confounding
had relatively little effect.
Hospital overheads, capital charges and the cost of man-
agement time accounted for 33% of the additional costs
incurred, while nursing care accounted for 42%, medical
care 6%, operations and consumables 6%, paramedics
and specialist nurses 4%, antimicrobials 2%, other drugs
3%, microbiology tests 1%,and other tests and investiga-
tions 3% (see Figure 1).
Figure I. The distribution of the additional costs incurred by
patients with one or more HAls compared with uninfected patients
during the in-patient hospital stay
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The mean costs of treating infected and uninfected
patients varied with specialty. Table 1 (page 4) shows the
mean costs incurred, the ratio of the costs incurred by
infected patients compared with uninfected patients, and
the additional costs incurred by infected patients in this
study. The figures in parentheses are the estimates
obtained from the regression analysis.
Impact of specific types of HAlon hospital
costs incurred during the in-patient phase
The impact that HAls had on hospital costs varied with
the site of infection. Table 2 (page 4) shows the mean costs
incurred, the ratio of the costs incurred by infected
patients compared with uninfected patients, and the
additional costs incurred by infected patients. The figures
in parentheses are the estimates obtained from the
regression analysis.
Infections of the urinary tract were found to be the least
expensive, with costs, on average, 1.8 times higher than
those for uninfected patients. Tnthese patients, this is, on
average, equivalent to an additional £1327 per patient.
Patients who acquired infections of the lower respiratory
tract, skin, surgical wound or 'other' sites experienced
similar patterns of increase in costs. Costs were, on aver-
age, two to 2.5 times greater than those incurred by unin-
fected patients, equivalent to an average increase of
between £1618 and £2398 peTpatient.
The four patients who acquired bloodstream infections
incurred costs that were, on average, over four times
those for uninfected patients. In these patients, this is
equivalent to an additional £5397 per patient. However,
since there were only four patients in this infection group,
two of whom died, general conclusions based on these
results must be treated with caution.
Patients who acquired more than one HAl incurred the
highest expenses, with costs, on average, 6.6 times greater
than those incurred by uninfected patients. In these patients,
this is equivalent to an additional £9152per patient.
For all sites of infection, adjustment for potential con-
founders made little difference and the relative magni-
tudes of effects were almost entirely unchanged.
Impact of HAlon length of hospital stay
Patients who acquired an infection in hospital remained
in hospital, on average, 2.9 times longer than uninfected
patients, equivalent to an extra 14 days. After adjusting
for other factors that might influence length of stay, the
ratio of increase was modified to 2.5 (95% Cl: 2.3; 2.7),
which is, on average, equivalent to an extra 11days.
Impact of specific types of HAlon length of
hospital stay
The extended hospital stay experienced by patients with
an HAl varied with site of infection (Table 3, see page 5).
Patients who acquired more than one infection were
observed to have the greatest increase in mean length of
stay. Patients with bloodstream infections had the lowest
increase. However, as mentioned above, there were only
four patients in this group, two of whom died while still
in hospital.
Impact of HAlon the health-care sector
post-discharge
With the exception of patients who presented with an
HAl as an in-patient and did not have an infection iden-
tified post-discharge, who on average incurred lower GP
costs than patients in the other infection groups, patients
who had an HAl identified during the in-patient phase,
and/ or an infection identified post-discharge, on average,
had greater contact with their Gp, visited the hospital
more frequently for outpatient appointments and
received more visits from district nurses compared with
uninfected patients. Patients who acquired an infection
therefore imposed an additional economic burden on
these services. Acquiring an infection was not found to
have a positive impact on the number or cost of health
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Table I. Mean cosu incurred durin. the In..patient phase by patients with and without an HAl and by admission specialty
Specialty Mean cosu (£) Ratio of casu Additional cosu (£)
No HAl n HAl (model estimate: 95% Cl) (model estimate)
(a) (b) (bla) (b-a)
Medicine 1559 800 7271 38 4.7 (4.6: 38, 5.6) 5712 (5621)
Surgery 1290 844 6189 54 4.8 (3.9: 3.3. 4.7) 4898 (3795)
Orthopaedcs 2089 473 5385 40 2.6 (2.6: 2.1, 3.1) 3296 (3285)
Urology 1276 439 2758 27 2.2 (2.2; 1.7,2.8) 1482 (1544)
Gynaecology 1661 339 2196 51 1.3 (1.3;1.1,1.5) 535 (470)
Elderly care 1748 508 52n 74 3.0 (3.1;2.6, 3.5) 3529 (3578)
ENT 2127 64 5644 2.7 (1.9: 0.8, 46) 3516 (2007)
Obstetrics" 2481 204 2761 23 1.1 (1,1;0.8,1.4) 280 (118)
Overall 1628 3671 4782 309 2,9 (28: 2.6, 3.0) 3154 (2917)
-Caesarean sections only
Table 2. Mean cosu incurred during the In-patient ph... by site of HAl
Site of infection Mean cosu (£) n Ratio ofcosu Additional cosu (£)
(model esamato: 95% Cl) (model estimate)
No HAl 1628 3671
UTI 2955 107 1.8 (1.7: 1.5, 1.9) 1327 (1122)
LRTI 4027 48 2.5 (2.3: 1.9.2.7) 2398 (2080)
SWI 3246 38 2.0 (2.0: 1.6,2.4) 1618 (1594)
BSI 7026 4 4.3 (4.8: 26, 8.8) 5397 (6209)
Skin 3418 25 2.1 (2.0. 1.6,2,5) 1790 (1615)
Other 3892 30 2.4 (2.5: 2.0, 3.1) 2263 (2465)
Multiple 10780 57 6.6 (6.3: 5.4, 7.4) 9152 (8631)
Any Infection 4782 309 2.9 (2.8: 2.6, 3.0) 3154 (2917)
UTI=urinary tract infection; LRTI=lower respiratory tract infection; SWI=surgical wound infection: BSI=bloodstream infection
visitor and community midwife visits. Table 4 (page 5)
summarises the impact of HAlon health sector costs post-
discharge. The mean costs incurred by patients in the four
HAl groups are presented, together with the ratio of the
costs incurred by infected patients compared with unin-
fected patients and the additional costs incurred by infect-
ed patients. The figures in parentheses are the estimates
obtained from the regression analysis.
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General practitioners
Patients who did not present with an HAl while in hos-
pital but reported symptoms and treatment that met the
study criteria for an infection post-discharge, and patients
who developed an HAl while in hospital and had an
infection identified post-discharge, on average, incurred
proportionally greater costs than patients in the other two
groups. However, the average increases in the absolute
costs observed were minimal.
Table l.Mean length of hospital stay by site of HAl
Site of Infection Mean LoS Ratio Additional days
(days) (model estimate; 95% Cl) (model estimate)
No HAl 3671
UTI i4 107 1.8 (1.7; i.5, 1.9) (5)
LRTI 20 48 2.6 (2.1; 1.7,2.6) 12 (8)
SWI 14 38 1.9 (1.9; 1.6,2.4) 7 (7)
BSI 10 1.2 (1.5;0.8,3.0) (4)
Skin 20 25 2.6 (2.4: 1.8,3.1) 12 (II)
Other 21 30 2.8 (2.6: 2.1,3.4) 13 (12)
Mu~iple 45 57 6,0 (4.8: 4.0, 5,8) 38 (29)
Any infection 22 309 2.9 (2.5: 2J. 27) 14 (II)
LoS=length of stay: UTI=unnary tract Infection; LRTI=lower respiratory tract infection; SWI=surgical wound Infection; BSI=bloodstream infection
Table 4. Impact of HAlon health sector cosu incurred post-discharge
One or more HAls One or more Health-care Mean observed Ratio of costs Additional costs (£)
identified during the infections identified professional visited* costs (£) (model estimate; 95% Cl) (model estimate)
In-patient phase post-discharge
No No 664 GP 18
658 HO/HN 32
558 ON 34
No Yes 159 GP 28 1.6 (1.7; 1.3.23) 10 (12)
160 HO/HN 39 1.2 (1.9: 13.2.6) 7 (28)
130 ON 39 1.2 (1.5: 1.0.2.1) 6 (16)
Yes No 99 GP 14 0.8 (0.8:0.5.1.1) -4 (-4)
102 HD/HN 36 1.1 (13: 0.9. 2.0) 4 (II)
89 ON 59 1.8 (1.6: 1.0.23) 25 (19)
Yes Yes 43 GP 24 1.4 (1.5:0.9.2.6) 6 (10)
43 HO/HN 40 1.3 (2.7: 1.5.4.7) (53)
39 ON 78 23 (2.6: 1.4,4.7) 44 (53)
·Sources: GP and HO/HN (the post-discharge questionnaire): ON (the ON database)
GP=general practitioner; HD/HN=hospital doctor/hospital nurse; DN=d,strict nurse
Hospital doctor/nurse
Patients who did not present with an HAl while in hospi-
tal but had an infection identified post-discharge, and
patients who presented with an HAl while in hospital and
had an infection identified post-discharge incurred slight-
ly higher costs than patients in the other two categories.
District nurses
Patients who had an HAl identified during the in-patient
phase, and/or an infection identified post-discharge, on
average, had a greater impact on district nursing costs
compared with uninfected patients. Patients who pre-
sented with an HAl as an in-patient and had an infection
identified post-discharge had the greatest impact on dis-
trict nursing costs.
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The results from the regression analysis suggest there was
some confounding and that the effects of HAlon Gp. dis-
trict nursing and hospital costs in a number of cases were
probably larger than those observed.
Impact of HAlon costs Incurred by patients
Personal expenditure on items such as drugs and dress-
ings was found to vary with HAl group. The mean costs
incurred by patients in the four HAl groups are presented
in Table 5, together with the ratio of the costs incurred by
infected patients compared with uninfected patients and
the additional costs incurred by infected patients. The fig-
ures in parentheses are the estimates obtained from the
regression analysis.
Increases in personal expenditure were greatest for patients
who presented with an HAl as an in-patient and had an
infection identified post-discharge. These patients experi-
enced costs that were 3.2 times greater than those incurred
by uninfected patients. Adjustment for potential con-
founders made little difference and the relative magnitudes
of effect remained similar to the observed effects.
Impact of HAlon the number of days from
admission to return to normal daily activities
The number of days from admission to resuming normal
daily activities varied with HAl group. The mean number
of days from admission to resuming normal daily activities
for patients in the four infection groups are presented in
Table 6, together with the ratio of the number of days
infected patients were away from normal daily activities,
compared with uninfected patients. The additional num-
ber of days that infected patients took to resume normal
daily activities, compared with uninfected patients, are also
presented.
Patients who had an HAl identified during the in-patient
phase and/or an infection identified post-discharge, on
average, took longer to resume normal daily activities
than patients in the uninfected group. Patients who had
an HAl identified during the in-patient period and report-
ed symptoms and treatment that met the criteria for an
infection post-discharge took longer to resume normal
daily activities than patients in the other infection groups.
Table S. Impact of HAlon personal costs Incurred by patients
On. or more HAls One or more n Mean observed Ratio of costs Additional costs (£)
identified during the infections identified costs (l) (model estimate: 95% Cl) (model estimate)
in-patient phase post-discharge
No No 691 9
No Yes 163 is 1.7 (1.5: r.i, 1.9) 6 (4)
Yes No i05 0.5 (0.9: 0.6. 1.3) -4 (I)
Yes Yes 45 30 3,2 (32: 20. S.O) 20 (20)
Table 6. Mean number of days from admission to return to normal daily activities by HAl statUI
One or more HAls One or more n Mean no.
identified during the Infections identified of days
in-patlont phase post-diSCharge
No No 642 29
No Yes iSS 35
Yes No 94 4i
Yes Yes 43 43
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Ratio of days
(model estimate: 95% Cl)
Additional days
(model estimate)
1.2 (1.2: 1.1. iA)
1.4 (lA: 1.3.1.6)
1.5 (1.6: 1.3.1.9)
6 (6)
12 (13)
13 (17)
Impact of HAlon the number and value
of days employed patients were away from
paid employment
The number and value of days from admission to return to
paid employment varied with HAl group. The mean number
and value of days from admission to return to paid employ-
ment for patients in the four infection groups are presented in
Tables 7-8, together with the ratio of the number and value of
days infected patients were away from emplnyment, com-
pared with uninfected patients. The additional number of
days infected patients were away from paid employment,
compared with uninfected patients, are also presented.
Patients who had an HAl identified during the in-patient
phase and/or an infection identified post-discharge had
a greater number of days away from employment than
uninfected patients.
Impact of HAlon the number of days
Informal carers spent caring for patients
and their dependants
The number and value of days informal carers spent car-
ing for the patient's dependants during the in-patient
period and the patient post-discharge varied with HAl
group. The mean number of days of care provided by
informal carers for patients in the four infection groups
are presented in Table 9 (page 8) and the estimated value
of this time is presented in Table 10 (page 8). The ratio of
the number of days of care received by infected compared
with uninfected patients and the associated value, togeth-
er with the number of additional days of care received by
infected compared with uninfected patients, are also pre-
sented in these tables.
Patients who reported symptoms and treatment that met the
study criteria for one or more infections present post-
discharge, regardless of whether they presented with an
infection in hospital, on average, received more care from
informal carers than patients who had not acquired an infec-
tion, or who presented with an infection in hospital but did
not have an infection identified post-discharge.
Impact of HAlon health status
The responses given to the general health status ques-
tionnaire, the SF-36, administered four weeks post-dis-
charge, provided information on eight dimensions of
health. Two summary measures relating to physical and
mental well-being were derived from these data. Patients
Table 7. Mean number of days from admission to return to employment by HAl Status
One or more HAls One or more n Mean no.
Identified during the infections identified of days
in·patient phase post-discharge
No No 267 23
No Yes 66 29
Yes No 30 29
Yes Yes II 28
Table 8. Mean value of days from admission to return to employment by HAl status
One or more HAls One or more n Mean value
Identified during the Infections identified of days
in-patient phase post-discharge
No No 267 1429
No Yes 66 1724
Yes No 30 1649
Yes Ye, II 1889
Ratio of days
(model estimate; 95% Cl)
Additional days
(model estimate)
1.2 (1.1; 1.0. 1.3)
1.3 (1.2; 1.0. 1.5)
1.2 (1.3; 0.9.1.7)
6 (2)
6 (6)
5 (6)
Ratio of cosu
(model estimate; 95% Cl)
Additional cosu (£)
(model estimate)
1.2 (1.1; 1.0. 1.3)
1.2 (1.2; 1.0. 1.5)
295 (200)
220 (300)
IJ (1.6; 1.1,2.2) 460 (801)
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Table 9. Mean number days Informal carers spent caring for dependants and patients by HAl status
One or more HAls One or more Mean no. RatiO of days Additional days
identified during the Infections Identified of days (model estimate; 95% Cl) (model estimate)
in·patient phase post-discharge
No No 691 10.3
No Yes 163 14.4 lA (1.2: 1.0, 1.6) 4.1 (2.1)
Yes No 105 10.5 1.0 (0.9: 0.6, 1.2) 0.2 (-1.3)
Yes Yes 45 20.9 2.0 (1.6; 1.0,2.5) 10.6 (6.1)
Table 10.Mean value of days informal carers spent caring for dependants and patients by HAl status
One or more HAls One or more Mean value Ratio of costs Additional costs (£)
Identified during the Infections Identified of days (£) (model estimate; 95% Cl) (model estimate)
In-patient phase post-discharge
No No 691 348
No Yes 163 488 1.4 (1.3;0.8,2.1) 140 (96)
Yes No 105 355 1.0 (0.7; 0.4, 1.3) (-100)
Yes Yes 45 707 2.0 (2.3: 0.9, 5.6) 359 (454)
with an HAl, on average, obtained lower scores for these
two measures than patients who did not acquire an infec-
tion, indicating a poorer outcome as determined by these
health measures. Patients who presented with an HAl as
an in-patient and reported symptoms and treatment
which met the study criteria for an infection present post-
discharge, on average, reported the lowest health status.
Impact of HAlon in-patient mortality
The in-patient death rate was found to be considerably
higher in patients with an HAl which presented during
the hospital stay: 13%of patients with an HAl died com-
pared with 2% of patients who did not present with an
HAl in hospital. After adjustment for the effects of age,
sex, diagnosis, number of co-morbidities, admission spe-
cialty and admission type, patients with an HAl were
found to be7.1 (95%Cl: 4.3; 11.7) times more likely to die
in hospital than uninfected patients.
Estimates were made of the number of years of life lost by
infected patients who died. Patients aged 25-44 years who
acquired an infection in hospital and subsequently died,
on average, lost 44 years; patients aged 45--64lost 19years,
patients aged over 65-84 years lost 11years, and patients
aged 85 years and over lost 4 years. Since it was not pas-
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sible to determine for each individual case whether the
HAl was the primary cause of death, a contributing factor,
or whether it made no contribution to the death, neither
the number nor value of the years of life lost as a result of
an HAl could be determined. However, it is important to
acknowledge that years of life lost do have a value and
represent an important cost associated with HAL
National estimates
The study results were used to estimate the economic bur-
den of HAls occurring in adult (~18 years) patients,
excluding day cases, admitted to the specialties covered in
this study throughout England. Patients admitted to these
specialties accounted for approximately 70%of adult, non-
day case NHS admissions in England in 1994-1995.
The results presented are based on the assumption that the
incidence of HAl, the ratio of increase in costs incurred by
infected compared with un infected patients and the mean
cost of treating uninfected patients observed in this study
are representative of the incidence and costs incurred by
patients admitted to the specialties covered in this study
throughout England.
Estimates of the economic burden of HAl to
the NHS in England
HAls were estimated to cost the NHS in England £986.36
million annually. Of this aggregate cost, £930.62 million
(95%Cl: £780.26;£1080.97million) was estimated to have
been incurred during the patients' hospital stay and £55.74
million post-discharge. These post-discharge costs were
distributed between GPs (£8.4 million), hospitals (outpa-
tient consultations) (£26.83 million) and district nursing
services (£20.51million). The estimates of the effect of HAl
on health sector costs incurred post-discharge varied con-
siderably, depending on whether the HAl presented dur-
ing the in-patient and/or post-discharge phase. The 95%
confidence intervals obtained for the different infection
groups were wide and this should be taken into account
when using these estimates.
The in-patient hospital estimates represent 9.1% of the
acute, geriatric and obstetric programme budget for 1994-
95, and estimates of the cost to the hospital sector post-
discharge 0.9% of the outpatient acute, geriatric and
obstetric programme budget for the same year (data from
Department of Health). The estimated burden to GPs rep-
resents 0.3% of the general medical services budget for
1994-95 (data from the Department of Health) and the
estimated burden to district nursing services represents
2.4% of their budget for the same year (data from the
Department of Health).
Table 11presents estimates of the impact of specific types
of infection on in-patient costs. The cost estimates are lim-
ited to those incurred by the hospital sector during the in-
patient stay. Nationally, infections of the urinary tract were
estimated to be the most expensive single-site infection,
costing an estimated £123.89million per annum (95%Cl:
£80.96;£166.83).These infections were relatively inexpen-
sive to treat (the additional cost per case observed in this
study was £1327, model estimate £1122), but their rela-
tively high incidence means that, nationally, they impose
a substantial burden on the NHS. No attempt was made to
derive site-specific estimates of the impact of HAlon
health sector costs incurred post-discharge.
Table II. National estimates of the burden of HAl to the hospital
sector in England by site of infection (in-patient costs only*)
Site of infection Estimates of the national burden or HAl
Figures expressed in £ (millions)
Estimate 9S%CI
Low High
UTI 123.89 80.96 166.83
LRTI 103.77 5941 148.12
SWI 6237 30.93 9182
BSI 2553 -6.86 57.91
Skin 41.79 15AO 68.17
Other 75.87 3652 115.23
MultIple 50777 348.89 666.65
UTI=unnary tract infection; LRTI=lower respiratory tract infection;
SWI=-=surglcal wound infection; B'Sl=bloodstream infection
-Estimates are limited to the additional costs incurred as a result of
HAls occurring in aduh. patients, excluding day cases, admitted to the
specialties covered In this study: approximately 70% of all adult, non-
day case NHS admissions
Estimates of the economic burden of HAl
to patients
Personal expenditure on items such as drugs and dress-
ings incurred by patients who acquire an infection in hos-
pital are estimated to amount to £4.74 million annually.
The estimates derived varied considerably depending on
whether the patient presented with an HAl in hospital
and/or had an infection identified post-discharge. The
confidence intervals derived for each HAl group were
wide and this should be taken into account when using
these estimates.
Estimates of the number of extra days
patients took to resume normal daily
activities
Nationally, patients who acquire an infection in hospital,
when compared with uninfected patients, were estimated
to take an additional 8.7 million days to resume normal
daily activities. The estimates varied considerably with
HAl group and the 95% confidence intervals were wide.
These factors should be taken into account when consid-
ering these estimates.
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The benefits of prevention
This study was not directly concerned with estimating the
benefits of prevention. However, the estimates presented
provide important information on the value of resources
that might be released for alternative use if a proportion
of infections are prevented. These may be viewed as the
gross benefits of prevention. Net benefits will depend on
the cost and effectiveness of prevention activities.
Estimates of the gross benefits which may result from a
10% reduction in the observed incidence rate, both in
terms of the benefits to the study hospital and to provider
units throughout England, are presented in the report. In
addition to estimates of the value of resources released for
alternative use, the value of consumables released and the
number of bed days released are presented.
At the level of the study hospital, a 10% reduction in the
observed incidence rate was estimated to result in the
release of resources valued at £361 297 (95% Cl: 302 924;
419670). A similar reduction at the national level was esti-
mated to result in the release of resources valued at
£93.06 million (95% Cl: 78.03; 108.10 million).
In the short term, only a relatively small proportion of
these benefits are likely to be in the form of cash savings.
However, over a longer period of time it is possible that
some of the fixed costs might be avoided and, as such, the
proportion of benefits that may accrue as cash benefits
may increase.
In terms of the number of bed days released for alternative
use, at the level of the study hospital a similar level of reduc-
tion may result in an estimated 1413 (95%Cl: 1168;1659)
bed days released for alternative use; equivalent to an esti-
mated 191 finished consultant episodes (95%Cl: 158;224).
At the national level, 364056 (95%a: 300880;427223)bed
days may be released; equivalent to an estimated 47902 fin-
ished consultant episodes (95%Cl: 39589;56214).
These estimates, although considerable, may be conserv-
ative estimates of the value of resources that might be
released. They are limited to the benefits that may result
from a reduction in the incidence of HAl occurring in
adult patients admitted to the specialties covered in this
study, and are based on a 10% reduction in the incidence
rate. The literature suggests that up to 30% of HAls may
be prevented through effective infection control pro-
grammes (Haley, 1986).
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Discussion
The results of this study clearly indicate that HAls impose
a substantial burden on the secondary and primary
health-care sectors, on infected patients and their infor-
mal carers. A detailed analysis of the effect of HAlon
resource use and costs was undertaken, the results of
which provide important information on the nature, mag-
nitude and distribution of the economic burden. The
approach taken is considerably more detailed than earli-
er studies which have generally limited the analysis of
costs to those incurred by the hospital sector and have not
attempted to determine the distribution of these costs in
any great detail.
Three main points should be borne in mind when inter-
preting these findings.
First, attributing costs to the presence of an HAl is
extremely complex. The characteristics of patients with an
HAl may differ systematically from those of uninfected
patients. If these differences result in additional resource
use, this would bias the estimates of the effects of HAls.
The In-patient regression analysis showed this was not
the case for age, sex, admission type, specialty, diagnosis
and co-morbidities. Nonetheless, the possibility that
there may be some other confounding factors cannot be
completely ruled out. For example, due to factors not
included in the regression analysis, patients with an HAl
may have remained in hospital longer than similar
patients who did not acquire an infection, regardless of
whether they acquired an infection or not. An analysis
investigating this possibility revealed some evidence that
the difference in length of stay between patients with and
without an HAl was not due entirely to the infection.
Consequently, the estimates of the effect of HAlon length
of stay and the associated costs may be biased. However,
estimates of the magnitude of this bias were very sensi-
tive to the strong simplifying assumptions on which they
were based and, as such, it would be unwise to conclude
more than that the estimated effects of HAlon length of
hospital stay presented may include an upward bias. The
post-discharge regression analysis indicated that there
was some confounding and that the effects in a number of
cases were probably larger than those observed in the
unadjusted figures.
Second, the study was restricted to patients admitted to
one NHS trust over a 13-month period. Future patients
admitted to this and other NHS trusts might differ in var-
ious ways. In addition, estimates of the costs of resources
used were, in most cases, specific to this NHS trust, and
clinical practice affecting resource use might differ with
time and with provider unit. However, it seems reason-
able to assume that any differences that occur will be the
same for patients with and without an HAl. On this
assumption, the proportion by which an HAl increases
resource use will not be affected and, consequently, the
proportional effects estimated from this study will be gen-
eralisable. Absolute increases in costs incurred by infect-
ed patients may differ with time and with provider unit.
However, since the study hospital was found to be broad-
ly similar to other provider units in terms of factors such
as average length of stay and average cost per bed day, it
is reasonable to assume that the estimated effects of HAl
on absolute costs are also fairly gencralisable.
Third, when considering both the gross and net benefits of
prevention, it is important to realise that any savings rep-
resent a reduction in individual treatment costs and not
necessarily an overall saving to the health sector. This will
depend on how released resources are utilised and this
will, to some extent, depend on the structure of the con-
tracts and agreements in place. If, for example, the pre-
vention of infection results in a reduction in length of
hospital stay, bed days will be released for alternative use.
If these released bed days are utilised by more expensive
patients then, rather than resulting in a cost saving for the
NHS, overall expenditure will increase. However, this will
be offset by benefits gained by the extra patients treated.
Conclusion
The results of this study provide a detailed account of the
socio-economic burden imposed by HAls occurring in
adult patients admitted to selected specialties common to
most NHS provider units. It represents the first compre-
hensive attempt to estimate these costs. The results pro-
vide valuable information that might be used at national
and local level to inform the management of HAl and,
when used alongside effectiveness studies of infection
prevention and control measures, will facilitate the devel-
opment of effective policies to control HAl.
Recommendations
Specific recommendations arising from this
research
CommissIoners of health care (purchasing agencies)
should:
• Be aware of the magnitude of the overall burden
imposed by HAl and how it is distributed.
• Ensure adequate details on infection control
arrangements and ongoing strategies for the
prevention of infection are in place in all provider
units with which they contract.
• Recognise that, in a number of cases, HAls present
after discharge from hospital, and that these
infections should be monitored and the needs of
affected patients met.
Providers of health care should:
• Use the findings of this study, together with
information on the effectiveness of different infection
control activities, to inform infection prevention and
control strategies within their provider unit.
• Ensure appropriate arrangements are in place to
monitor infections presenting post-discharge and the
needs of affected patients are met.
Educational institutions involved in the education of health
care personnel should:
• Include the socio-economic burden imposed by HAl
in their educational programmes on HAl and in so
doing raise awareness of the issues relating to HAl
and the importance of infection prevention and
control strategies.
Further research and development
During the course of this study a number of areas which
would benefit from further research and development
were identified. These are briefly presented below.
The first area that requires some further work relates to
how gcneralisable the results of this study are to future
patients in other health-care settings. For reasons dis-
cussed above, it seems reasonable to assume that the
results are generalisable, but further work will be carried
out to assess in greater detail whether the pattern of
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resource use observed in this study is broadly similar to
that found in other provider units. It is also recommend-
ed that further methodological work be undertaken to
increase knowledge of how best to estimate the cost of
hospital services.
Attributing costs to the presence of an HAl presented a
number of methodological difficulties. In this study,
regression analysis was used to control for a range of fac-
tors. However, as discussed above, factors not included
may have had an impact on resource use and costs. For
example, patients with an HAl may have remained in
hospital longer than uninfected patients due to factors
other than those included in the regression analysis. An
analysis has been undertaken to investigate this, but the
results were sensitive to the strong simplifying assump-
tions on which the analysis was based. It is therefore rec-
ommended that further work on the complex relationship
between length of stay and HAl. be undertaken to assess
more precisely what part of the length of stay can be
ascribed to the effect of HAl and the associated costs.
Following discharge from hospital, patients with an HAl
were found to make more visits to their GP and/or doc-
tor or nurse at the hospital than uninfected patients.
Consequently, infected patients had a greater economic
impact on these health-care services than uninfected
patients. The analysis to date has not taken into account
the resource intensity of these visits. It is possible that vis-
its made by patients with an HAl were more resource-
intensive, and thus the economic impact was greater, than
that estimated in this study. It is therefore recommended
that the data obtained in this study be further analysed to
determine the resource intensity of visits made to GPs
and hospital doctors/nurses, and how this varies
between patients with and without an HAl. It is also rec-
ommended that further work be conducted to determine
whether the health needs of patients experiencing HAls
in the community are being met.
Acquiring an HAl in hospital was associated with a
reduction in mental and physical well-being, as measured
by the SF-36. It is recommended that further work be car-
ried out to explore the nature and reasons for the appar-
ent reduction in mental and physical well-being observed
in patients with an HAl compared with uninfected
patients, and that the results of this work are used, where
possible, to inform clinical practice.
As part of this study, a decision support system to model
and predict the effects of HAlon components of resource
use and their costs within different provider units was
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developed. It is recommended that this system be further
developed to create a user-friendly decision support
mechanism which meets the information needs of both
purchasers and providers of health care.
The results of this study provide information on the
nature, distribution and magnitude of the burdens
imposed by HAL These burdens represent the potential
gross benefits of prevention. Further work is required to
determine the cost-effectiveness of selected infection con-
trol practices. The information derived may then be used
to inform infection control practice and the overall allo-
cation of resources to infection control.
Finally, the results of this study relate to adult patients,
excluding day cases, admitted to the general specialties of
a district general hospital. Patients admitted to these spe-
cialties accounted for approximately 70% of adult, non-
day case NHS admissions in 1994-95. It is recommended
that future work examine the socio-economic burden of
HAls occurring in the other patient groups, in particular
in patients at high risk of acquiring an infection ill hospi-
tal (e.g, babies cared for in special care baby units) and
patients undergoing major and specialised surgery (e.g.
cardiothoracic surgery and organ transplantation).
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